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Preface
Male reproductive health is an important area affecting men’s overall health and 
well-being. Over the last few decades, there has been increasing concern regarding 
human male reproductive health. Estimates report that about one in three males
suffers from andrological diseases. Infertility is a worldwide problem that affects
approximately 15% of married couples. Half of these cases can be traced to male
partners. Several risk factors have been identified that may have a negative impact
on men’s reproduction health, such as endocrine-disrupting chemicals. There is also
evidence that endocrine-disrupting chemical exposure has multigenerational and 
transgenerational effects on reproductive disease. Infertile men are at an elevated 
risk of cancer development later in life, primarily genitourinary malignancies such
as testicular and prostate cancer. This book will focus on male reproductive health, 
from the aspects of semen quality, male infertility, testicular cancer, and prostate
cancer, and their detection, diagnosis, treatment, and prevention.
Section 1 discusses male infertility risk factors and therapy. The seven chapters
of this section cover the potential early life causes of male infertility, effects of
endocrine-disrupting chemicals in the male reproductive system and the decline of
male fertility, evidence for the developmental programming of male reproductive
maturation and function, mechanisms of Sertoli cell phagocytosis in spermato-
genesis, polymorphism of xenobiotic detoxification genes and male infertility, and 
mesenchymal stem cell therapy of male infertility.
Section 2 discusses testicular cancer and prostate cancer. The five chapters in this
section cover testicular cancer and its early diagnosis, the role of MRI-TRUS fusion
biopsy in the diagnosis of clinically significant prostate cancer, pelvic health physi-
cal therapy and prostate cancer, combinatorial drug therapy with phytochemicals as
adjuvants in prostate cancer management, and sexual and psychoemotional disor-
ders in male patients treated for prostate carcinoma.
Many individuals have made this book a reality. Its completion would not have
been possible without the efforts of numerous contributors. I would like to thank
Ms. Dolores Kuzelj and Ms. Andrea Koric at IntechOpen for their strong support
from inception to completion of this book. I would also like to acknowledge my
coeditors and coauthors for their efforts.
Wei Wu
Department of Toxicology,
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Increasing concern exists regarding male reproductive health worldwide. This 
is due to the appearance of medical reports outlining apparent adverse trends, such 
as a worldwide decline in total fertility rate, and an increase in testicular disorders 
such as testicular cancer, cryptorchidism—in parallel with a probable decline in 
semen quality. This is of particular concern as there is evidence to suggest that a 
poor sperm count is potentially associated with overall lifelong morbidity and mor-
tality, and is effectively a predictor of lifelong health risk. This chapter examines the 
evidence for this decline and its potential early life causes, from in-utero exposures 
to childhood development.
Keywords: male reproduction health, sperm, testosterone, in-utero, phthalate, BPA
1. Introduction
Between 1986 and 1993, British physician and epidemiologist David Barker pub-
lished a series of articles in the Lancet, proposing his hypothesis of the foetal origins 
of adult health and disease [1–3]. In these publications, he argued that adverse altera-
tions in the developmental early life environment in utero, had potential to induce 
and initiate phenotypic and adaptive changes affecting an individual’s responses to 
their later life environment, which might prove maladaptive when the early and late 
environments were markedly different [4, 5]. Barker’s specific foetal concerns were 
inadequate nutrition, [6] intrauterine growth retardation, low birth weight and 
premature birth and their causal relationship to the origins of hypertension, coronary 
heart disease and non-insulin-dependent diabetes, in later life [7]. However there is 
now growing evidence to suggest that this ‘developmental programming’ and the foe-
tal environment, which includes placental function, maternal metabolism, exposures 
and lifestyle factors (including maternal smoking), may influence additional systems 
including reproductive health and development in both males and females [5, 8].
Increasing concern exists regarding male reproductive health worldwide due to the 
appearance of medical reports outlining apparent adverse trends, in the context of a 
worldwide decline in total fertility rate (Figure 1) [9, 10]. This includes an increase in 
the incidence of the proposed ‘testicular dysgenesis syndrome’ [10] which encompasses 
a constellation of testicular disorders including testicular cancer, [11, 12] cryptorchi-
dism and hypospadias [13]. This is in parallel with population-based evidence to suggest 
declining semen quality, [14] alterations in serum testosterone levels and a change in 
the timing of onset of male puberty [9]. Worryingly, one comprehensive review of the 
literature proposed that semen quality had declined by 52.4% between 1973 and 2011 
among unselected men from Western countries [14]. Another recent report, published 
3
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in 2015, found that a high proportion of healthy, unselected 20-year-old Caucasian 
men displayed suboptimal semen quality which did not meet the lower limit of World 
Health Organization reference ranges for sperm concentration, motility and morphol-
ogy values [15]. These findings were echoed by a further Swiss study published in 2019 
where over 60% of participants displayed suboptimal median sperm concentration 
[12]. Sperm count is of obvious importance in fertility and reproduction, however 
recent studies have now demonstrated that poor sperm count is potentially associated 
with overall lifelong morbidity and mortality, and is effectively a ‘canary in the mine’ 
marker for lifelong health risk [14, 16–18]. To elicit a greater understanding of the early 
life influences on these important, early determinants of male reproduction and health 
are therefore of great importance.
In this chapter, we present and discuss the evidence for the developmental 
programming of male reproductive maturation and function.
2. Male reproductive development
Male reproductive development has a long time to maturation, with onset in the 
embryo and completion in puberty. The critical and narrow prenatal window for 
the normal differentiation and growth of male reproductive tissue during which 
testosterone and its potent metabolite dihydrotestosterone, (DHT) masculinise the 
male foetus is estimated to be around 8–14 weeks of gestation [19–21]. The forma-
tion of the indifferent bipotential gonad occurs between the fourth and sixth weeks 
of foetal life, and male reproductive development subsequently begins when the 
SRY gene, encoding a ‘testis-determining factor’ on the Y chromosome stimulates 
the development of the primitive sex cords to form the medullary cords. Sertoli cells 
appear, and in the eighth week, Leydig cells appear and commence production of 
testosterone. In the presence of this testosterone, the mesonephric ducts develop 
to form the primary male genital ducts. They give rise to the efferent ductules, 
epididymis, vas deferens and seminal vesicles, whilst the paramesonephric ducts 
degenerate. Meanwhile, in the presence of DHT, the male external genitalia differ-
entiate as the genital tubercle elongates to become the phallus and the urethral folds 
close over, forming the penile urethra.
Figure 1. 
Total fertility rates for Australia, United States, Europe and Central Asia 1960–2017. Reprinted with 
permission from the World Bank: www.worldbank.org.
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The hypothalamic-pituitary-gonadal axis is active in the mid-gestational foetus, 
but silenced towards the end of gestation. This restraint is removed at birth, leading 
to reactivation of the axis and an increase in serum gonadotropin concentrations, 
often labelled the ‘mini-puberty’ [22, 23]. Testosterone concentration rises to a peak 
at age 1–3 months, but then falls in conjunction with the falling luteinising hormone 
(LH) concentration [22]. Prenatal and postnatal activation of the hypothalamic-
pituitary-gonadal axis is associated with penile and testicular growth and testicular 
descent, and is therefore regarded as important for the development of male genita-
lia. These concentrations then gradually decrease towards age 6 months when there 
is an active inhibition of gonadotrophin-releasing hormone (GnRH) secretion, 
which persists throughout childhood, [22, 24] and the hypothalamic-pituitary-
gonadal axis remains quiescent until puberty.
3. Male pubertal development
Male puberty marks the transitional period during which the infantile boy 
attains adult reproductive capacity with usual age of onset around 11.5 years.
Pubertal development of secondary sexual characteristics is initiated, at least in 
part, by a sustained increase in pulsatile release of GnRH from the hypothalamus. 
There is testicular growth as the seminiferous tubules are stimulated by follicle-
stimulating hormone (FSH), and once their volume exceeds 3–4 ml pubertal onset 
is confirmed. Leydig cells, stimulated by LH, produce testosterone which influences 
penile growth and pubic hair development. Spermatogenesis occurs under the regu-
lation of multiple endocrine and local factors [9]. Although the exact mechanisms 
underlying the commencement of puberty in both males and females is unclear, 
there is evidence for influence of a multitude of factors including genetic, environ-
mental factors, body composition, physical fitness, nutritional and socioeconomic 
status, ethnicity, residence and exposure to endocrine disrupters [25]. Other 
important stimulatory and inhibitory pathways involving glutamate kisspeptin and 
the G protein-coupled receptor GPR54 exist [26, 27].
In essence, the increase of pulsatile GnRH secretion at puberty represents the 
cumulative effect of highly complex and intricate hypothalamic interactions that 
are markedly influenced by genetic factors and environmental signals [26]. An 
advancement in the timing of puberty has been reported worldwide over the past 
two decades [28]. The timing of puberty has important public health ramifications 
because it is related to a number of health outcomes [29]. Early puberty is poten-
tially associated with increased risk of testicular cancer, as well as adolescent alco-
hol abuse, smoking, drug use, early sexual debut, sexually transmitted infections, 
aggressive behaviour and poor academic performance [15, 30]. These observations 
urge further study of the onset of puberty as a possible sensitive and early marker 
of the interactions between environmental conditions and genetic susceptibility 
that can influence physiological and pathological processes [25].
4.  Potential influences of male reproductive development and pubertal 
development
4.1 Placental malfunction and antenatal factors
Impaired placental malfunction, which has the potential to disrupt foetal andro-
gen production, has been theorised to affect male reproductive development, and 
a definite link between impaired foetal growth and reproductive function has been 
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established. Consequences on gonadal differentiation, sexual organ development, 
onset of puberty, gamete quality, hormonal status and fertility have been observed 
[31, 32]. Several studies have described an association between foetal growth 
restriction and an increased risk of male reproductive health problems, includ-
ing hypospadias, cryptorchidism and testicular cancer [13, 33, 34]. In addition, 
twin or triplet pregnancy and preterm birth have also been shown to be associated 
with non-gestational-related impaired reproductive development [35]. One study 
demonstrated an inverse relationship between the incidence of cryptorchidism, and 
decreasing gestational age at birth, suggesting that premature delivery is important 
in view of the timing of testicular descent in foetal life [36]. A strong association 
between low birth weight and hypospadias has been demonstrated [37, 38].
Increasing birth weight in males has also been shown to be positively correlated 
with adult serum testosterone levels, however no effect on other reproductive hor-
mone levels has been shown [39]. Adult men born with lower birth weights have, in 
another study, been shown to display features of hypogonadism, with reduced tes-
ticular size, lower testosterone levels and higher LH values, than controls born with 
appropriate weights [39]. Male children with early onset of their pubertal growth 
spurt are more likely to have been born underweight [40]. In a cohort of Australian 
men followed from birth, men born with gestational appropriate birth weights were 
significantly less likely to be grouped in the lowest quartile for their total motile 
sperm counts. Those men who were born preterm demonstrated reduced serum 
testosterone levels in adulthood, suggesting an adverse influence of growth restraint 
and prematurity on later life testicular function [41]. A prospective Danish birth 
cohort study of more than 2500 live born males found statistically significant asso-
ciations between cryptorchidism and low birth weight, prematurity, being small for 
gestational age, substantial vaginal bleeding in pregnancy and breech presentation, 
which is in accordance with other studies [42].
4.2 Maternal medical complications of pregnancy
Abnormal maternal glucose metabolism in pregnancy may be associated with 
an increased risk of genital malformation for the male offspring [8, 43]. In women 
with gestational diabetes, the risk of delivering a male infant with cryptorchidism 
is increased by a factor of four compared to women without diabetes [43]. It is 
postulated that early growth delay of the foetus in the first trimester might play a 
role. This early failure of normal growth has been demonstrated even in children 
of diabetic mothers who are ultimately born large for gestational age [44]. The 
evidence is conflicting however, as no association between gestational diabetes 
and cryptorchidism was found in another registry-based study from Israel [45]. 
Maternal hypertension during pregnancy and preeclampsia are associated with 
hypospadias and other genital malformations, [37, 46] suggesting that placental 
insufficiency may play an important role in male foetal genital development.
4.3 Maternal undernutrition
The 5 month Dutch Winter Hunger Famine in 1944 gave rise to the suggestion 
that maternal nutrient restriction may play a role in determination of subsequent 
pathologic outcomes [47, 48]. This relationship has been demonstrated in several 
animal models [49–51]. Whilst the exact mechanism is unknown, it is theorised 
that maternal nutrient restriction might reprogram the development of the 
pituitary-adrenal axis, alter the male pituitary response to GnRH, lead to excess 
glucocorticoid exposure and thus exert an adverse effect on gonadal development 
and function [49]. This may vary according to the timing and magnitude of the 
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undernutrition. More studies in both humans and animals are required to further 
explore the effect of maternal undernutrition during the critical programming 
window in the foetus [50].
4.4 Maternal obesity
The prevalence of overweight and obese individuals in their reproductive 
years is increasing worldwide, and there is an established link between obesity 
and reduced fecundity in men and women [52]. Maternal obesity (and potentially 
paternal obesity around the time of conception) creates an adverse intrauterine 
environment for the developing foetus, and may have a detrimental reprogramming 
effect on offspring [52, 53]. Maternal obesity may alter the molecular composition 
of gametes, leading to epigenetic changes which impair the developmental trajec-
tory of the resultant embryo and of future generations [32]. In male rats, maternal 
obesity during pregnancy and lactation has been shown to increase testicular and 
sperm oxidative stress leading to premature ageing of reproductive capacity [54]. 
In humans, one epidemiologic study reported a detrimental influence of high 
maternal body mass index (BMI) on the semen quality and plasma concentration 
of inhibin B of male offspring, [31, 52] a finding confirmed by other studies [52]. 
The exact processes through which maternal nutrition or maternal environment 
affect reproductive function in the offspring remain unclear, and may be due to an 
alteration of oestrogen exposure with the hormonal control of the development of 
the male foetal urogenital organs. Epigenetic modifications are also a clear link [31].
4.5 Maternal smoking
Exposure to cigarette smoking in utero has consistently been shown to negatively 
impact on male reproductive development, and in fact maternal smoking exposure 
during pregnancy may have a stronger effect on subsequent spermatogenesis than 
a man’s own smoking in later life [8]. Reductions in median sperm output and total 
motile sperm are evident, and substantial [41]. One Danish cross-sectional study 
showed maternal smoking during pregnancy to be associated with earlier onset 
of puberty, lower final adult height, higher BMI, reduced testicular volume, lower 
total sperm count, reduced spermatogenesis-related hormones (inhibin-B and FSH) 
and higher free testosterone [55]. Likewise, a study of 1770 young men from the 
general population in Denmark, Norway, Finland, Lithuania and Estonia reported 
that maternal smoking during pregnancy was associated with a 20% reduction in 
sperm concentration [8, 56].
The effect of prenatal exposure to maternal cigarette smoke has been evaluated 
in another study where human gonadal cell numbers were examined by histopatho-
logical analysis following first trimester termination of pregnancy. A significant 
reduction in the number of germ cells and somatic cells in embryonic male (and 
female) gonads and the effect was dose dependent in heavy smokers [57].
4.6 Maternal gestational stress
Maternal exposure to stress in pregnancy has been shown to be a significant 
determinant of male reproductive development later in life. One prospective 
longitudinal cohort study examined this association in almost 650 males at 20 years 
of age. Maternal gestational stress, measured by exposure to stressful life events 
in early gestation was associated with lower total sperm counts, reduced number 
of progressive motile sperm and lower morning serum testosterone concentra-
tion. There was no effect of stressful events in late pregnancy (beyond 18 weeks’ 
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undernutrition. More studies in both humans and animals are required to further 
explore the effect of maternal undernutrition during the critical programming 
window in the foetus [50].
4.4 Maternal obesity
The prevalence of overweight and obese individuals in their reproductive 
years is increasing worldwide, and there is an established link between obesity 
and reduced fecundity in men and women [52]. Maternal obesity (and potentially 
paternal obesity around the time of conception) creates an adverse intrauterine 
environment for the developing foetus, and may have a detrimental reprogramming 
effect on offspring [52, 53]. Maternal obesity may alter the molecular composition 
of gametes, leading to epigenetic changes which impair the developmental trajec-
tory of the resultant embryo and of future generations [32]. In male rats, maternal 
obesity during pregnancy and lactation has been shown to increase testicular and 
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affect reproductive function in the offspring remain unclear, and may be due to an 
alteration of oestrogen exposure with the hormonal control of the development of 
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impact on male reproductive development, and in fact maternal smoking exposure 
during pregnancy may have a stronger effect on subsequent spermatogenesis than 
a man’s own smoking in later life [8]. Reductions in median sperm output and total 
motile sperm are evident, and substantial [41]. One Danish cross-sectional study 
showed maternal smoking during pregnancy to be associated with earlier onset 
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and higher free testosterone [55]. Likewise, a study of 1770 young men from the 
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sperm concentration [8, 56].
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in another study where human gonadal cell numbers were examined by histopatho-
logical analysis following first trimester termination of pregnancy. A significant 
reduction in the number of germ cells and somatic cells in embryonic male (and 
female) gonads and the effect was dose dependent in heavy smokers [57].
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Maternal exposure to stress in pregnancy has been shown to be a significant 
determinant of male reproductive development later in life. One prospective 
longitudinal cohort study examined this association in almost 650 males at 20 years 
of age. Maternal gestational stress, measured by exposure to stressful life events 
in early gestation was associated with lower total sperm counts, reduced number 
of progressive motile sperm and lower morning serum testosterone concentra-
tion. There was no effect of stressful events in late pregnancy (beyond 18 weeks’ 
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gestation), in keeping with the proposed early foetal masculinisation programming 
window [19]. This is in keeping with animal models reported previously [58]. It is 
unclear as to the mechanism of impact, however it is theorised that alterations in 
cortisol levels within the critical window of programming and development of the 
male reproductive organs may be responsible [59].
4.7 Maternal serum oestrogens
A relationship between increasing incidence of disorders of development of the 
male reproductive tract, declining sperm counts and exposure to exogenous oestro-
gen in utero has been postulated for many years [53]. Animal studies have previously 
shown that exposure to exogenous oestrogens [60, 61] and environmental xenoes-
trogens [61, 62] can damage testicular function, however concern that ubiquitous 
and increasing global oestrogen pollution may have effect on testicular function 
have so far been unconfirmed by the lack of alteration in domestic animal sperm 
production over the past century [41, 63]. Hence this view does have its detractors 
[64]. The first study to formally examine the association of maternal oestrogen 
exposure on male reproductive development was a longitudinal cohort study of 
almost 400 adult males. It found that sperm output in adulthood was inversely 
correlated with cord serum oestradiol and oestrone [41]. Furthermore it has been 
reported that oestrogenic chemical exposure can also cause cryptorchidism [9]. 
It has been suggested that endogenous oestrogens may inhibit the hypothalamic-
pituitary-gonadal axis via steroid negative feedback to reduce LH secretion, which 
may lead to a reduction in intra-testicular testosterone during the crucial window 
of development and programming in the male foetus [41]. A vegetarian diet with 
iron supplementation in pregnant women has been associated with a higher risk of 
hypospadias, perhaps due to greater exposure to phytoestrogens [37, 65].
4.8 Growth and adiposity in childhood and adolescence
Following the conclusion of the gestational period, growth and adiposity in 
childhood and adolescence are also important determinants of future male repro-
ductive health. It is possible that normal growth and BMI through childhood and 
adolescence are associated with better adult testicular function [41]. Optimal body 
mass index trajectory through childhood and adolescence is associated with larger 
testicular volume and higher serum inhibin B and testosterone in adulthood. Rapid 
weight gain between birth and 24 months of age is associated with earlier onset of 
puberty [40]. Rapid early life weight gain has been linked to elevated insulin-like 
growth factor I concentrations and insulin resistance, elevated adrenal androgen 
concentrations, exaggerated adrenarche, obesity and consequently to concentrations 
of hormones such as leptin. These could all promote the activity of the GnRH pulse 
generator, thereby influencing the timing of puberty [40, 66]. It is unclear whether it 
is the predisposition to metabolic disorder that leads to later adverse testicular func-
tion or vice versa. However, it is probable that adverse dietary patterns exacerbate the 
problem, as adopting a Western dietary pattern in adolescence is well known to be 
linked with poor metabolic health, [67] but it is also associated with reductions in 
sperm concentration and serum DHT in young men [68].
Consistent height above the 50th percentile for age through childhood is associ-
ated with larger adult mean testicular volume [41]. In addition, adolescents with 
features of metabolic disorder at 17 years, or insulin resistance at 20 years of age, 
have been shown to have impaired testicular function and altered hormone levels 
compared to those without metabolic disorder. One study showed that men with 
features of metabolic risk evident at age 17 years of age had lower concentrations 
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of serum testosterone and inhibin B compared with those considered at low risk of 
metabolic disorder. Furthermore men with ultrasound evidence of non-alcoholic 
fatty liver disease (NAFLD) had reduced total sperm output, testosterone and 
inhibin B compared to men without NAFLD, when assessed at 20 years of age [69]. 
In analysing the data higher concentrations of systemic inflammatory markers 
were associated with an apparent gonadotoxic influence; with reductions in sperm 
output, seminal volume, sperm concentration, serum inhibin B, with increases in 
serum LH and FSH. Whereas, a higher concentration of systemic C-reactive protein 
had an apparent central negative influence on serum FSH and LH secretion induc-
ing a central hypogonadal state with reductions in serum testosterone and seminal 
volume [59].
4.9 Oestrogenic endocrine disruptors: bisphenol A and phthalate exposure
A large number of ubiquitous anti-androgenic endocrine disruptors exist in 
increasing volumes within the environment. These chemicals interfere with the 
synthesis, secretion, transport, binding, action or elimination of hormones with 
potential adverse effects on male reproductive health. Endocrine-disrupting 
chemicals have been shown in animal models to decrease spermatogenic capacity 
and increase incidence of male infertility. In rats, exposure to anti-androgenic 
chemicals during the masculinisation programming window resulted in cryptor-
chidism, hypospadias, micropenis, short anogenital distance (a surrogate marker of 
androgen activity) and reduced sperm count [8, 20]. It is postulated that exposure 
to endocrine disruptors during the initiation of male reproductive tract develop-
ment may interfere with the normal hormonal signalling and formation of male 
reproductive organs [70]. Of note, oestrogenic and anti-androgenic compounds are 
well established to induce hypospadias in humans and mice [37, 38].
Bisphenol A (BPA) has been used extensively for decades in the manufacture of 
polycarbonates, epoxy resins and plastics [71]. Unconjugated BPA binds to oestro-
gen receptors producing weak oestrogenic activity. Anti-androgenic effects are also 
seen. Free BPA is metabolised by the liver of the mother and foetus, and even at low 
environmental levels can transfer across the human placenta [72]. BPA studies on 
experimental animals show that effects are generally more detrimental during in 
utero exposure, a critical developmental stage for the embryo [73]. In vivo studies 
on rats showed a relationship between BPA exposure and inhibition of testicular 
steroidogenesis, hypogonadotropic hypogonadism, decreased sperm count and 
proliferation of mammary tissue [74–77].
In human studies, there is conflicting evidence for the reproductive effects of 
BPA. Concurrent BPA exposure has been shown to be associated with decreased 
sperm concentration and total sperm count, [78] increase in sperm DNA damage, 
[79]altered serum reproductive hormone levels and reduced semen quality [80]. 
However, the influences with regard to antenatal maternal BPA exposure are less 
evident, as a recent longitudinal cohort study of 700 healthy men evaluated stored 
maternal antenatal serum from a birth cohort and related total maternal BPA 
concentrations (as a surrogate of foetal exposure) to mature male reproductive 
function [71]. Whilst a small positive correlation between maternal serum BPA 
level and sperm concentration and motility was present, no other associations of 
maternal serum BPA with testicular function were observed [81]. In another review 
of concurrent adult exposure, whilst evidence of a link was noted in five of six 
included studies, no consistent relationships or trends could be observed across all 
studies [82].
Phthalates are another group of environmentally pervasive industrial endocrine-
disrupting chemicals, some of which are potent anti-androgens, [83] which are 
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gestation), in keeping with the proposed early foetal masculinisation programming 
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chemicals have been shown in animal models to decrease spermatogenic capacity 
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maternal serum BPA with testicular function were observed [81]. In another review 
of concurrent adult exposure, whilst evidence of a link was noted in five of six 
included studies, no consistent relationships or trends could be observed across all 
studies [82].
Phthalates are another group of environmentally pervasive industrial endocrine-
disrupting chemicals, some of which are potent anti-androgens, [83] which are 
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suspected to interfere with developmental androgen action [84]. In rats, prenatal 
exposure to several phthalates elicits a syndrome of genital dysmorphology in 
males, including incomplete testicular descent, smaller testis weight and penile 
size, alterations to the vas deferens and epididymis, and most notably, shortened 
anogenital distance [85]. Animal studies demonstrating adverse effects of phthalate 
exposure on semen quality, preceded those showing the same effect in humans [86]. 
Critical to the induction of these effects is a marked reduction in foetal testicular 
testosterone production at the critical window for the development of the repro-
ductive tract normally under androgen control [85]. In infants exposed in-utero to 
higher concentrations of maternal phthalates there are reports of a reduction in the 
anogenital distance, a reproducible marker of prenatal androgenisation [83, 87]. 
In human adult males, the data suggests equally concerning effects, with antenatal 
maternal serum phthalate levels showing negative associations with testicular 
volume, total serum testosterone and serum FSH concentration [84]. However, it 
is important to state that it is more customary in the scientific literature to report 
urine concentrations of phthalates rather than serum. In addition to in-utero expo-
sures, phthalate levels in breast milk have been linked to an increased LH to free 
testosterone ratio in male offspring at 3 months of age, suggesting testicular impair-
ment may occur postnatally during lactation and breast feeding [9]. However, no 
definite association has been made between breastmilk phthalates and cryptorchi-
dism [88, 89]. Later in adulthood, adult exposure to environmental phthalates has 
been linked with reductions in semen parameters in men seeking paternity [90].
Endocrine-disrupting chemicals clearly present potential for significant impact 
on male reproductive health related to early exposures, however further research is 
necessary to clarify their risk, as there are a myriad of chemicals within the environ-
ment with endocrine-disrupting properties. Their effects may be synergistic, [91] 
non-dose dependent and the influence of each chemical may vary according to an 
individual’s genetic susceptibility [92].
4.10 Multigenerational and transgenerational environmental effects
There is increasing evidence to suggest that early life perturbations due to 
various exposures are able to exert a direct effect on the human epigenome, both 
in utero and in adulthood. Both multigenerational and transgenerational effects of 
certain environmental or lifestyle exposures are possible due to epigenetic dys-
regulation and inheritance in germ cells [62, 93]. These epigenetic effects include 
DNA methylation, histone post-translational modifications and non-coding RNAs 
[93]. As shown in Figure 2, these two phenomena differ depending on whether 
the affected generation had direct exposure to the original endocrine disruptor or 
not. If a pregnant mother (designated as the filial or F0) is exposed to an adverse 
stimulus, her child (F1) may be affected as a consequence of direct exposure to the 
same stimulus in utero. Because the germ cells of the F1 offspring are developing 
throughout gestation, their children (F2) are also directly exposed. Effects seen in 
the F2 generation are therefore multigenerational. In contrast, effects observed in 
the F3 generation that had no direct exposure would be transgenerational [93].
Numerous exposures described above, including endocrine disrupters and other 
lifestyle-related factors such as smoking, diet and stress may affect the male repro-
ductive health of future generations. DNA methylation is perhaps the best known 
mechanism of epigenetic gene modification, and a direct effect of some environ-
mental factors on DNA methylation has been demonstrated in experimental studies 
in animal models [9]. In a rat model, gestational exposure to endocrine disruptors 
led to heritable effects in second and third generation offspring, [94] including 
decreased spermatogenic capacity and increased incidence of male infertility [95]. 
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Although no human data exist to attest to this, this exciting and evolving area of 
research requires further work to validate findings.
5. Conclusion
There is a growing body of clear and compelling evidence for the early life 
origins of male reproductive health (Figure 3). Considering the central role the 
Figure 2. 
Multigenerational and transgenerational effects. Reprinted with permission from Elsevier. © Xin et al. [93].
Figure 3. 
Early determinants of male reproductive health. Reprinted with permission from Oxford university press.  
© Parent et al. [25].
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non-dose dependent and the influence of each chemical may vary according to an 
individual’s genetic susceptibility [92].
4.10 Multigenerational and transgenerational environmental effects
There is increasing evidence to suggest that early life perturbations due to 
various exposures are able to exert a direct effect on the human epigenome, both 
in utero and in adulthood. Both multigenerational and transgenerational effects of 
certain environmental or lifestyle exposures are possible due to epigenetic dys-
regulation and inheritance in germ cells [62, 93]. These epigenetic effects include 
DNA methylation, histone post-translational modifications and non-coding RNAs 
[93]. As shown in Figure 2, these two phenomena differ depending on whether 
the affected generation had direct exposure to the original endocrine disruptor or 
not. If a pregnant mother (designated as the filial or F0) is exposed to an adverse 
stimulus, her child (F1) may be affected as a consequence of direct exposure to the 
same stimulus in utero. Because the germ cells of the F1 offspring are developing 
throughout gestation, their children (F2) are also directly exposed. Effects seen in 
the F2 generation are therefore multigenerational. In contrast, effects observed in 
the F3 generation that had no direct exposure would be transgenerational [93].
Numerous exposures described above, including endocrine disrupters and other 
lifestyle-related factors such as smoking, diet and stress may affect the male repro-
ductive health of future generations. DNA methylation is perhaps the best known 
mechanism of epigenetic gene modification, and a direct effect of some environ-
mental factors on DNA methylation has been demonstrated in experimental studies 
in animal models [9]. In a rat model, gestational exposure to endocrine disruptors 
led to heritable effects in second and third generation offspring, [94] including 
decreased spermatogenic capacity and increased incidence of male infertility [95]. 
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Although no human data exist to attest to this, this exciting and evolving area of 
research requires further work to validate findings.
5. Conclusion
There is a growing body of clear and compelling evidence for the early life 
origins of male reproductive health (Figure 3). Considering the central role the 
Figure 2. 
Multigenerational and transgenerational effects. Reprinted with permission from Elsevier. © Xin et al. [93].
Figure 3. 
Early determinants of male reproductive health. Reprinted with permission from Oxford university press.  
© Parent et al. [25].
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reproductive hormones have in male sex differentiation, it is more than reasonable 
to suspect the involvement of factors that affect the production and the action of 
androgens during crucial windows of foetal development. However, although this 
developmental programming begins in utero, there is further convincing evidence 
for the effect of additional postnatal influences in early and later life. The specific 
mechanisms through which these associations exert their effect are as yet poorly 
understood. Disorders of male reproduction are clearly on the rise worldwide, and 
this escalation is predicted to only increase exponentially given the current obesity 
epidemic and the increasing impact of humans on the environment. Therefore, given 
the significant disease burden expected to result from declining male reproductive 
health, attention to further research and public health policy in this area is of the 
utmost importance. In addition, given the evidence for a significant number of 
maternal exposures and behaviours, public health measures and education focusing 
on maternal health are of obvious importance.
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Abstract
Endocrine-disrupting chemicals (EDCs) are exogenous compounds with natural 
or anthropogenic origin omnipresent in the environment. These compounds disrupt 
endocrine function through interaction with hormone receptor or alteration of 
hormone synthesis. Humans are environmentally exposed to EDCs through the 
air, water, food and occupation. During the last decades, there has been a concern 
that exposure to EDCs may contribute to an impairment of human reproductive 
function. EDCs affect male fertility at multiple levels, from sperm production and 
quality to the morphology and histology of the male reproductive system. It has 
been proposed that exposure to EDCs may contribute to an impairment of sperm 
motility, concentration, volume and morphology and an increase in the sperm DNA 
damage. Moreover, EDCs exert reproductive toxicity inducing structural damage on 
the testis vasculature and blood-testis barrier and cytotoxicity on Sertoli and Leydig 
cells. This chapter will explore the effects of EDCs in male reproductive system and 
in the decline of male fertility.
Keywords: endocrine-disrupting chemicals, male infertility, lifestyle, 
environmental pollutants, body burden
1. Introduction
Endocrine-disrupting chemicals (EDCs) are exogenous substances or mixtures 
of chemicals that can disrupt male and female endocrine function through the 
interaction with hormone receptors. They lead to alterations in hormone action, 
synthesis, transport and metabolic processes [1]. Several compounds such as 
dioxins, plastic contaminants (e.g., bisphenols (BP)), triclosan (TCS), pesticides 
and herbicides (e.g., diphenyl-dichloro-trichloroethane (DDT)), metals and others 
are known EDCs [2].
Humans may be exposed to EDCs due to contamination of water and food 
chain, inhalation of contaminated house dust and through occupational exposure 
[2]. Although, in some westernized countries the use of certain EDCs has been 
banned, there are cases that human exposure to these chemicals is inevitable. Thus, 
during the past decades, human exposure to EDCs has received increased atten-
tion, and particular focus has been given to the harmful effects of EDCs to the male 
reproductive system. Evidences suggest that EDCs may have significant adverse 
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effects on human health and are contributing to the trends in occurrence of male 
reproductive health problems and the decline in male fertility [3]. According 
to the literature, male reproductive decline may result from a combination of 
morphological, functional and molecular alterations in the reproductive organs, 
often due to exposure to EDCs. Most studies are focused either on the evaluation 
of basic seminal parameters or reproductive outcomes, but there are evidences 
that EDCs may impact at the level of the reproductive and endocrine systems. 
For example, there are evidences that TCS has a tendency to bioaccumulate in the 
epididymis [4]. Bisphenol A (BPA) has been reported to have both estrogenic and 
antiandrogenic effects [5–7]. It has been also negatively associated with sperm 
quality [8–10]. Toxicological studies showed that BPA caused adverse reproductive 
outcomes, namely, decreased epididymal weight, daily sperm production and tes-
tosterone (T) levels in rodents [11–13]. Recently, our group performed a systematic 
review regarding the effect of exposure to mercury (Hg) on human fertility [14]. 
Results revealed that higher levels of Hg in blood and hair were associated with 
male subfertility or infertility status.
This chapter summarizes the effects of male exposure to EDCs on markers of 
male fertility. The agents discussed here, which include TCS, BPA, metals (such as 
cadmium (Cd) and Hg), polychlorinated biphenyls (PCBs) and others were chosen 
based on their human exposure prevalence and adverse effects on human reproduc-
tive health.
2.  EDCs induce reproductive system toxicity: ultrastructural, cellular 
and molecular changes
The male reproductive system is composed by two testes, a system of genital 
ducts, the accessory glands (seminal vesicles, prostate, Cowper and Littre glands) 
and the penis [15]. Testes, the male sexual glands, are ovoid organs localized 
outside the abdominal cavity within the scrotum. This localization maintains the 
temperature at 2–4°C lower than the body temperature, optimal for the testes 
function. Testes are surrounded by two different layers of protective tissue, the 
tunica albuginea and the tunica vaginalis. The testicular parenchyma is composed of 
one to three seminiferous tubules, the functional unit of the testis, and of inter-
stitial tissue surrounding the tubules that contain the Leydig cells (LC), which are 
responsible for the production of T in the presence of luteinizing hormone (LH) 
(Figure 1) [16]. The seminiferous tubules are composed of male germ cells (sper-
matogonia, spermatocytes and spermatids) and Sertoli cells (SC). SC are involved 
in the mechanical support and nutrition of germ cells, regulation of male germ cell 
proliferation and differentiation, phagocytosis, steroid hormone synthesis and 
metabolism and maintenance of the integrity of seminiferous epithelium. The male 
reproductive system is responsible for the production of spermatozoa, for the syn-
thesis and secretion of male sex hormones and for the delivery of male gametes into 
the female reproductive tract. The process of spermatogenesis is highly regulated by 
the hypothalamic-pituitary-gonadal (HPG) axis.
Evidences suggest that the normal morphology and function of the male 
reproductive system are affected by several factors including environmental 
pollutants (Figure 1) (e.g., EDCs). In addition to altered testicular morphology 
and dysfunction, exposure to EDCs also increased the incidence of testicular 
pathologies. For instance, exposure to phthalates was associated with the 
development of testicular cancer, cryptorchidism and hypospadias [17]. This 
section discusses the current knowledge on reproductive system EDC toxicity in 
humans and other animals.
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2.1 Changes in volume/weight of reproductive organs
The volume/weight of the male reproductive organs is an important indica-
tor of the integrity of this system. Several animal studies showed a significant 
decrease in the weight of the testes and sex accessory tissues in animals exposed 
to EDCs [4, 18–23]. For instance, male rats treated with 10 and 20 mg/(kg day) 
of TCS revealed a significant decrease in the weight of the testes, epididymis, 
ventral prostate, vas deferens and seminal vesicles [18]. However, an adminis-
tration of 5 mg/(kg day) of TCS did not cause significant change in the testes 
and sex accessory tissues [18]. Recently, Lan et al. [4] showed that the absolute 
Figure 1. 
Schematic representation of the effects of EDCs on HPG axis and testicular morphology.
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and dysfunction, exposure to EDCs also increased the incidence of testicular 
pathologies. For instance, exposure to phthalates was associated with the 
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weights of testes and epididymis of rats treated with 10, 50 or 200 mg/kg of TCS 
were not significantly affected.
Rodents were exposed to BPA by the oral route or subcutaneous injections 
[24, 25]. A dose of 2 ng/g body weight induced a decrease in epididymal weight 
and an increase in prostate weight. Bisphenol S (BPS), considered a safe substi-
tute for BPA, has chemical similarities with BPA and may act as an EDC. Thus, 
a recent work compared the effects of BPA and BPS on the morphology and 
physiology of the ventral prostate of adult gerbils [26]. Animals treated with BPA 
and BPS showed no alterations in prostate weight. Regarding histopathology, 
BPS-treated animals showed intense prostatic hyperplasia; increased relative 
frequency of epithelium, muscular stroma and non-muscular stroma; and 
decreased luminal compartment, and BPA-treated animals showed increased 
occurrence of hyperplastic growth. But, in general the authors found that BPS 
promoted more structural and histopathological changes than BPA.
Exposure to metals also induced effects on testes size. A dose of 5 mg/kg body 
weight of cadmium chloride (CdCl2) administered to rats by oral gavage caused a 
significant decrease in testes and epididymis weight [19]. Moreover, Hg and zinc 
(Zn) significantly decreased the absolute and relative testicular weights in murine, 
with Hg producing the highest reduction in weight [27]. Similar results were 
obtained by Narayana et al. [22] and Geng et al. [23] that showed a decrease in the 
weights of reproductive organs of rats exposed to pesticides.
Rats exposed to phthalates demonstrated reduced testicular weights and histo-
logic changes in the seminiferous tubules [20, 21]. Moreover, rats exposed to phthal-
ates during the prenatal period developed reproductive anomalies, namely, smaller 
testes and penis size [28].
Human studies related to the effects of exposure to EDCs on testicular volume/
weight are limited but in accordance with animal studies. For instance, in a study 
in Croatian men, no occupational exposures were exposed to metals, and blood Cd 
was negatively correlated with testes size, suggesting that this metal exerts toxicity 
on human testes [29].
2.2 Alterations in testicular morphology
Experimental studies showed that exposure to EDCs had adverse effects on testes, 
resulting in testicular damage at structural and consequently functional level. Male 
rats treated with 20 mg/(kg day) of TCS exhibited several histopathological malfor-
mations in the testes and sex accessory tissues [18]. Lumen of vas deferens from the 
treated rats exhibited the presence of stereocilia detached from the epithelium and 
the presence of eosinophilic bodies. Moreover, the stereocilia were found to be thin, 
few or absent in the epithelium of TCS-treated rats. Rats treated with a high dose of 
TCS (200 mg/kg) showed changes in the cauda epididymis and in the testis com-
pared with the control group [4]. In the cauda epididymis, the alterations included 
vacuolated and exfoliated epithelial cells. Moreover, these authors identified the 
absence of sperm tails in the seminiferous tubules in the TCS-treated groups.
Mice exposed to BPA showed the formation of morphologically multinucleated 
giant cells in testicular seminiferous tubules [30], disruption of the blood-testis 
barrier (BTB) and impaired spermatogenesis [31, 32]. Similar results were obtained 
by other study using pesticides that induced severe degenerative changes in seminif-
erous tubules [23]. Metals, such as Cd and Hg, also induced structural alterations in 
the testis structure, including damage in the vascular endothelium and in the BTB 
integrity and necrosis and disintegration of spermatocytes [27, 33]. In general, these 
animal studies showed that EDCs induced changes in testicular morphology, which 
may be a reason for the decline of male fertility. For instance, damage in epididymis 
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compromise the transport of testicular sperm out of the testis, the acquisition of 
progressive spermatozoa motility and the sperm storage. Moreover, damage at SC 
and LC levels compromise the structure of the BTB and seminiferous tubules.
2.3 Testicular dysfunction due to EDC exposure
The two main functions of the testes are spermatogenesis (exocrine function) 
and steroidogenesis (endocrine function). In normal conditions the gonadotrophin-
releasing hormone (GnRH) is secreted by the hypothalamus, stimulating the 
synthesis of LH and the follicle-stimulating hormone (FSH) [34]. LH is recognized 
by LH receptors in LC stimulating T biosynthesis (steroidogenesis). FSH is recog-
nized by FSH receptors in SC having an important role in spermatozoa production 
(spermatogenesis). Several studies showed that these functions are affected by 
exposure to EDCs (Figure 1) [10, 18, 35–39]. Prenatal exposure to EDCs was associ-
ated with testicular anomalies later in life, which includes reduced semen volume 
and quality, increased incidence of cryptorchidism and hypospadias and increased 
incidence of testicular cancer [40]. EDCs reduced SC number and impaired LC 
development, inducing testicular anomalies at morphological and functional level 
[39]. This section presents the studies that assessed the relationship between animal 
and human exposure to EDCs and testicular dysfunction, including alterations in 
reproductive hormone levels.
Evidences from animal studies suggest that TCS reduces the production of T in 
LC and disturbs the function of major steroidogenic enzymes [41, 42]. Male rats 
treated with TCS or pesticides showed a significant decrease in the levels of serum 
LH, FSH, cholesterol, pregnenolone and T compared to control [18, 23]. Regarding 
human studies, a case-control study showed that urinary levels of phthalates 
and TCS were negatively associated with inhibin B and positively with LH [39]. 
Additionally, an inverse association was found between urinary levels of phthalates 
or BPA and testosterone and estradiol (E2) [38, 39]. Similar results were obtained by 
Meeker et al. [35] that showed an inverse association between BPA concentrations 
in urine and serum levels of inhibin B and E2:T ratio in men recruited through an 
infertility clinic. Moreover, a positive association between BPA concentrations in 
urine and FSH and FSH:inhibin B ratio was found. Hanoaka et al. [36] did not found 
an association between exposure to BPA and free T and LH concentrations in men. 
However, a significant decrease in FSH concentrations was found in the BPA exposed 
men. Urinary levels of BPA were not associated with sperm quality in fertile men 
but were associated with markers of androgenic action [37]. A significant inverse 
association was found between urinary levels of BPA and free androgen index (FAI) 
levels and the FAI:LH ratio. Further, a significant positive association between BPA 
and sex hormone-binding globulin (SHBG) was found in fertile men. Recently, 
Lassen et al. [10] examined associations between urinary BPA concentration and 
reproductive hormones in young men from the general population. The authors 
found positive associations between urinary BPA concentrations and T, E2, LH and 
free T levels. BPA and BPS induced significant changes in T and estradiol [26].
Meeker et al. [38] demonstrated that exposure to phthalates may be associated 
with altered male endocrine function. Urinary concentrations of some phthalates 
were inversely associated with T, E2 and FAI.
Metals, namely, Cd, also affect the development of the male reproductive system 
and testis function. Mice prenatal exposed to Cd showed defects on the development 
of gonads, depletion of germ cells and impairment of spermatozoa maturation [43]. 
Cd also induces testicular dysfunction, which results of the functional impairment 
of SC and LC. Regarding human studies, the effect of Cd exposure to male endocrine 
function was assessed by several authors (as reviewed by de Angelis et al. [33]).  
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The results obtained are controversial; some authors found that Cd concentrations 
were positively correlated with FSH, T, E2, LH and inhibin B and negatively corre-
lated with prolactin [29, 44]. However, other authors did not find significant cor-
relations between Cd concentrations and serum hormone levels [45, 46]. In general, 
these results suggest that exposure to EDCs may be associated with alterations in 
circulating hormone levels in men. Additionally, Yang et al. [47] showed that levels 
of GnRH and LH were significantly higher in occupationally manganese (Mn)-
exposed group compared with the non-exposed men. The levels of T were lower in 
the exposed group. However, this study demonstrated that there was no association 
between exposure to Mn and E2 and FSH and prolactin levels.
2.4 Molecular effects of EDCs
The effects of EDCs on the morphology and function of the male reproductive 
system may be attributed to the interactions of these chemicals with several mol-
ecules. Male rats treated with 20 mg/(kg day) of TCS showed a significant reduc-
tion in the testicular levels of mRNA for cholesterol side-chain cleavage enzyme 
(Cyp11a1), 25-hydroxyvitamin D-1 alpha hydroxylase (Cyp27b1), 3β-hydroxysteroid 
dehydrogenase (Hsd3b1), 17β-hydroxysteroid dehydrogenase (Hsd17b6), steroido-
genic acute regulatory protein (Star) and androgen receptor (Ar) as compared to 
control [18]. Moreover, the authors found that there was a decreased localization 
of StAR protein in testicular LC as determined by immunolocalization indicating 
a reduced expression of this protein in animals treated with TCS as compared to 
control. These results could be correlated to the reduction in LC number.
In vitro studies investigated the effect of BPA on steroidogenesis [48, 49]. The 
authors found that BPA inhibited the production of testosterone in a concentration-
dependent manner over the course of the 24 h incubation [48]. Moreover, the 
concentrations of E2 were greater in the presence of BPA. The decrease in the 
concentrations of T is related with the inhibition of activities of some enzymes, 
such as 3β-hydroxysteroid dehydrogenase (HSD3B1) and 17α-hydroxylase 
(CYP17A). However, the activity of aromatase was not altered by BPA treatment. 
More recently, additional results in MA-10 Leydig cell line showed that BPA affects 
steroidogenic genes, for instance, induces the upregulation of CYP11A1 and CYP19 
genes [49]. Moreover, the authors found that BPA treatment induced the phos-
phorylation levels of c-Jun and the levels of protein expression of SF-1, suggesting 
that the JNK/c-Jun pathway may be involved in BPA toxicity. Similar results were 
observed in an animal study [49].
The testes from male Sprague-Dawley rats treated with CdCl2 showed a sig-
nificant increase in the activities of aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) [19]. Geng et al. [23] found that pesticides altered the 
testicular protein expression of B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated 
X protein (Bax). Moreover, these authors showed that the activities of testicular 
enzymes including acyl carrier protein (ACP), lactate dehydrogenase (LDH) and 
gamma-glutamyltransferase (γ-GT) were significantly altered by exposure to 
pesticides.
3. Spermatozoa
Sperm motility, together with concentration and morphology, is considered as 
one of the important predictors of male fertility in vivo. Declining human sperm 
quality has been demonstrated in several recent studies. Age, lifestyle, environ-
mental pollutants and nutritional factors can affect semen quality [14, 50–52]. 
27
The Role of Endocrine-Disrupting Chemicals in Male Fertility Decline
DOI: http://dx.doi.org/10.5772/intechopen.88330
The present section focuses on studies of environmental exposure to EDCs and 
male reproductive function, as measured by declines in semen quality parameters 
or increased sperm DNA damage/fragmentation.
3.1 Effects of EDCs on sperm production, morphology, motility and velocity
Several studies have been published regarding the association of exposure to 
phenols and human semen quality [53–55]. A case–control study was conducted to 
evaluate the association between exposure to phenols and idiopathic male infertility 
[55]. For that, the authors recruited idiopathic infertile men and fertile controls and 
measured urinary levels of BPA, benzophenone-3, pentachlorophenol, TCS, 4-tert-
octylphenol (4-t-OP), 4-n-octylphenol (4-n-OP) and 4-n-nonylphenol (4-n-NP) 
and semen parameters. The authors found that exposure to 4-t-OP, 4-n-OP and 4-n-
NP was associated with idiopathic male infertility, and exposure to 4-t-OP and 4-n-
NP was also associated with abnormal semen quality parameters. However, in this 
study the authors did not find more relationships between exposure to other phe-
nols and idiopathic male infertility. In another study, urinary BPA concentrations 
were associated with declines in sperm concentration, motility and morphology 
[53]. An increasing urine BPA level was associated with lower semen concentra-
tion, lower total sperm count, lower sperm vitality and lower sperm motility [54]. 
Moreover, the authors demonstrated a dose–response relationship between increas-
ing urine BPA level and reduction in semen quality. Lassen et al. [10] also found an 
inverse association between BPA concentrations and progressive motility, but in this 
study, BPA excretion was not associated with semen volume, sperm concentration, 
total sperm count or percentage morphologically normal forms. However, some 
authors did not find any association between urinary BPA concentrations and some 
semen parameters, such as semen volume or sperm morphology [8, 54].
TCS has been shown to decrease sperm density probably due to reduced testicu-
lar spermatogenesis [18]. A reduced sperm density was observed in the lumina of 
epididymal tubule from the treated rats. Rats treated with high doses of TCS (50 
and 200 mg/kg) showed a significant decrease in the daily sperm production and an 
increase in the percentage of sperm abnormalities, which included elevated ratios 
of abnormal sperm head and tails [4]. Zhu et al. [56] performed a cross-sectional 
study to evaluate the association between exposure to TCS measured by urinary 
TCS concentration and semen quality in humans. The authors found an association 
between urinary TCS concentrations and poor semen quality parameters; namely, 
the authors found an inverse association between urinary TCS concentrations and 
percentage of sperm motility, sperm count, sperm concentration and percentage 
of normal morphology, suggesting that environmental exposure to TCS may have 
impact on semen quality.
Regarding exposure to PCBs, several studies showed an inverse association 
between exposure to PCB 153 and sperm motility, while relationships with sperm 
concentration or total sperm count were inconsistent [57–59]. Additionally, Hauser 
et al. [60] found an inverse dose–response relationship between PCB 138 and sperm 
concentration, motility and morphology.
The correlation between exposure to metals and adverse consequences for human 
and animal fertility is not completely established. Several studies determined the 
effects of exposure to metals on male gametes. In vitro studies, using bovine sperm, 
determined the effect of direct exposure to Hg on male gametes [61, 62]. Arabi et al. 
[61] showed that exposure to Hg (50, 100, 200, and 300 μmol/l) induced LPO (lipid 
peroxidation), decreased the glutathione (GSH) content and decreased the percent-
age of viable spermatozoa. Additionally, a more recent study showed that bovine 
sperm exposed to Hg at 8 nM and 8 μM have less motility and have impaired sperm 
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The results obtained are controversial; some authors found that Cd concentrations 
were positively correlated with FSH, T, E2, LH and inhibin B and negatively corre-
lated with prolactin [29, 44]. However, other authors did not find significant cor-
relations between Cd concentrations and serum hormone levels [45, 46]. In general, 
these results suggest that exposure to EDCs may be associated with alterations in 
circulating hormone levels in men. Additionally, Yang et al. [47] showed that levels 
of GnRH and LH were significantly higher in occupationally manganese (Mn)-
exposed group compared with the non-exposed men. The levels of T were lower in 
the exposed group. However, this study demonstrated that there was no association 
between exposure to Mn and E2 and FSH and prolactin levels.
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membrane integrity, increasing levels of reactive oxygen species (ROS) and LPO and 
decreasing the antioxidant activity and diminished fertility ability [62]. Regarding 
human fertility, in a cross-sectional study, participants with high blood Hg level had 
lower sperm with a normal morphology [63]. Cd is another male reproductive toxi-
cant that exerts effects even at low levels of exposure by several mechanisms [64]. In 
vitro studies on human spermatozoa obtained through ejaculation allow to evaluate 
the effect of Cd treatment in semen parameters [65, 66]. Cd decreased sperm motil-
ity and sperm viability and induced detrimental effects on spermatozoa metabolism 
by inhibition of the activity of glycogen phosphorylase, glucose-6-phosphatase,  
fructose-1,6-diphosphatase, glucose-6-phosphate isomerase, amylase, Mg2+− 
dependent ATPase and lactic and succinic acid dehydrogenases. As reviewed by 
de Angelis et al. [33], significant negative correlations were found between Cd levels 
and semen parameters, including total sperm count, concentration, motility and 
morphology. Results from a meta-analysis indicate that men with low fertility had 
higher semen Pb and Cd levels and lower semen Zn levels [67]. Sperm motility was 
significantly decreased in men occupationally exposed to Mn [47].
Occupational exposure to pesticides increased the risk of morphological 
abnormalities in sperm in addition with a decline in sperm count and a decreased 
percentage of viable spermatozoa. For instance, the exposure to pesticides reduced 
the seminal volume, sperm motility and concentration and increased the seminal 
pH and the abnormal sperm head morphology [68–70]. A study showed that young 
Swedish men exposed to phthalates presented a decrease in progressive sperm 
motility [71]. Additionally, levels of urinary phthalates and insecticides were also 
associated with lower sperm concentration, lower motility and increased percent-
age of sperm with abnormal morphology [72–75]. These results confirmed the 
results obtained by in vitro and in vivo studies [76, 77].
3.2 Sperm DNA damage
Sperm DNA integrity is essential for the correct transmission of genetic informa-
tion [78]. Damage at sperm DNA level may result in male infertility. Sperm DNA 
damage is caused by oxidative stress that causes impairment in the sperm membrane 
[79]. It is well-known that some EDCs may induce oxidative stress and decrease the 
cellular levels of GSH and protein-sulfhydryl groups. Preclinical studies with male 
rats showed that exposure to BPA was associated with a significant increase in sperm 
DNA damage [80]. A statistically significant positive association between urinary 
concentrations of parabens and BPA and sperm DNA damage was found in male 
partners of subfertile couples [53, 81]. Contrary results were obtained by Goldstone 
et al. [8] that found a negative relationship between BPA and DNA fragmentations.
Additionally, other EDCs such as heavy metals (e.g., Hg), PCBs and insecticides 
induce sperm DNA damage [59, 61, 73, 75, 82–84]. Urinary levels of Hg and nickel 
in infertile men were associated with increasing trends for tail length, and the levels 
of Mn were associated with increasing trend for tail distributed moment [82]. The 
adverse effects of phthalates on sperm DNA were assessed by several studies among 
infertile men [75, 84]. Urinary concentrations of phthalate metabolites were associ-
ated with sperm DNA damage. These studies suggest that environmental and occu-
pational exposure to EDCs may be associated with increased sperm DNA damage.
4. Conclusions
The results yielded in this chapter showed that both environmental and occu-
pational exposures to EDCs affect male reproductive function at multiple levels. 
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In human populations, the majority of studies point toward an association between 
exposure to EDCs and male reproduction system disorders, such as infertility, 
testicular cancer, poor sperm quality and/or function. Exposure to EDCs was 
associated with declined semen quality, increased sperm DNA damage, alterations 
in testis morphology and endocrine function. However, there are studies exploring 
the effect of EDCs on male reproductive health including semen quality, reproduc-
tive hormones and male fertility that produced inconsistent results probably due 
to small-sized study populations and lack of control for potential confounding 
variables. These contrary results highlight the need to discuss and investigate the 
effect of environmental pollutants in the male reproductive health. Moreover, the 
identification of the sequence of events and mechanisms might be important to 
better understand the effect of exposure to EDCs on male reproductive system and 
their contribution to male fertility decline.
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Endocrine Disruptors: Very Low 
Doses with Genuinely High 
Impacts on Male Reproduction
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Abstract
Endocrine disruptors (EDs) are chemical substances that affect physiological 
processes in the body via hormonal regulation. They are often detected in food, 
plastic water bottles, cosmetics, and many other daily need items. Thereafter, EDs 
are detected in many bodily fluids, pointing out the real exposure to even very low 
doses. Permanent and long-term utilization of EDs has harmful effects on male 
reproductive health mainly due to interference with sex hormone synthesis and 
mechanism of action. However, with decreasing dosage of EDs, the possibilities 
of unpredictable modes of action arise. In addition to various molecular actions of 
individual EDs, the interference of individual ones represents another dimension of 
the ED issue. This review provides an overview of the EDs and their possible impact 
on reproductive health in males, with focus on sperm quality with the mighty 
potential of epigenetic transmission to further generations. The “posttranslational” 
effect of EDs in really low doses in real exposure routes is stigmatized in this review, 
being strongly considered as creeping molecular action of individual EDs as well as 
amplifications of their copresence in the environment.
Keywords: endocrine disruptor, bisphenol, regretable substitution, 
posttranslational modification
1. Introduction
Maturation of sperm cells (spermatogenesis) is a continuous process starting 
in puberty. The process is stimulated by follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH). Until the onset of puberty, spermatogonia are quiescent 
and their quantity does not change significantly. After sexual maturity is reached, 
an expressive activation of mitochondrial activity and the process of spermatogen-
esis begin, leading to the formation of spermatids. They are then transformed into 
spermatozoa by the spermiohistogenesis process, when a round spermatid changes 
into a sperm cell with a tail, middle section, and head. However, whole spermato-
genesis, including gonadal ridge colonization and differentiation of primordial 
germ cells (PGCs), followed by further development, begins during early embryo-
genesis. In light of this fact, there are several exposure windows when environmen-
tal noxi can hit spermatogenesis along the entire process.
Considering the transmission of extraneous agents, the hemotesticular barrier 
(HTB) represents the morphological division of the seminiferous tubulus into two 
Male Reproductive Health
36
young men from the general Swedish 
population. Environment International. 
2015;85:54-60
[72] Duty SM, Silva MJ, Barr DB,  
Brock JW, Ryan L, Chen Z, et al. 
Phthalate exposure and human 
parameters. Epidemiology. 
2003;14(3):269-277
[73] Meeker JD, Barr DB, Hauser R.  
Human semen quality and sperm DNA 
damage in relation to urinary metabolites 
of pyrethroid insecticides. Human 
Reproduction. 2008;23(8):1932-1940. 
DOI: 10.1093/humrep/den242
[74] Duty SM, Calafat AM, Silva MJ, 
Brock JW, Ryan L, Chen Z, et al. The 
relationship between environmental 
exposure to phthalates and computer-
aided sperm analysis motion 
parameters. Journal of Andrology. 
2004;25(2):293-302
[75] Duty SM, Silva MJ, Barr DB,  
Brock JW, Ryan L, Chen Z, et al. 
Phthalate exposure and human 
semen parameters. Epidemiology. 
2003;14(3):269-277
[76] Pant N, Pant A, Shukla M, Mathur N,  
Gupta Y, Saxena D. Environmental and 
experimental exposure of phthalate 
esters: The toxicological consequence on 
human sperm. Human & Experimental 
Toxicology. 2011;30(6):507-514. DOI: 
10.1177/0960327110374205
[77] Barakat R, Lin P-CP, Rattan S, 
Brehm E, Canisso IF, Abosalum ME, 
et al. Prenatal exposure to DEHP 
induces premature reproductive 
senescence in male mice. Toxicological 
Sciences. 2017;156(1):96-108. DOI: 
10.1093/toxsci/kfw248
[78] Agarwal A. Role of sperm chromatin 
abnormalities and DNA damage in male 
infertility. Human Reproduction Update. 
2003;9(4):331-345. DOI: 10.1093/
humupd/dmg027
[79] Wright C, Milne S, Leeson H. Sperm 
DNA damage caused by oxidative 
stress: Modifiable clinical, lifestyle and 
nutritional factors in male infertility. 
Reproductive Biomedicine Online. 
2014;28(6):684-703
[80] Tiwari D, Vanage G. Mutagenic 
effect of bisphenol a on adult rat 
male germ cells and their fertility. 
Reproductive Toxicology. 2013;40:60-68
[81] Meeker JD, Yang T, Ye X, Calafat AM, 
Hauser R. Urinary concentrations of 
parabens and serum hormone levels, 
semen quality parameters, and sperm 
DNA damage. Environmental Health 
Perspectives. 2011;119(2):252-257
[82] Zhou Y, Fu XM, He DL, Zou XM, 
Wu CQ , Guo WZ, et al. Evaluation 
of urinary metal concentrations and 
sperm DNA damage in infertile men 
from an infertility clinic. Environmental 
Toxicology and Pharmacology. 
2016;45:68-73. DOI: 10.1016/j.
etap.2016.05.020
[83] Rignell-Hydbom A, Axmon A,  
Lundh T, Jönsson BA, Tiido T, Spano M.  
Dietary exposure to methyl mercury and 
PCB and the associations with semen 
parameters among Swedish fishermen. 
Environmental Health. 2007;6(1):14. 
DOI: 10.1186/1476-069X-6-14
[84] Hauser R, Meeker JD, Singh NP, 
Silva MJ, Ryan L, Duty S, et al. DNA 
damage in human sperm is related to 
urinary levels of phthalate monoester 




Endocrine Disruptors: Very Low 
Doses with Genuinely High 
Impacts on Male Reproduction
Michal Ješeta and Jan Nevoral
Abstract
Endocrine disruptors (EDs) are chemical substances that affect physiological 
processes in the body via hormonal regulation. They are often detected in food, 
plastic water bottles, cosmetics, and many other daily need items. Thereafter, EDs 
are detected in many bodily fluids, pointing out the real exposure to even very low 
doses. Permanent and long-term utilization of EDs has harmful effects on male 
reproductive health mainly due to interference with sex hormone synthesis and 
mechanism of action. However, with decreasing dosage of EDs, the possibilities 
of unpredictable modes of action arise. In addition to various molecular actions of 
individual EDs, the interference of individual ones represents another dimension of 
the ED issue. This review provides an overview of the EDs and their possible impact 
on reproductive health in males, with focus on sperm quality with the mighty 
potential of epigenetic transmission to further generations. The “posttranslational” 
effect of EDs in really low doses in real exposure routes is stigmatized in this review, 
being strongly considered as creeping molecular action of individual EDs as well as 
amplifications of their copresence in the environment.
Keywords: endocrine disruptor, bisphenol, regretable substitution, 
posttranslational modification
1. Introduction
Maturation of sperm cells (spermatogenesis) is a continuous process starting 
in puberty. The process is stimulated by follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH). Until the onset of puberty, spermatogonia are quiescent 
and their quantity does not change significantly. After sexual maturity is reached, 
an expressive activation of mitochondrial activity and the process of spermatogen-
esis begin, leading to the formation of spermatids. They are then transformed into 
spermatozoa by the spermiohistogenesis process, when a round spermatid changes 
into a sperm cell with a tail, middle section, and head. However, whole spermato-
genesis, including gonadal ridge colonization and differentiation of primordial 
germ cells (PGCs), followed by further development, begins during early embryo-
genesis. In light of this fact, there are several exposure windows when environmen-
tal noxi can hit spermatogenesis along the entire process.
Considering the transmission of extraneous agents, the hemotesticular barrier 
(HTB) represents the morphological division of the seminiferous tubulus into two 
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compartments: basal and adluminal. The barrier is crucial for full functionality 
of germinal epithelium, as well as for the elimination of negative impacts of envi-
ronmental pollutants. Physiologically, this strict division ensures free paracellular 
movement of substances among the compartments, such as water, nutrients, elec-
trolytes, hormones, and paracrine factors. HTB provides protection of the emerging 
sperm cells from autoimmune damage by antibodies to sperm cells produced if 
the barrier was impaired, and the immune system would be in contact with sper-
matozoa during puberty when the body has already reached immunocompetence. 
Therefore, the cross talk of the immune system and HTB is potentially another 
sensitive target to a pollutant impact.
There is a basal compartment in close proximity to the basal membrane. This seg-
ment contains vessels and nerves, and spermatogenesis is initiated here. Spermatogonia 
and spermatocytes up to the proleptotene stage are present here. This segment is 
necessary for nutrition. The spermatogonia are subsequently transported through tight 
intercellular junctions to the adluminal compartment which is a place of spermatogen-
esis completion and subsequent metamorphosis of spermatids to spermatozoa. Both 
compartments are demarcated by the blood-testis barrier (BTB). Vessels and nerves are 
no longer present in this segment, and the nutrition of the germinal epithelium cells is 
covered by the Sertoli cells. The impact of various doses and concentrations of EDs on 
the male reproductive system can affect the functions of this barrier. The differentiation 
and development of the male reproductive system depends on elementary estrogen/
androgen ratio, and the antagonistic and agonistic effects of EDs often disrupt their 
balance. The development of testicular tissue is crucial for further development of the 
entire reproductive system, as the endocrine activity of testicles determines overall 
masculinization of the body. Any disruption in the development of the testicles can 
therefore impair the overall masculinization process and sperm production.
Sperm concentration in men decreases worldwide, and spermiogram param-
eters deteriorate mainly in the Western world population [1]. Among others, huge 
amounts of endocrine disruptors (EDs) in our environment can cause this state. 
This final manifestation of the noxious effect of EDs has an unknown background, 
such as dose, kinds of EDs, interactions, and crosstalk of individual EDs and/or 
the timing of the exposure. Therefore, biomonitoring data represents significant 
input for experimental designing, leading to the description of molecular action 
in simulated conditions. Based on the newest findings, the record of the biologi-
cal impact of individual EDs is an ongoing research issue leading to indicating the 
found compounds as endocrine disruptors.
Many cases of impaired sexual development due to the effects of EDs are also 
known from the animal kingdom. For example, reduction of penile length was 
observed in crocodiles living in waters contaminated with EDs [2]. EDs can signifi-
cantly influence not only the process of spermatogenesis but also the development 
of testicular tissue. It has been documented that increased exposition of pregnant 
mice to BPA caused alterations of organelles, that is, mitochondria and lysosomes, 
in Sertoli and Leydig cells, respectively. These alterations led to maturation disor-
ders in spermatocytes and androgen synthesis inhibition [3].
2.  Spermatogenesis, epigenetics, biochemical status of spermatozoa, 
and implications for male reproduction
The creation of the spermatozoon leads to the terminally differentiated cell with 
an extremely high level of chromatin methylation and silencing. The final shape 
of the spermatozoon, often species-specific, requires many morphological and 
biochemical changes, in particular, dynamic remodelation of the chromatin [4]. 
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Protamination, histone-protamine exchange in elongating spermatids, represents 
a drastic, expressible change of sperm chromatin [5]. A tight protamine-derived 
DNA package protects sperm chromatin against damage and, interestingly, even 
the ratio of protamines PRM1 (sperm protamine P1) and PRM2 (sperm protamine 
P2) is decisive about sperm quality [6]. In accordance with the tight chromatin 
package, DNA is strongly methylated, and, therefore, general chromatin silencing 
is required for sperm stability [7, 8]. Protamination represents a tool for the protec-
tion of paternal gene imprinting [9]. Temporal protamine-packaged sperm DNA 
undergoes a second exchange of chromatin proteins after fertilization, and then 
maternal histones are incorporated into the paternal pronucleus. Both protamine-
histone transition events, first and second in testicular seminiferous tubuli and 
fertilized oocyte, respectively, are obviously sensitive to environmental influences 
and represent susceptible exposure windows [10, 11].
Although most core histone is substituted by protamines, a residual species-
specific amount of histones resists in the sperm head. In addition to DNA methylome, 
epigenetic hallmarks of mature spermatozoa include the epigenetic code of residual 
histones, based on many posttranslational modifications (PTMs) of individual amino 
acids [12, 13]. These chromatin-repressive histone marks positively correlate with 
DNA methylome and accompany imprinted genes. Moreover, the sperm histone 
code shows an exact physiological role in fertilization and early embryonic develop-
ment [14]. The histone code establishment is highly orchestrated [15] and, therefore, 
enforces spermatid sensitivity to exposure to environmental pollutants.
Following comprehensive demethylation of parental chromatin after fertiliza-
tion, the total erasure of the methylation pattern, including gene imprinting on 
paternal and maternal alleles, is needed for the re-establishment of gene imprinting 
adequate to the paternal pattern in the sperm cell. This erasure comes early after 
gonadal ridge colonization, and primordial germ cells (PGCs) occur, at human 
embryonic days E32 and E10.5 in mice [16]. The recurrent “writing” of the epigene-
tic pattern into imprinted loci occurs in the late prenatal period when the spermato-
gonia are formed. This period between erased PGCs and remethylated spermatozoa 
represents a highly sensitive and quite extensive exposure window, when the 
epigenetic status can be changed by environmental factors during embryonic 
development in utero. There is another dynamic chromatin demethylation, many 
years later, when sperm chromatin remodeling occurs when paternal and maternal 
pronuclei are developed in the early zygote. This methylation erasure is not com-
plete and excludes parent-of-origin methylation, that is, erasure-resistant loci, such 
as IAPs, LINEs, and transposon-related loci. Taken together, the transgenerational 
and intergenerational inheritances of epigenetic shifts (i.e., non-genomic or non-
Mendelian inheritance) are based on these two exposure windows, when epigenetic 
erasure, including gene imprinting in PGCs and imprinted gene-excluding erasure, 
occur, respectively [17]. The renewal of gene imprinting between PGCs and mature 
gamete is another power of transgenerational epigenetic inheritance [18]. The 
dynamics of the epigenetic code is subjected to a well-tuned orchestra of “erasures” 
(TET oxygenases, histone deacetylases, and demethylases) and “writers” (DNA 
methyltransferases, histone methyl transferases, and acetyl transferases) (reviewed 
in [19]). It is assumed that, via EDs, they change the epigenetic code through these 
upstream factors (the possible methods of exposure are summarized in Figure 1).
Doubtless, a properly established epigenetic code plays an extremely important 
role, in particular in imprinted genes in epimutation-prone gametes. The epigenetic 
code of the spermatozoon is highly protected by the protamination, determining 
the stability of the genome and gene imprinting. Otherwise, epigenetic disorders 
arise: Prader-Willi syndrome, Angelman syndrome, or Silver-Russell syndrome. 
Moreover, residual histones bring the epigenetic information via histone PTMs. 
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the stability of the genome and gene imprinting. Otherwise, epigenetic disorders 
arise: Prader-Willi syndrome, Angelman syndrome, or Silver-Russell syndrome. 
Moreover, residual histones bring the epigenetic information via histone PTMs. 
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Obviously, in addition to the genetic information, the sperm head carries a pack-
age of epigenetic notice, very sensitive to the disruption through its establishment 
throughout the spermatogenesis.
In addition to the establishment of epigenetic code of sperm histones, achieve-
ment of other PTMs of regulating proteins is required. Frequently, the loss of a 
PTM leads to protein activity lacking, sometimes leading to fatal clinical manifesta-
tions, for example, the inability of PARKIN1 S-sulfhydration of cysteine followed 
by sporadic Parkinson’s disease [20]. During post-ejaculation the sperm changes, 
such as capacitation and acrosomal reaction; there are many PTMs of key proteins 
necessary for the achievement of fertilization ability. Therefore, protein kinase A 
(PKA)-driven phosphorylation of Arg-X-X-(Ser/Thr) motifs is required, as the 
result of upstream regulation by soluble adenylyl cyclase and cAMP production [21]. 
However, acetylation of ε-amino group of lysine residues arises as regulatory tool for 
Figure 1. 
Endocrine disruptors induce non-genomic inheritance through posttranslational modifications (PTMs) of 
various epigenetic factors. (A) Environmentally impacted posttranslational modifications of proteins incoming 
into intergenerational and transgenerational effects. (B) Endocrine disruptors are able to affect developing 
gonads through transplacental transmission in utero. Gonad activity is changed and hormonal levels, puberty 
onset, and sperm quality are affected. Sperm quality contributes to embryonic development and can influence 
the health of an offspring, and, therefore, the intergenerational transmission of the ED effect to F2 generation is 
obvious. Gene imprinting and epigenetic erasure are assumed to be the tools of this effect. The epigenetic code of 
erasure-resistant loci is possibly affected by ED, and the transgenerational effect appears. Nonspecific symptoms 
accompany these epigenetic faults, and many disorders are classified as idiopathic. (C) From the molecular 
point of view, inadequate changes in DNA and chromatin proteins, including PTMs of core histones and/or 
RNA polymerases, are responsible for the epigenetic record and gene manifestation, and ED becomes potentially 
dangerous for these protein modifications through “posttranslational” effect. Obviously, male reproduction 
is endangered through several exposure windows during gamete formation, including epigenetic code erasure 
and re-establishment. Therefore, in addition to direct modification of chromatin, responsible “erasures” and 
“writers” (responsible for de-differentiation and gene imprinting, respectively) undergo regulation via PTMs 
when the EDs’ effect is considered.
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PKA, and, accordingly, the hyperacetylation of sperm proteins is needed for sperm 
capacitation [22], essential for sperm hyperactivation in female reproductive tract. 
Versatile role of protein acetylation is obvious, including aforementioned residual 
histones as well as protein kinases. Taken together, the impact of endocrine disrup-
tors on histone PTMs [23, 24] as well as sperm phosphorylation [25–27] has been 
described, and, therefore, the modifications of proteins (protein PTMs) become the 
likely manner in which disruptors (EDs) work in their real doses.
3. Endocrine disruptors: mode of action and nonlinear effect
There are many shared features of EDs, such as spatiotemporal omnipres-
ence, exposure to very low doses, and, therefore, often a nontoxic effect [28]. 
Nevertheless, the affection of hormonal balance represents a major sign of them, 
giving the name to endocrine disruptors [29]. Indeed, there is an increasing number 
of observations of exposure to EDs, across all age, race, profession, lifestyle, and 
health status categories [30]. These findings are in accordance with the ubiquity of 
EDs through the presence in daily need items.
Compound Phenotype of filial generation Species Reference
Antibiotics (Geneticin) Up-/downregulation of genes 
responsible for basic metabolism, 





Atrazine Reproduction, altered transcriptome 







Reduction of lipid accumulation Caenorhabditis 
elegans
[110]
BPA Affected neurogenesis and damaged 
social interactions
Mouse (C57BL/6 J) [111]
DDT Pathology of gonads, obesity Rat (Sprague 
Dawley)
[112]





Reproduction failure Mouse (CD-1) [114]
Glyphosate Obesity, prostate, and ovary diseases; 




Methoxychlor Obesity, ovary, and kidney diseases Rat (Sprague 
Dawley)
[116]
Vinclozolin Alterations transcriptome with 
disease susceptibility of gonads, 




Representative studies are included, testing different compounds (in toxic and sub-toxic doses) on various 
biomodels, mostly exposed during the establishment of germ cells and gonad maturation. These exposures lead to 
changed phenotype of filial generation through the epimutation of germ cells. In addition to pregnant exposure, 
PTMs of epigenetic factors and/or histone code represent a molecular tool of endocrine disruptor-inherited impact 
along generations, even though the exposure is during adulthood. Although direct human evidence is lacking, there 
are several indications of the effect of transmission of endocrine disruptors in very low doses, on further generations 
due to PTM-driven epimutations [106, 107].
Table 1. 
Overview of recent knowledge of environmental inheritance of endocrine disruptor effects.
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Male Reproductive Health
42
The “family” of EDs is wide and still growing, as is our awareness of their bio-
logical impact. Therefore, EDs include polybrominated diphenyl ethers, phthalates, 
polyethylene terephthalate (PET), bisphenols, and others (Table 1). Hence, flame 
retardants in electronic devices, perfumes, plastic bottles, and polycarbonates, 
respectively, are the most usual source of EDs. Surprisingly, some daily need items, 
such as paper bags, cans, receipts, and dental sealants, include bisphenols, although 
they seem to be free of any endocrine disruptors. Even strict elimination and usage 
control of pesticides are not able to exclude the endocrine-disrupting effect through 
contamination of food with residua of some of them, for example, glyphosate 
[31], atrazine [32], and imidacloprid [33]. Because EDs are so widespread, humans 
are exposed to them via different routes: oral intake with food and beverages and 
transdermal exposure and/or inhalation. Some specific routes of exposure are 
derived from the uniqueness of the stage of ontogenesis, such as transplacental in 
utero exposure during pregnancy, followed by translactational exposure when a 
baby is nursed.
Most EDs are released into the environment in a very low amount, and, there-
fore, the human intake is appropriately much smaller. This is the result of the legacy 
action of responsible authorities (European Food Safety Authority, EFSA; Food and 
Drug Administration, FDA), which has established the limits of intakes (tolerable 
daily intake, TDI) for many ED compounds. However, extremely low doses have 
been recognized as having a biological effect. In the light of this fact, the earlier 
Figure 2. 
Molecular structure of BPA and its alternatives. BPA, bisphenol A (2,2-Bis(4-hydroxyphenyl)propane); BPE, 
bisphenol E (4-(1-(4-hydroxyphenyl)ethyl)phenol); BPF, bisphenol S (4,4’-dihydroxydiphenylmethane); BPS, 
bisphenol S (4,4’-sulfonylbisphenol).
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accepted quantities of no-observed-adverse-effect level (NOAEL) and lowest-
observed-adverse-effect level (LOAEL) lose importance. Interestingly, lower doses 
show often more deleterious effect than the higher ones, pointing out the nonlinear 
effect [29]. The response of the cell, tissue, or an organism on the dose is in a non-
monotonic (i.e., U-shape) curve [34]. It was difficult to accept this phenomenon, 
but recently we consider it to be one of the features of EDs [35–37].
After many substances were described to be an ED, elimination or total restric-
tion followed. Therefore, several compounds have been introduced as a substitution. 
n-Hexane and alternative bisphenols (BPS, BPF, and BPAF) have become wide-
spread, such as alternatives to dichloromethane and bisphenol A (BPA), respec-
tively, although the unambiguous safety of these substitutions has not been proved 
(chemical structure of selected bisphenols is presented in Figure 2). For instance, 
BPA usage has been banned in children’s toys and baby bottles, and, in addition to 
these, BPA-free products were introduced based on the consumer preferences [30]. 
However, BPS to BPA exchange has taken place, although “endocrine” safety has not 
been elucidated. In this point of view, we can denote it to be a regrettable substitu-
tion, and comprehensive testing of these alternative compounds is required.
4. The impact of EDs on male reproductive health
According to a range of studies, the effect of EDs is significant mainly during 
the development of the male reproductive system. The cocktail effect of multiple 
substances in low concentrations with similar action target has been described 
many times. Particularly trans-uterine exposition during embryonic development is 
critical, when testicular dysgenesis syndrome can develop [38]. There is a presump-
tion that it is caused by impaired function of Leydig cells and testosterone produc-
tion [39]. For initiation of prostate development and masculinization of the sex 
ducts, the presence and correct ratio of steroid hormones is necessary. Nevertheless, 
EDs often act as inhibitors of 5-alpha reductase enzyme that is necessary for the 
conversion of androgens to testosterone and inhibitors of aromatase necessary for 
androgens aromatization to estrogens [40].
4.1 Effect on gonads and accessory glands
Cryptorchidism: This is a serious developmental disorder which may be also 
caused by exposition of the fetus to EDs in utero and subsequent feeding with 
breast milk with a high concentration of EDs [41].
Hypospadias: It has been documented that utilization of EDs in the form 
of medication for pregnant women led to various disorders of testicular 
 development [42].
Testicular cancer: The half-life of the EDs with lipophilic character is up to 
30 years. It has been observed that mothers of adult men with testicular cancer 
had high levels of polychlorinated biphenyls (PCBs) in the blood, which led to the 
conclusions that the ability of PCBs to accumulate in the body makes their pres-
ence one of the factors contributing to development of this type of cancer [43]. 
Considering the half-life of many toxins, for example, PCBs, we can assume that 
these toxins will achieve their endocrine-disrupting effect as their real amount 
in the environment decreases, while their toxic effects are not taken into account 
anymore.
Prostate hyperplasia: It has been described in rats that exposition of males to 
low doses of estrogens and xenoestrogens led to prostate hyperplasia. These results 
support concerns that, in today’s plastic era, this phenomenon will also manifest 
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in adult men [44]. Moreover, in 2017, it was documented that doses of BPA equiva-
lent to doses potentially present in the environment caused increased growth of 
prostate cells [45].
4.2 Effect on spermatogenesis
Sperm concentration in ejaculates of men has been decreasing for a long time, 
mainly in Western world populations (the USA, Europe, Australia, and New 
Zealand) [1]. This long-term process has been observed since the 1970s. The situa-
tion might be caused by environmental changes, primarily by the increased occur-
rence of various EDs [46]. It is generally acknowledged that the process of sperm 
production is significantly reduced by FSH and LH, while alterations on this level 
may cause impairment of spermatogenesis to infertility [47].
4.3 Effect on cells of germinal epithelium
It is known that EDs are capable of influencing the offspring in utero through 
transplacental transmission and via breast milk and that they cause disorders that 
can be transferred epigenetically to further generations. In certain periods of fetal 
development, testicles are estrogen-sensitive, and their excessive exposure to this 
hormone can result in complete arrest of steroidogenesis. EDs with an estrogenic 
character can interfere with the correct functioning of the reproductive system.
During spermatogenesis, spermatogonia are transformed to spermatozoa when a 
round spermatid changes into a sperm cell with tail, middle piece, and sperm head. 
For this process, Sertoli cells play a key role as they form the functional blood-testis 
barrier (BTB) with very tight junctions. This barrier is dynamic and demarcates 
the basal compartment and adluminal compartment of seminiferous tubules. The 
barrier is necessary to prevent damaging of sperm cells by the immune system, 
since contact of blood and mature sperm cells leads to the production of antibodies 
to spermatozoa. These antibodies can then enter the seminal plasma and damage 
sperm cells. The principle of the hemotesticular barrier are very tight junctions 
between the Sertoli cells which divide the structure of seminiferous tubules into 
basal and adluminal compartments.
4.4 Disruption of the blood-testis barrier (BTB)
Effects on the hemotesticular barrier can significantly affect spermatogenesis 
and can have an impact on embryonic development of testicular tissue. The 
division contributes to unlimited capillary supply of nutrients, hormones, and 
other biomolecules which are needed for mitotic renewal of spermatogonia, their 
proliferation, and differentiation. However, the other developmental stages must 
not come into contact with blood. If this barrier did not exist or was damaged, 
antibodies to sperm cells would be produced, which could ultimately result in male 
infertility [48].
BTB and effect of EDs: Detachment of both compartments is ensured by tight 
intercellular junctions of adjacent Sertoli cells. These are very tight connections 
represented mainly by tight junction, adherens junction, desmosome, and gap 
junction types. The riskiest period is when spermatocyte at the proleptotene stage 
passes through the barrier, which needs to undergo structural changes. It is this 
particular period when the effect of substances such as the endocrine disruptors is 
most significant.
It is known that the level of free BPA in blood plasma decreases the con-
centrations of occludin, N-cadherin, and connexin 43, which are proteins that 
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significantly contribute to the production and regeneration of tight junctions. 
Decreased levels of these proteins affect the function of BTB [49].
Taken together, a very low dose of EDs seems to have the most deleterious 
impact. There are obviously different modes of action of EDs, and, all the more so, 
the molecular targets of EDs are the center of interest of the current studies describ-
ing disruptors.
5. Molecular mechanism of EDs in extremely low doses
The toxic effects of many compounds are well-known and described, and the 
amount of published findings is still growing by thousands of papers each year. 
In general, genotoxicity and carcinogenesis [50], oxidative stress induction [51], 
and DNA damage and cell senescence [52–54] are known impacts of several toxic 
compounds. However, sub-toxic effects of toxic compounds (pesticides and drugs) 
described earlier as well as seemingly safe compounds (alternative bisphenols) 
represent a serious risk for human public health. For this reason, there are many 
biomonitoring initiatives, followed by legislation and the development of next-
generation plastics.
In accordance with toxin elimination during the last decades, people in devel-
oped countries have been recently exposed to rather sub-toxic doses in trace 
amounts. This effect is known as endocrine disrupting, affecting the body in other 
ways than toxins, that is, genomic, non-genomic, and epigenetic modes of action. 
While the genomic effect is similar to toxin action, the non-genomic effect is the 
closest to endocrine disruption; the mimicking of the presence of a hormone, 
targeting of hormonal signaling, and/or misregulation of hormone production and 
expression of receptors are known mechanisms of endocrine-disrupting effects 
[55–57]. Hormonal disbalance impacts the hypothalamus-pituitary-gonadal axis 
[58], with possible clinical manifestations: changed anogenital distance, morpho-
logical changes of sex determinations, and earlier puberty onset [59]. However, the 
tested doses are very high, whereas, on the contrary, very low doses correspond 
to the real exposure, often leading to small differences on the level of tissue and 
cell, without any demonstration of clinical aspects. Although changes in hormonal 
balance are well-known [60, 61], EDs are even capable of affecting hormonal action 
directly in a cell without a shift in hormonal profile. Therefore, the estrogen-like 
and estrogenic effects of BPA have been described in germ [62], ovarian [63], and 
testicular cells [64, 65]. Frequently, the G-protein-coupled estrogen receptor is a 
target of the estrogen-like effect of BPA [65, 66], as well as alternative bisphenols 
[67]. Transcription and subcellular distribution of estrogen receptors ERα and ERβ 
and aromatase, an enzyme converting adro- to estrogens, are changed in bisphenol 
S-exposed oocytes [68]. These non-genomic alterations are accompanied by cyto-
skeleton abnormalities. In particular, the meiotic spindle is extremely sensitive [69] 
and, indeed, affected in mammalian oocytes exposed to bisphenols [68, 70, 71], 
leading to increased incidence of aneuploidy [72].
The comparable effect of EDs is known during spermatogenesis: BPA is capable 
of affecting meiotic division and chromosome segregation, increasing the incidence 
of aneuploidy-derived disorders [73]. In addition, the molecular mechanism of 
BPA consists in impacting several signal pathways and results in the change of 
 protein kinase A activity and protein tyrosine phosphorylation, ATP generation, 
and oxidative stress-related enzymes (i.e., peroxiredoxin-5, glutathione peroxidase 4, 
succinate dehydrogenase), crucial for sperm motility and ability of oocyte fer-
tilization [26, 27, 74]. Dose-response association of BPA and motility parameters 
of human sperm has been observed [75]. Interestingly, some EDs have shown a 
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sperm cells. The principle of the hemotesticular barrier are very tight junctions 
between the Sertoli cells which divide the structure of seminiferous tubules into 
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other biomolecules which are needed for mitotic renewal of spermatogonia, their 
proliferation, and differentiation. However, the other developmental stages must 
not come into contact with blood. If this barrier did not exist or was damaged, 
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infertility [48].
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intercellular junctions of adjacent Sertoli cells. These are very tight connections 
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particular period when the effect of substances such as the endocrine disruptors is 
most significant.
It is known that the level of free BPA in blood plasma decreases the con-
centrations of occludin, N-cadherin, and connexin 43, which are proteins that 
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significantly contribute to the production and regeneration of tight junctions. 
Decreased levels of these proteins affect the function of BTB [49].
Taken together, a very low dose of EDs seems to have the most deleterious 
impact. There are obviously different modes of action of EDs, and, all the more so, 
the molecular targets of EDs are the center of interest of the current studies describ-
ing disruptors.
5. Molecular mechanism of EDs in extremely low doses
The toxic effects of many compounds are well-known and described, and the 
amount of published findings is still growing by thousands of papers each year. 
In general, genotoxicity and carcinogenesis [50], oxidative stress induction [51], 
and DNA damage and cell senescence [52–54] are known impacts of several toxic 
compounds. However, sub-toxic effects of toxic compounds (pesticides and drugs) 
described earlier as well as seemingly safe compounds (alternative bisphenols) 
represent a serious risk for human public health. For this reason, there are many 
biomonitoring initiatives, followed by legislation and the development of next-
generation plastics.
In accordance with toxin elimination during the last decades, people in devel-
oped countries have been recently exposed to rather sub-toxic doses in trace 
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closest to endocrine disruption; the mimicking of the presence of a hormone, 
targeting of hormonal signaling, and/or misregulation of hormone production and 
expression of receptors are known mechanisms of endocrine-disrupting effects 
[55–57]. Hormonal disbalance impacts the hypothalamus-pituitary-gonadal axis 
[58], with possible clinical manifestations: changed anogenital distance, morpho-
logical changes of sex determinations, and earlier puberty onset [59]. However, the 
tested doses are very high, whereas, on the contrary, very low doses correspond 
to the real exposure, often leading to small differences on the level of tissue and 
cell, without any demonstration of clinical aspects. Although changes in hormonal 
balance are well-known [60, 61], EDs are even capable of affecting hormonal action 
directly in a cell without a shift in hormonal profile. Therefore, the estrogen-like 
and estrogenic effects of BPA have been described in germ [62], ovarian [63], and 
testicular cells [64, 65]. Frequently, the G-protein-coupled estrogen receptor is a 
target of the estrogen-like effect of BPA [65, 66], as well as alternative bisphenols 
[67]. Transcription and subcellular distribution of estrogen receptors ERα and ERβ 
and aromatase, an enzyme converting adro- to estrogens, are changed in bisphenol 
S-exposed oocytes [68]. These non-genomic alterations are accompanied by cyto-
skeleton abnormalities. In particular, the meiotic spindle is extremely sensitive [69] 
and, indeed, affected in mammalian oocytes exposed to bisphenols [68, 70, 71], 
leading to increased incidence of aneuploidy [72].
The comparable effect of EDs is known during spermatogenesis: BPA is capable 
of affecting meiotic division and chromosome segregation, increasing the incidence 
of aneuploidy-derived disorders [73]. In addition, the molecular mechanism of 
BPA consists in impacting several signal pathways and results in the change of 
 protein kinase A activity and protein tyrosine phosphorylation, ATP generation, 
and oxidative stress-related enzymes (i.e., peroxiredoxin-5, glutathione peroxidase 4, 
succinate dehydrogenase), crucial for sperm motility and ability of oocyte fer-
tilization [26, 27, 74]. Dose-response association of BPA and motility parameters 
of human sperm has been observed [75]. Interestingly, some EDs have shown a 
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stronger negative impact on Y-chromosome-bearing spermatozoa, and the sex ratio 
of offsprings can be changed [76, 77].
Many non-genomic methods of ED action lead to inappropriate epigenetic 
changes of DNA and core histones. Although the sequence of nucleotide remains 
unaffected, the changes of genome-wide methylation status, as well as silencing 
or enhancing the individual loci, follow the exposure of EDs. These epimuta-
tions result in changed transcriptional activity of the genome with many negative 
impacts, such as failure of scavenging of reactive oxygen species, DNA damage 
repair, and/or inadequate mitochondrial biogenesis. These cellular changes lead to 
clinical manifestations, most of which are diagnosed as “idiopathic.” Obviously, 
exposure to EDs causes obesity [78], type 2 diabetes [79], metabolic disorders, and 
infertility [80].
While the exposure of somatic cells creates health problems for exposed 
individuals, influence on gametes leads to an intergenerational effect when the 
burden is transduced to the next generation of daughters and sons [81]. Indeed, the 
exposure to bisphenols impairs genome-wide DNA methylation, as well as histone 
code in oocytes [71, 82], followed by changes in the imprinting of genes in the 
embryo and placenta [83]. In spermatozoa, DNA methylation [84] is potentially 
affected by environmental pollutants, leading to aberrant gene imprinting [85, 86]. 
It can be assumed that the sperm histone code is sensitive to endocrine disruptors, 
with effect similar to estrogens, as well as to the involvement of estrogen receptors 
in histone code establishment [15]. Moreover, the negative role of environmental 
pollutants in the influence on noncoding RNAs in spermatozoa, another tool of 
epigenetic regulation [87] with ability to drive epigenetic inheritance [88], is well-
known [89, 90].
The exposure in utero and transplacental transmission of an ED affect DNA 
demethylation in developing PGCs and result in transgenerational inheritance of 
this burden. Accordingly, the exposure of pregnant rat females to fungicide vin-
clozolin [91] or DDT [92] leads to modified epigenome, that is, DNA methylome, 
histone retention in sperm, and ncRNAs. Translactational exposure, another way 
of indirect influence with environmental agents, is a reason of changes of male 
reproduction after lactating female mice were exposed to BPA [93]. Moreover, this 
type of exposure to bisphenols creates a risk of changed nursing behavior and also 
affects the mammary glands of mothers [94].
Whereas endocrine-disrupting hypothesis is assumed for very low doses of EDs, 
there is a relevant phenomenon of interactions of individual EDs. The comprehen-
sive work of T. Pollock and his colleagues produced valuable results, describing 
cross talk of common EDs. The combined presence of bisphenols is considered to be 
deleterious [95] as well as the simultaneous presence of triclosan, a soap compound 
[96, 97]. Degradation of bisphenol is inhibited under other ED exposure, and, 
obviously, the co-exposure achieves various modes on how to affect the body [98]. 
In addition to human and mammalian models, there is evidence of interaction of 
xenobiotics and pesticide residua [99], as well as synergistic interactions of organo-
phosphates and pyrethroids [100], potentially leading to the collapse of honey bee 
colonies [101]. In contrast to synergic effects leading to the increase of the deleteri-
ous impact, competition of some pollutants is known, and, surprisingly, a reverse 
effect of the synergic activity of pollutants has been described, where one pollutant 
protects cells against damage caused by another pollutant [102]. The molecular 
action of interacting pollutants remains to be unexplained in mammalian models, 
and there is obvious need for further study. Also the results of these studies will 
influence public health protection.
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6. Perspectives
The aforementioned routes of exposure to EDs, including their interactions, 
obviously lead to different systemic response as the result of molecular action in tissues 
and cells. The molecular mode of action seems to be the key for the elimination of 
EDs’ negative effect on the body. Based on already described manifestations of EDs 
in higher and lower doses, two dose-dependent modes of action are recognized: toxic 
effect and endocrine disruption. It seems that the current issue of EDs is in extremely 
low doses without clinical manifestations, leading to “idiopathic” infertility, metabolic 
syndrome, and other failures with nonspecific symptoms. Moreover, intergenerational 
and transgenerational inheritances occur because of the change of the epigenetic code 
of germ cells. The posttranslational modifications of crucial proteins, particularly 
regulating epigenetic factors, seem to be a common feature of these very low doses. In 
accordance with this, we can mark this effect to be “posttranslational.” The possible 
contribution of posttranslational modifications of key proteins is indicated in Figure 1.
There is an obvious direct impact of EDs on male reproduction due to oral, respi-
ratory, and/or transdermal exposure. Thereafter, both the gonads and accessory 
glands are affected, leading to the failure of male reproduction, often diagnosed as 
idiopathic. On the spermatozoon level, direct protein targeting is assumed, includ-
ing cytosolic proteins as well as sperm histone code. Even protamine PTMs are 
considered to have a biological role, and, in accordance with the abovementioned 
importance of acetylated lysines, protamine acetylation seems to be most potent 
for sperm quality. The impact on DNA and chromatin proteins (i.e., histones and 
protamines) represent hazardous mode of inter- and transgenerational transmis-
sion of ED-driven epigenome.
In addition to the direct impact of EDs, indirect impact is also observed. The 
exposure of EDs during pregnancy and prenatal life represents the most dangerous 
exposure method when the germline is affected during gene imprinting erasure and 
re-imprinting in developing spermatozoa [85] and oocytes [103]. This exposure 
window allows an ED to affect the health of a generation of grandchildren through 
transgenerational inheritance [104, 105]. Epigenetic transmission to further 
generations involves various modifications, such as DNA and histone methylation, 
histone acetylation, and other PTMs of core histones, as well as epigenetic writers 
and erasures, translational factors, and others. Obviously, PTMs actually drive the 
phenomenon of the epigenetic inheritance, and the molecular impact of individual 
EDs is still unknown, as is their interaction (Table 1).
There is a strong need for further study focused on the ED-modulated epigenetic 
code and its manifestation in the body. In accordance with our “posttranslational” 
hypothesis of ED action, comprehensive screening of the most crucial PTMs 
should be taken into account in an assessment of individual EDs. Taken together, 
biomonitoring has an extremely significant role in the fight against EDs, as does the 
subsequent testing of EDs in the ascertained doses. Simulation of real exposures to 
individual EDs and their interactions are appropriate, using both in vitro and in vivo 
experimental assessments. Finally, advanced screening methods capable of identify-
ing PTMs are needed for qualified recognition of an ED as harmful/harmless.
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Chapter 4
Infertility Worldwide: The Lack
of Global Pediatric Andrologists
and Prevention
Zampieri Nicola, Bianchi Federica, Patanè Simone,
Vestri Elettra and Camoglio Francesco Saverio
Abstract
Andrology is the medical specialty dealing with men’s health and reproductive
system, including the genital, hormonal, reproductive, sexual, as well as psycholog-
ical aspects, from birth to adulthood. Regular andrological checkups are essential
both to reveal possible problems and to receive thorough advice and information so
as to ensure that sexual and reproductive functions are well preserved. Estimates
report that about one in three males suffers from andrological diseases, their rates
varying according to the age: 27–30% of pediatric male subjects have reproductive
and/or sexual conditions. In adulthood, 40% of men are affected by andrological
diseases, in particular infertility and sexual problems. We studied medical literature
about infertility, its prevention, and its treatment; our outcomes were to evaluate
the role of research to prevent infertility especially in pediatric and adolescent age.
The analysis of the data shows that in absolute numbers, the conditions directly
associated with infertility are less studied than the treatment with medically assisted
procreation. This research is intended as a warning to the countries worldwide: all
those involved in the pediatric treatment area should be stimulated to act toward
this goal, and each country should bear the responsibility of promoting and
financing andrological screening campaigns.
Keywords: infertility, varicocele, pediatric, adolescence, undescended testes,
medical-assisted reproduction
1. Introduction
Andrology is the medical specialty dealing with men’s health and reproductive
system, this including the genital, hormonal, reproductive, sexual, as well as psy-
chological aspects, from birth to adulthood. Regular andrological checkups are
essential both to reveal possible problems and to receive thorough advice and
information as to ensure that sexual and reproductive functions are well preserved.
Estimates report that about one in three males suffers from andrological dis-
eases, their rates varying according to the age: 27–30% of pediatric male subjects
have reproductive and/or sexual conditions, especially cryptorchidism, varicocele,
hypogonadism, congenital anomalies of the genitourinary tract, and sexually trans-
mitted diseases. In adulthood, 40% of men are affected by andrological diseases, in
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particular infertility and sexual problems. The main surgically correctable diseases
to prevent hypofertility are varicocele (30%) and undescended testes (<5%) [1–3].
The origin of many of the andrological conditions appearing during adulthood is
to be traced before the age of 18 and sometimes even during gestation. The male
gonad is extremely sensitive to external events even during gestation and soon after
childbirth up until puberty. The andrological evaluation of pediatric patients is
therefore extremely important for the early diagnosis of genital anomalies such as
penile alterations or abnormal positions of the testis; early evaluation is helpful also
to search for risk factors in terms of male general and sexual health.
Andrology greatly trusts primary prevention to reduce the incidence of
andrological diseases and conditions. Clinical studies and primary prevention inter-
ventions in andrology should be focused on the most vulnerable crucial phases of
male gonad development that can be affected by a variety of external agents.
The preservation of the genital and sexual health of young people also means
protecting their fertility, a very important action within the broader scope of the
interventions aimed at reducing the drop in the birthrate affecting modern society.
Despite few exceptions, the prevention and early diagnosis of the andrological
conditions have been neglected worldwide for too long. This has favored an increase
in the incidence and prevalence of diseases that are otherwise easy to prevent and
treat if diagnosed early.
The data collected during screening procedures in young males show that <5%
receive an andrological examination before the age of 20. Female patients of the
same age adhere to gynecological screening tests with decidedly higher rates. A real
“gender discrimination” about prevention [4].
This leads to an increase in undiagnosed andrological diseases that remain so
until adulthood when the treatment becomes more complex for the patient and
more expensive for the national healthcare system.
Therefore, it is necessary to promote awareness on this social issue: undergoing
regular and well-timed andrological checkups is essential for the early diagnosis
of andrological conditions as well as for the general health of men’s sexual and
genital functions.
This point in mind, in order to safeguard the reproductive and sexual health of
young men, the synergic approach involving pediatricians, general practitioners,
doctors at family planning clinics, and andrologists for the adults plays a key role
together with the implementation of territorial networks integrating the know-how
and expertise of all these health professionals.
This is especially true in the extremely vulnerable period of life generally rang-
ing from 11 to 18 years of age, when young male patients experience the transition
to adult life and maturity from the reproductive and sexual point of view.
All this can be achieved also increasing the social awareness on the matter via
systematic information and education of the population thanks to campaigns and
primary prevention interventions. To this end, research and study of andrological
diseases in the pediatric-adolescent patients are crucial, especially research, whose
main aim is to anticipate the treatment of all those conditions that can alter the
fertility potential of men.
These are the grounds for this study, which compares good clinical practices
worldwide for the preservation of male fertility in young patients by comparing the
results with the evidence from the scientific research carried out on the treatment of
male infertility.
In the last 40 years, the number of spermatozoa in the semen of male patients of
childbearing potential has decreased by more than a half [5].
Incorrect lifestyles, pollution, and poor prevention are the main causes of a
dramatical drop in the male fertility rates. According to the latest international
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reports, the rate of male infertility among the couples who seek advice from spe-
cialized centers to bear a child is 30–35%, and age is not the only liable factor;
correctable causes include varicocele, which accounts for 30–35% of cases, and
evidence of previous untreated or poorly followed cryptorchidism (5%) [5–7].
Medically assisted procreation is suggested as one solution to the human and
social problem of sterility. But, as reported by many authors, can assisted procre-
ation be considered as a suitable therapy?
In many countries, assisted procreation is funded from public health insurance.
Without this coverage, it would be used much less frequently. What is then more
important? The treatment of sterility or the increase in the birthrate? The answer to
this question is manifold.
One of the reports by the International Committee for Monitoring Assisted
Reproductive Technology (ICMART) re-established that over 1 million ART cycles
were performed worldwide in 2002, with a progressive increase compared to the
previous years. The progressive increase shows how research and clinical medicine
are drastically moving away from the real investigation of infertility [6–8].
The costs associated with the ART can be divided into direct and indirect costs;
the direct costs, which vary according to the mother’s age, are those necessary to
“guarantee” a pregnancy, from the medically assisted treatment to childbirth. The
indirect costs include the costs directly related to childbirth, to a possibly premature
birth, to twin pregnancies, to the management of any complications, and to the
management of chronic diseases of the newborn child and of the mother as
well [7–9].
Obviously, the average direct cost of each procedure is calculated by dividing the
total number of procedures performed per year by the number of live births. These
costs are country-related, with variations of up to tenfold values; direct ART treat-
ment costs show considerable variations among countries, with the USA standing
out as the most expensive and Northern European countries and Japan as the least
expensive countries. For example, reports show that the costs per live birth are
similar for ages 24 (€17,000) and 33 (€ 18,500), after which they begin to increase,
with the cost per live birth reaching € 54,000 at age 42.
Indirect costs, especially when associated with multiple gestations, vary from
country to country: in 2004 such costs ranged between € 24,377 for a singleton
pregnancy and € 35,042 for a twin pregnancy up to 27 days after birth [6–9].
The first international report on the results of assisted medical procreation
(AMP) was published in Paris in 1991 on the occasion of the 7th World IVF
Congress. From a scientific point of view, the role of international reports is to
monitor the number of procedures as well as to study the efficacy of the treatments
indicated.
Every year the procedure registers are updated. The recorded data show a
constant increase in these procedures with a steady increase in live births. The latest
data, published in 2018 and referring to 2011, show that approximately 1.6 million
procedures were performed with approximately 400,000 births worldwide.
These figures allow to calculate the costs per year for the national healthcare
systems [7–9].
2. Literature searching
This research was performed by taking into consideration two aspects sepa-
rately: infertility and pediatric andrological diseases associated with infertility.
Browsing the most important engines for scientific research (PubMed, Scopus,
Google Scholar), several keywords were considered: infertility, male, semen,
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particular infertility and sexual problems. The main surgically correctable diseases
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fertility potential of men.
These are the grounds for this study, which compares good clinical practices
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adolescent, varicocele, undescended testes, cryptorchidism, hormone, and assisted
medical procreation (Table 1).
We searched with association like: adolescent and infertility; varicocele and
semen, etc.
A number of papers and number of the most important associations are
explained in the table.
Some considerations are essential: the literature regarding medically assisted
procreation should be considered only from 1990 onward, and, from a strictly
epidemiological point of view, also for varicocele some distinctions should be made.
Varicocele seems to have a clear phenotypic trend, for which it is possible that in
some countries the prevalence of the disease is lower than in others, justifying a
paucity of literature on this topic. However, when comparing the origin of scientific
publications on pediatric varicocele and cryptorchidism, Europe and North America
cover about 70% of the overall publications worldwide, reaching 80% of the
published literature about infertility and assisted medical procreation. Asia and
Africa, on the contrary, show poor preventive research while favoring the research
on assisted medical procreation.
The analysis of the data offers some interesting insights:
1.Most of the literature on the topics of this research was published after the year
2000, with the two maximum rates of 84 and 79% for medically assisted
procreation. This can be reasonably associated with the widespread use of the
procedures after the 1990s. If such figures are correlated to the other
percentages found, they also show how the focus of scientific research has
slanted toward the treatment of infertility rather than its prevention.
2.In absolute numbers, the conditions directly associated with infertility are less
studied than the treatment with medically assisted procreation.
Group Key Total >2000 % of paper Statistical
comparison per group
1 Infertility-male 46103 26296 (57%) 1/2: p < 0.05
2 Varicocele 5292 2788 (52%) 1/3: p < 0.05
3 Undescended
testes
10245 4250 (41%) 1/3: p < 0.05
4 Assisted
reproduction
25399 20309 (79%) 1/4: p < 0.05
5 V-adolescence/
pediatric age
1396 147 (real pediatric-
adolescent age-range with
follow-up)
776 (55%) 2/5: p < 0.05
6 Infertility-U 1195 676 (56%) 6/3: p < 0.05
7 Infertility-semen 11289 6556 (58%) 1/7: p > 0.05
8 Assisted medical
procreation
6701 5635 (84%) 1/8: p < 0.05
9 Infertility-VAR 2429 1349 (55%) 1/9: p < 0.05
Statistical analysis: Statistical analysis was performed using the student t-test. Significance value was set at p < 0.05.
Associations: varicocele and pediatric age/adolescence; infertility and undescended testes; infertility and varicocele;
statistical comparison between groups: chi-square test comparing number of total paper published and paper
published after 2000 per each -group and sub groups.
Table 1.
Data from the research: number of papers published per disease and with multiple associations.
62
Male Reproductive Health
3.A comparison between varicocele and cryptorchidism, namely, the two main
male infertility diseases, shows that although varicocele is the first treatable
cause of infertility, it is not as much investigated as cryptorchidism,
accounting for <5% of the curable causes of infertility. From a purely
numerical point of view, cryptorchidism is studied more than varicocele, with
varicocele being more investigated after the year 2000. This means that long-
term studies on varicocele have been done only in the last 20 years.
4.A comparison between group 1 (infertility and male), which is the most
represented in terms of number of publications pre- and post-2000, and all the
other subgroups points out that the “infertility and semen” subgroup is the
only comparable group within the main scope of the survey. This indicates that
most of the studies on male infertility do not investigate the causes leading to
these conditions, because they focus only on their effects
5.The correlation between infertility and varicocele offers some insights: while
in numerical terms, there is little investigation of varicocele in association with
infertility, which is one of its effects; more is studied about its treatment
(surgical treatment, percutaneous treatment, etc.). It is important to report
that since 2000, only 147 papers focused on pediatric-adolescent varicocele
and its management with a long time follow-up (>3 years).
3. Pediatric varicocele
3.1 Focus about pediatric varicocele: the first infertility-related and treatable
andrological disease
About this specific topic, where varicocele is the first treatable cause of infertil-
ity in adulthood, we found that a total of 625 articles was published since 2000,
matching the mentioned criteria; after our selection only 147 articles resulted pro-
viding innovative topics in the pediatric range. As a first consideration, we can state
that most publications concentrate in Europe, Asia, and North America (the USA
being by far the most represented in North America). The percentage of pediatric
works is 27.0% being above average in Europe and North and South America. Asia
has a considerable number of published articles even though the percentage of
pediatric ones is far below average. Africa and Oceania have, respectively, 2 and 1
pediatric articles.
Then we analyzed the main topic and secondary topics of the selected articles.
Prevalence of different categories in each continent was summarized, and the main
subjects for Europe are surgical technique, videolaparoscopy, and diagnosis; for
North America, surgical technique, diagnosis, and endocrinology; and for Asia,
video laparoscopy, endocrinology, and screening.
South America includes 10 articles discussing mainly about fertility and semen
analysis, being the only region in which this topic appears to be central. Africa had
only two publications in the pediatric field, centered on diagnosis and non-
operative treatment. The only pediatric publication published in Oceania was cen-
tered on video laparoscopy.
Overall prevalence of topics in the discussed articles was considered as well, and
we found that in North America and Asia follow-up prevails as a concomitant topic
in many articles, together with complications and relapses. Another topic strongly
represented in these regions is endocrinology. On the other side, Europe maintains
topics that mainly represented surgical technique and videolaparoscopy, accounting
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2.In absolute numbers, the conditions directly associated with infertility are less
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9 Infertility-VAR 2429 1349 (55%) 1/9: p < 0.05
Statistical analysis: Statistical analysis was performed using the student t-test. Significance value was set at p < 0.05.
Associations: varicocele and pediatric age/adolescence; infertility and undescended testes; infertility and varicocele;
statistical comparison between groups: chi-square test comparing number of total paper published and paper
published after 2000 per each -group and sub groups.
Table 1.
Data from the research: number of papers published per disease and with multiple associations.
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for about 50% of all topics, and then diagnosis is still present, showing little differ-
ence between main topic and all mentioned topics in the publications.
Eventually, a study of the topics and their prevalence over years was performed
to see the trend of interest. A significant trend in publications could not be evinced,
neither overall nor for single continent. Publication numbers by year underwent
cyclic changes over the last 20 years with a peak in 2008 including 16 publications
about pediatric varicocele.
A natural comment to the number of publication is the fact that pediatric articles,
focusing on pure research, account for <1 third of overall articles about varicocele.
This could be due to the fact that historically varicocele is considered as an adult
pathology; thus not enough interest is found in its pediatric side. Different series of
studies report a higher prevalence of varicocele in adult population than in pediatric
one. However it must be taken into account the lack, in almost all countries, of
pediatric screening programs for varicocele that could give a strong bias about the
exact prevalence of the pathology in pediatric population. Moreover the study of
varicocele related to infertility is considered more imminent in adult life, when
looking for paternity that during adolescence when study of future fertility may seem
premature. In fact many studies on varicocele are performed retrospectively when
the patient in adult life has not the possibility to become father (see table).
Concerning the major topics of the publications, in the most represented conti-
nents, the first interest of research is surgical technique, may it be traditional
surgery or videolaparoscopy technique. We can also see that in the first three
majorly represented topics and figures either screening or diagnosis this reflects an
attention of research to detection and treatment rather than to follow-up or pre-
vention of infertility. Other topics were only minimally represented. It must be
stated that healthcare organization of each single country may influence the topics
and publications: in fact screening would not be so represented in countries with
private healthcare or, on the other hand, countries with increased population den-
sity would feel less important the problem of infertility. The prevalence of varico-
cele according to the literature remains constant in different ethnic groups; thus,
differences in publication do not reflect a difference of entity of the disease but
rather a different contribution to publications.
In South America the research group for the published articles is the same, and
the works represent mainly an evolution of the same study focusing on semen
analysis, metabolomics, infertility pathophysiology, and endocrinology.
The three most prevalent topics in North America and Asia underline an atten-
tion to study the evolution of the pathology in time even after treatment and to
evaluate if the outcomes of surgical treatment meet the standards for good practice.
Articles discussing endocrinology often evaluate testicular volume at diagnosis and
follow catch-up growth after surgery, trying to give an indication of the best timing
to prevent infertility. On the other side, the spectrum of topics in Europe reflects
poor attention to prevention of infertility and follow-up after surgery.
Of particular interest is that there is no increasing trend during the years despite
an increase in the trend of publications about overall causes of infertility and
medically assisted procreation. In fact in delivering a PubMed research, it appears
that publications about MAP are more than 30 times higher than those about
varicocele.
We must report the fact that Asia appears abundantly below average, but a
strong bias is given that the fact that many publications from China were in original
language [10–17].
The same applies to the correlation between undescended testes and infertility if
compared to the studies on cryptorchidism alone. Both associations between infertil-




This research is intended as a warning to the countries worldwide: when talking
about fertility, it is right to give a couple the chance to access medically assisted
procreation; consequently, scientific studies to improve its outcomes are reason-
able. International reports are therefore necessary and should foster research with
increasing outcomes. More space should also be given to investigate and prevent
male fertility diseases starting from the pediatric age, especially when they might
impair the patient’s future fertile potential [18].
All those involved in the pediatric treatment area should be stimulated to act
toward this goal, and each country should bear the responsibility of promoting and
financing andrological screening campaigns. At the international level, there are still
few opportunities, in terms of funds and staff, for the adolescents to receive
andrological counseling. This is then the bottom line: Is medically assisted procre-
ation the cure to one or more diseases, or is it the answer to the lack of a social
support network?
When talking about couple infertility, male causes account for about 35–40%,
among these, varicocele figures as the first [19].
Thus collective interest, research efforts, and healthcare funding aim to study
couple infertility at the time of inability of procreation, correction of varicocele in
adult age, and medically assisted procreation. This choice is taken despite the
increased risk of chronic irreversible damage of treating varicocele and other pedi-
atric andrological diseases in adult age and despite the costs and risks of MAP with
the additional risk of failure of medically assisted procreation.
In conclusion, the research effort and the capital invested in prevention of
infertility are not balanced with respect to efforts and investments relied into
medical assisted procreation.
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Sertoli Cell Phagocytosis: 




During spermatogenesis, most male germ cells undergo apoptosis, and the 
cytoplasmic portions of the elongating spermatids are shed as residual bodies (RB). 
Both apoptotic germ cells (AGC) and RB must be phagocytosed by Sertoli cells, 
which are essential to maintain testicular homeostasis for normal spermatogenesis. 
The phagocytosis of AGC and RB by Sertoli cells confers various meanings, includ-
ing elimination of apoptotic components, removal of autoantigens, and the recycle 
of degenerated substrates as an energy source. Sertoli cell phagocytosis can be 
regulated by various mechanisms. The impairment of Sertoli cell phagocytosis may 
disrupt tissue homeostasis in the testis, thereby impairing to testicular function and 
spermatogenesis. This chapter discusses the mechanisms underlying phagocytic 
removal of AGC and RB by Sertoli cells and the consequences of this biological 
event for spermatogenesis and male fertility.
Keywords: Sertoli cell, phagocytosis, spermatogenesis, apoptosis, male fertility
1. Introduction
Mammalian spermatogenesis is a cell-organized differentiation process of male 
germ cells in the testis. This process includes spermatogonium mitosis, spermato-
cyte meiosis, and spermatid morphogenesis. Throughout spermatogenesis, Sertoli 
cells tightly embrace differentiating germ cells in the seminiferous epithelium 
and create a microenvironment essential for germ cell differentiation. In addition 
to physical support, Sertoli cells provide nutrition for developing germ cells and 
take up apoptotic components. During spermatogenesis, most of male germ cells 
undergo apoptosis, and those that finalize differentiation process will shed their 
most cytoplasmic components as residual bodies (RB). Apoptotic germ cells (AGC) 
and RB must be timely eliminated by Sertoli cells via phagocytosis.
The phagocytic elimination of AGC and RB by Sertoli cells has been proposed to 
contribute to spermatogenesis in several ways: (1) reducing space competition for 
enormous male germ cells to finalize differentiation process, (2) preventing nox-
ious cellular contents that may be released by necrosis of apoptotic germ cells, (3) 
removing autoantigens that may induce an autoimmune response, and (4) recycling 
of AGC and RB as an energy source for Sertoli cells.
Various mechanisms are involved in the regulation of Sertoli cell phagocytosis of 
AGC and RB. The interaction of class B scavenger receptor type I (SR-BI) expressed 
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on phagocytes and phosphatidylserine (PS) exposed on apoptotic cell surfaces is a 
universal mechanism by which phagocytes engulf apoptotic cells [1]. This mecha-
nism is also involved in the regulation of the phagocytosis of AGC and RB by Sertoli 
cells [2]. Tyro3, Axl, and Mer (TAM) tyrosine kinase receptors and their functional 
common ligand, growth arrest specific gene 6 (Gas6), are also essential for optimal 
phagocytosis of AGC by Sertoli cells. Several other genes that regulate Sertoli cell 
phagocytosis of AGC have been recognized. The mechanisms underlying phago-
cytic removal of AGC by Sertoli cells are the main focus of this article.
Impairment of Sertoli cell phagocytosis is associated with pathogenesis and dys-
function of the testis, thus impairing male fertility. The inhibition of Sertoli cell phago-
cytic ability disrupts spermatogenesis [3]. Gene mutation that impairs Sertoli cell 
phagocytosis may lead to autoimmune orchitis and male infertility [4]. The pathogenic 
conditions due to impaired Sertoli cell phagocytosis are mentioned in the text.
2. Germ cell apoptosis and Sertoli cell phagocytosis
The mammalian testis consists of two distinct compartments: the seminiferous 
tubules and the interstitial spaces among the tubules (Figure 1). The two major 
functions of the testis include spermatogenesis, occurring within the seminiferous 
epithelium, and steroidogenesis by Leydig cells that are in the interstitial spaces.
Figure 1. 
Human testicular schematic of histological structure and cellular constituents. The testis consists of two 
separate regions, namely, seminiferous tubules and interstitial spaces (left panels). The seminiferous tubules 
are composed of multiple layers of peritubular myoid cells (PMC) that constitute a tubular wall and Sertoli 
cells embracing different stages of male germ cells to form the seminiferous epithelium where spermatogenesis is 
fulfilled (right upper panel). The seminiferous epithelium is divided into two compartments, namely, the basal 
compartments and adluminal compartments, by the BTB that is formed by various junctions (right low panel) 
between two adjacent Sertoli cells, near the basal side. Different stages of developing germ cells, including 
spermatogonia (Sg), primary spermatocytes (PSc), secondary spermatocytes (SSc), round spermatids (RS), 
and elongated spermatids (ES), are localized on the seminiferous epithelium from the basal compartments to 
adluminal compartments. The interstitial spaces are composed of various cell types, the majority of which are 
Leydig cells (LC), but also macrophages (Mφ), as well as minor dendritic cells (DC) and T lymphocytes (T).
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The seminiferous tubules possess a special microenvironment essential for 
spermatogenesis, which is composed of columnar Sertoli cells tightly encompassing 
developing germ cells. The blood-testis barrier (BTB) that is formed by two adjacent 
Sertoli cells near the basal side of the tubules is critical for maintaining the tissue 
homeostasis and immune microenvironment for normal germ cell development. 
During spermatogenesis, more than 75% germ cells have been estimated to undergo 
apoptosis [5, 6]. Apoptosis can occur at any stage of germ cells. Male germ cell sur-
vival and apoptosis are highly regulated by endocrine hormones [7]. In particular, 
follicle-stimulating hormone (FSH) produced by the pituitary and testosterone syn-
thesized in Leydig cells is essential for healthy spermatogenesis. Low level of FSH 
increases germ cell apoptosis. The administration of testosterone in vivo inhibits 
germ cell apoptosis. Both FSH and testosterone could not act on germ cells because 
these cells do not express the receptors of two hormones. By contrast, FSH and 
testosterone can regulate the functions of Sertoli cells that express the hormonal 
receptors. Therefore, FSH and testosterone indirectly regulate germ cell apoptosis 
via Sertoli cells. The cascade of caspase activation is involved in the initiation of 
germ cell apoptosis [8]. Caspase 2 activation initiates the caspase cascade, in which 
BAX is involved in the cleavage of caspases.
Like other apoptotic cells, the translocation of phosphatidylserine (PS) to the 
surface of the cellular membrane is a characterization of male germ cell apopto-
sis [9]. The PS on the surface of apoptotic cells can be recognized by SR-BI and 
engulfed by phagocytes. At the final stage of germ cell development, most of the 
cytoplasm portions of spermatozoa are shed as RB before spermatozoa release to the 
lumen of the seminiferous tubules. However, immunohistochemical staining only 
detects a limited number of AGC. The RB are also rarely observed by histological 
analysis. These phenomena are assumed due to the rapid removal of apoptotic cells 
and RB through phagocytosis, a common way for engulfing apoptotic cells [1]. In 
accordance with this speculation, the inhibition of Sertoli cell phagocytosis in vivo 
greatly increases AGC numbers within the seminiferous tubules [3].
Phagocytosis of AGC and RB by Sertoli cells can be assessed by various 
approaches [10]. Confocal and transmission electron microscopy are reliable 
approaches that can distinguish apoptotic components ingested by Sertoli cells. 
However, these expensive and time-consuming approaches are not suitable for 
routine tests. Several simplified protocols to indirectly measure Sertoli cell phago-
cytosis have been reported [11–13]. These protocols require further optimization to 
avoid data misinterpretation. Lipid droplets are cyclically formed in the cytoplasm 
of Sertoli cells, which coincides with the spermatogenic cycle [14]. Therefore, it has 
been proposed that lipid droplets in Sertoli cells might result from the degradation 
of apoptotic components, including RB and AGC. An in vitro study confirmed that 
phagocytosis of AGC by Sertoli cells resulted in lipid droplet formation in Sertoli 
cells, which was used for evaluation of phagocytosis of AGC by Sertoli cells [13].
3. Mechanisms underlying phagocytosis of AGC and RB by Sertoli cells
3.1 Role of SR-BI/PS system
SR-BI is a receptor for high-density lipoprotein and can bind to acidic liposomes 
and apoptotic cells [15–17]. PS is a type of phospholipid that is located on the 
inner leaflet of the plasma membrane bilayer of healthy cells [18]. However, PS 
translocates to the outer leaflet of the cellular membrane during cell apoptosis and 
is exposed on the surface of apoptotic cells [9]. PS on the apoptotic cell surface can 
be recognized and bound by SR-BI on phagocytes, which is a key mechanism by 
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which phagocytes engulf apoptotic cells (Figure 2). The interaction of PS and SR-BI 
induces cytoskeletal changes that form phagocytic cup, thereby resulting in the 
engulfment of apoptotic cells. As shown in Figure 3 (right side), SR-BI is expressed 
in Sertoli cells, and PS is exposed on the surfaces of AGC and RB [19–21]. Several 
in vitro studies provide evidence that Sertoli cells engulf AGC and RB through 
the interaction of SR-BI and PS. The phagocytosis of AGC and RB by Sertoli cells 
can be inhibited by the presence of annexin V that specifically binds to PS on the 
surfaces of AGC and RB [3, 21]. Moreover, an antibody against SR-BI disables the 
phagocytosis of AGC by Sertoli cells [19]. The SR-BI/PS-mediated phagocytosis of 
AGC and RB by Sertoli cells is confirmed in vivo, in which injection of anti-SR-BI 
antibody and annexin V into the seminiferous tubules increases the number of AGC 
[3]. Therefore, both in vitro and in vivo studies confirm that Sertoli cells recognize 
and engulf AGC and RB in the SR-BI/PS-dependent fusion.
3.2 Role of TAM receptors in mediating Sertoli cell phagocytosis
TAM receptors belong to a subfamily of the transmembrane receptor tyrosine 
kinases (Figure 4), which include three members, Tyro3, Axl, and Mer [22]. Gas6 
is a functional common ligand of TAM receptors [23]. The TAM/Gas6 system 
regulates cell survival, innate immune response, and phagocytosis of apoptotic 
cells [24–27]. TAM receptors are involved in several pathological conditions, such 
as chronic inflammatory and autoimmune diseases [28, 29], viral infection [30–32], 
and cancer [33–35]. Notably, TAM receptors are essential for spermatogenesis and 
male fertility [36, 37].
The mechanisms by which the TAM/Gas6 system regulates testicular functions 
have been intensively investigated [38]. TAM receptors and Gas6 are abundantly 
expressed in Sertoli and Leydig cells [39]. All three Tyro3, Axl, and Mer receptors 
are expressed in Sertoli cells, whereas Leydig cells express Axl and Mer. Gas6 is 
uniquely expressed in Leydig cells. TAM receptors negatively regulate the expres-
sion of pro-inflammatory cytokines in both Sertoli and Leydig cells [40, 41], which 
might contribute to the immunoprivileged status of the testis [42]. In particular, 
the TAM receptors and Gas6 are essential for the phagocytic removal of AGC by 
Sertoli cells [43]. TAM receptors cooperatively regulate Sertoli cell phagocytosis of 
AGC. All three Tyro3, Axl, and Mer receptors participate in recognizing and bind-
ing AGC to Sertoli cells, whereas Mer is responsible for triggering phagocytic intra-
cellular signaling that promotes engulfment of AGC. Any individual TAM receptors 
in Sertoli cells exhibit similar binding ability to AGC. However, Sertoli cells lacking 
all three TAM receptors remarkably decrease the binding between Sertoli cells and 
AGC. The TAM-mediated binding of Sertoli cells to AGC cannot be homologous 
Figure 2. 
SR-BI/PS-mediated phagocytosis. PS is translocated from the inner leaflet to outer leaflet of cellular membrane 
during apoptosis. PS is recognized by SR-BI located on the surface of phagocytes, and subsequently apoptotic cell 
is engulfed by phagocytosis via cytoskeletal changes.
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adhesion because germ cells do not express any TAM receptors. Gas6 is required for 
TAM-mediated phagocytosis of AGC by Sertoli cells. The N-terminal region of Gas6 
binds to PS on the surface of AGC, and the C-terminal of Gas6 is recognized by 
TAM receptors, allowing Gas6 to bridge the binding between Sertoli cells and AGC 
(Figure 3, right side). Gas6 also plays a role in mediating Sertoli cell phagocytosis of 
AGC through the activation of Mer, thus triggering intracellular phagocytic signal-
ing that modulates the cytoskeleton of Sertoli cells for engulfing AGC.
3.3 Other molecules regulating Sertoli cell phagocytosis
Sertoli cells abundantly express dynamin 2, and dynamin 2 is involved in the 
regulation of Sertoli cell phagocytosis [12]. Dynamin 2 regulates the actin assembly 
in Sertoli cells during phagocytosis. A dynamin 2 inhibitor reduces Sertoli cell 
phagocytosis through the impairment of phagocytic cup formation. Knockdown 
of dynamin 2 perturbs actin polymerization and recruitment to target liposomes. 
The role of dynamin 2 in regulating Sertoli cell phagocytosis requires the interac-
tion between dynamin and amphiphysin 1 [44]. Dynamin 2 and amphiphysin 1 
Figure 3. 
Mechanisms and consequences of Sertoli cell phagocytosis of apoptotic germ cells (AGC) and residual bodies 
(RB). AGC and RB are phagocytized by Sertoli cells through two mechanisms (right side). SR-BI expressed on 
the Sertoli cell membrane binds with phosphatidylserine (PS) located on the surfaces of AGC and RB, thereby 
engulfing AGC and RB. TAM receptors mediate the phagocytosis of AGC and RB by Sertoli cells through 
Gas6 that bridges TAM receptors on Sertoli cell membrane and PS on the surfaces of AGC and RB. After 
phagocytosis, AGC and RB fuse with lysosomes and are recycled as energy sources for ATP production. If AGC 
and RB are not efficiently engulfed by Sertoli cells (left side), AGC and RB break down and release damage-
associated molecular patterns (DAMPs). DAMPs can be recognized by toll-like receptors (TLRs) and initiate 
innate immune responses through TRIF and MyD88 signaling pathways. These pathways activate nuclear factor 
kappa B (NF-κB), mitosis antigen protein kinases (MAPKs), and interferon regulatory factors (IRFs), thereby 
inducing the expression of inflammatory cytokines, including TNF-α, IL-1, IL-6, INF-α, and IFN-β.
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can be specifically bound and simultaneously accumulated at ruffles of phagocytic 
cups. The interaction of dynamin 2 and amphiphysin 1 depends on the PS exposure 
on AGC.
Dimeric transferrin inhibits phagocytosis of RB by Sertoli cells in an autocrine 
manner [45]. Transferrin is a glycoprotein that transports iron and is highly 
expressed in Sertoli cells. Iron is essential for the inhibitory effect of transferrin on 
Sertoli cell phagocytosis. Transferrin can be physiologically secreted by Sertoli cells 
and inhibits the phagocytic removal of RB in autocrine manner.
ELMO1 is an evolutionarily conserved engulfment protein that mediates the 
internalization of apoptotic cells. However, ELMO1-deficient mice are viable and 
largely normal except for evident testicular pathology [46]. The seminiferous epi-
thelium is disrupted, and AGC number is increased in the testis of ELMO1-deficient 
mice, therefore reducing sperm output. ELMO1 mediates the phagocytic removal 
of AGC by Sertoli cells. The engulfment receptors BAL1 and RAC1 (upstream and 
downstream of ELMO1, respectively) are involved in ELMO1-mediated Sertoli cell 
phagocytosis of AGC.
Noncoding miRNA regulates Sertoli cell phagocytosis. An early study showed 
that Dicer, a key enzyme that processes miRNA precursors into its functional form, 
is required for Sertoli cell function [47]. Dicer knockout mice are fetal lethal. The 
conditional Dicer knockout in Sertoli cells remarkably increases AGC numbers 
and leads to primary infertility, suggesting that miRNAs are involved in Sertoli 
Figure 4. 
TAM receptors and Gas6 system. TAM receptors belong to transmembrane proteins. The extracellular 
N-terminal region of TAM receptors binds to C-terminal domain of Gas6. The binding of Gas6 to TAM 
receptors results in the activation of intracellular tyrosine kinase (TK) domain of TAM receptors, thereby 
promoting  cell survival and phagocytosis of apoptotic cells and inhibiting  innate immunity.
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cell function and spermatogenesis in mice. Whether phagocytic ability of Sertoli 
cells is impaired by Dicer mutation remains unclear. However, the miR-471-5p has 
been recently identified to regulate phagocytosis of AGC by Sertoli cells [48]. The 
overexpression of miR-471-5p in Sertoli cells increases AGC number due to a defec-
tive phagocytic ability of Sertoli cells in transgenic mice. The role of miR-471-5p 
in regulating Sertoli cell phagocytosis requires its interaction with the autophagy 
protein LC3. Interestingly, androgen favors Sertoli cell phagocytosis by regulating 
the expression of miR-471-5p and its target proteins.
4. Pathophysiological meaning of Sertoli cell phagocytosis
The sperm production and testosterone synthesis are two major functions 
of testis. To fulfill these functions, the testis is highly organized, considering its 
anatomical location, histological structure, and cellular compositions. The testis 
is constituted by several types of tissue-specific cells. In addition to numerous 
germ cells, major testicular somatic cell types, including Leydig and Sertoli cells, 
are crucial for spermatogenesis. Leydig cells, localizing in the interstitial spaces 
of the testis, synthesize testosterone essential for spermatogenesis and multiple 
other extratesticular target organs. Sertoli cells embrace developing germ cells 
and constitute the seminiferous epithelium within the seminiferous tubules where 
spermatogenesis occurs (Figure 1). Sertoli cells are the only type of somatic cells in 
the seminiferous epithelium and play critical roles in regulating spermatogenesis by 
building a niche for germ cell development, providing nutrition to germ cells, and 
removing AGC and RB by phagocytosis. Sertoli cell phagocytosis is the most notice-
able. Several consequences of phagocytotic removal of AGC and RB by Sertoli cells 
have been proposed. Removal of AGC and RB provides appropriate spaces in the 
seminiferous epithelium for healthy spermatogenesis. AGC can release autoantigens 
when necrosis occurs, which may induce autoimmune responses. Therefore, timely 
elimination of AGC before releasing autoantigens prevents autoimmune responses. 
After phagocytosis of AGC and RB, Sertoli cells recycle these apoptotic components 
as an energy source. This energy source would be important for Sertoli cells because 
circulating nutrients barely reach to the seminiferous epithelium due to the BTB 
and lacking blood vessels.
4.1 Space saving
Based on origin, phagocytes can be classified into professional or nonprofes-
sional phagocytes, respectively [49]. The hematopoietic phagocytes belong to 
professional and can infiltrate into the infected sites to ingest microbes and clean up 
damaged cells, which is critical for the innate defense against microbial infection. 
However, circulating phagocytes cannot migrate into tissues separated by the BTB, 
where resident tissue-specific phagocytes, which are considered as nonprofessional, 
are essential for maintaining tissue homeostasis by phagocytic removal of apoptotic 
substrates. The typical example is the mammalian testis. More than one hundred 
million sperms are produced each day in men during their whole reproductive 
age. Since a large number of male germ cells develop simultaneously within the 
seminiferous epithelium, there is a competition for space and nutrient if all the 
germ cells would develop into spermatozoa. Therefore, before maturing to sperm, 
most developing germ cells die through apoptosis, and the remaining spermatids 
shed most of their cytoplasmic portions as RB. Since the number of germ cells 
that Sertoli cells can support for finalizing their development is limited, we can 
speculate that the elimination of AGC and RB by Sertoli cells is important to ensure 
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enough spaces for a healthy germ cell production and maintain tissue homeostasis. 
However, this speculation lacks experimental evidence. By contrast, there is a body 
of substantial evidence that the phagocytic removal of AGC and RB prevents an 
autoimmune response.
4.2 Removal of autoantigens
Male germ cells, which are mostly developed after the establishment of central 
immune tolerance, express a large number of novel proteins. These new proteins 
of male germ cells can be recognized as “foreign antigens” by the immune system. 
However, male germ cells do not induce an autoimmune response in the male repro-
ductive tracts under physiological conditions due to their special immune micro-
environment. The testis is a distinct immunoprivileged organ. Immune privilege 
represents a special immunological status that exists in several mammalian organs, 
including the eye, brain, pregnant uterus, and testis, where allografts or/and xeno-
grafts can survive without evoking immune rejection [50]. The testis tolerates both 
alloantigens and immunogenic autoantigens [51]. Various mechanisms are involved 
in the maintenance of testicular immune privilege [42], in which Sertoli cells play 
crucial roles.
Sertoli cells modulate testicular immune privilege with different mechanisms 
(Figure 5). The BTB protects the majority of the antigenic germ cells by sequester-
ing autoantigens behind the BTB from immune components in the interstitial 
spaces. The BTB is formed between adjacent Sertoli cells near the basal membrane 
of the seminiferous epithelium (Figure 1). Several cellular junctions, including 
tight junction, gap junction, and basal ectoplasmic specialization, are involved 
in the BTB formation. The BTB divides the seminiferous epithelium to the basal 
and adluminal compartments [52]. The BTB limits the access of immune contents 
residing in the interstitial spaces into the adluminal compartment and sequesters 
the germ cell autoantigens within the adluminal compartments. Therefore, the 
BTB plays an important role in maintaining immune privilege within the adluminal 
compartments of the seminiferous epithelium. Although the BTB sequesters the 
late stage of germ cells in the adluminal compartments, the early stage of germ cells, 
including preleptotene spermatocytes and spermatogonia that reside outside the 
BTB, also produces antigenic proteins [53]. Moreover, certain germ cell antigens 
behind the BTB can egress into the interstitial spaces, and these antigens do not 
induce an immune response in the testis [54]. These observations suggest that the 
BTB cannot completely sequester germ cell antigens and should be only partially 
responsible for testicular immune privilege. In fact, the interstitial spaces outside 
the BTB also enjoy immunoprivileged status. A dense network, including the 
tissue structure, local immunosuppressive milieu, and systemic immune tolerance, 
coordinately regulates the immunoprivileged environment in the testis [42, 55]. 
In addition to the BTB, Sertoli cells produce various anti-inflammatory factors 
that regulate the testicular immune microenvironment [56]. Sertoli cells express 
activin A and activin B [57]. Activin A inhibits the expression of pro-inflammatory 
cytokines, thereby suppressing the testicular inflammatory responses. TGF-β is 
also predominantly produced by Sertoli cells in the testis. As an anti-inflammatory 
factor, TGF-β1 protects islet β-cell grafts after co-transplantation with Sertoli cells 
[58]. Moreover, Sertoli cells express Fas ligand (FasL) and programmed death 
ligand-1 (PD-L1), two negative immunoregulatory ligands which are both involved 
in the maintenance of testicular immune privilege [59, 60].
Phagocytosis is a biological process that regulates immunity [61]. The phago-
cytic removal of AGC and RB by Sertoli cells is critical for timely elimination 
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of autoantigens that may be released if AGC and RB are broken down. Toll-like 
receptors (TLRs) belong to a subfamily of pattern recognition receptors that initiate 
innate immune responses. Several TLRs are expressed in testicular cells and can be 
activated by their relative ligands [41, 62, 63]. Damaged tissues and necrotic cells 
may release endogenous TLR ligands, namely, damage-associated molecule patterns 
(DAMPs), which can induce noninfectious inflammatory response (Figure 3, left 
side). Various DAMPs, including high-mobility group box 1 (HMGB1) and several 
heat stock proteins (HSPs), have been recognized to activate TLR2 and TLR4  
[64, 65]. Notably, HMGB1 and HSPs are abundantly expressed in male germ cells 
and can be released under stress conditions [66, 67]. Therefore, necrotic germ cells 
and RB breakdown may release endogenous TLR ligands, thus inducing inflam-
matory responses. Accordingly, physical trauma and chemical noxae that may 
damage germ cells are risk factors of chronic testicular orchitis [68]. An impaired 
removal of AGC leads to autoimmune orchitis [69]. The damaged male germ cells 
(DMGCs) induce the expression of various inflammatory mediators, including 
pro- inflammatory factors and chemokines, in Sertoli cells, thereby promoting leu-
kocytes’ infiltration to the testis [70]. The DMGC-induced inflammatory cytokine 
expression and immune cell infiltrations require TLR2 and TLR4 in Sertoli cells. 
Therefore, timely removal of AGC and RB by Sertoli cells is essential for maintain-
ing immune homeostasis in the testis to prevent autoimmune orchitis.
Figure 5. 
Role of Sertoli cells in testicular immune privilege. Sertoli cells produce various anti-inflammatory cytokines, 
including activin A and TGF-β, which inhibit immune response of dendritic cells (DC) and testicular macrophages 
(Mφ). Sertoli cells, together with germ cells, also express high level of Fas ligand (FasL) and programmed death 
ligand 1 (PD-L1) that can inhibit immune response by inducing apoptosis of T lymphocytes. Sg, spermatogonia; 
PSc, primary spermatocyte; SSc, secondary spermatocyte; Rs, round sperm; ES, elongated sperm.
Male Reproductive Health
76
enough spaces for a healthy germ cell production and maintain tissue homeostasis. 
However, this speculation lacks experimental evidence. By contrast, there is a body 
of substantial evidence that the phagocytic removal of AGC and RB prevents an 
autoimmune response.
4.2 Removal of autoantigens
Male germ cells, which are mostly developed after the establishment of central 
immune tolerance, express a large number of novel proteins. These new proteins 
of male germ cells can be recognized as “foreign antigens” by the immune system. 
However, male germ cells do not induce an autoimmune response in the male repro-
ductive tracts under physiological conditions due to their special immune micro-
environment. The testis is a distinct immunoprivileged organ. Immune privilege 
represents a special immunological status that exists in several mammalian organs, 
including the eye, brain, pregnant uterus, and testis, where allografts or/and xeno-
grafts can survive without evoking immune rejection [50]. The testis tolerates both 
alloantigens and immunogenic autoantigens [51]. Various mechanisms are involved 
in the maintenance of testicular immune privilege [42], in which Sertoli cells play 
crucial roles.
Sertoli cells modulate testicular immune privilege with different mechanisms 
(Figure 5). The BTB protects the majority of the antigenic germ cells by sequester-
ing autoantigens behind the BTB from immune components in the interstitial 
spaces. The BTB is formed between adjacent Sertoli cells near the basal membrane 
of the seminiferous epithelium (Figure 1). Several cellular junctions, including 
tight junction, gap junction, and basal ectoplasmic specialization, are involved 
in the BTB formation. The BTB divides the seminiferous epithelium to the basal 
and adluminal compartments [52]. The BTB limits the access of immune contents 
residing in the interstitial spaces into the adluminal compartment and sequesters 
the germ cell autoantigens within the adluminal compartments. Therefore, the 
BTB plays an important role in maintaining immune privilege within the adluminal 
compartments of the seminiferous epithelium. Although the BTB sequesters the 
late stage of germ cells in the adluminal compartments, the early stage of germ cells, 
including preleptotene spermatocytes and spermatogonia that reside outside the 
BTB, also produces antigenic proteins [53]. Moreover, certain germ cell antigens 
behind the BTB can egress into the interstitial spaces, and these antigens do not 
induce an immune response in the testis [54]. These observations suggest that the 
BTB cannot completely sequester germ cell antigens and should be only partially 
responsible for testicular immune privilege. In fact, the interstitial spaces outside 
the BTB also enjoy immunoprivileged status. A dense network, including the 
tissue structure, local immunosuppressive milieu, and systemic immune tolerance, 
coordinately regulates the immunoprivileged environment in the testis [42, 55]. 
In addition to the BTB, Sertoli cells produce various anti-inflammatory factors 
that regulate the testicular immune microenvironment [56]. Sertoli cells express 
activin A and activin B [57]. Activin A inhibits the expression of pro-inflammatory 
cytokines, thereby suppressing the testicular inflammatory responses. TGF-β is 
also predominantly produced by Sertoli cells in the testis. As an anti-inflammatory 
factor, TGF-β1 protects islet β-cell grafts after co-transplantation with Sertoli cells 
[58]. Moreover, Sertoli cells express Fas ligand (FasL) and programmed death 
ligand-1 (PD-L1), two negative immunoregulatory ligands which are both involved 
in the maintenance of testicular immune privilege [59, 60].
Phagocytosis is a biological process that regulates immunity [61]. The phago-
cytic removal of AGC and RB by Sertoli cells is critical for timely elimination 
77
Sertoli Cell Phagocytosis: An Essential Event for Spermatogenesis
DOI: http://dx.doi.org/10.5772/intechopen.86808
of autoantigens that may be released if AGC and RB are broken down. Toll-like 
receptors (TLRs) belong to a subfamily of pattern recognition receptors that initiate 
innate immune responses. Several TLRs are expressed in testicular cells and can be 
activated by their relative ligands [41, 62, 63]. Damaged tissues and necrotic cells 
may release endogenous TLR ligands, namely, damage-associated molecule patterns 
(DAMPs), which can induce noninfectious inflammatory response (Figure 3, left 
side). Various DAMPs, including high-mobility group box 1 (HMGB1) and several 
heat stock proteins (HSPs), have been recognized to activate TLR2 and TLR4  
[64, 65]. Notably, HMGB1 and HSPs are abundantly expressed in male germ cells 
and can be released under stress conditions [66, 67]. Therefore, necrotic germ cells 
and RB breakdown may release endogenous TLR ligands, thus inducing inflam-
matory responses. Accordingly, physical trauma and chemical noxae that may 
damage germ cells are risk factors of chronic testicular orchitis [68]. An impaired 
removal of AGC leads to autoimmune orchitis [69]. The damaged male germ cells 
(DMGCs) induce the expression of various inflammatory mediators, including 
pro- inflammatory factors and chemokines, in Sertoli cells, thereby promoting leu-
kocytes’ infiltration to the testis [70]. The DMGC-induced inflammatory cytokine 
expression and immune cell infiltrations require TLR2 and TLR4 in Sertoli cells. 
Therefore, timely removal of AGC and RB by Sertoli cells is essential for maintain-
ing immune homeostasis in the testis to prevent autoimmune orchitis.
Figure 5. 
Role of Sertoli cells in testicular immune privilege. Sertoli cells produce various anti-inflammatory cytokines, 
including activin A and TGF-β, which inhibit immune response of dendritic cells (DC) and testicular macrophages 
(Mφ). Sertoli cells, together with germ cells, also express high level of Fas ligand (FasL) and programmed death 
ligand 1 (PD-L1) that can inhibit immune response by inducing apoptosis of T lymphocytes. Sg, spermatogonia; 




Another meaning of male germ cell death and removal of AGC and RB serves 
as energy sources for Sertoli cells [71]. After phagocytosis by Sertoli cells, AGC 
and RB fuse with lysosomes. AGC and RB are subsequently broken down and 
recycled as energy sources for ATP production. The most noticeable phenotype 
of Sertoli cells is the formation of numerous lipid droplets in the cell cytoplasm. 
These lipid droplets result from the breakdown of engulfed AGC and RB [13, 72]. 
Unlike the majority of cell types that mainly use glucose as an energy source, 
Sertoli cells predominantly use lipids to produce ATP [71]. The lipids from AGC 
and RB should be the main energy sources for Sertoli cells. Sertoli cells provide 
essential physical and environmental support for spermatogenesis, which are 
energy consumers. Corresponding to their function, Sertoli cells exhibit an active 
energy metabolism and produce high levels of ATP [71, 73]. While lipids and 
glucoses can be substrates for ATP production within cells under physiological 
conditions, the majority of cell types use glycogen to produce ATP, whereas lipids 
serve as energy storage. Only minor cell types, such as adipocytes, myocardial 
cells, and Sertoli cells, have been confirmed to actively utilize lipids to produce 
ATP. Why these cell types predominantly use lipids as energy sources remains 
unclear. However, the active usage of lipids by Sertoli cells is compatible with 
the special microenvironment in the testis. Sertoli cells are barely reached by 
the nutrition from the peripheral circulation due to the barriers in the basement 
membrane, BTB, and the absence of blood capillaries within the seminiferous 
epithelium. The simplest way for Sertoli cells to have enough energy to support 
spermatogenesis is to recycle the lipid contents of AGC and RB. Therefore, the 
phagocytic removal of AGC and RB by Sertoli cells is necessary for Sertoli cells to 
ensure their functions, which confers a novel meaning for a large number of germ 
cells to undergo apoptosis during spermatogenesis.
5. Conclusive remarks
The mammalian testis possesses a special microenvironment for fulfilling 
its functions. The adluminal compartments of the seminiferous epithelium are 
separated from blood circulation by the BTB, and the circulating phagocytes 
cannot reach these regions. Therefore, Sertoli cells are responsible for the clearance 
of numerous AGC and RB during spermatogenesis. The phagocytic removal of 
apoptotic components by Sertoli cells is not only for waste disposal but also confers 
more meaning. In addition to prevention of autoimmune responses by removing 
autoantigens, recycling of apoptotic components can be used as an energy source 
for Sertoli cells. These biological processes would be particularly important in the 
tissues where immunogenic autoantigens are produced and seldom reached by cir-
culating nutritious substrates. The mechanisms behind cell death and their removal 
by phagocytes, and their tissue-specific significance, are worthwhile to investigate 
in depth.
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Abstract
Infertility is a multifactorial disease caused by both genetic and environmental 
factors. It is observed in 10–15% of couples, among which male infertility contrib-
utes for half the cases. Thus, identifying underlying causes of male infertility and 
for proper methods for treating and/or preventing sperm damage is of paramount 
importance. It is found that one of the factors that has been recently implicated 
in male infertility is oxidative stress, mediated by reactive oxygen species (ROS) 
that are produced during the metabolic process, as well as during the exposure to 
environmental chemical agents and their interaction with tissue-specific enzymes. 
Several studies have identified genetic variations at different loci, connected with 
male infertility, that may shed light on some idiopathic cases of seminal fluid abnor-
malities. In this chapter, we make an effort to decipher the contribution of polymor-
phisms in xenobiotic detoxification genes in the male infertility development.
Keywords: male infertility, xenobiotics, arylamine N-acetyltransferase 2, GSTM1, 
GSTT1, GSTP1, cytochrome P4501A1, genetic polymorphism, oxidative stress,  
DNA fragmentation, detoxification
1. Introduction
Deterioration of male reproductive health has become a serious problem in 
most countries [1]. Contributing factors for male infertility comprise genital 
infections, ejaculatory duct obstruction (EDO), hypogonadism, varicoceles, or 
exposure to environmental factors (e.g., xenobiotics, ionizing radiation), lifestyle 
factors (e.g., alcohol, smoking and obesity), genetic causes, systemic diseases, 
and abnormal ejaculation [2]. However, in approximately 30–45% of male 
infertility cases, the etiology remains undetermined and is called the idiopathic 
 infertility [3]. Genetic factors make a significant contribution to the development 
of idiopathic male infertility. For example, oligozoospermia and azoospermia have 
been recently determined to be tied with such genetic deviations as translocations, 
microdeletions and mutations [4] in genes that play a role in testicular develop-
ment, gametogenesis and metabolism of xenobiotics associated with reproductive 
system disorders. Xenobiotic metabolism causes the main damage to the organism 
by creating covalent bounds with cellular macromolecules (DNA or protein). This 
indicates that the expression regulation and activity of xenobiotic-metabolizing 
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Infertility is a multifactorial disease caused by both genetic and environmental 
factors. It is observed in 10–15% of couples, among which male infertility contrib-
utes for half the cases. Thus, identifying underlying causes of male infertility and 
for proper methods for treating and/or preventing sperm damage is of paramount 
importance. It is found that one of the factors that has been recently implicated 
in male infertility is oxidative stress, mediated by reactive oxygen species (ROS) 
that are produced during the metabolic process, as well as during the exposure to 
environmental chemical agents and their interaction with tissue-specific enzymes. 
Several studies have identified genetic variations at different loci, connected with 
male infertility, that may shed light on some idiopathic cases of seminal fluid abnor-
malities. In this chapter, we make an effort to decipher the contribution of polymor-
phisms in xenobiotic detoxification genes in the male infertility development.
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1. Introduction
Deterioration of male reproductive health has become a serious problem in 
most countries [1]. Contributing factors for male infertility comprise genital 
infections, ejaculatory duct obstruction (EDO), hypogonadism, varicoceles, or 
exposure to environmental factors (e.g., xenobiotics, ionizing radiation), lifestyle 
factors (e.g., alcohol, smoking and obesity), genetic causes, systemic diseases, 
and abnormal ejaculation [2]. However, in approximately 30–45% of male 
infertility cases, the etiology remains undetermined and is called the idiopathic 
 infertility [3]. Genetic factors make a significant contribution to the development 
of idiopathic male infertility. For example, oligozoospermia and azoospermia have 
been recently determined to be tied with such genetic deviations as translocations, 
microdeletions and mutations [4] in genes that play a role in testicular develop-
ment, gametogenesis and metabolism of xenobiotics associated with reproductive 
system disorders. Xenobiotic metabolism causes the main damage to the organism 
by creating covalent bounds with cellular macromolecules (DNA or protein). This 
indicates that the expression regulation and activity of xenobiotic-metabolizing 
enzymes may play the crucial role in determination of male reproductive system 
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susceptibility to chemically induced damages. Thus, xenobiotic-mediated adverse 
effects of male reproductive system are associated with the polymorphisms in 
xenobiotic detoxification genes. Different variants of one gene are categorized as 
polymorphism if their frequency in the population exceeds 1% [5]. In contrast to 
mutations, polymorphisms have indirect connections with particular seminal fluid 
abnormalities but may be indispensable during the investigation of multifactorial 
diseases. Polymorphic variants may change the expression or function of encoded 
protein, leading to its conformational changes that would result in different 
pharmacokinetics, chemical reaction capacities and efficiency of the xenobiotic-
detoxifying enzymes. In this chapter, we discuss polymorphisms in the main 
enzymes capable of maintaining the oxidants/antioxidants balance in reproduc-
tive tissues, focusing mainly on phase I cytochrome P4501A1 (CYP1A1) and 
phase II (GSTM1, GSTT1, GSTP1 and arylamine N-acetyltransferase 2 (NAT2)) 
 detoxifying enzymes.
2. Xenobiotic metabolism
The foreign environmental chemicals are known as xenobiotics (Gk. xenos—
“stranger”) and include drugs, drug metabolites and environmental pollutants 
(such as synthetic pesticides, herbicides and industrial pollutants). Xenobiotics 
may cause damages in the innate state (alkyl iodides, acyl halides and nitrogen 
mustards) or after activation in the metabolizing process.
Xenobiotic metabolism is performed in three stages (Figure 1):
1. Phase I enzymes initiate the detoxification process, during which the lipophilic 
xenobiotics become more polar and acquire sites for subsequent conjugation 
reactions. Phase I enzymes comprise mainly the cytochrome P450 (CYP) 
superfamily of microsomal enzymes, which include the 36 gene families. It is 
considered that CYP1, CYP2, CYP3, CYP4 and CYP7 families play the key roles 
in hepatic and extra-hepatic metabolism and in the elimination of xenobiotics 
and drugs in human [6].
2. Phase II enzymes catalyze the conjugation process. These enzymes can interact 
with xenobiotics either directly or, more generally, interact with the metabo-
lites produced by phase I enzymes. Phase II enzymes include a lot of super-
families, namely, the sulfotransferases (SULT), UDP-glucuronosyltransferases 
(UGT), DT-diaphorase or NAD(P)H quinone oxidoreductase (NQO) or 
NAD(P)H menadione reductase (NMO), glutathione S-transferases (GST) 
and N-acetyltransferases (NAT). Each superfamily consists of families and 
subfamilies of genes encoding the various isoforms with different substrate 
and tissue specificities [7].
3. Phase III elimination via transporters or passive transport. Phase III transport-
ers involve P-glycoprotein (P-gp), multidrug resistance-associated protein 
(MRP), which belongs to the subfamily of the ATP binding cassette (ABC) 
transporters and organic anion transporting polypeptide 2 (OATP2).
3. Potential mechanisms for idiopathic male infertility
Male infertility is a complex, multifactorial disorder and often its etiology 
remains poorly understood. Increasing volume of data suggests that oxidative 
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stress is the most probable cause of idiopathic male infertility. Oxidative stress 
is mediated by reactive oxygen species (ROS), if their level exceeds antioxidant 
capacity of the organism. An increased ROS level is observed in 40–80% of 
infertile men and in 11–78.5% of infertile men with normal sperm count [8]. 
Elevated ROS levels can be explained by several reasons such as increased leu-
kocytes’ activity due to inflammation in the genital tract, varicocele or presence 
of immature spermatozoa as well as external causes like exposure to noxious 
chemical compounds, radiation and lifestyle factors [9]. A small amount of ROS is 
necessary in some physiological processes such as capacitation [10], while exces-
sive ROS may damage sperms. Spermatozoa have restricted volume of cytoplasm, 
therefore the quantity of ROS-metabolizing enzymes is also limited and make 
them more vulnerable to ROS compared to other cells [9]. ROS cause sperm dam-
ages in several ways: first, ROS are capable of interacting with the sperm plasma 
membrane, which is rich in polyunsaturated fatty acids, promoting the decrease 
of its flexibility and, hence, tail motility [11]. Second, ROS may lead to the sperm’s 
acrosome membrane peroxidation and decline in acrosin activity, thus making 
fertilization less probable [12]. Lastly, an increased ROS level is associated with 
the increase in sperm DNA fragmentation (that is used as an assessment tool for 
unexplained male infertility) and diminished sperm motility [13]. Moreover, 
considering that ROS are intensively produced in the mitochondria of stressed 
spermatozoids, they may cause mutations of mitochondrial DNA of different 
cells which participate in spermatogenesis. As a result, sperm maturation and 
functioning could be violated. Thus, the development of effective antioxidant 
treatment and antistress strategies has become one of the paramount tasks for the 
scientific society [10].
Figure 1. 
The three-step detoxification of xenobiotics. Lipophilic substances subjected to metabolic activation by phase 
I enzyme cytochrome P450 (CYP) acquire reactive center for phase II conjugation reactions that lead to 
formation of hydrophilic compounds, following elimination by phase III transporters or passive transport. Most 
of the noxious effects are caused by reactive electrophiles after phase I activation, but some xenobiotics pose a 
threat before metabolic activation. CYP—cytochrome P450; NATs—N-acetyltransferases; GSTs—glutathione 
S-transferases; SULT—sulfotransferase; UGT—UDP-glucuronosyltransferase; NQO—NAD(P)H quinone 
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Mutations (that include both chromosomal and single-gene alterations) in sev-
eral hundred genes are the other important and significant factor that potentially 
may lead to male infertility. For instance, Y-chromosome microdeletions (YCM), 
which influence genes responsible for spermatogenesis, are one of the best-studied 
types of mutations that may cause male infertility. Thus, recent meta-analysis has 
shown that oligospermic men with sperm concentration > 1 million/mL had signifi-
cantly higher rates of YCM compared to normospermic men [14]. Among the other 
examples of mutations, there are the Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR) gene mutations, which lead to the absence of vas deferens; 
deletions of the autosomal Doublesex and Mab-3 Related Transcription factor 1 
(DMRT1) gene in the azoospermic men (which is critical for germ cells develop-
ment), ranging in size from 54 kb to over 2 Mb; and alterations in autosomal PLEC1 
(plectin) and microRNA 661 (MIR661) genes in an azoospermic and oligozoosper-
mic men and various single-nucleotide polymorphisms (SNPs) [15]. The latter is 
one of the most promising candidates for the elucidation of “hidden” genetic factors 
responsible for idiopathic male infertility. For example, rs1801133 (677C > T) 
variant in the methylenetetrahydrof>olate reductase (MTHFR) (NAD (P) H) gene 
found in males with impaired spermatogenesis [16], rs4986938 (1406 + 1872G > A) 
polymorphism of estrogen receptor 2 (ESR2) gene, rs2070744 (786C > T in the 
promoter region) and rs61722009 (27 bp Variable Number Tandem Repeat (VNTR) 
polymorphisms in the intron 4, also known as 4a4b polymorphisms) variants 
of NOS3 (nitric oxide synthase 3) are the potential predisposal factors of male 
infertility [15].
Still, male infertility depends not only on mutations alone but also on the com-
plex system of gene–environmental interactions and epigenetic factors. A bright 
example of environmental factors, which may cause seminal fluid abnormalities 
in the corresponding genetic background, is xenobiotics, which is discussed in the 
following sections.
4. Association of xenobiotics with male infertility
Xenobiotics may interact with macromolecules in reversible (forming non-
covalent bindings, for example, ion pairing, hydrogen bonding, hydrophobic 
interactions, etc.) or irreversible ways through covalent bond formation between 
electrophilic xenobiotics or their active metabolites and endogenous molecules. 
The first variant may lead to the alteration in enzyme and transporter activity, ion 
channels blockade, activation of specific receptors and violation in DNA transcrip-
tion, if the specific structure of the xenobiotic fits to macromolecule-binding sites. 
Irreversible covalent interaction does not demand such fitness of structures and 
leads to the formation of endogenous adducts of nucleophiles (such as nucleophilic 
amino acid or nucleic acids). As a result, such reactions may cause genetic muta-
tions, carcinogenesis (if the violated gene participates in regulation of cell repro-
duction and differentiation) and protein malfunctions, which consequently may 
promote cell death and tissue toxicity.
It is worth mentioning that xenobiotics injure the male reproductive system 
not only by themselves and their metabolites but also via defensive reactions of the 
organism, such as innate and specific acquired immune responses. Thus, locally 
available reactive metabolites may cause disruption of testis immunoprivilege 
through the immunocompetent cells activation. This would lead to organ-specific 
immunopathology. Xenobiotics may have a toxic effect due to the malfunction 
of both the first and the second phase enzymes because of their hyperactive or 
inhibited functioning. In the case of increased phase I enzyme activity, or decreased 
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phase II enzyme activity, electrophilic intermediates of the xenobiotic metabolism 
are accumulated in the cells and mediate the abovementioned damages. At the same 
time, the reduced activity of the first phase enzymes leads to metabolism retarda-
tion and accumulation of noxious chemical compounds in different tissues of the 
organism, including in those of the reproductive system. For example, decreased 
activity of GST (phase II enzyme that transfers glutathione (GSH) to activated 
environmental chemicals) will probably lead to the formation of reactive inter-
mediates that will mediate cell damage mechanisms. On the other hand, phase I 
enzyme CYP1A1 is able to metabolize the polycyclic aromatic hydrocarbons (PAHs) 
to intermediate substances, which prompt genotoxic and mutagenic effects before 
they are further detoxified by phase II enzymes. This indicates that the increased 
activity of CYP1A1 may contribute to the accumulation of these compounds in the 
organism and to the elevation of the PAH-DNA adducts level. Although the liver 
performs the main functions of detoxification, reactive metabolites can also be 
generated in a particular organ, mediating organ specific toxicity. For example, 
experiments on laboratory animals such as rats and mice showed the presence of 
both phase I and phase II enzymes in their testicles. [17, 18]. The possibility of PAHs 
(benzo(a)pyrene) detoxification was also shown on the rats’ Leydig cells [19]. The 
xenobiotic-detoxification enzymes are much needed in the reproductive system, 
since some endocrine-deteriorating agents (phthalates, dioxins, polychlorinated 
biphenyls (PCBs) and pesticides) have been shown to exert a negative influence on 
the reproductive tissues [20]. Thus, stable and lipophilic chlorinated hydrocarbons 
are capable of penetrating into the male reproductive tract, promoting idiopathic 
sterility and other reproductive impairments. One of the well-studied examples of 
male testicular toxins is occupational xenobiotic nematocide 1,2-dibromo 3-chlo-
ropropane (DBCP) that causes a partially reversible damage to the seminiferous 
epithelium, leading to diminished sperm counts and sterility [21]. Another occu-
pational and environmental toxin dichlorodiphenyldichloroethylene also reduces 
sperm count and mediates male infertility [22].
5. Polymorphism of genes that affect spermatogenesis
Except xenobiotic detoxification gene polymorphisms, another target group of 
genes that are most probably involved in development of male infertility is genes 
take part in spermatogenesis. This group includes genes with different functions 
such as endocrine regulation of spermatogenesis (i.e., androgen receptor (AR), 
follicle-stimulating hormone receptor (FSHR) and Estrogen receptor α and β), 
specific spermatogenic functions (i.e., deleted azoospermia-like (DAZL), Ubiquitin 
carboxyl-terminal hydrolase 26 (USP26), protamine-1 (PRM1) and gonadotro-
phin-regulated testicular helicase (GRTH)), regulation of cell functions such as 
metabolism, cell cycle and mutation repair (i.e., mtDNA polymerase γ (POLG) and 
Methylene tetrahydrofolate reductase (MTHFR)) and Y-chromosome haplogroups. 
Y-chromosome abnormalities are the best studied, while data about association of 
male infertility with the other spermatogenesis regulation genes remain contradic-
tory. For example, the spermatogenesis locus azoospermia factor c (AZFc) region 
partial deletion (gr/gr deletions, which include DAZ (Deleted in azoospermia) 
genes) is regarded as classical Y-chromosome mutation. Its role in male infertility 
was proven by several studies, although it is present in normospermic men as well 
[16, 23]. Here are some examples of the other probable risk factors obtained by 
meta-analysis [23]. One of gene candidates, which is regarded as the most probable 
risk factor of male infertility, is MTHFR, which encodes methylenetetrahydrofolate 
reductase—one of the key enzymes in folate metabolism. The C → T substitution in 
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Mutations (that include both chromosomal and single-gene alterations) in sev-
eral hundred genes are the other important and significant factor that potentially 
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polymorphism of estrogen receptor 2 (ESR2) gene, rs2070744 (786C > T in the 
promoter region) and rs61722009 (27 bp Variable Number Tandem Repeat (VNTR) 
polymorphisms in the intron 4, also known as 4a4b polymorphisms) variants 
of NOS3 (nitric oxide synthase 3) are the potential predisposal factors of male 
infertility [15].
Still, male infertility depends not only on mutations alone but also on the com-
plex system of gene–environmental interactions and epigenetic factors. A bright 
example of environmental factors, which may cause seminal fluid abnormalities 
in the corresponding genetic background, is xenobiotics, which is discussed in the 
following sections.
4. Association of xenobiotics with male infertility
Xenobiotics may interact with macromolecules in reversible (forming non-
covalent bindings, for example, ion pairing, hydrogen bonding, hydrophobic 
interactions, etc.) or irreversible ways through covalent bond formation between 
electrophilic xenobiotics or their active metabolites and endogenous molecules. 
The first variant may lead to the alteration in enzyme and transporter activity, ion 
channels blockade, activation of specific receptors and violation in DNA transcrip-
tion, if the specific structure of the xenobiotic fits to macromolecule-binding sites. 
Irreversible covalent interaction does not demand such fitness of structures and 
leads to the formation of endogenous adducts of nucleophiles (such as nucleophilic 
amino acid or nucleic acids). As a result, such reactions may cause genetic muta-
tions, carcinogenesis (if the violated gene participates in regulation of cell repro-
duction and differentiation) and protein malfunctions, which consequently may 
promote cell death and tissue toxicity.
It is worth mentioning that xenobiotics injure the male reproductive system 
not only by themselves and their metabolites but also via defensive reactions of the 
organism, such as innate and specific acquired immune responses. Thus, locally 
available reactive metabolites may cause disruption of testis immunoprivilege 
through the immunocompetent cells activation. This would lead to organ-specific 
immunopathology. Xenobiotics may have a toxic effect due to the malfunction 
of both the first and the second phase enzymes because of their hyperactive or 
inhibited functioning. In the case of increased phase I enzyme activity, or decreased 
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phase II enzyme activity, electrophilic intermediates of the xenobiotic metabolism 
are accumulated in the cells and mediate the abovementioned damages. At the same 
time, the reduced activity of the first phase enzymes leads to metabolism retarda-
tion and accumulation of noxious chemical compounds in different tissues of the 
organism, including in those of the reproductive system. For example, decreased 
activity of GST (phase II enzyme that transfers glutathione (GSH) to activated 
environmental chemicals) will probably lead to the formation of reactive inter-
mediates that will mediate cell damage mechanisms. On the other hand, phase I 
enzyme CYP1A1 is able to metabolize the polycyclic aromatic hydrocarbons (PAHs) 
to intermediate substances, which prompt genotoxic and mutagenic effects before 
they are further detoxified by phase II enzymes. This indicates that the increased 
activity of CYP1A1 may contribute to the accumulation of these compounds in the 
organism and to the elevation of the PAH-DNA adducts level. Although the liver 
performs the main functions of detoxification, reactive metabolites can also be 
generated in a particular organ, mediating organ specific toxicity. For example, 
experiments on laboratory animals such as rats and mice showed the presence of 
both phase I and phase II enzymes in their testicles. [17, 18]. The possibility of PAHs 
(benzo(a)pyrene) detoxification was also shown on the rats’ Leydig cells [19]. The 
xenobiotic-detoxification enzymes are much needed in the reproductive system, 
since some endocrine-deteriorating agents (phthalates, dioxins, polychlorinated 
biphenyls (PCBs) and pesticides) have been shown to exert a negative influence on 
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reductase—one of the key enzymes in folate metabolism. The C → T substitution in 
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the position 667 changes an alanine to a valine (Ala222Val) and decreases activity 
of enzyme, thus leading to the decrement of spermatogenesis. FSHR SNP showed a 
significant association with seminal fluid abnormalities only in the case when both 
the exon 10 SNPs and SNP of promoter at position 29 are present. G197 T SNP in 
PRM1 gene, which encodes DNA-binding protein, responsible for packing of DNA 
into the sperm head, may by a novel risk factor for patients with a normal sperm 
count but elevated levels of sperm DNA fragmentation and/or teratozoospermia. 
Studying of the genes affecting spermatogenesis also demonstrated significant 
influence of ethnicity on the association of polymorphisms and the risk of male 
infertility. Thus, AR repeat length polymorphism with repeat number more than 23 
is a risk factor for Asiatic but not the European population. T54A mutation in exon 3 
of DAZL gene was significantly associated with oligospermia or azoospermia in the 
Chinese population, while in Japanese or Caucasian populations, such an associa-
tion was not established. The POLG gene, which encodes mtDNA polymerase γ and 
thus important for mitochondria functioning, has common 10-fold repeated CAG 
motif in the first exon. It is known that mitochondria are one of the main determi-
nants of sperm motility, and their altered regulation may be connected with asthe-
nozoospermia (which is characterized by reduced sperm motility). Nevertheless, 
only one study [24] among four considered [24–27] established that the absence of 
this allele was significantly associated with male infertility. These results may not 
be relevant enough, as far as the sample size was not sufficiently big, (verum group 
included 99 infertile men, while control, 98 fertile men). In spite of the increased 
interest in the genetic causes of male infertility, there are no clear predictive and 
diagnostic criteria, except few polymorphisms such as AZF gr/gr deletions (OR 
1.81, 1.46–2.24 CI, P < 0.00001) and MTHFR 677C → T (OR 1.39, 1.15–2.69 95% 
CI, P = 0.0006) [16]. The only way to build an adequate picture of reasons standing 
behind idiopathic male infertility is application of methods based on whole genome 
analysis, taking into account environmental factors.
6. Polymorphism of xenobiotic detoxification genes
The reasons behind the idiopathic cases of male infertility can probably be 
explained by the existence of unidentified genetic abnormalities involving several 
hundred genes, environmental interaction and epigenetics. Each of these genes is 
accountable for only a small part of the cases. In the late 1990s, the polymorphisms-
based approach to searching for genetic factors in patients with idiopathic infertility 
was reinforced because of the findings of other investigations related to multifacto-
rial impairments. Potential polymorphic genes that participate in male infertility 
development were determined from the increasing data on model organisms, 
expression analyses (transcriptome and proteome analyses) associated with poor 
germ cells quality and from data available from the Genome-Wide Association 
Studies (GWAS). In total, 2000 genes (housekeeping and germ cell specific genes) 
are engaged in spermatogenesis [28], but 314 single-nucleotide polymorphisms 
(SNPs) have been reported only in 123 genes for the year 2015 [15]. Nearly 70% of 
these SNPs are responsible for general cell functions (regulation of apoptosis, DNA 
repair, xenobiotic metabolism and detoxification of reactive oxygen species), while 
the rest are involved in specific processes associated with spermatogenesis, meiosis 
and endocrine regulation of the reproductive system. However, available data are 
often contradictory and only a small amount of genetic polymorphisms are well 
studied. Meta-analyses were conducted for such genes as AR, CYP1A1, GSTP1, 
GSTM1, GSTT1, DAZL, ESR1, ESR2, MTHFR, NOS3, POLG, TP53 and USP26, 
among which CYP1A1, GSTP1, GSTM1 and GSTT1 detoxify the environmental 
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chemicals and are of great interest. In addition to the abovementioned genes, NAT2 
will also be regarded as an important candidate carrying SNPs that alter xenobiotic 
detoxification phenotypes. Readers considering the represented data should always 
bear in mind that determination of connections between xenobiotic detoxifica-
tion genes polymorphisms and male infertility is significantly complicated by 
the existence of intricate interactions among phase I and phase II metabolizing 
enzymes, as well as among the phase III transporters and their nuclear receptors 
(aryl hydrocarbon receptor (AhR), orphan nuclear receptors, nuclear factor-
erythroid 2 p45-related factor 2 (Nrf2), constitutive androstane receptor (CAR) 
and pregnane X receptor (PXR)). These receptors can act as transcriptional fac-
tors for some xenobiotic metabolizing enzymes. For instance, CYP1 genes can be 
induced by AhR in response to PAHs, while CYP2B and CYP3A genes are activated 
by CAR and PXR in response to phenobarbital-like compounds and dexamethasone 
and rifampin-type of agents, respectively. It was also assumed that Nrf2 is the most 
likely transcriptional factor for phase II detoxification enzymes (such as GST) [29]. 
Thus, mutations or polymorphisms of these genes may contribute to alteration of 
xenobiotic metabolism indirectly that can also lead to a damage of the male repro-
ductive system.
6.1 Cytochrome P4501A1 polymorphism
Cytochrome P4501A1 (CYP1A1) is a heme-thiolate containing monooxygenase 
that plays a central role in phase I extra-hepatic metabolism of lipophilic xenobiot-
ics, such as polycyclic aromatic hydrocarbons (PAHs) that are produced during 
the combustion of fossil fuels, protein pyrolysis in well-fried meat, as well as from 
aromatic amines, which are present in cigarette smoke, pesticides, dyes, drugs and 
industrial products. CYP1A1 is expressed in male reproductive organs. Thus, its 
polymorphisms may define susceptibility to male infertility [30]. In addition to 
PAHs metabolism, CYP1A1 participates in the synthesis of cholesterol, steroids 
and other lipids, as well as in steroid hormone metabolism. Thus, its polymorphic 
variants can intervene in the endocrine and paracrine regulation of testicular 
function [31]. Cytochrome P4501A1 gene is located on 15q22-q24 chromosome. It 
is 5987-bp long and encodes a 512 amino acid protein. Benzo(a)pyrene, 3-meth-
ylcholanthrene, PCBs or 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) activate its 
expression. Although the CYP1A1 is a polymorphic gene, only two common SNPs 
have been found to be functionally significant, namely, CYP1A1*2A (3801 T > C in 
the 3′-flanking region, rs4646903) and CYP1A1*2C (Ile462Val, 2455A > G (exon 
7), rs1048943) [32]. The T > C substitution in CYP1A1*2A promotes the creation of 
a new MspI restriction site in the noncoding 3′-flanking region that causes eleva-
tion of transcript half-life and consequently enzyme activity, leading to increased 
levels of reactive metabolites [33]. The A > G substitution prompts an isoleucine-
valine exchange in the heme-binding region of the enzyme, and according to some 
studies, it changes the enzyme’s kinetics during the generation of diol metabolites 
of benzo[a]pyrene or causes a -threefold increase in transcripts quantity and 
microsomal enzyme activity in Asians [34]. Such data can be explained by the fact 
that the CYP1A1*2A and CYP1A1*2C allelic variants appear much more frequently 
in Asians compared with other ethnic groups, namely, Caucasians and African 
Americans [35]. However, these data are contradictory. A recent meta-analysis 
of 1060 cases and 1225 controls from 7 published case–control studies revealed 
that the homozygous CYP1A1*2A genotype was significantly associated with the 
susceptibility to idiopathic male infertility in Asians (CC vs. TT: OR = 2.88, 95% 
CI: 1.20–6.89, TC vs. TT: OR = 1.42, 95% CI: 1.03–1.98, recessive model: OR = 1.63, 
95% CI: 1.08–2.45.) but not in Caucasians, while no association with male infertility 
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95% CI: 1.08–2.45.) but not in Caucasians, while no association with male infertility 
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risk was found in the case of CYP1A1*2C genotype (GG vs. AA: OR = 1.03, 95% CI: 
0.53–1.99, GA vs. AA: OR = 1.51, 95% CI: 0.51–4.43, dominant model: OR = 0.81, 
95% CI: 0.42–1.54, recessive model: OR = 1.57, 95% CI: 0.55–4.47) [36]. Still, these 
results seem to be preliminary, since such individual characteristics as age, body 
mass index, smoking status and environmental factors, as well as the sperm concen-
tration, motility and other semen parameters were not taken into account during 
the data analysis. Another meta-analysis of 6 studies including 1060 cases and 1225 
controls also confirmed a valid association between CYP1A1*2A genotype and the 
male infertility risk with the highest figures for the homozygous variant (OR = 2.18, 
95% CI: 1.15–4.12) [37]. Subgroup analysis based on ethnicity, sample size and 
quality assessment score failed to expose any significant level probably due to 
limited studies and population numbers discussed in the meta-analysis. Moreover, 
these conclusions may be irrelevant and need to be confirmed, as only two of six 
considered studies showed significant correlation and the abovementioned meta-
analysis did not account the differences in exposure to environmental factors. The 
latter factor is of prime importance in the case of xenobiotic detoxification genes. 
Thus, Yarosh et al. [38] revealed a significant association between CYP1A1*2C 
and idiopathic male infertility risk only among smokers but not among nonsmok-
ers. Finally, CYP1A1 may participate in male infertility through induction of the 
oxidative imbalance in cells as far as together with ligand-dependent transcription 
factor—Aryl hydrocarbon receptor (AhR)—it is capable of generating local reactive 
oxygen species (ROS) [39]. Considering that morphologically abnormal semen has 
reduced antioxidant capacity and increased ROS production [40], CYP1A1 may 
play a crucial role in male infertility development.
6.2 GSTM1, GSTT1 and GSTP1 polymorphisms
Human semen is rich in Glutathione S-transferases (GSTs) [41], which belongs 
to phase II superfamily of antioxidant enzymes involved in the cellular detoxifica-
tion of various physiological substances (e.g., excessive ROS) or exogenous electro-
philes. Detoxification process depends on the gene family class. At least seven gene 
classes of GSTs can be allocated: alpha (α), mu (μ), pi (π), sigma (ς), theta (θ), 
kappa (k) and zeta (ζ). They are coding GSTA, GSTM, GSTP, GSTS, GSTT, GSTK 
and GSTZ enzymes, respectively. Polymorphisms are encountered most frequently 
in GSTM1, GSTT1 and GSTP1 subfamilies. According to the available data, GSTM1 
and GSTT1 null polymorphic variants are the most studied GST SNPs and are 
associated with the increased susceptibility to several diseases and hypersensitiv-
ity to toxic xenobiotics [42]. For instance, GSTM1 was shown to have homozygous 
deletion in nearly half of the people from various ethnicities. Such deletion results 
in decreased enzyme function [43]. In general, inhibited GST activity leads to 
diminished semen motility via membrane damage. Considering that unmetabo-
lized toxic substances, which accumulate in the cellular matrix of the testis, cause 
spermatogenesis deterioration, another probable reason for sperm impairment in 
subjects with GSTM1 or GSTT1 null genotypes may be considered to be the insuf-
ficient functioning of seminiferous tubules and fibrosis developed in the testicular 
tissue [44].
GSTM1 is located on 1p13.3 chromosome; three alleles have been identified at 
its locus: GSTM1*A, GSTM1*B (causing the lysine 172 replacement by aspartic acid 
(534C > G) and not exhibiting alterations in enzyme activity) and GSTM1 null 
genotype (gene deletion) [45].
GSTT1 is located on 22q11 chromosome and has one polymorphism 
(GSTT1 null genotype) that leads to the inhibition of enzyme production in 
homozygote [46].
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Several studies have suggested that GSTM1, as well as GSTT1, might be crucial 
isozymes in the metabolism of ROS [47, 48]; meanwhile, diminished antioxidant 
capacity of seminal plasma turned out to promote subfertility.
Numerous studies reported the connection between the polymorphisms of GST 
genes and the DNA fragmentation increased due to the impaired defense against 
oxidative stress [49], which may result in some kinds of cancers. Considering that 
surplus of reactive oxygen species is a damaging factor for spermatozoa, GST 
SNPs most likely contribute to idiopathic male infertility. A possible explanation 
for the spermatogenesis impairment in GSTT1 and GSTM1 null allele carriers was 
proposed by Wu et al. [50]. Considering that null genotypes eliminate the bind-
ing site for some transcription factors, such as nuclear factor 1 (NF-1) (may act 
as transcriptional repressor or activator, determined by target gene expression), 
specificity protein 1 (SP1) (involved in cell differentiation, cell growth, apoptosis, 
immune responses, response to DNA damage and chromatin remodeling) and serum 
response factor (SRF) (participates in transforming extracellular signals into specific 
nuclear responses), GSTT1 and GSTM1 null variants may cause changes in gene 
expression through the removal of transcription factors. Such alterations in gene 
expression may entail deterioration of sperm maturation and impaired fertility.
Another polymorphic gene (GSTP1) is approximately 4 kb in length and is 
located on 11q13.2 chromosome. It includes 7 exons and encodes a 210 amino acid 
protein. Two polymorphisms of GSTP1 rs1138272 (341C > T (exon 6) leading to 
the alanine 114 replacement by valine) and rs1695 (313A > G (exon 5) encoding 
the amino acid exchange (replacement of isoleucine in the position 105 by valine) 
were associated with a decreased heat stability and the detoxification ability of this 
enzyme [51].
Most of the current data on the polymorphisms of xenobiotic detoxification 
gene are devoted to GST SNPs. A pooled analysis of 11 studies (7 involve Asians 
and 4 involve Caucasians), which included 1323 cases and 1054 controls, revealed 
that GSTM1 (OR = 2.75, 95%; CI: 1.72–3.84, P = 0.003) and GSTT1 null (OR = 1.54, 
95%; CI: 1.43–3.47, P = 0.02) genotypes showed significant association with strong/
moderate risk of impaired male fertility, respectively. At the same time, GSTP1 
Ile/Val genotype was proved to mediate the protective effect on male reproductive 
system (OR = 0.48, 95%; CI: 0.27–0.77) [52]. These results are reliable enough, 
as far as researchers took into account the age, ethnicity and the smoking status. 
Interestingly, that in contrast to CYP1A1 polymorphism, there was no difference 
between smokers and nonsmokers (P = 0.26). At the same time, GSTM1 null geno-
type, considered in the research on Indian subjects, showed 8.6 times increment 
of infertility risk if the subject was a smoker. Going back to the pooled analysis, 
synergistic effects of GSTM1 null allele, GSTT1 null allele and GSTP1 Ile/Ile poly-
morphism on male infertility was recognized as a valuable feature of this research 
[53]. However, further analysis showed that GSTM1 null genotype was associated 
with male infertility only at a borderline level of significance [53]. Such inconsis-
tency may be explained by more rigid selection criteria in the latter meta-analysis. 
Since 161 of 168 studies were excluded, only 6 case-control studies concerning the 
GSTM1 genotype and 5 studies concerning the GSTT1 were eligible. Moreover, 
most studies referred to Caucasian subjects (except one, concerning the GSTM1 
polymorphism, and two, concerning the GSTT1 polymorphism). On this basis, no 
ethnic variations were analyzed. Another doubtful issue touches upon the possibil-
ity of association between GSTP1 Ile/Ile polymorphism and the susceptibility to 
idiopathic male infertility. The fact is that in human population, Ile allele is encoun-
tered more frequently than the Val allele is. Thus, its positioning as a risk factor 
for male infertility contradicts the principles of evolutionary genetics, as Ile allele 
should have disappeared from the population. Furthermore, recent meta-analysis, 
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risk was found in the case of CYP1A1*2C genotype (GG vs. AA: OR = 1.03, 95% CI: 
0.53–1.99, GA vs. AA: OR = 1.51, 95% CI: 0.51–4.43, dominant model: OR = 0.81, 
95% CI: 0.42–1.54, recessive model: OR = 1.57, 95% CI: 0.55–4.47) [36]. Still, these 
results seem to be preliminary, since such individual characteristics as age, body 
mass index, smoking status and environmental factors, as well as the sperm concen-
tration, motility and other semen parameters were not taken into account during 
the data analysis. Another meta-analysis of 6 studies including 1060 cases and 1225 
controls also confirmed a valid association between CYP1A1*2A genotype and the 
male infertility risk with the highest figures for the homozygous variant (OR = 2.18, 
95% CI: 1.15–4.12) [37]. Subgroup analysis based on ethnicity, sample size and 
quality assessment score failed to expose any significant level probably due to 
limited studies and population numbers discussed in the meta-analysis. Moreover, 
these conclusions may be irrelevant and need to be confirmed, as only two of six 
considered studies showed significant correlation and the abovementioned meta-
analysis did not account the differences in exposure to environmental factors. The 
latter factor is of prime importance in the case of xenobiotic detoxification genes. 
Thus, Yarosh et al. [38] revealed a significant association between CYP1A1*2C 
and idiopathic male infertility risk only among smokers but not among nonsmok-
ers. Finally, CYP1A1 may participate in male infertility through induction of the 
oxidative imbalance in cells as far as together with ligand-dependent transcription 
factor—Aryl hydrocarbon receptor (AhR)—it is capable of generating local reactive 
oxygen species (ROS) [39]. Considering that morphologically abnormal semen has 
reduced antioxidant capacity and increased ROS production [40], CYP1A1 may 
play a crucial role in male infertility development.
6.2 GSTM1, GSTT1 and GSTP1 polymorphisms
Human semen is rich in Glutathione S-transferases (GSTs) [41], which belongs 
to phase II superfamily of antioxidant enzymes involved in the cellular detoxifica-
tion of various physiological substances (e.g., excessive ROS) or exogenous electro-
philes. Detoxification process depends on the gene family class. At least seven gene 
classes of GSTs can be allocated: alpha (α), mu (μ), pi (π), sigma (ς), theta (θ), 
kappa (k) and zeta (ζ). They are coding GSTA, GSTM, GSTP, GSTS, GSTT, GSTK 
and GSTZ enzymes, respectively. Polymorphisms are encountered most frequently 
in GSTM1, GSTT1 and GSTP1 subfamilies. According to the available data, GSTM1 
and GSTT1 null polymorphic variants are the most studied GST SNPs and are 
associated with the increased susceptibility to several diseases and hypersensitiv-
ity to toxic xenobiotics [42]. For instance, GSTM1 was shown to have homozygous 
deletion in nearly half of the people from various ethnicities. Such deletion results 
in decreased enzyme function [43]. In general, inhibited GST activity leads to 
diminished semen motility via membrane damage. Considering that unmetabo-
lized toxic substances, which accumulate in the cellular matrix of the testis, cause 
spermatogenesis deterioration, another probable reason for sperm impairment in 
subjects with GSTM1 or GSTT1 null genotypes may be considered to be the insuf-
ficient functioning of seminiferous tubules and fibrosis developed in the testicular 
tissue [44].
GSTM1 is located on 1p13.3 chromosome; three alleles have been identified at 
its locus: GSTM1*A, GSTM1*B (causing the lysine 172 replacement by aspartic acid 
(534C > G) and not exhibiting alterations in enzyme activity) and GSTM1 null 
genotype (gene deletion) [45].
GSTT1 is located on 22q11 chromosome and has one polymorphism 
(GSTT1 null genotype) that leads to the inhibition of enzyme production in 
homozygote [46].
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Several studies have suggested that GSTM1, as well as GSTT1, might be crucial 
isozymes in the metabolism of ROS [47, 48]; meanwhile, diminished antioxidant 
capacity of seminal plasma turned out to promote subfertility.
Numerous studies reported the connection between the polymorphisms of GST 
genes and the DNA fragmentation increased due to the impaired defense against 
oxidative stress [49], which may result in some kinds of cancers. Considering that 
surplus of reactive oxygen species is a damaging factor for spermatozoa, GST 
SNPs most likely contribute to idiopathic male infertility. A possible explanation 
for the spermatogenesis impairment in GSTT1 and GSTM1 null allele carriers was 
proposed by Wu et al. [50]. Considering that null genotypes eliminate the bind-
ing site for some transcription factors, such as nuclear factor 1 (NF-1) (may act 
as transcriptional repressor or activator, determined by target gene expression), 
specificity protein 1 (SP1) (involved in cell differentiation, cell growth, apoptosis, 
immune responses, response to DNA damage and chromatin remodeling) and serum 
response factor (SRF) (participates in transforming extracellular signals into specific 
nuclear responses), GSTT1 and GSTM1 null variants may cause changes in gene 
expression through the removal of transcription factors. Such alterations in gene 
expression may entail deterioration of sperm maturation and impaired fertility.
Another polymorphic gene (GSTP1) is approximately 4 kb in length and is 
located on 11q13.2 chromosome. It includes 7 exons and encodes a 210 amino acid 
protein. Two polymorphisms of GSTP1 rs1138272 (341C > T (exon 6) leading to 
the alanine 114 replacement by valine) and rs1695 (313A > G (exon 5) encoding 
the amino acid exchange (replacement of isoleucine in the position 105 by valine) 
were associated with a decreased heat stability and the detoxification ability of this 
enzyme [51].
Most of the current data on the polymorphisms of xenobiotic detoxification 
gene are devoted to GST SNPs. A pooled analysis of 11 studies (7 involve Asians 
and 4 involve Caucasians), which included 1323 cases and 1054 controls, revealed 
that GSTM1 (OR = 2.75, 95%; CI: 1.72–3.84, P = 0.003) and GSTT1 null (OR = 1.54, 
95%; CI: 1.43–3.47, P = 0.02) genotypes showed significant association with strong/
moderate risk of impaired male fertility, respectively. At the same time, GSTP1 
Ile/Val genotype was proved to mediate the protective effect on male reproductive 
system (OR = 0.48, 95%; CI: 0.27–0.77) [52]. These results are reliable enough, 
as far as researchers took into account the age, ethnicity and the smoking status. 
Interestingly, that in contrast to CYP1A1 polymorphism, there was no difference 
between smokers and nonsmokers (P = 0.26). At the same time, GSTM1 null geno-
type, considered in the research on Indian subjects, showed 8.6 times increment 
of infertility risk if the subject was a smoker. Going back to the pooled analysis, 
synergistic effects of GSTM1 null allele, GSTT1 null allele and GSTP1 Ile/Ile poly-
morphism on male infertility was recognized as a valuable feature of this research 
[53]. However, further analysis showed that GSTM1 null genotype was associated 
with male infertility only at a borderline level of significance [53]. Such inconsis-
tency may be explained by more rigid selection criteria in the latter meta-analysis. 
Since 161 of 168 studies were excluded, only 6 case-control studies concerning the 
GSTM1 genotype and 5 studies concerning the GSTT1 were eligible. Moreover, 
most studies referred to Caucasian subjects (except one, concerning the GSTM1 
polymorphism, and two, concerning the GSTT1 polymorphism). On this basis, no 
ethnic variations were analyzed. Another doubtful issue touches upon the possibil-
ity of association between GSTP1 Ile/Ile polymorphism and the susceptibility to 
idiopathic male infertility. The fact is that in human population, Ile allele is encoun-
tered more frequently than the Val allele is. Thus, its positioning as a risk factor 
for male infertility contradicts the principles of evolutionary genetics, as Ile allele 
should have disappeared from the population. Furthermore, recent meta-analysis, 
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devoted to the association between GSTP1 polymorphism and cancer susceptibility, 
revealed that Val allele was a risk factor for carcinogenesis, and no accumulation 
effect of Ile/Ile genotype was revealed [54]. All this indicates the necessity of 
additional researches that would comprise GSTP1 Ile/Ile polymorphism.
Another GSTP1 polymorphism—Ala/Val (rs1138272) substitution—was studied 
even less extensively than the Ile/Val polymorphism. Recently, this SNP was shown 
to be associated with the increased risks of infertility in Vietnam male subjects 
(OR = 7.42, 95%; CI: 3.86–14.30) [55], while previously, another work, devoted to the 
oxidative damage in infertile men with varicoceles, revealed no significant differences 
between the indices recorded in the patient and control groups [56]. Further meta-
analysis that focused on the relationship between the prostate cancer and the GSTP1 
Ala/Val polymorphism revealed no significant associations [57]. Although Aydemir 
et al. did not report such a correlation, they revealed a connection between the 
GSTM1 null polymorphic variant with markers of oxidative stress in patients and the 
idiopathic male infertility [58]. Thus, most investigations, including five meta-analy-
ses, confirmed the GSTM1 association with the risk of male infertility [52, 59–61].
A meta-analysis of 15 researches (8 involve Asian people, 6—European people, 
and 1 comprises a mixed population) that included 1897 cases and 1785 controls 
showed that GSTM1 null genotype was significantly associated with susceptibil-
ity to idiopathic male infertility, but not with sperm concentration. In the case 
of GSTT1 null genotype, no association with oligoasthenoteratozoospermia and 
sperm concentration was revealed. Subgroup analysis on ethnicity did not show any 
reliable association between the idiopathic male infertility and the GSTM1 null or 
GSTT1 null genotype [59].
Contradicting data were obtained via the case-control study of Han people from 
East China, which included 1476 infertile men with normozoospermia, oligozoo-
spermia and nonobstructive azoospermia and 895 healthy controls, matched by age, 
drinking and smoking status, body mass index and semen volume [50]. The research 
revealed that GSTT1 null genotype is a predisposing factor for idiopathic male infer-
tility (OR = 1.26; 95%; CI: 1.07–1.50; P = 0.007), while GSTM1 null genotype showed 
no significant association with the idiopathic male infertility risk (OR = 1.15; 95%; CI: 
0.97–1.36; P = 0.116). At the same time, GSTM1 null variant was prevalent in oligo-
zoospermic patients (OR = 1.55; 95%; CI: 1.15–2.08; P = 0.004), while the GSTT1 null 
polymorphism was associated with normozoospermia (OR = 1.23; 95%; CI: 1.03–1.48; 
P = 0.025) and azoospermia (OR = 1.58; 95%; CI: 1.18–2.11; P = 0.002). Interestingly, 
no differences were found in GSTM1 expression between the present and deleted 
genotypes, but such were found in the GSTT1 null polymorphism, which expression 
was significantly decreased in comparison with the present variant.
The authors also conducted a meta-analysis of 19 case-control studies in 
2002–2013. The meta-analysis included 3981 cases and 2953 controls involving the 
Asian and Caucasian ethnic groups [50]. As a result, GSTM1 null allele carriers were 
subjected to the risk of male infertility (OR = 1.39; 95%; CI: 1.14–1.70; P = 0.001) 
and to oligoasthenoteratozoospermia (OR = 1.53; 95%; CI: 1.25–1.89; P < 0.001). 
This association persisted in the case of subgroup analyses that involved Asians 
(OR = 1.51; 95%; CI: 1.13–2.10; P = 0.005) and Caucasians (OR = 1.24; 95%; CI: 
1.00–1.52; P = 0.046). The GSTT1 null variant, however, was significantly associ-
ated with male infertility only among Asian people (OR = 1.44; 95%; CI: 1.10–1.90; 
P = 0.009). Such results may be explained by the fact that the GSTT1 null genotype 
is most frequently encountered in individuals of Asian origin than in other popula-
tions [62]. On the whole, differences from the previous meta-analysis [59] may be 
explained by the fact that they have added some recent studies.
Data of numerous studies revealing the GST polymorphism effect on the 
male infertility development remain contradictory. The list of the most probable 
95
Polymorphism of Xenobiotic Detoxification Genes and Male Infertility
DOI: http://dx.doi.org/10.5772/intechopen.79233
underlying causes includes the relatively small number of participants, ignoring 
some gene-environment and gene–gene interactions and the possible small influ-
ence of the GST SNPs on the risk of idiopathic male infertility.
6.3 Arylamine N-acetyltransferase 2 polymorphism
Arylamine N-acetyltransferase 2 (NAT2) is a phase II xenobiotic detoxification 
enzyme metabolizing such chemicals as arylamines, aromatic and heterocyclic 
amines and hydrazines via N-acetylation and O-acetylation. In other words, it 
transfers the acetyl group from acetyl-coenzyme A to the nitrogen or oxygen of the 
substrate. It takes part in the metabolism of such drugs as sulfadimidine, sulfameth-
azine, isoniazid, nitrazepam, dapsone or caffeine [63]. Therefore, it determines 
human susceptibility to cancer and the side effects of drugs [64].
Biological significance of NAT2 could be demonstrated through the association 
between its polymorphisms with susceptibility and different types of cancer—lung, 
colon or bladder cancer [65, 66].
NAT2 is expressed in the male reproductive organs (genital ducts, testicular 
tissues, exocrine and prostate glands), promoting protective effect against the 
environmental chemicals that may lead to male urogenital diseases [67].
NAT2 is a 290 amino acid protein, encoded by intronless 9.9 kb gene, located on 
the 8p22 chromosome and consists of 3 exons. Scientists identified the acetylation 
polymorphism more than 60 years ago in tuberculosis patients, who reacted to isonia-
zid toxicity in different ways [68]. NAT2 is characterized by a high number of poly-
morphic genes, comprising more than 66 alleles [69]. Most of these polymorphisms 
are synonymous and do not always cause variations in enzyme activity [70]. The most 
common and important variants of SNPs are rs1799929 (481C > T that does not cause 
leucine alteration at amino acid 161, L161 L) marked as NAT2*11A and rs1799930 
(590G > A that leads to the charged arginine replacement by polar glutamine at the 
codon 197 (R197Q )) marked as NAT2*6 [71]. NAT2*6 corresponds to a slow acetylator 
phenotype, while the NAT2*11A to a rapid one that may differ from the NAT2*6 by 
a threefold incensement in the metabolic rate [72]. These two extreme acetylator 
phenotypes are considered as risk factors for disease development after the subjection 
to arylamines and other NAT2 targets. For instance, NAT1 and NAT2 slow acetylator 
phenotypes were shown to be predisposing factors for prostate cancer [73], while the 
rapid NAT2 phenotypes had higher frequencies in contact-allergic patients [74]. It 
is considered that the existence of canonical isoniazid slow acetylator phenotype is 
caused by the reduction in NAT2 protein [75]. Among the other reasons, there are low 
levels of expression, instability or reduced catalytic activities [76].
There are substantial interethnic variations of the slow acetylator phenotype. Thus, 
it can be found in 40–70% of Caucasian and African people. At the same time, its 
frequency ranges from 10 to 30% in Japanese, Chinese, Korean and Thai people [77].
There is a lack of evidence to confirm the role of NAT2 polymorphism in the 
development of male infertility. However, recently it was proved that gene-envi-
ronment interactions play a very important role in the case of NAT2 polymorphism 
and determine whether it will predispose male infertility. Thus, several data have 
showed that rs1799929 and rs1799929 SNPs themselves were not associated with 
the increased risks of idiopathic male infertility [78]. However, if the subject was 
exposed to cigarette smoking (OR = 1.71, 95% CI: 1.02–2.87, P = 0.042), alcohol 
abuse (OR = 2.14, 95% CI: 1.08–4.27, P = 0.029) and low fruit/vegetable intake 
(OR = 1.68, 95% CI: 1.01–2.79, P = 0.04), the risk of male infertility significantly 
increased in the case of slow acetylator phenotype rs1799930.
Contrariwise, rapid acetylator phenotype was found to cause higher DNA-
fragmentation levels after 2 days of meat diet [79]. Considering that the level of 
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devoted to the association between GSTP1 polymorphism and cancer susceptibility, 
revealed that Val allele was a risk factor for carcinogenesis, and no accumulation 
effect of Ile/Ile genotype was revealed [54]. All this indicates the necessity of 
additional researches that would comprise GSTP1 Ile/Ile polymorphism.
Another GSTP1 polymorphism—Ala/Val (rs1138272) substitution—was studied 
even less extensively than the Ile/Val polymorphism. Recently, this SNP was shown 
to be associated with the increased risks of infertility in Vietnam male subjects 
(OR = 7.42, 95%; CI: 3.86–14.30) [55], while previously, another work, devoted to the 
oxidative damage in infertile men with varicoceles, revealed no significant differences 
between the indices recorded in the patient and control groups [56]. Further meta-
analysis that focused on the relationship between the prostate cancer and the GSTP1 
Ala/Val polymorphism revealed no significant associations [57]. Although Aydemir 
et al. did not report such a correlation, they revealed a connection between the 
GSTM1 null polymorphic variant with markers of oxidative stress in patients and the 
idiopathic male infertility [58]. Thus, most investigations, including five meta-analy-
ses, confirmed the GSTM1 association with the risk of male infertility [52, 59–61].
A meta-analysis of 15 researches (8 involve Asian people, 6—European people, 
and 1 comprises a mixed population) that included 1897 cases and 1785 controls 
showed that GSTM1 null genotype was significantly associated with susceptibil-
ity to idiopathic male infertility, but not with sperm concentration. In the case 
of GSTT1 null genotype, no association with oligoasthenoteratozoospermia and 
sperm concentration was revealed. Subgroup analysis on ethnicity did not show any 
reliable association between the idiopathic male infertility and the GSTM1 null or 
GSTT1 null genotype [59].
Contradicting data were obtained via the case-control study of Han people from 
East China, which included 1476 infertile men with normozoospermia, oligozoo-
spermia and nonobstructive azoospermia and 895 healthy controls, matched by age, 
drinking and smoking status, body mass index and semen volume [50]. The research 
revealed that GSTT1 null genotype is a predisposing factor for idiopathic male infer-
tility (OR = 1.26; 95%; CI: 1.07–1.50; P = 0.007), while GSTM1 null genotype showed 
no significant association with the idiopathic male infertility risk (OR = 1.15; 95%; CI: 
0.97–1.36; P = 0.116). At the same time, GSTM1 null variant was prevalent in oligo-
zoospermic patients (OR = 1.55; 95%; CI: 1.15–2.08; P = 0.004), while the GSTT1 null 
polymorphism was associated with normozoospermia (OR = 1.23; 95%; CI: 1.03–1.48; 
P = 0.025) and azoospermia (OR = 1.58; 95%; CI: 1.18–2.11; P = 0.002). Interestingly, 
no differences were found in GSTM1 expression between the present and deleted 
genotypes, but such were found in the GSTT1 null polymorphism, which expression 
was significantly decreased in comparison with the present variant.
The authors also conducted a meta-analysis of 19 case-control studies in 
2002–2013. The meta-analysis included 3981 cases and 2953 controls involving the 
Asian and Caucasian ethnic groups [50]. As a result, GSTM1 null allele carriers were 
subjected to the risk of male infertility (OR = 1.39; 95%; CI: 1.14–1.70; P = 0.001) 
and to oligoasthenoteratozoospermia (OR = 1.53; 95%; CI: 1.25–1.89; P < 0.001). 
This association persisted in the case of subgroup analyses that involved Asians 
(OR = 1.51; 95%; CI: 1.13–2.10; P = 0.005) and Caucasians (OR = 1.24; 95%; CI: 
1.00–1.52; P = 0.046). The GSTT1 null variant, however, was significantly associ-
ated with male infertility only among Asian people (OR = 1.44; 95%; CI: 1.10–1.90; 
P = 0.009). Such results may be explained by the fact that the GSTT1 null genotype 
is most frequently encountered in individuals of Asian origin than in other popula-
tions [62]. On the whole, differences from the previous meta-analysis [59] may be 
explained by the fact that they have added some recent studies.
Data of numerous studies revealing the GST polymorphism effect on the 
male infertility development remain contradictory. The list of the most probable 
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underlying causes includes the relatively small number of participants, ignoring 
some gene-environment and gene–gene interactions and the possible small influ-
ence of the GST SNPs on the risk of idiopathic male infertility.
6.3 Arylamine N-acetyltransferase 2 polymorphism
Arylamine N-acetyltransferase 2 (NAT2) is a phase II xenobiotic detoxification 
enzyme metabolizing such chemicals as arylamines, aromatic and heterocyclic 
amines and hydrazines via N-acetylation and O-acetylation. In other words, it 
transfers the acetyl group from acetyl-coenzyme A to the nitrogen or oxygen of the 
substrate. It takes part in the metabolism of such drugs as sulfadimidine, sulfameth-
azine, isoniazid, nitrazepam, dapsone or caffeine [63]. Therefore, it determines 
human susceptibility to cancer and the side effects of drugs [64].
Biological significance of NAT2 could be demonstrated through the association 
between its polymorphisms with susceptibility and different types of cancer—lung, 
colon or bladder cancer [65, 66].
NAT2 is expressed in the male reproductive organs (genital ducts, testicular 
tissues, exocrine and prostate glands), promoting protective effect against the 
environmental chemicals that may lead to male urogenital diseases [67].
NAT2 is a 290 amino acid protein, encoded by intronless 9.9 kb gene, located on 
the 8p22 chromosome and consists of 3 exons. Scientists identified the acetylation 
polymorphism more than 60 years ago in tuberculosis patients, who reacted to isonia-
zid toxicity in different ways [68]. NAT2 is characterized by a high number of poly-
morphic genes, comprising more than 66 alleles [69]. Most of these polymorphisms 
are synonymous and do not always cause variations in enzyme activity [70]. The most 
common and important variants of SNPs are rs1799929 (481C > T that does not cause 
leucine alteration at amino acid 161, L161 L) marked as NAT2*11A and rs1799930 
(590G > A that leads to the charged arginine replacement by polar glutamine at the 
codon 197 (R197Q )) marked as NAT2*6 [71]. NAT2*6 corresponds to a slow acetylator 
phenotype, while the NAT2*11A to a rapid one that may differ from the NAT2*6 by 
a threefold incensement in the metabolic rate [72]. These two extreme acetylator 
phenotypes are considered as risk factors for disease development after the subjection 
to arylamines and other NAT2 targets. For instance, NAT1 and NAT2 slow acetylator 
phenotypes were shown to be predisposing factors for prostate cancer [73], while the 
rapid NAT2 phenotypes had higher frequencies in contact-allergic patients [74]. It 
is considered that the existence of canonical isoniazid slow acetylator phenotype is 
caused by the reduction in NAT2 protein [75]. Among the other reasons, there are low 
levels of expression, instability or reduced catalytic activities [76].
There are substantial interethnic variations of the slow acetylator phenotype. Thus, 
it can be found in 40–70% of Caucasian and African people. At the same time, its 
frequency ranges from 10 to 30% in Japanese, Chinese, Korean and Thai people [77].
There is a lack of evidence to confirm the role of NAT2 polymorphism in the 
development of male infertility. However, recently it was proved that gene-envi-
ronment interactions play a very important role in the case of NAT2 polymorphism 
and determine whether it will predispose male infertility. Thus, several data have 
showed that rs1799929 and rs1799929 SNPs themselves were not associated with 
the increased risks of idiopathic male infertility [78]. However, if the subject was 
exposed to cigarette smoking (OR = 1.71, 95% CI: 1.02–2.87, P = 0.042), alcohol 
abuse (OR = 2.14, 95% CI: 1.08–4.27, P = 0.029) and low fruit/vegetable intake 
(OR = 1.68, 95% CI: 1.01–2.79, P = 0.04), the risk of male infertility significantly 
increased in the case of slow acetylator phenotype rs1799930.
Contrariwise, rapid acetylator phenotype was found to cause higher DNA-
fragmentation levels after 2 days of meat diet [79]. Considering that the level of 
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DNA fragmentation is significantly higher in infertile men [80], this study also 
proves that NAT2 polymorphism is involved in the process of impaired reproductive 
development in men.
The latest study, conducted on Vietnam males, revealed that idiopathic male infer-
tility is associated with both the rs1799930 (OR = 3.10, 95%; CI: 1.92–5.01) and the 
rs1799929 (OR = 3.74, 95%; CI: 2.26–6.18) alleles. The current research also shows that 
GSTP1 and NAT2 have a synergetic effect—they cause the biggest risk of infertility 
only when both polymorphisms are present. Namely, the 481C > T rs1799929 (NAT2) 
and the 341C > T or 341 T > T rs1138272 (GSTP1) cause the 17-fold increase in the risk 
of idiopathic male infertility (OR = 17.24, 95%; CI: 7.30–40.74, P = 0.0001) [55].
Thereby, the NAT2 involvement in the process of male infertility development 
is highly probable, but more data are needed to confirm its role in mediating the 
impaired male reproduction.
7. Conclusions
Male infertility is a worldwide health problem with multifactorial etiology, show-
ing an upward trend during the last decade. One of the most significant reasons 
behind this trend is the exposure to environmental factors—xenobiotics, hypo/
hyperthermia, stress or harmful radiations (such as X-rays). All this phenomena may 
lead to oxidative stress, treated as one of the most common trigger of male infertility 
and found in nearly half of all the infertile men [81]. It causes impairment of sperm 
maturation, testis injury, sperm motility reduction and DNA damages. Research on 
the polymorphisms of xenobiotic detoxification genes may be helpful for determining 
the interethnic and interindividual peculiarities of noxious chemicals metabolism 
(including possible risks of male infertility development) based on gene-environment 
interactions. Overall, knowledge about the SNPs of xenobiotic metabolizing genes 
associated with male infertility is rather inconsistent or even contradictory. Thus, more 
comprehensive analysis is required that would be stratified according to the age, body 
mass index, ethnic background, diet, smoking and drinking status, environmental 
exposures and other lifestyle factors. Moreover, many studies were carried out on 
small samples. This factor increases the probability of overestimating the association. 
Numerous studies indicated that such polymorphisms as CYP1A1, GSTM1, GSTT1, 
GSTP1 and NAT2 are most likely to be involved in male infertility development. Their 
polymorphic transcripts were shown to change the xenobiotic metabolism. In some 
cases, they failed to provide sufficient antioxidant defense. Knowledge of the role that 
the polymorphisms of xenobiotic detoxification genes have in male infertility develop-
ment could be useful for providing sufficient diagnostic methods, as well as for provid-
ing reliable recommendations for infertile men on disease prevention and treatment.
Acknowledgements
The authors would like to take this opportunity to extend their sincere thanks 
to the Ministry of Health for providing financial support for this study. We are also 
grateful for the technical support of the Hanoi Medical University Hospital. We 
thank Dr. Shkurat TP for a critical reading of the chapter.
Conflict of interest
The authors declare that they have no conflict of interest.
97
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Polymorphism of Xenobiotic Detoxification Genes and Male Infertility
DOI: http://dx.doi.org/10.5772/intechopen.79233
Author details
Nguyen Thi Trang* and Vu Thi Huyen
Hanoi Medical University, Hanoi, Vietnam
*Address all correspondence to: trangnguyen@hmu.edu..vn
Male Reproductive Health
96
DNA fragmentation is significantly higher in infertile men [80], this study also 
proves that NAT2 polymorphism is involved in the process of impaired reproductive 
development in men.
The latest study, conducted on Vietnam males, revealed that idiopathic male infer-
tility is associated with both the rs1799930 (OR = 3.10, 95%; CI: 1.92–5.01) and the 
rs1799929 (OR = 3.74, 95%; CI: 2.26–6.18) alleles. The current research also shows that 
GSTP1 and NAT2 have a synergetic effect—they cause the biggest risk of infertility 
only when both polymorphisms are present. Namely, the 481C > T rs1799929 (NAT2) 
and the 341C > T or 341 T > T rs1138272 (GSTP1) cause the 17-fold increase in the risk 
of idiopathic male infertility (OR = 17.24, 95%; CI: 7.30–40.74, P = 0.0001) [55].
Thereby, the NAT2 involvement in the process of male infertility development 
is highly probable, but more data are needed to confirm its role in mediating the 
impaired male reproduction.
7. Conclusions
Male infertility is a worldwide health problem with multifactorial etiology, show-
ing an upward trend during the last decade. One of the most significant reasons 
behind this trend is the exposure to environmental factors—xenobiotics, hypo/
hyperthermia, stress or harmful radiations (such as X-rays). All this phenomena may 
lead to oxidative stress, treated as one of the most common trigger of male infertility 
and found in nearly half of all the infertile men [81]. It causes impairment of sperm 
maturation, testis injury, sperm motility reduction and DNA damages. Research on 
the polymorphisms of xenobiotic detoxification genes may be helpful for determining 
the interethnic and interindividual peculiarities of noxious chemicals metabolism 
(including possible risks of male infertility development) based on gene-environment 
interactions. Overall, knowledge about the SNPs of xenobiotic metabolizing genes 
associated with male infertility is rather inconsistent or even contradictory. Thus, more 
comprehensive analysis is required that would be stratified according to the age, body 
mass index, ethnic background, diet, smoking and drinking status, environmental 
exposures and other lifestyle factors. Moreover, many studies were carried out on 
small samples. This factor increases the probability of overestimating the association. 
Numerous studies indicated that such polymorphisms as CYP1A1, GSTM1, GSTT1, 
GSTP1 and NAT2 are most likely to be involved in male infertility development. Their 
polymorphic transcripts were shown to change the xenobiotic metabolism. In some 
cases, they failed to provide sufficient antioxidant defense. Knowledge of the role that 
the polymorphisms of xenobiotic detoxification genes have in male infertility develop-
ment could be useful for providing sufficient diagnostic methods, as well as for provid-
ing reliable recommendations for infertile men on disease prevention and treatment.
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Abstract
Nowadays mesenchymal stem cell (MSC) therapy offers a broad spectrum of 
treatment of different conditions, including male infertility. Lots of studies sug-
gest that injection of MSC promotes differentiation of germ cells and/or stimulates 
gonadal tissue development. Currently, there are plenty of MSC therapies of 
azoospermia which have been studied on animal models and demonstrated good 
results. Most of the studies were conducted using MSC derived from adipose tissue, 
the bone marrow, and umbilical cord. Despite the fact that this type of treatment in 
humans is not established as a first choice option, the use of these techniques gives 
us hope for a gradual introduction into our daily practice.
Keywords: infertility, azoospermia, stem cell therapy, mesenchymal stem cell
1. Introduction
Infertility is a disease of the reproductive system defined by the failure to 
achieve a clinical pregnancy after 12 months or more of regular unprotected sexual 
intercourse [1]. This disorder affects one in six couples [2]. Different factors includ-
ing genetics, environmental factors, and anatomical defects have been illustrated to 
play a role in the fertility ability of individuals [3, 4].
After identifying the high capability of stem cells to produce different cell 
types, a number of scientists have proposed the use of stem cells and cell-based 
therapies as a possible new therapeutic choice for male infertility [5]. Stem cells are 
undifferentiated cell types that have two main characteristics, self-renewal with 
the production of identical daughter cells, and the ability to differentiate into more 
specialized cell types. The two main non-manipulated stem cell classes are embry-
onic (ESCs) and adult stem cells (ASCs) [5]. The next type of stem cells is induced 
pluripotent stem cells (iPSCs) which are genetically manipulated somatic cells [6]. 
The experimental platform for understanding the development of germ cells could 
be provided by the in vitro generation of male germ cells from stem cells [7, 8].
The ESCs, iPSCs, and spermatogonial stem cells (SSCs) are among the most 
investigated stem cells for the production of male germ cells in in vitro conditions 
[9, 10]. Application of these cell types has some limitations. ESCs present with some 
ethical problems and their sources are limited. iPSCs have both oncological and 
genetic instabilities. SSCs have low content in the testis, and their isolation, identifi-
cation, and culturing are difficult in vitro.
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On the other hand, mesenchymal stem cells (MSCs) do not have such problems 
in applications. MSCs are a group of ASCs which are available in most tissues. These 
cells were separated from the bone marrow [11], adipose tissue [12–14], hair follicle 
[15], endometrium [16, 17], dental pulp [18], nose [19], umbilical cord [20], and 
menstrual blood [21]. The MSCs in bone marrow stromal comprise a restricted 
area; but it can be easily proliferated [22]. These cells have the potential to prolifer-
ate and differentiate into other cells such as osteoblast [23, 24], adipocyte [25], 
chondroblasts [26], and neuron-like cells [27, 28] which can be a good candidate for 
treatment of male infertility. MSCs contains heterogeneous population of cells and 
contain pluripotent stem cells, namely multilineage-differentiating stress-enduring 
cells, which is the same as ESCs, which has the ability to differentiate into all cells 
from three germ layers spontaneously [29, 30].
2. Treatment of male infertility by MSC transplantation
Several animal studies have been conducted to investigate the effect of MSC trans-
plantation on azoospermia. The effect of bone marrow-derived MSCs (BM-MSCs) 
and adipose tissue-derived MSCs (AD-MSCs) in induced azoospermia rodents was 
explored [11, 12, 24, 26, 31, 32]. After busulfan injection for azoospermia induction 
[33], the rats were injected with the MSCs into rete testes. After 2 months, testes 
treated with MSCs appeared morphologically normal. Spermatogenesis was detected, 
not in every but in some tubules of cell-treated testes. The trans-differentiation of 
MSCs into spermatogenetic cells in the appropriate microenvironment has been 
shown in some studies [32]. To demonstrate the entire recovery of spermatogenesis, 
rats, which were under cell treatment, were mated, and consequently next genera-
tions were obtained. The GFP expression was identified in the MSCs derived from the 
bone marrow and adipose tissue and in the sperm of offsprings as well [32].
Numerous in vivo research surveys have been conducted to assess the spermato-
genesis induction potential of mesenchymal stem cells in mouse and rat animal 
models. In the mentioned study groups, bone marrow-derived mesenchymal stem 
cells have been used for the induction of spermatogenesis. There are some disputes, 
in mice model, regarding advisability of bone marrow-derived mesenchymal stem 
cell transplantation in azoospermic mice, for example, there was a report that bone 
marrow-derived mesenchymal stem cells could not differentiate into sperm [34], but 
other studies confirmed the generation of germ cells in vivo in BM-MSC-transplanted 
mice [35, 36]. At the same time, in azoospermic rat model, BM-MSC allotransplanta-
tion amplified endogenous fertility recovery in both testicular torsion model and 
busulfan-induced model of azoospermia induction [26, 37–40]. The potential of 
BM-MSCs to differentiate or trans-differentiate into multi-lineage cells, secrete para-
crine factors to recruit the resident stem cells to participate in tissue regeneration, or 
fuse with the local cells in the affected region has been demonstrated [39].
The next group used AT-MSCs for induction of spermatogenesis. Intra-tubal 
injection of AT-MSCs in rat model of busulfan-treated azoospermia led to recovery 
of fertility [12, 32]. The last group of studies induces spermatogenesis using xeno-
transplantation of human umbilical cord MSCs in immunodeficient mice seminifer-
ous tubule [41] or a combination of in vitro differentiation of induced pluripotent 
stem cells from mice and humans into germ cells, and also their transplantation was 
performed to obtain advanced differentiated spermatozoa [42]. Interestingly, the 
capability of human umbilical cord MSCs (UC-MSCs) for differentiation into germ 
cells in the lumen of seminiferous tubules of immunocompetent mice has been 
shown [41, 43]. Furthermore, the therapeutic effects of BM-MSCs against toxic 
effects of lead (Pb) in the male gonads of rats have been shown [44].
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MSC transplantation may induce reconstitution of the tubular microenviron-
ment in azoospermic hamster which helps the remaining inactivated germinal 
cells to proliferate in the host seminiferous tubules. Sertoli cells play a major role in 
cooperation with seminiferous tubules, providing cyclic and dynamic regulation of 
spermatogenesis. In recent time, it has been demonstrated that in in vitro co-culture 
system, there is an availability of Sertoli cells to mediate differentiation of male 
germ cell-like cells, which were derived from human umbilical cord mesenchymal 
stem cells [45]. Moreover, Sertoli cells are considered as immune tolerant cells [46], 
and they can cause protection and survival of the allotransplanted donor AT-MSCs 
against inflammatory or immune reaction. In contrast, the hypoimmunogenic char-
acter of mesenchymal stem cells makes them appropriate for allogenic transplanta-
tion [47]. Nevertheless, mesenchymal stem cells generate immunosuppression or 
immunosurveillance upon transplantation [48]. It is interesting to mention that, 
related to the treatment of azoospermia, IV allogenic bone marrow-derived mes-
enchymal stem cell transfusion encourages the production of antisperm antibody 
modulated by immune system, after testis rupture in mice [49], which illustrates the 
other therapeutic potential of mesenchymal stem cells in the treatment of infertil-
ity. In fact, the possible mechanisms of azoospermia healing by mesenchymal stem 
cells are unclear; three main mechanisms could be responsible for the recovering of 
testicular function during the tissue regeneration process period by mesenchymal 
stem cells. The first option of mesenchymal stem cells differentiation into the 
spermatozoa via appropriate induction conditions as it has been demonstrated in 
rats models [32]. Another mechanism which is not confirmed yet is that secretion of 
growth factors by mesenchymal stem cells stimulates the restoration of spermato-
genesis in the inactivated spermatogonia stem cells or Sertoli cells. And the last one 
is that mesenchymal stem cells merged with the endogenous spermatogonia stem 
cells recover the spermatogenesis, which is also needed to be further studied deeply.
The necessity for consideration of another point in cell therapy of azoospermia 
was illustrated by histomorphometric analysis of the treated seminiferous tubules 
[31]. The increase of the area of the seminiferous tubules before transplantation 
caused the decline of the number of tubes per unit area in azoospermia. This patho-
logical condition may be created due to decrease of cellular layers which caused the 
reduction of the tubal structure and collapsing of several tubules under the pressure 
of intratubular hydrostatic pressure of hamster seminiferous tubules. The growth 
of the amount of the spaces in testis may result in rise of the other tubes’ diameter 
and also decrease in intratubular hydrostatic pressure. It is necessary to mention 
that the role of this pressure in the mechanism of spermatogenesis has not been 
clarified, but it could be the one reason for the increase of diameter of cellular layer 
in mesenchymal stem cell-treated tubes. Next, histomorphometric analysis with the 
increase of the number of tubules per unit area in mesenchymal stem cells treated 
tubes has been obtained [31]. This alteration may be caused by the decline of the 
volumes of intertubular spaces or by the busulfan therapy complications. Moreover, 
the increase of the whole area of tubes during azoospermia induction could reduce 
the ability of contraction of contractile myofibroblast cells, in which the decrease 
of intratubular hydrostatic pressure in peritubular layer probably resulted in the 
reduction of spermatozoa concentration in epididymis after mesenchymal stem cell 
therapy.
3. Conclusion
The obtained results of performed research trials on animal models provide 
a better and deeper overview of MSC therapy in male infertility conditions. The 
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On the other hand, mesenchymal stem cells (MSCs) do not have such problems 
in applications. MSCs are a group of ASCs which are available in most tissues. These 
cells were separated from the bone marrow [11], adipose tissue [12–14], hair follicle 
[15], endometrium [16, 17], dental pulp [18], nose [19], umbilical cord [20], and 
menstrual blood [21]. The MSCs in bone marrow stromal comprise a restricted 
area; but it can be easily proliferated [22]. These cells have the potential to prolifer-
ate and differentiate into other cells such as osteoblast [23, 24], adipocyte [25], 
chondroblasts [26], and neuron-like cells [27, 28] which can be a good candidate for 
treatment of male infertility. MSCs contains heterogeneous population of cells and 
contain pluripotent stem cells, namely multilineage-differentiating stress-enduring 
cells, which is the same as ESCs, which has the ability to differentiate into all cells 
from three germ layers spontaneously [29, 30].
2. Treatment of male infertility by MSC transplantation
Several animal studies have been conducted to investigate the effect of MSC trans-
plantation on azoospermia. The effect of bone marrow-derived MSCs (BM-MSCs) 
and adipose tissue-derived MSCs (AD-MSCs) in induced azoospermia rodents was 
explored [11, 12, 24, 26, 31, 32]. After busulfan injection for azoospermia induction 
[33], the rats were injected with the MSCs into rete testes. After 2 months, testes 
treated with MSCs appeared morphologically normal. Spermatogenesis was detected, 
not in every but in some tubules of cell-treated testes. The trans-differentiation of 
MSCs into spermatogenetic cells in the appropriate microenvironment has been 
shown in some studies [32]. To demonstrate the entire recovery of spermatogenesis, 
rats, which were under cell treatment, were mated, and consequently next genera-
tions were obtained. The GFP expression was identified in the MSCs derived from the 
bone marrow and adipose tissue and in the sperm of offsprings as well [32].
Numerous in vivo research surveys have been conducted to assess the spermato-
genesis induction potential of mesenchymal stem cells in mouse and rat animal 
models. In the mentioned study groups, bone marrow-derived mesenchymal stem 
cells have been used for the induction of spermatogenesis. There are some disputes, 
in mice model, regarding advisability of bone marrow-derived mesenchymal stem 
cell transplantation in azoospermic mice, for example, there was a report that bone 
marrow-derived mesenchymal stem cells could not differentiate into sperm [34], but 
other studies confirmed the generation of germ cells in vivo in BM-MSC-transplanted 
mice [35, 36]. At the same time, in azoospermic rat model, BM-MSC allotransplanta-
tion amplified endogenous fertility recovery in both testicular torsion model and 
busulfan-induced model of azoospermia induction [26, 37–40]. The potential of 
BM-MSCs to differentiate or trans-differentiate into multi-lineage cells, secrete para-
crine factors to recruit the resident stem cells to participate in tissue regeneration, or 
fuse with the local cells in the affected region has been demonstrated [39].
The next group used AT-MSCs for induction of spermatogenesis. Intra-tubal 
injection of AT-MSCs in rat model of busulfan-treated azoospermia led to recovery 
of fertility [12, 32]. The last group of studies induces spermatogenesis using xeno-
transplantation of human umbilical cord MSCs in immunodeficient mice seminifer-
ous tubule [41] or a combination of in vitro differentiation of induced pluripotent 
stem cells from mice and humans into germ cells, and also their transplantation was 
performed to obtain advanced differentiated spermatozoa [42]. Interestingly, the 
capability of human umbilical cord MSCs (UC-MSCs) for differentiation into germ 
cells in the lumen of seminiferous tubules of immunocompetent mice has been 
shown [41, 43]. Furthermore, the therapeutic effects of BM-MSCs against toxic 
effects of lead (Pb) in the male gonads of rats have been shown [44].
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against inflammatory or immune reaction. In contrast, the hypoimmunogenic char-
acter of mesenchymal stem cells makes them appropriate for allogenic transplanta-
tion [47]. Nevertheless, mesenchymal stem cells generate immunosuppression or 
immunosurveillance upon transplantation [48]. It is interesting to mention that, 
related to the treatment of azoospermia, IV allogenic bone marrow-derived mes-
enchymal stem cell transfusion encourages the production of antisperm antibody 
modulated by immune system, after testis rupture in mice [49], which illustrates the 
other therapeutic potential of mesenchymal stem cells in the treatment of infertil-
ity. In fact, the possible mechanisms of azoospermia healing by mesenchymal stem 
cells are unclear; three main mechanisms could be responsible for the recovering of 
testicular function during the tissue regeneration process period by mesenchymal 
stem cells. The first option of mesenchymal stem cells differentiation into the 
spermatozoa via appropriate induction conditions as it has been demonstrated in 
rats models [32]. Another mechanism which is not confirmed yet is that secretion of 
growth factors by mesenchymal stem cells stimulates the restoration of spermato-
genesis in the inactivated spermatogonia stem cells or Sertoli cells. And the last one 
is that mesenchymal stem cells merged with the endogenous spermatogonia stem 
cells recover the spermatogenesis, which is also needed to be further studied deeply.
The necessity for consideration of another point in cell therapy of azoospermia 
was illustrated by histomorphometric analysis of the treated seminiferous tubules 
[31]. The increase of the area of the seminiferous tubules before transplantation 
caused the decline of the number of tubes per unit area in azoospermia. This patho-
logical condition may be created due to decrease of cellular layers which caused the 
reduction of the tubal structure and collapsing of several tubules under the pressure 
of intratubular hydrostatic pressure of hamster seminiferous tubules. The growth 
of the amount of the spaces in testis may result in rise of the other tubes’ diameter 
and also decrease in intratubular hydrostatic pressure. It is necessary to mention 
that the role of this pressure in the mechanism of spermatogenesis has not been 
clarified, but it could be the one reason for the increase of diameter of cellular layer 
in mesenchymal stem cell-treated tubes. Next, histomorphometric analysis with the 
increase of the number of tubules per unit area in mesenchymal stem cells treated 
tubes has been obtained [31]. This alteration may be caused by the decline of the 
volumes of intertubular spaces or by the busulfan therapy complications. Moreover, 
the increase of the whole area of tubes during azoospermia induction could reduce 
the ability of contraction of contractile myofibroblast cells, in which the decrease 
of intratubular hydrostatic pressure in peritubular layer probably resulted in the 
reduction of spermatozoa concentration in epididymis after mesenchymal stem cell 
therapy.
3. Conclusion
The obtained results of performed research trials on animal models provide 
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demonstrated results of used options in the treatment of these conditions revealed 
that methods using the MSCs derived from umbilical cord, adipose tissue, and the 
bone marrow appear more appropriate to recover the fertility due to better results. 
Although a case report is available for treatment of azoospermia in man [50], 
applying those methods into the human practice seems to be investigated before 
introducing this method into clinic.
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Testicular Cancer and the 
Importance of Early Diagnosis
Serife Zehra Altunkurek
Abstract
Prevalence of cancers is growing rapidly in all parts of the world. Testicular 
cancer (TC) is one of the greatest threats to health among 15- to 34-year-old males. 
Since testicular cancer peaks in incidence among young men of reproductive age, 
it is an important type of cancer for men. Risk factors for testicular cancer include 
cryptorchidism (i.e., undescended testicles), family history, infertility, tobacco use, 
and white race. Therefore increasing awareness in this regard, a joint effort that 
encourages risk factors and preventive measures, must be shown. The treatments 
are very effective, which greatly increases the 5-year survival rate by approximately 
98%. Prevention is the best option to tackle TC. Secondary preventive measures, 
the most important testicular self-examination (TSE), are well known and are 
encouraged to them. TSE helps prevent the diagnosis of late-stage TSE. Because the 
treatment of testicular cancer detected early is often associated with very positive 
results, routine screening and monthly self-examination in young men have been 
suggested. Although testicular cancer is rare, it is very effective to treat symptoms 
when they are diagnosed by TSE. As with breast cancer, early detection of TC is best 
done through self-examination.
Keywords: testicular cancer, men’s health, early diagnosis, self examination
1. Introduction
Cancer is the second leading cause of death globally and is responsible for 
an estimated 9.6 million deaths in 2018 [1]. A number of malignancies can be 
prevented through screening; an example is predominantly affecting males 
between 15 to 35 years of age and a relatively rare testicular malignancy that is a 
treatable cancer [2, 3]. However, TC incidence has risen worldwide in the past two 
decades [4]. Advances in the treatment of TC over the last 25 years have resulted 
in survival figures of 80–90%. Since TC peaks in incidence among young men of 
reproductive age, it is an important type of cancer for men [5]. Early diagnosis 
and treatment of TC is very important. TC is completely cured when detected at 
an early stage. Early diagnosis and 5-year survival rate is 99% [6–8]. Ninety to 
ninety-five percent of testicular tumors are caused by germinal tissue [9]. In this 
group, seminoma is the most common tumor with 40% [10]. The rate of cure with 
radiotherapy following orchiectomy in stage I seminoma is 99% [11]. Risk factors 
for TC include cryptorchidism (undescended testicles), abnormal development of 
testicles, adolescent and young adult age, family history, infertility, and white race 
[12–14]. Treatment is highly effective even when the diagnosis is made through 
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examination or because of symptoms [15]. As with breast cancer, early detection 
of TC is best done through self-examination [16]. Although routine screening and 
monthly self-examination in young men have been recommended, studies have 
not shown that they improve outcomes [17].
This chapter explains the epidemiology, etiology, stages, treatment of TC, and 
importance of early diagnosis for TC as well as TSE, as far as possible, with special 
considerations for adolescent and young adult populations.
2. Epidemiology
TC incidence is increasing worldwide, but the reasons for this increase 
are not fully documented [18]. There were a total of 36,747 cases of TC in the 
Scandinavian countries from 1960 to 2014 [19]. 9.4 affected individuals per 
100,000 males in Denmark had the highest incidence of TC for decades, but 
while the incidence rate stabilized in Denmark, the rate is now highest, 9.9 
affected individuals per 100,000 males in Norway [20, 21]. In the United States, 
TC is more common in white individuals (6.9 affected individuals per 100,000 
males) than in African Americans (1.2 affected individuals per 100,000 males) 
[18]. TC took first place with 24.8 percent of men in the 15-24 age group in 
Turkey [22]. An analysis from the International Agency for Research on Cancer 
indicates age-standardized rates of TC varied from less than 1/100,000 person 
14-35 years in Africa and Asia [23]. Worldwide, there are approximately 72,000 
cases and 9000 deaths per year attributable to TC [24]. TC death in the United 
States accounts for approximately 4% of the annual incidence [25]. There is a 
significant global variability in mortality rates that are largely inverse in inci-
dence rates. TC mortality is highest in low-income countries compared with 
higher-income countries [20]. Also, in spite of the highest incidences of this 
disease in Europe, North America and New Zealand account for only one-fifth 
of mortalities caused by TC [26]. About 50% of patients worldwide with TC are 
diagnosed with seminoma and the median ages at diagnosis 37 years [27].
2.1 Risk factors
The majority of TC (98%) had germ cell tumors; therefore, the terms testicular 
germ cell tumor and TC are often used interchangeably [28]. While most cancers 
occur in adulthood, the incidence of TC does not increase with age. The peak ages 
of occurrence are 25–29 years for non-seminomas and 35–39 years for seminomas 
[29]. The risk factors for TC are not well understood, but the risk factors most 
consistently associated with cryptorchidism, contralateral testicular tumor, a family 
history of TC, male factor ınfertility, and testicular microlithiasis [30–32].
Cryptorchidism, also referred to as maldescended testis, is the failure of descent 
of one or both of the testes into the scrotum and is a common clinical diagnosis 
in newborn boys and one of the strongest risk factors for infertility and testicular 
cancer [33–35]. Approximately 10% of all cases of testicular tumors occur in boys 
with a history of cryptorchidism [36]. In a study of patients with bilateral germ 
cell tumor, while 9.5% had cryptorchidism history, cryptorchidism was found 
in 2.2% of patients with unilateral tumors [37]. In addition, in a cohort study, 
cryptorchidism repair prior to puberty was associated with a doubling in risk of 
testicular cancer; postponement of the repair after the age of 12 showed that the 
risk increased fivefold [38].
TC is associated with a family history link as well [33–35]. Men, who have a first-
degree relative with testicular cancer, have a reasonably increased risk [39]. Patients 
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with a history of personal testicular cancer have a 12-fold higher risk of developing 
TC than the general population [40]. Family cancer studies have shown that sons 
whose fathers have TC have four times the risk of testicular cancer and brothers of 
patients with TC have eight times the risk of having testicular cancer [41]. Family 
history of this relationship is white men are more likely than black men to develop 
TC [15]. In a study with a large population, contralateral testicular cancer explained 
that a man younger than age of 30 with testicular seminoma has a 3.1% risk of 
developing a TC [42].
TC has increased in the last 30 years, while in Western countries there has 
been a decrease in semen quality and fertility [41]. Men with infertility have an 
increased risk of TC, with an incidence ratio of 1.6–2.8 [43]. The cohort study, 
based on more than 22,000 men undergoing evaluation for infertility, examined 
an association between infertility and the development of testicular cancer [44]. 
Other risk factors in TC are vasectomy, scrotal trauma, inguinal hernia, diet, 
smoking, the gene, environment (such as heavy metals exposure and endocrine 
disruptors), and hormones [45–50].
3. Diagnosing testicular cancer
TC is often seen as a painless mass in the testis, but in many patients there is 
a widespread pain, swelling, or stiffness in the scrotum [51]. Testicular masses 
appear more often on the right side [8]. Acute testicular pain is less widespread and 
is reasoned by swift expansion of the testis owing to intratumor hemorrhage or 
infarction caused by swift tumor growth [39]. Men often notice a history of testicu-
lar trauma, though accidental trauma is probably liable for leading the testicular 
mass to the men’ s attention, firstly. Men may complain of unclear scrotal pain or 
heaviness [39]. Testicular masses can be urgently evaluated by physical exam and 
bilateral testicular ultrasound [6]. Physical examination may be determinative but 
is sometimes vague in differentiating a malignancy from nonmalignant testicular 
masses [52].
The physician should carefully examine the testes, noting their notional size 
and density and palpating for any testicular masses [39]. Any doubtful symptoms 
should give rise to adjuvant studies [53]. Table 1 shows the signs and symptoms of 
TC [15].
Discomfort Metastases*
Dull ache in the scrotum or abdomen Gastrointestinal symptoms
Acute pain in the testicle or scrotum Gynecomastia
Scrotal heaviness Lumbar back pain
Mass effect Neck mass
Firmness of the testicle Respiratory symptoms (e.g., cough, hemoptysis, dyspnea)
Infertility
Intratesticular mass
Painless swelling and redness
*About 5% of patients with testicular cancer have symptoms of metastases.
Information from Ref. [15].
Table 1. 
Signs and symptoms of testicular cancer.
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TC is often seen as a painless mass in the testis, but in many patients there is 
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appear more often on the right side [8]. Acute testicular pain is less widespread and 
is reasoned by swift expansion of the testis owing to intratumor hemorrhage or 
infarction caused by swift tumor growth [39]. Men often notice a history of testicu-
lar trauma, though accidental trauma is probably liable for leading the testicular 
mass to the men’ s attention, firstly. Men may complain of unclear scrotal pain or 
heaviness [39]. Testicular masses can be urgently evaluated by physical exam and 
bilateral testicular ultrasound [6]. Physical examination may be determinative but 
is sometimes vague in differentiating a malignancy from nonmalignant testicular 
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Table 1. 
Signs and symptoms of testicular cancer.
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In men showing with testicular mass, unexplained scrotal pain or signs, 
ultrasonography should be regarded an appendage of the physical examination 
due to being broadly existing, cheap, and noninvasive [54]. After Physical exami-
nation, for revealing a mass in the testicle and the first radiological evaluation 
was Ultrasonography [55]. First of all intratesticular mass or the extratesticular 
location is examined. The intratesticular masses tend to be malignant, and the 
extratesticular masses tend to be benign. The nature of the detected masses (solid 
or cystic) is determined by Ultrasonografi (US). Solid masses suggest more malig-
nancy, whereas cystic masses are often benign, such as rete testis ectasia, simple 
cyst, and tunica albuginea cyst [55].
Tumor markers are also an important part of the diagnostic workup. Beta-
human chorionic gonadotropin (Bhcg), alpha-fetoprotein (AFP), and lactate 
dehydrogenase (LDH) levels are checked for the diagnosis of testicular tumors [56]. 
At the same time, these marker levels should be acquired after orchiectomy and to 
monitor chemotherapy treatment [39]. At the beginning of cancer, levels of these 
markers tend to be in the normal level. LDH levels are often elevated metastatic 
testicular cancer [15].
A biopsy can damage the testicles and spread the cancer into scrotum, so biopsy 
is not recommended [57]. But if suspected of having testicular tumor, one should 
undergo a radical inguinal orchiectomy for pathologic evaluation [39].
4. The stages of testicular cancer
Testicular cancers are classified as seminomas or non-seminomas. The semino-
mas are most common tumor with 40%. Three histological subtypes are defined. 
The most common type is classical type seminoma with 85%. Firstly, it makes lenfoj 
metastasis. It responds to radiotherapy and chemotherapy very well [58]. Non-
seminoma tumors account for 4% of all testicular tumors. Leydig cell tumors are 
the most common and this tumor constitutes 1–2% of all testicular tumors. It has a 
benign character in children but it is 10% malignant in adults [59].
Staging in TC is useful for determining prognosis and treatment. Patients are 
classified as Stage I (limited to the testis), Stage II (lymph node involvement), and 
Stage III (metastasis to visceral organs) [60] (Table 2). Among the important fac-
tors to be considered when staging are the degree of metastasis, elevation of tumor 
markers, and histology (seminoma or nonseminoma).
Stage I The tumor is in the testis. No evidence of metastasis was found in any of the testis
Stage IM After orchiectomy tumor markers in height is observed
Stage II Retroperitoneal lymphadenopathy is present
 IIA Lymphadenopathy <2 cm across
 IIB = 2–5 cm across
 IIC >5 cm across
Stage III Supradiaphragmatic lymphadenopathies are present
Stage IV Organ metastasis/hematogenous spread
Information from Refs. [61, 62].
Table 2. 
Classifications of testicular cancer staging.
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5. Treating testicular cancer
The primary treatment for testicular tumors is radical inguinal orchiectomy 
involving the removal of the testis and spermatic cord. After orchiectomy, the type 
of tumor (seminoma or nonseminoma tumor) and its stage are determined by 
microscopic diagnosis for further treatment [63]. Treatment options include obser-
vation, dissection of the retroperitoneal lymph node, radiation, and chemotherapy 
[15]. Treatment options for specific stages of disease are summarized in Table 3. To 
determine the success and continuity of treatment, evaluation is made by looking at 
the changes in serum tumor markers [15].
6. Fertility issue
Studies have shown that fertility decreased after treatment in TC patients. In 
addition, treatment with chemotherapy and radiotherapy was reported to cause 
significant gonadal damage in men [64, 65].
In one study, half of the patients wanted to have children after TC treatment. 
However, according to the results of the study, fertility rate was lower after treat-
ment than before treatment [66]. In the other study after treating for TC, 13 percent 
of patients developed hypogonadism [67]. Therefore, since the treatments to be 
applied to TC patients have a negative effect on fertility, solutions such as sperm 
banking, testicular tissue freezing, or removal of testicular sperm should be dis-
cussed with the patient before starting the treatment [68, 69].
Stage Seminoma Nonseminoma
I Usually low-dose radiotherapy as a 
preservative
Retroperitoneal lymph node dissection or monthly 
follow-up observations
IB: Take into two courses of chemotherapy
IS: The whole-dose chemotherapy if serum tumor 
marker levels do not drop swiftly after surgery
II IIA: Radiation therapy of the local lymph 
nodes
IIB or IIC: Three courses of three-drug 
chemotherapy
IIA: Retroperitoneal lymph node dissection, 
followed by monthly monitoring and frequent lab 
tests or observation, was made by two courses of 
chemotherapy, two drugs
IIB or IIC: If computed tomography still indicates 
lymph nodes, three or four courses of three-drug 
chemotherapy followed by retroperitoneal lymph 
node dissection
III Three-drug chemotherapy: If there is no 
answer, think of the clinical tests of other 
chemotherapy drugs in combination
Have brain metastasis: Treat with brain 
radiation or operating disposal
Three-drug chemotherapy: operating disposal of 
permanent tumors
High serum tumor marker levels: These patients 
often do not respond to usual chemotherapy; 
therefore, more aggressive clinical trials may be 
considered
High serum tumor marker levels: These 
patients frequently do not answer to normal 
chemotherapy; hence, more aggressive clinical 
trials can be thought
Information from Ref. [15].
Table 3. 
Treatment types for the stages of testicular cancer.
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7. The importance of early detection of TC and TSE
The aim of any cancer screening program is to diagnose the disease at an earlier 
and more easily treatable stage by improving disease-specific survival and minimiz-
ing treatment morbidity [70].
As with all cancer cases, when testicular cancer is diagnosed in early stages, the 
rate of treatment for TC is approximately 96%, significantly affecting survival [71]. 
Unfortunately, more than 50% of cases are diagnosed after the disease has spread 
to the primary site, and men must be persuaded to avoid medical treatment as soon 
as a mass is detected [72]. Once the cancer has expanded over the local nodes (Stage 
III), the survival rate decreases extremely. This is because approximately every 
10–30 days, the tumor doubling times were fast. Therefore, early diagnosis equates 
with a better long-term overall prognosis [6]. Obviously, for testicular cancer, a 
potentially lethal disease, early detection and early treatment are very important [6]. 
Rapid diagnosis of these neoplasms provides the opportunity to treat these patients 
at the earliest stage of the disease and thus minimize long-term morbidity [70].
Despite the importance of early diagnosis, invisible dangers are common in early 
and definitive diagnosis of testicular tumors. There are many studies based on delay 
in the diagnosis of testicular cancer [73–75]. In a comprehensive study on delayed 
diagnosis (DD) in testicular cancer, DD confirmed that it had a significant effect on 
survival in TC patients receiving modern treatments, including chemotherapy [76]. 
On the other hand, Nikzas et al. found no effect on survival in delay between 1980 
and 1987 in 232 patients studied in Great Britain [77].
Both patients and health professionals can contribute to delay in diagnosis. 
Patient-induced delays due to unawareness, embarrassment, fear of cancer, or fear 
of emasculation are accepted [75, 78–80]. The results of literature reviews suggest 
that approximately 20–30% of cancer patients delay seeking help for more than 
3 months after having experienced possible symptoms of cancer [81].
TC affects young and generally healthy males who do not accept the threat of 
deadly disease. Moreover, that testicular cancer requires loss of external genitals dur-
ing a time in the man’s life when sexuality is very important is additionally stressful 
[70]. The physician-mediated delay is most often the misdiagnosis of a testicular 
tumor as an infection. Unluckily for clinicians, classic painless testicular mass of 
patients ultimately diagnosed with TC is only half the resulting symptoms [82].
For early diagnosis several organizations, including the American Cancer 
Society and American Urological Association, recommend that physicians include 
testicular examination as part of routine control [83].It is also recommended that 
primary healthcare professionals teach and encourage TSE to males between the 
ages of 15 and 35 years [84]. At the same time, the American Cancer Society recom-
mends to men, especially who at high risk for TC, TSE as an effective and cost-free 
method [71]. Studies have shown that men at risk for TC are not educated and do 
not know how to perform TSE [6]. Moreover, many studies reported that close to all 
men of the risk group (adult men below age 35) had never performed TSE and very 
few knew that men who were in the 18- to 50-year-old age group should perform 
TSE every month [16, 85].
TSE is the cheapest and easiest method for screening firstly taught by the nurses 
or physicians to the man. The man is taught to perform the TSE when the scrotum 
is soft and relaxed, usually after a shower. In addition, TSE is recommended to be 
done at least once a month starting at the onset of puberty [17]. TSE teaching begins 
when the man becomes familiar with the major structures of the testis, scrotum, 
testicle, and epididymis [86]. After being familiar with the normal tissue and 
structures of the testes, the man is better readied to identify normal physiological 
structures. Any suspicious masses are notified to a healthcare professional as soon 
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as possible [86]. However, the role of TSE in screening of testicular cancer is still a 
matter of debate. In testicular cancer, regular TSE to prove the relationship between 
life and life US Preventive Services Task Force Some organizations such as the 
Canadian Task Force are out of the ordinary they do not recommend regular TSE 
because they can cause anxiety and unnecessary doctor visits [87, 88]. However, 
self-testis may be useful in increasing the incidence of testicular cancer and in 
early diagnosis because of the very low number of men participating in preven-
tive healthcare [89]. TSE is a convenient method to detect testicular cancer and 
contribute to healthier lifestyles for men at risk [71]. Furthermore, TSE, potentially 
positive, can produce sustainable health behavior choices [90].
8. Conclusions
In conclusion, studies have shown that the incidence of TC is increasing, espe-
cially in developed countries, where it is the most commonly diagnosed malignancy 
in young men. For this reason, young men should be encouraged to be aware of 
early detection of TC, to raise awareness and to apply to the health institution. In 
general, with rates of treatment above 95% (80% for metastatic disease), TC is 
considered to be a curable cancer when diagnosed early. At the same time, contrary 
to the supposition of men, treatment of TC is generally a type of cancer that does 
not cause sexual problems and does not affect fertility, and men’s masculinity is 
maintained unless both testicles are affected for a long time. The men that will be 
given TSE training may need to be present as educators because some men find the 
discussion of their testicles embarrassing. Furthermore, teaching young men to 
conduct TSE may result in these men taking increased responsibility for their own 
healthcare. When men are aware of what is normal for themselves, they are more 
likely to consult in the absence of false assurances from the absence of a lack of 
precariousness when they detect any abnormal condition. It is equally important to 
tell men that the diagnosis of testicular cancer is not death and the rate of treatment 
is excellent. Efforts should be made to make men aware that there may be a disease 
in their testicles even when there is no pain.
Conflict of interest
The author declared no potential conflicts of interest with respect to the publica-
tion of this chapter.
Thanks




7. The importance of early detection of TC and TSE
The aim of any cancer screening program is to diagnose the disease at an earlier 
and more easily treatable stage by improving disease-specific survival and minimiz-
ing treatment morbidity [70].
As with all cancer cases, when testicular cancer is diagnosed in early stages, the 
rate of treatment for TC is approximately 96%, significantly affecting survival [71]. 
Unfortunately, more than 50% of cases are diagnosed after the disease has spread 
to the primary site, and men must be persuaded to avoid medical treatment as soon 
as a mass is detected [72]. Once the cancer has expanded over the local nodes (Stage 
III), the survival rate decreases extremely. This is because approximately every 
10–30 days, the tumor doubling times were fast. Therefore, early diagnosis equates 
with a better long-term overall prognosis [6]. Obviously, for testicular cancer, a 
potentially lethal disease, early detection and early treatment are very important [6]. 
Rapid diagnosis of these neoplasms provides the opportunity to treat these patients 
at the earliest stage of the disease and thus minimize long-term morbidity [70].
Despite the importance of early diagnosis, invisible dangers are common in early 
and definitive diagnosis of testicular tumors. There are many studies based on delay 
in the diagnosis of testicular cancer [73–75]. In a comprehensive study on delayed 
diagnosis (DD) in testicular cancer, DD confirmed that it had a significant effect on 
survival in TC patients receiving modern treatments, including chemotherapy [76]. 
On the other hand, Nikzas et al. found no effect on survival in delay between 1980 
and 1987 in 232 patients studied in Great Britain [77].
Both patients and health professionals can contribute to delay in diagnosis. 
Patient-induced delays due to unawareness, embarrassment, fear of cancer, or fear 
of emasculation are accepted [75, 78–80]. The results of literature reviews suggest 
that approximately 20–30% of cancer patients delay seeking help for more than 
3 months after having experienced possible symptoms of cancer [81].
TC affects young and generally healthy males who do not accept the threat of 
deadly disease. Moreover, that testicular cancer requires loss of external genitals dur-
ing a time in the man’s life when sexuality is very important is additionally stressful 
[70]. The physician-mediated delay is most often the misdiagnosis of a testicular 
tumor as an infection. Unluckily for clinicians, classic painless testicular mass of 
patients ultimately diagnosed with TC is only half the resulting symptoms [82].
For early diagnosis several organizations, including the American Cancer 
Society and American Urological Association, recommend that physicians include 
testicular examination as part of routine control [83].It is also recommended that 
primary healthcare professionals teach and encourage TSE to males between the 
ages of 15 and 35 years [84]. At the same time, the American Cancer Society recom-
mends to men, especially who at high risk for TC, TSE as an effective and cost-free 
method [71]. Studies have shown that men at risk for TC are not educated and do 
not know how to perform TSE [6]. Moreover, many studies reported that close to all 
men of the risk group (adult men below age 35) had never performed TSE and very 
few knew that men who were in the 18- to 50-year-old age group should perform 
TSE every month [16, 85].
TSE is the cheapest and easiest method for screening firstly taught by the nurses 
or physicians to the man. The man is taught to perform the TSE when the scrotum 
is soft and relaxed, usually after a shower. In addition, TSE is recommended to be 
done at least once a month starting at the onset of puberty [17]. TSE teaching begins 
when the man becomes familiar with the major structures of the testis, scrotum, 
testicle, and epididymis [86]. After being familiar with the normal tissue and 
structures of the testes, the man is better readied to identify normal physiological 
structures. Any suspicious masses are notified to a healthcare professional as soon 
121
Testicular Cancer and the Importance of Early Diagnosis
DOI: http://dx.doi.org/10.5772/intechopen.89241
as possible [86]. However, the role of TSE in screening of testicular cancer is still a 
matter of debate. In testicular cancer, regular TSE to prove the relationship between 
life and life US Preventive Services Task Force Some organizations such as the 
Canadian Task Force are out of the ordinary they do not recommend regular TSE 
because they can cause anxiety and unnecessary doctor visits [87, 88]. However, 
self-testis may be useful in increasing the incidence of testicular cancer and in 
early diagnosis because of the very low number of men participating in preven-
tive healthcare [89]. TSE is a convenient method to detect testicular cancer and 
contribute to healthier lifestyles for men at risk [71]. Furthermore, TSE, potentially 
positive, can produce sustainable health behavior choices [90].
8. Conclusions
In conclusion, studies have shown that the incidence of TC is increasing, espe-
cially in developed countries, where it is the most commonly diagnosed malignancy 
in young men. For this reason, young men should be encouraged to be aware of 
early detection of TC, to raise awareness and to apply to the health institution. In 
general, with rates of treatment above 95% (80% for metastatic disease), TC is 
considered to be a curable cancer when diagnosed early. At the same time, contrary 
to the supposition of men, treatment of TC is generally a type of cancer that does 
not cause sexual problems and does not affect fertility, and men’s masculinity is 
maintained unless both testicles are affected for a long time. The men that will be 
given TSE training may need to be present as educators because some men find the 
discussion of their testicles embarrassing. Furthermore, teaching young men to 
conduct TSE may result in these men taking increased responsibility for their own 
healthcare. When men are aware of what is normal for themselves, they are more 
likely to consult in the absence of false assurances from the absence of a lack of 
precariousness when they detect any abnormal condition. It is equally important to 
tell men that the diagnosis of testicular cancer is not death and the rate of treatment 
is excellent. Efforts should be made to make men aware that there may be a disease 
in their testicles even when there is no pain.
Conflict of interest
The author declared no potential conflicts of interest with respect to the publica-
tion of this chapter.
Thanks






Gulhane Faculty of Nursing, Public Health Nursing Department, University of 
Health Sciences, Ankara, Turkey
*Address all correspondence to: serifezehra.atunkurek@sbu.edu.tr
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
123
Testicular Cancer and the Importance of Early Diagnosis
DOI: http://dx.doi.org/10.5772/intechopen.89241
References
[1] Cancer. World Health Organization 
[Internet]. 2018. Available from: https://
www.who.int/news-room/fact-sheets/
detail/cancer [Accessed: June 21, 2018]
[2] Nigam M, Aschebrook-Kilfoy B, 
Shikanov S, Eggener S. Increasing 
incidence of testicular cancer in the 
United States and Europe between 1992 
and 2009. World Journal of Urology. 
2015;33(5):623-631. DOI: 10.1007/
S00345-014-1361-Y
[3] Saab MM, Landers M, Hegarty J. 
Promoting testicular cancer awareness 
and screening: A systematic review 
of interventions. Cancer Nursing. 
2016;39(6):473-487. DOI: 10.1097/
NCC.0000000000000333
[4] Siegel RL, Miller KD, Jemal A. 
Cancer statistics, 2018. CA: A Cancer 
Journal for Clinicians. 2018;68:7-30. 
DOI: 10.3322/caac.21442
[5] Shanmugalingam T, Soultati A, 
Chowdhury S, Rudman S, Van 
Hemelrijck M. Global incidence and 
outcome of testicular cancer. Clinical 
Epidemiology. 2013;5:417. DOI: 10.2147/
CLEP.S34430. https://www.nhs.uk/
conditions/testicular-cancer/
[6] Brown CG. Testicular cancer: 
An overview. Urologic Nursing. 
2004;24:83-93
[7] Bahrami A, Ro JY, Ayala AG. An 
overview of testicular germ cell tumors. 
Archives of Pathology & Laboratory 
Medicine. 2007;131(8):1267-1280. DOI: 
10.1043/1543-2165(2007)131[1267:AOO
TGC]2.0.CO;2
[8] Viatori M. Testicular cancer. 
Seminars in Oncology Nursing. 
2012;28(3):180-189. DOI: 10.1016/j.
soncn.2012.05.007. WB Saunders
[9] Coursey Moreno C, Small WC, 
Camacho JC, et al. Testicular tumors: 
What radiologists need to 
know--differential diagnosis, staging, 
and management. Radiographics. 
2015;35:400-415. DOI: 10.1148/
rg.352140097
[10] Akyüz M, Topaktaş R, Ürkmez A, 
Koca O, Öztürk Mİ. Evaluation of 
germ-cell neoplasia in situ entity in 
testicular tumors. Turkish Journal of 
Urology. 2018;16:1-5. DOI: 10.5152/
tud.2018.48855
[11] Birch R, Williams S, Cone A, 
Einhorn L, Roark P, Turner S, et al. 
Prognosis factors for favorable 
outcome in disseminated germ cell 
tumors. Journal of Clinical Oncology. 
1986;4:400-407. DOI: 10.1200/
JCO.1986.4.3.400
[12] Gurney JK, McGlynn KA, Stanley J, 
Merriman T, Signal V, Shaw C, et al. 
Risk factors for cryptorchidism. Nature 
Reviews Urology. 2017;14(9):534. DOI: 
10.1038/nrurol.2017.90
[13] Garner MJ, Turner MC, Ghadirian P, 
Krewski D. Epidemiology of testicular 
cancer: An overview. International 
Journal of Cancer. 2005;116(3):331-
339. DOI: 10.1002/ijc.21032. Available 
at: http://www.ncbi.nlm.nih.gov/
pubmed/15818625 [Accessed: August 
21, 2013]
[14] Akre O, Ekbom A, Hsieh CC, 
Trichopoulos D, Adami HO. Testicular 
nonseminoma and seminoma in relation 
to perinatal characteristics. Journal 
of the National Cancer Institute. 
1996;88(13):883-889. DOI: 10.1093/
jnci/88.13.883. Available at: http://www.
ncbi.nlm.nih.gov/pubmed/8656440 
[Accessed: October 24, 2013]
[15] Shaw J. Diagnosis and treatment 
of testicular cancer. American Family 
Physician. 2008;77:469-474
[16] Ugboma HA, Aburoma HLS. Public 





Gulhane Faculty of Nursing, Public Health Nursing Department, University of 
Health Sciences, Ankara, Turkey
*Address all correspondence to: serifezehra.atunkurek@sbu.edu.tr
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
123
Testicular Cancer and the Importance of Early Diagnosis
DOI: http://dx.doi.org/10.5772/intechopen.89241
References
[1] Cancer. World Health Organization 
[Internet]. 2018. Available from: https://
www.who.int/news-room/fact-sheets/
detail/cancer [Accessed: June 21, 2018]
[2] Nigam M, Aschebrook-Kilfoy B, 
Shikanov S, Eggener S. Increasing 
incidence of testicular cancer in the 
United States and Europe between 1992 
and 2009. World Journal of Urology. 
2015;33(5):623-631. DOI: 10.1007/
S00345-014-1361-Y
[3] Saab MM, Landers M, Hegarty J. 
Promoting testicular cancer awareness 
and screening: A systematic review 
of interventions. Cancer Nursing. 
2016;39(6):473-487. DOI: 10.1097/
NCC.0000000000000333
[4] Siegel RL, Miller KD, Jemal A. 
Cancer statistics, 2018. CA: A Cancer 
Journal for Clinicians. 2018;68:7-30. 
DOI: 10.3322/caac.21442
[5] Shanmugalingam T, Soultati A, 
Chowdhury S, Rudman S, Van 
Hemelrijck M. Global incidence and 
outcome of testicular cancer. Clinical 
Epidemiology. 2013;5:417. DOI: 10.2147/
CLEP.S34430. https://www.nhs.uk/
conditions/testicular-cancer/
[6] Brown CG. Testicular cancer: 
An overview. Urologic Nursing. 
2004;24:83-93
[7] Bahrami A, Ro JY, Ayala AG. An 
overview of testicular germ cell tumors. 
Archives of Pathology & Laboratory 
Medicine. 2007;131(8):1267-1280. DOI: 
10.1043/1543-2165(2007)131[1267:AOO
TGC]2.0.CO;2
[8] Viatori M. Testicular cancer. 
Seminars in Oncology Nursing. 
2012;28(3):180-189. DOI: 10.1016/j.
soncn.2012.05.007. WB Saunders
[9] Coursey Moreno C, Small WC, 
Camacho JC, et al. Testicular tumors: 
What radiologists need to 
know--differential diagnosis, staging, 
and management. Radiographics. 
2015;35:400-415. DOI: 10.1148/
rg.352140097
[10] Akyüz M, Topaktaş R, Ürkmez A, 
Koca O, Öztürk Mİ. Evaluation of 
germ-cell neoplasia in situ entity in 
testicular tumors. Turkish Journal of 
Urology. 2018;16:1-5. DOI: 10.5152/
tud.2018.48855
[11] Birch R, Williams S, Cone A, 
Einhorn L, Roark P, Turner S, et al. 
Prognosis factors for favorable 
outcome in disseminated germ cell 
tumors. Journal of Clinical Oncology. 
1986;4:400-407. DOI: 10.1200/
JCO.1986.4.3.400
[12] Gurney JK, McGlynn KA, Stanley J, 
Merriman T, Signal V, Shaw C, et al. 
Risk factors for cryptorchidism. Nature 
Reviews Urology. 2017;14(9):534. DOI: 
10.1038/nrurol.2017.90
[13] Garner MJ, Turner MC, Ghadirian P, 
Krewski D. Epidemiology of testicular 
cancer: An overview. International 
Journal of Cancer. 2005;116(3):331-
339. DOI: 10.1002/ijc.21032. Available 
at: http://www.ncbi.nlm.nih.gov/
pubmed/15818625 [Accessed: August 
21, 2013]
[14] Akre O, Ekbom A, Hsieh CC, 
Trichopoulos D, Adami HO. Testicular 
nonseminoma and seminoma in relation 
to perinatal characteristics. Journal 
of the National Cancer Institute. 
1996;88(13):883-889. DOI: 10.1093/
jnci/88.13.883. Available at: http://www.
ncbi.nlm.nih.gov/pubmed/8656440 
[Accessed: October 24, 2013]
[15] Shaw J. Diagnosis and treatment 
of testicular cancer. American Family 
Physician. 2008;77:469-474
[16] Ugboma HA, Aburoma HLS. Public 
awareness of testicular cancer and 
Male Reproductive Health
124
testicular self-examination in academic 
environments: A lost opportunity. 
Clinics. 2011;66(7):1125-1128. DOI: 
10.1590/S1807-59322011000700001
[17] Fadich A, Giorgianni SJ, Rovito MJ, 
Pecchia GA, Bonhomme JJ, Adams WB, 
et al. USPSTF testicular examination 
nomination–self-examinations and 
examinations in a clinical setting. 
American Journal of Men’s Health. 
Sep 2018;12(5):1510-1516. DOI: 
10.1177/1557988318768597
[18] Ghazarian AA, Trabert B, 
Devesa SS, McGlynn KA. Recent trends 
in the incidence of testicular germ cell 
tumors in the United States. Andrology. 
2015;3:13-18. DOI: 10.1111/andr.288
[19] Engholm G, Ferlay J, Christensen N, 
et al. NORDCAN: Cancer incidence, 
mortality, prevalence and prediction 
in the Nordic countries, Version 7.3 
(08.07.2016). Association of the Nordic 
Cancer Registries, Danish Cancer 
Society. Available at: https://www.ancr.
nu/ [Accessed: January 2017]
[20] Znaor A, Lortet-Tieulent J, Jemal A, 
Bray F. International variations and 
trends in testicular cancer incidence 
and mortality. European Urology. 
2014;65:1095-1106. DOI: 10.1016/j.
eururo.2013.11.004
[21] Ylönen O, Jyrkkiö S, Pukkala E, 
Syvänen K, Boström PJ. Time trends 
and occupational variation in the 
incidence of testicular cancer in the 
Nordic countries. BJU International. 
2018;122(3):384-393. DOI: 10.1111/
bju.14148
[22] Turkey of Cancer Statistics 
[Internet]. 2015. Available from: https://
hsgm.saglik.gov.tr/depo/birimler/
kanserdb/istatistik/Turkiye_Kanser_
Istatistikleri_2015.pdf [Accessed: June 
11, 2018]
[23] Woldu SL, Bagrodia A. Update 
on epidemiologic considerations 
and treatment trends in testicular 
cancer. Current Opinion in Urology. 
2018;28(5):440-447. DOI: 10.1097/
MOU.0000000000000532
[24] Fitzmaurice C, Allen C, Barber RM, 
et al. Global, regional, and National 
cancer incidence, mortality, years of 
life lost, years lived with disability, 
and disability-adjusted life-years for 
32 cancer groups, 1990 to 2015: A 
systematic analysis for the global burden 
of disease study. JAMA Oncology. 
2017;3(4):524-548. DOI: 10.1001/
jamaoncol.2016.5688
[25] Society AC. Key Statistics for 
Testicular Cancer. Atlanta, GA: The 
American Cancer Society; 2018. 
Available from: https://www.cancer.
org/cancer/testicular-cancer/about/
key-statistics.html. [Updated: January 
4, 2018]
[26] Ferlay J, Soerjomataram I, 
Dikshit R, Eser S, Mathers C, Rebelo M, 
et al. Cancer incidence and mortality 
worldwide: Sources, methods and 
major patterns in GLOBOCAN 2012. 
International Journal of Cancer. 
2015;136(5):359-386. DOI: 10.1002 / 
ijc.29210
[27] Mortensen MS et al. A nationwide 
cohort study of stage I seminoma 
patients followed on a surveillance 
program. European Urology. 
2014;66:1172-1178. DOI: 10.1016/j.
eururo.2014.07.001
[28] Surveillance, Epidemiology, 
and End Results (SEER) Program. 
SEER*Stat. Database: Incidence—SEER 
9 Regs Research Data; 2011
[29] McGlynn KA et al. Trends in the 
incidence of testicular germ cell tumors 
in the United States. Cancer. 2003;97: 
63-70. DOI: 10.1002/cncr.11054
[30] Purdue MP, Devesa SS, Sigurdson AJ, 
McGlynn KA. International patterns 
and trends in testis cancer incidence. 
125
Testicular Cancer and the Importance of Early Diagnosis
DOI: http://dx.doi.org/10.5772/intechopen.89241
International Journal of Cancer. 
2005;115:822-827. DOI: 10.1002/
ijc.20931
[31] Bray F et al. Trends in testicular 
cancer incidence and mortality in 
22 European countries: Continuing 
increases in incidence and declines 
in mortality. International Journal of 
Cancer. 2006;118:3099-3111. DOI: 
10.1002/ijc.21747
[32] Osterlind A, Berthelsen JG, 
Abildgaard N, et al. Risk of bilateral 
testicular germ cell tumor in Denmark: 
1960-84. Journal of the National Cancer 
Institute. 1991;83:1391-1395. DOI: 
10.1093/jnci/83.19.1391
[33] Ferguson L, Agoulnik AI. Testicular 
cancer and cryptorchidism. Frontiers in 
Endocrinology. 2013;4:32. DOI: 10.3389/
fendo.2013.00032
[34] Herrinton LJ, Zhao W, Husson G. 
Management of cryptorchidism and risk 
of testicular cancer. American Journal of 
Epidemiology. 2003;157:602-605. DOI: 
10.1093/aje/kwg012
[35] Roy RK, Casson K. Attitudes toward 
testicular cancer and self-examination 
among northern Irish males. American 
Journal of Men’s Health. 2017;11(2):253-
261. DOI: 10.1177/1557988316668131
[36] Mannuel HD, Mitikiri N, Khan M, 
Hussain A. Testicular germ cell tumors: 
Biology and clinical update. Current 
Opinion in Oncology. 2012;24:266-271. 
DOI: 10.1097/CCO.0b013e32835167fc
[37] Sarıcı H, Telli O, Eroğlu M. Bilateral 
testicular germ cell tumors. Turkish 
Journal of Urology. 2013;39(4):249. DOI: 
10.5152/tud.2013.062
[38] Pettersson A, Richiardi L, 
Nordenskjold A, Kaijser M, Akre O. Age 
at surgery for undescended testis 
and risk of testicular cancer. The 
New England Journal of Medicine. 
2007;356(18):1835-1841. DOI: 10.1056/
NEJMoa067588
[39] McDougal WS, Wein AJ, 
Kavoussi LR, Partin AW, Peters CA. 
Campbell-Walsh Urology 11th Edition 
Review E-Book. Philadelphia: Elsevier 
Health Sciences; 2015
[40] Hu JS, Baird DC, Meyers GJ. 
Testicular cancer: Diagnosis and 
treatment. American Family Physician. 
2018;97(4):261-268
[41] Manecksha RP, Fitzpatrick JM. 
Epidemiology of testicular cancer. BJU 
International. 2009;104(9b):1329-1333. 
DOI: 10.1111/j.1464-410X.2009.08854.x
[42] Fosså SD, Chen J, Schonfeld SJ, 
McGlynn KA, McMaster ML, Gail MH, 
et al. Risk of contralateral testicular 
cancer: A population-based study of 
29 515 US men. Journal of the National 
Cancer Institute. 2005;97(14):1056-
1066. DOI: 10.1093/jnci/dji185
[43] Eisenberg ML, Li S, Brooks JD, 
Cullen MR, Baker LC. Increased risk of 
cancer in infertile men. The Journal of 
Urology. 2015;193(5):1596-1601. DOI: 
10.1016/j.juro.2014.11.080
[44] Walsh TJ, Croughan MS, 
Schembri M, Chan JM, Turek PJ. 
Increased risk of testicular germ cell 
cancer among infertile men. Archives of 
Internal Medicine. 2009;169(4):351-356. 
DOI: 10.1001/archinternmed.2008.562
[45] Tamimi RULLA, Adami HO. 
Testicular cancer. In: Textbook of 
Cancer Epidemiology. Hans-Olov A, 
David H, Dimitrios T. editors. Oxford 
University; 2002. p. 429. DOI: 10.1093/
acprof:oso/9780195311174.003.0021
[46] Cale AR, Farouk M, Prescott RJ, 
Wallace IW. Does vasectomy accelerate 
testicular tumour? Importance of 
testicular examinations before and after 
vasectomy. BMJ. 1990;300(6721):370. 
DOI: 10.1136/bmj.300.6721.370
[47] Møller H, Prener A, Skakkebxk NE. 
Testicular cancer, cryptorchidism, 
Male Reproductive Health
124
testicular self-examination in academic 
environments: A lost opportunity. 
Clinics. 2011;66(7):1125-1128. DOI: 
10.1590/S1807-59322011000700001
[17] Fadich A, Giorgianni SJ, Rovito MJ, 
Pecchia GA, Bonhomme JJ, Adams WB, 
et al. USPSTF testicular examination 
nomination–self-examinations and 
examinations in a clinical setting. 
American Journal of Men’s Health. 
Sep 2018;12(5):1510-1516. DOI: 
10.1177/1557988318768597
[18] Ghazarian AA, Trabert B, 
Devesa SS, McGlynn KA. Recent trends 
in the incidence of testicular germ cell 
tumors in the United States. Andrology. 
2015;3:13-18. DOI: 10.1111/andr.288
[19] Engholm G, Ferlay J, Christensen N, 
et al. NORDCAN: Cancer incidence, 
mortality, prevalence and prediction 
in the Nordic countries, Version 7.3 
(08.07.2016). Association of the Nordic 
Cancer Registries, Danish Cancer 
Society. Available at: https://www.ancr.
nu/ [Accessed: January 2017]
[20] Znaor A, Lortet-Tieulent J, Jemal A, 
Bray F. International variations and 
trends in testicular cancer incidence 
and mortality. European Urology. 
2014;65:1095-1106. DOI: 10.1016/j.
eururo.2013.11.004
[21] Ylönen O, Jyrkkiö S, Pukkala E, 
Syvänen K, Boström PJ. Time trends 
and occupational variation in the 
incidence of testicular cancer in the 
Nordic countries. BJU International. 
2018;122(3):384-393. DOI: 10.1111/
bju.14148
[22] Turkey of Cancer Statistics 
[Internet]. 2015. Available from: https://
hsgm.saglik.gov.tr/depo/birimler/
kanserdb/istatistik/Turkiye_Kanser_
Istatistikleri_2015.pdf [Accessed: June 
11, 2018]
[23] Woldu SL, Bagrodia A. Update 
on epidemiologic considerations 
and treatment trends in testicular 
cancer. Current Opinion in Urology. 
2018;28(5):440-447. DOI: 10.1097/
MOU.0000000000000532
[24] Fitzmaurice C, Allen C, Barber RM, 
et al. Global, regional, and National 
cancer incidence, mortality, years of 
life lost, years lived with disability, 
and disability-adjusted life-years for 
32 cancer groups, 1990 to 2015: A 
systematic analysis for the global burden 
of disease study. JAMA Oncology. 
2017;3(4):524-548. DOI: 10.1001/
jamaoncol.2016.5688
[25] Society AC. Key Statistics for 
Testicular Cancer. Atlanta, GA: The 
American Cancer Society; 2018. 
Available from: https://www.cancer.
org/cancer/testicular-cancer/about/
key-statistics.html. [Updated: January 
4, 2018]
[26] Ferlay J, Soerjomataram I, 
Dikshit R, Eser S, Mathers C, Rebelo M, 
et al. Cancer incidence and mortality 
worldwide: Sources, methods and 
major patterns in GLOBOCAN 2012. 
International Journal of Cancer. 
2015;136(5):359-386. DOI: 10.1002 / 
ijc.29210
[27] Mortensen MS et al. A nationwide 
cohort study of stage I seminoma 
patients followed on a surveillance 
program. European Urology. 
2014;66:1172-1178. DOI: 10.1016/j.
eururo.2014.07.001
[28] Surveillance, Epidemiology, 
and End Results (SEER) Program. 
SEER*Stat. Database: Incidence—SEER 
9 Regs Research Data; 2011
[29] McGlynn KA et al. Trends in the 
incidence of testicular germ cell tumors 
in the United States. Cancer. 2003;97: 
63-70. DOI: 10.1002/cncr.11054
[30] Purdue MP, Devesa SS, Sigurdson AJ, 
McGlynn KA. International patterns 
and trends in testis cancer incidence. 
125
Testicular Cancer and the Importance of Early Diagnosis
DOI: http://dx.doi.org/10.5772/intechopen.89241
International Journal of Cancer. 
2005;115:822-827. DOI: 10.1002/
ijc.20931
[31] Bray F et al. Trends in testicular 
cancer incidence and mortality in 
22 European countries: Continuing 
increases in incidence and declines 
in mortality. International Journal of 
Cancer. 2006;118:3099-3111. DOI: 
10.1002/ijc.21747
[32] Osterlind A, Berthelsen JG, 
Abildgaard N, et al. Risk of bilateral 
testicular germ cell tumor in Denmark: 
1960-84. Journal of the National Cancer 
Institute. 1991;83:1391-1395. DOI: 
10.1093/jnci/83.19.1391
[33] Ferguson L, Agoulnik AI. Testicular 
cancer and cryptorchidism. Frontiers in 
Endocrinology. 2013;4:32. DOI: 10.3389/
fendo.2013.00032
[34] Herrinton LJ, Zhao W, Husson G. 
Management of cryptorchidism and risk 
of testicular cancer. American Journal of 
Epidemiology. 2003;157:602-605. DOI: 
10.1093/aje/kwg012
[35] Roy RK, Casson K. Attitudes toward 
testicular cancer and self-examination 
among northern Irish males. American 
Journal of Men’s Health. 2017;11(2):253-
261. DOI: 10.1177/1557988316668131
[36] Mannuel HD, Mitikiri N, Khan M, 
Hussain A. Testicular germ cell tumors: 
Biology and clinical update. Current 
Opinion in Oncology. 2012;24:266-271. 
DOI: 10.1097/CCO.0b013e32835167fc
[37] Sarıcı H, Telli O, Eroğlu M. Bilateral 
testicular germ cell tumors. Turkish 
Journal of Urology. 2013;39(4):249. DOI: 
10.5152/tud.2013.062
[38] Pettersson A, Richiardi L, 
Nordenskjold A, Kaijser M, Akre O. Age 
at surgery for undescended testis 
and risk of testicular cancer. The 
New England Journal of Medicine. 
2007;356(18):1835-1841. DOI: 10.1056/
NEJMoa067588
[39] McDougal WS, Wein AJ, 
Kavoussi LR, Partin AW, Peters CA. 
Campbell-Walsh Urology 11th Edition 
Review E-Book. Philadelphia: Elsevier 
Health Sciences; 2015
[40] Hu JS, Baird DC, Meyers GJ. 
Testicular cancer: Diagnosis and 
treatment. American Family Physician. 
2018;97(4):261-268
[41] Manecksha RP, Fitzpatrick JM. 
Epidemiology of testicular cancer. BJU 
International. 2009;104(9b):1329-1333. 
DOI: 10.1111/j.1464-410X.2009.08854.x
[42] Fosså SD, Chen J, Schonfeld SJ, 
McGlynn KA, McMaster ML, Gail MH, 
et al. Risk of contralateral testicular 
cancer: A population-based study of 
29 515 US men. Journal of the National 
Cancer Institute. 2005;97(14):1056-
1066. DOI: 10.1093/jnci/dji185
[43] Eisenberg ML, Li S, Brooks JD, 
Cullen MR, Baker LC. Increased risk of 
cancer in infertile men. The Journal of 
Urology. 2015;193(5):1596-1601. DOI: 
10.1016/j.juro.2014.11.080
[44] Walsh TJ, Croughan MS, 
Schembri M, Chan JM, Turek PJ. 
Increased risk of testicular germ cell 
cancer among infertile men. Archives of 
Internal Medicine. 2009;169(4):351-356. 
DOI: 10.1001/archinternmed.2008.562
[45] Tamimi RULLA, Adami HO. 
Testicular cancer. In: Textbook of 
Cancer Epidemiology. Hans-Olov A, 
David H, Dimitrios T. editors. Oxford 
University; 2002. p. 429. DOI: 10.1093/
acprof:oso/9780195311174.003.0021
[46] Cale AR, Farouk M, Prescott RJ, 
Wallace IW. Does vasectomy accelerate 
testicular tumour? Importance of 
testicular examinations before and after 
vasectomy. BMJ. 1990;300(6721):370. 
DOI: 10.1136/bmj.300.6721.370
[47] Møller H, Prener A, Skakkebxk NE. 
Testicular cancer, cryptorchidism, 
Male Reproductive Health
126
inguinal hernia, testicular atrophy, and 
genital malformations: Case-control 
studies in Denmark. Cancer Causes 
& Control. 1996;7(2):264-274. DOI: 
10.1007/BF00051302
[48] Srivastava A, Kreiger N. Relation 
of physical activity to risk of 
testicular cancer. American Journal 
of Epidemiology. 2000;151(1):78-87. 
DOI: 10.1093/oxfordjournals.aje.
a010126
[49] UK Testicular Cancer Study Group. 
Social, behavioural and medical factors 
in the aetiology of testicular cancer: 
Results from the UK study. British 
Journal of Cancer. 1994;70:513-520. 
DOI: 10.1038/bjc.1994.337
[50] Garner MJ, Birkett NJ, Johnson KC, 
Shatenstein B, Ghadirian P, Krewski D. 
Canadian cancer registries epidemiology 
research group. Dietary risk factors 
for testicular carcinoma. International 
Journal of Cancer. 2003;106(6):934-941. 
DOI: 10.1002/ijc.11327
[51] Cheng L, Albers P, Berney DM, 
Feldman DR, Daugaard G, Gilligan T, 
et al. Testicular cancer. Nature Reviews 
Disease Primers. 2018;4(1):29. DOI: 
10.1038/s41572-018-0029-0
[52] Dieckmann KP, Frey U, Lock G. 
Contemporary diagnostic work-up of 
testicular germ cell tumours. Nature 
Reviews Urology. 2013;10(12):703-712. 
DOI: 10.1038/nrurol.2013.254
[53] Schmoll HJ, Jordan K, Huddart R, 
Pes ML, Horwich A, Fizazi K. ESMO 
guidelines working group. Testicular 
non-seminoma: ESMO clinical practice 
guidelines for diagnosis, treatment 
and follow-up. Annals of Oncology. 
2010;21(5):147-154. DOI: 10.1093/
annonc/mdq177
[54] DeCastro BJ, Peterson AC, 
Costabile RA. A 5-year followup study 
of asymptomatic men with testicular 
microlithiasis. The Journal of Urology. 
2008;179:1420-1423. DOI: 10.1016/j.
juro.2007.11.080
[55] Yagil Y, Naroditsky I, Milhem J, 
et al. Role of Doppler ultrasonography 
in the triage of acute scrotum in the 
emergency department. Journal of 
Ultrasound in Medicine. 2010;29:11-21. 
DOI: 10.7863/jum.2010.29.1.11
[56] Murray MJ, Huddart RA, 
Coleman N. The present and future 
of serum diagnostic tests for testicular 
germ cell tumours. Nature Reviews 
Urology. 2016;13(12):715-725. DOI: 
10.1038/nrurol.2016.170
[57] National Comprehensive Cancer 
Center (NCCN). Clinical practice 
guidelines in oncology: testicular cancer. 
2012. National Comprehensive Cancer 
Network. Available from: http://www.
nccn.org/professionals/physician_gls/
pdf/testicular.pdf [Accessed: March 20, 
2019]
[58] Rashid HH, Cos LR, Weinberg E, 
et al. Testicular microlithiasis: A review 
and its association with testicular 
cancer. Urologic Oncology. 
2004;22(4):285-289. DOI: 10.1016/
S1078-1439(03)00177-7
[59] Petersen PM, Giwercman A, 
Daugaard G, et al. Effect of graded 
testicular doses of radiotherapy in 
patients treated for carcinoma-in-situ in 
the testis. Journal of Clinical Oncology. 
2002;20(6):1537-1543. DOI: 10.1200/
JCO.2002.20.6.1537
[60] Oldenburg J et al. Testicular 
seminoma and non-seminoma: ESMO 
clinical practice guidelines for diagnosis, 
treatment and follow- up. Annals of 
Oncology. 2013;24(6):125-132. DOI: 
10.1093/annonc/mdt304
[61] Tanagho EA, McAninch JW. In: 
Kazancı G, editor. Smith Genel Üroloji, 
JenitalTümörler. İstanbul: Nobel Tıp 
Kitabevleri; 1999. pp. 435-441
127
Testicular Cancer and the Importance of Early Diagnosis
DOI: http://dx.doi.org/10.5772/intechopen.89241
[62] Anafarta K, Göğüş O, Bedük Y, 
Arıkan N, editors. Temel Üroloji, Testis 
Tümörleri. Ankara: Güneş Kitabevi; 
1998. pp. 751-759
[63] American Cancer Society. 




[Accessed: March 1, 2019]
[64] Fosså SD, Kravdal O. Fertility in 
Norwegian testicular cancer patients. 
British Journal of Cancer. 2000;82:737-
741. DOI: 10.1054/bjoc.1999.0989
[65] Fosså SD. Long-term sequelae after 
cancer therapy—Survivorship after 
treatment for testicular cancer. Acta 
Oncologica. 2004;43:134-141. Review
[66] Matos E, Škrbinc B, Zakotnik B. 
Fertility in patients treated for 
testicular cancer. Journal of Cancer 
Survivorship. 2010;4(3):274-278. DOI: 
10.1007/s11764-010-0135-9
[67] Huddart RA, Norman A, 
Moynihan C, et al. Fertility, gonadal and 
sexual function in survivors of testicular 
cancer. British Journal of Cancer. 
2005;93(2):200-207. DOI: 10.1038/
sj.bjc.6602677
[68] King L, Quinn GP, Vadaparampil ST, 
et al. Oncology nurses’ perceptions 
of barriers to discussion of fertility 
preservation with patients with cancer. 
Clinical Journal of Oncology Nursing. 
2008;12:467-476. DOI: 10.1188/08.
CJON.467-476
[69] Rodriguez-Wallberg KA, Oktay K. 
Fertility preservation during cancer 
treatment: Clinical guidelines. Cancer 
Management and Research. 2014;6:105. 
DOI: 10.2147/CMAR.S32380
[70] Moul JW. Timely diagnosis of 
testicular cancer. The Urologic Clinics 
of North America. 2007;34(2):109-117. 
DOI: 10.1016/j.ucl.2007.02.003
[71] Rovito MJ, Cavayero C, Leone JE, 
Harlin S. Interventions promoting 
testicular self-examination 
(TSE) performance: A systematic 
review. American Journal of Men’s 
Health. 2015;9(6):506-518. DOI: 
10.1177/1557988314555360
[72] Steadman L, Quine L. Encouraging 
young males to perform testicular 
self-examination: A simple, but 
effective, implementation intentions 
intervention. British Journal of Health 
Psychology. 2004;9(4):479-487. DOI: 
10.1348/1359107042304551
[73] Moul JW, Paulson DF, Dodge RK, 
et al. Delay in diagnosis and survival 
in testicular cancer: Impact of effective 
therapy and changes during 18 years. 
The Journal of Urology. 1990;143:520. 
DOI: 10.1016/s0022-5347(17)40007-3
[74] Hernes EH, Harstad K, Fossa SD. 
Changing incidence and delay of 
testicular cancer in southern Norway 
(1981-1992). European Urology. 
1996;30:349-357
[75] Wishnow KI, Johnson DE, 
Preston WL, Tenney DM, Brown BW. 
Prompt orchiectomy reduces morbidity 
and mortality from testicular 
carcinoma. British Journal of Urology. 
1990;65:629-633. DOI: 10.1111/j.1464-
410x.1990.tb14834.x
[76] Huyghe E, Muller A, Mieusset R, 
Bujan L, Bachaud JM, Chevreau C, 
et al. Impact of diagnostic delay in testis 
cancer: Results of a large population-
based study. European Urology. 
2007;52(6):1710-1716. DOI: 10.1016/j.
eururo.2007.06.003
[77] Nikzas D, Champion AE, Fox M. 
Germ cell tumors of testis: Prognostic 




inguinal hernia, testicular atrophy, and 
genital malformations: Case-control 
studies in Denmark. Cancer Causes 
& Control. 1996;7(2):264-274. DOI: 
10.1007/BF00051302
[48] Srivastava A, Kreiger N. Relation 
of physical activity to risk of 
testicular cancer. American Journal 
of Epidemiology. 2000;151(1):78-87. 
DOI: 10.1093/oxfordjournals.aje.
a010126
[49] UK Testicular Cancer Study Group. 
Social, behavioural and medical factors 
in the aetiology of testicular cancer: 
Results from the UK study. British 
Journal of Cancer. 1994;70:513-520. 
DOI: 10.1038/bjc.1994.337
[50] Garner MJ, Birkett NJ, Johnson KC, 
Shatenstein B, Ghadirian P, Krewski D. 
Canadian cancer registries epidemiology 
research group. Dietary risk factors 
for testicular carcinoma. International 
Journal of Cancer. 2003;106(6):934-941. 
DOI: 10.1002/ijc.11327
[51] Cheng L, Albers P, Berney DM, 
Feldman DR, Daugaard G, Gilligan T, 
et al. Testicular cancer. Nature Reviews 
Disease Primers. 2018;4(1):29. DOI: 
10.1038/s41572-018-0029-0
[52] Dieckmann KP, Frey U, Lock G. 
Contemporary diagnostic work-up of 
testicular germ cell tumours. Nature 
Reviews Urology. 2013;10(12):703-712. 
DOI: 10.1038/nrurol.2013.254
[53] Schmoll HJ, Jordan K, Huddart R, 
Pes ML, Horwich A, Fizazi K. ESMO 
guidelines working group. Testicular 
non-seminoma: ESMO clinical practice 
guidelines for diagnosis, treatment 
and follow-up. Annals of Oncology. 
2010;21(5):147-154. DOI: 10.1093/
annonc/mdq177
[54] DeCastro BJ, Peterson AC, 
Costabile RA. A 5-year followup study 
of asymptomatic men with testicular 
microlithiasis. The Journal of Urology. 
2008;179:1420-1423. DOI: 10.1016/j.
juro.2007.11.080
[55] Yagil Y, Naroditsky I, Milhem J, 
et al. Role of Doppler ultrasonography 
in the triage of acute scrotum in the 
emergency department. Journal of 
Ultrasound in Medicine. 2010;29:11-21. 
DOI: 10.7863/jum.2010.29.1.11
[56] Murray MJ, Huddart RA, 
Coleman N. The present and future 
of serum diagnostic tests for testicular 
germ cell tumours. Nature Reviews 
Urology. 2016;13(12):715-725. DOI: 
10.1038/nrurol.2016.170
[57] National Comprehensive Cancer 
Center (NCCN). Clinical practice 
guidelines in oncology: testicular cancer. 
2012. National Comprehensive Cancer 
Network. Available from: http://www.
nccn.org/professionals/physician_gls/
pdf/testicular.pdf [Accessed: March 20, 
2019]
[58] Rashid HH, Cos LR, Weinberg E, 
et al. Testicular microlithiasis: A review 
and its association with testicular 
cancer. Urologic Oncology. 
2004;22(4):285-289. DOI: 10.1016/
S1078-1439(03)00177-7
[59] Petersen PM, Giwercman A, 
Daugaard G, et al. Effect of graded 
testicular doses of radiotherapy in 
patients treated for carcinoma-in-situ in 
the testis. Journal of Clinical Oncology. 
2002;20(6):1537-1543. DOI: 10.1200/
JCO.2002.20.6.1537
[60] Oldenburg J et al. Testicular 
seminoma and non-seminoma: ESMO 
clinical practice guidelines for diagnosis, 
treatment and follow- up. Annals of 
Oncology. 2013;24(6):125-132. DOI: 
10.1093/annonc/mdt304
[61] Tanagho EA, McAninch JW. In: 
Kazancı G, editor. Smith Genel Üroloji, 
JenitalTümörler. İstanbul: Nobel Tıp 
Kitabevleri; 1999. pp. 435-441
127
Testicular Cancer and the Importance of Early Diagnosis
DOI: http://dx.doi.org/10.5772/intechopen.89241
[62] Anafarta K, Göğüş O, Bedük Y, 
Arıkan N, editors. Temel Üroloji, Testis 
Tümörleri. Ankara: Güneş Kitabevi; 
1998. pp. 751-759
[63] American Cancer Society. 




[Accessed: March 1, 2019]
[64] Fosså SD, Kravdal O. Fertility in 
Norwegian testicular cancer patients. 
British Journal of Cancer. 2000;82:737-
741. DOI: 10.1054/bjoc.1999.0989
[65] Fosså SD. Long-term sequelae after 
cancer therapy—Survivorship after 
treatment for testicular cancer. Acta 
Oncologica. 2004;43:134-141. Review
[66] Matos E, Škrbinc B, Zakotnik B. 
Fertility in patients treated for 
testicular cancer. Journal of Cancer 
Survivorship. 2010;4(3):274-278. DOI: 
10.1007/s11764-010-0135-9
[67] Huddart RA, Norman A, 
Moynihan C, et al. Fertility, gonadal and 
sexual function in survivors of testicular 
cancer. British Journal of Cancer. 
2005;93(2):200-207. DOI: 10.1038/
sj.bjc.6602677
[68] King L, Quinn GP, Vadaparampil ST, 
et al. Oncology nurses’ perceptions 
of barriers to discussion of fertility 
preservation with patients with cancer. 
Clinical Journal of Oncology Nursing. 
2008;12:467-476. DOI: 10.1188/08.
CJON.467-476
[69] Rodriguez-Wallberg KA, Oktay K. 
Fertility preservation during cancer 
treatment: Clinical guidelines. Cancer 
Management and Research. 2014;6:105. 
DOI: 10.2147/CMAR.S32380
[70] Moul JW. Timely diagnosis of 
testicular cancer. The Urologic Clinics 
of North America. 2007;34(2):109-117. 
DOI: 10.1016/j.ucl.2007.02.003
[71] Rovito MJ, Cavayero C, Leone JE, 
Harlin S. Interventions promoting 
testicular self-examination 
(TSE) performance: A systematic 
review. American Journal of Men’s 
Health. 2015;9(6):506-518. DOI: 
10.1177/1557988314555360
[72] Steadman L, Quine L. Encouraging 
young males to perform testicular 
self-examination: A simple, but 
effective, implementation intentions 
intervention. British Journal of Health 
Psychology. 2004;9(4):479-487. DOI: 
10.1348/1359107042304551
[73] Moul JW, Paulson DF, Dodge RK, 
et al. Delay in diagnosis and survival 
in testicular cancer: Impact of effective 
therapy and changes during 18 years. 
The Journal of Urology. 1990;143:520. 
DOI: 10.1016/s0022-5347(17)40007-3
[74] Hernes EH, Harstad K, Fossa SD. 
Changing incidence and delay of 
testicular cancer in southern Norway 
(1981-1992). European Urology. 
1996;30:349-357
[75] Wishnow KI, Johnson DE, 
Preston WL, Tenney DM, Brown BW. 
Prompt orchiectomy reduces morbidity 
and mortality from testicular 
carcinoma. British Journal of Urology. 
1990;65:629-633. DOI: 10.1111/j.1464-
410x.1990.tb14834.x
[76] Huyghe E, Muller A, Mieusset R, 
Bujan L, Bachaud JM, Chevreau C, 
et al. Impact of diagnostic delay in testis 
cancer: Results of a large population-
based study. European Urology. 
2007;52(6):1710-1716. DOI: 10.1016/j.
eururo.2007.06.003
[77] Nikzas D, Champion AE, Fox M. 
Germ cell tumors of testis: Prognostic 




[78] Chapple A, Ziebland S, 
McPherson A. Qualitative study of men’s 
perceptions of why treatment delays 
occur in the UK for those with testicular 
cancer. The British Journal of General 
Practice. 2004;54(498):25-32
[79] Smith LK, Pope C, Botha JL. 
Patients’ help-seeking experiences 
and delay in cancer presentation: A 
qualitative synthesis. The Lancet. 
2005;366(9488):825-831. DOI: 10.1016/
S0140-6736(05)67030-4
[80] Oliver RT. Factors contributing 
to delay in diagnosis of testicular 
tumours. British Medical Journal. 
1985;290(6465):356. DOI: 10.1136/
bmj.290.6465.356
[81] Pedersen AF, Olesen F, Hansen RP, 
Zachariae R, Vedsted P. Social support, 
gender and patient delay. British Journal 
of Cancer. 2011;104(8):1249. DOI: 
10.1038/bjc.2011.87
[82] Bosl GJ, Vogelzang NJ, Goldman A, 
Fraley EE, Lange PH, Levitt SH, et al. 
Impact of delay in diagnosis on 
clinical stage of testicular cancer. 
Lancet. 1981;2:970-972. DOI: 10.1016/
s0140-6736(81)91165-x
[83] American Cancer Society [Internet]. 
2004. Available from: http://www.
cancer.org/ [Accessed: March 10, 2019]
[84] Ward KD, Vander Weg MW, 
Read MC, Sell MA, Beech BM. Testicular 
cancer awareness and self-examination 
among adolescent males in a 
community-based youth organization. 
Preventive Medicine. 2005;41(2):386-
398. DOI: 10.1016/j.ypmed.2005.02.003
[85] Ugurlu Z, Akkuzu G, Karahan A, 
et al. Testicular cancer awareness and 
testicular self -examination among 
university students. Asian Pacific 
Journal of Cancer Prevention. 
2011;12(3):695-698
[86] Cook R. Teaching and promoting 
testicular self-examination. Nursing 
Standard. 2000;14(24):48-54. DOI: 
10.7748/ns2000.03.14.24.48.c2774
[87] Rovito MJ, Leone JE, Cavayero CT. 
“Off-label” usage of testicular self-
examination (TSE): Benefits beyond 
cancer detection. American Journal of 
Men’s Health. 2018;12(3):505-513. DOI: 
10.1177/1557988315584942
[88] Canadian Task Force on the Periodic 
Health Examination. Canadian Guide 
to Clinical Preventive Health Care. 
Ottawa: Canada Communication 
Group; 1994. pp. 892-898. DOI: 
10.1177/1557988315584942
[89] Cronholm PF, Mao JJ, 
Nguyen GT, Paris RT. A dilemma in 
male engagement in preventive services: 
Adolescent males’ knowledge and 
attitudes toward testicular cancer and 
testicular self-exam. American Journal 
of Men’s Health. 2009;3(2):134-140. 
DOI: 10.1177/1557988308315071
[90] Murphy WG, Brubaker RG. Effects 
of a brief theory-based intervention 
on the practice of testicular self-
examination by high school males. The 




The Role of MRI-TRUS Fusion
Biopsy in the Diagnosis of Clinical
Significant Prostate Cancer (CsPca)
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Abstract
Despite its limitations, ultrasound-guided biopsy is still the “gold standard”
for the diagnosis of prostate cancer (PCa). Multiparametric magnetic resonance
imaging (mp-MRI) plays an increasingly important role in patients with prior
negative biopsy; several studies report an improved clinically significant prostate
cancer (Cs PCa) detection rate for MRI-targeted biopsy compared to the standard
biopsy. There are currently three techniques for the MRI-targeted biopsy: the
cognitive registration, the software-assisted fusion registration, and the in-bore
biopsy. The best MRI-targeted biopsy technique is still a matter of debate in
literature; however, MRI/TRUS fusion-guided biopsy is often described as the
most accurate and cost-effective approach; we describe the technique and
its results.
Keywords: fusion biopsy, prostate cancer, prostate biopsy, prostate
magnetic resonance, PI-RADS score
1. Introduction
Prostate cancer is the most common cancer expected to occur in men,
accounting for 19% of the new cancer cases diagnosed worldwide [1, 2].
Currently, the only way to make a definitive diagnosis of prostate cancer is
considered to be the prostate biopsy and the subsequent histopathological exami-
nation. For many years, the transrectal ultrasound (TRUS)-guided biopsy has
been considered the gold standard in the diagnosis of prostate adenocarcinoma.
This standard technique makes use of random 12-cores to sample the entire
prostate gland [3].
The criteria for submitting patients to prostate biopsy are either a persistently
elevated/rising prostate-specific antigen (PSA) level or an abnormal digital rectal
examination (DRE). Prostate biopsy may also be recommended on the basis of the
pathologic results of previous biopsy specimens: men who are found to have a high-
grade prostatic intraepithelial neoplasia (HG-PIN), atypical small acinar prolifera-
tion (ASAP), or low-risk prostate cancer should be subjected to a follow-up biopsy
[2]. The TRUS-guided biopsy has significant limitations; several nonmalignant
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Abstract
Despite its limitations, ultrasound-guided biopsy is still the “gold standard”
for the diagnosis of prostate cancer (PCa). Multiparametric magnetic resonance
imaging (mp-MRI) plays an increasingly important role in patients with prior
negative biopsy; several studies report an improved clinically significant prostate
cancer (Cs PCa) detection rate for MRI-targeted biopsy compared to the standard
biopsy. There are currently three techniques for the MRI-targeted biopsy: the
cognitive registration, the software-assisted fusion registration, and the in-bore
biopsy. The best MRI-targeted biopsy technique is still a matter of debate in
literature; however, MRI/TRUS fusion-guided biopsy is often described as the
most accurate and cost-effective approach; we describe the technique and
its results.
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1. Introduction
Prostate cancer is the most common cancer expected to occur in men,
accounting for 19% of the new cancer cases diagnosed worldwide [1, 2].
Currently, the only way to make a definitive diagnosis of prostate cancer is
considered to be the prostate biopsy and the subsequent histopathological exami-
nation. For many years, the transrectal ultrasound (TRUS)-guided biopsy has
been considered the gold standard in the diagnosis of prostate adenocarcinoma.
This standard technique makes use of random 12-cores to sample the entire
prostate gland [3].
The criteria for submitting patients to prostate biopsy are either a persistently
elevated/rising prostate-specific antigen (PSA) level or an abnormal digital rectal
examination (DRE). Prostate biopsy may also be recommended on the basis of the
pathologic results of previous biopsy specimens: men who are found to have a high-
grade prostatic intraepithelial neoplasia (HG-PIN), atypical small acinar prolifera-
tion (ASAP), or low-risk prostate cancer should be subjected to a follow-up biopsy
[2]. The TRUS-guided biopsy has significant limitations; several nonmalignant
conditions of the prostate (such as inflammation, prostatitis, and benign prostatic
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hyperplasia) can appear hypoechoic, and some carcinoma can appear isoechoic [4].
A cancer detection rate (DR) of 33–57% can be achieved with the standard biopsy,
and following the first negative biopsy, the detection rate decreases further [5].
Furthermore, the standard biopsy may lead to an underdiagnosis of clinically sig-
nificant prostate cancers, missing 50–80% of cases [6]. The multiparametric mag-
netic resonance imaging plays nowadays an increasingly important role in the
diagnostic approach to prostate cancer. It provides anatomic and functional images
allowing detection and localization of the suspicious lesions that could harbor
prostate cancer.
Several studies indicate that the MRI-targeted biopsy approach improves the
overall and clinically significant PCa detection rate. It also strongly reduces the
number of clinically insignificant prostate cancers diagnosed, therefore preventing
overtreatment.
According to the European Association of Urology (EAU) guidelines, an mp-
MRI evaluation and a subsequent MRI-targeted biopsy should be recommended for
patients with persistent clinical suspicion of prostate cancers even if a previous
standard biopsy has provided negative results. Based on the guideline recommen-
dations, if the targeted and standard biopsies are used in conjunction, significantly
better results can be achieved [7].
The role of mp-MRI in the diagnostic pathway of biopsy-naïve patients is instead
still a matter of debate.
2. Technology and techniques
2.1 Interpretation and reporting of multiparametric MRI
The magnetic resonance imaging (MRI) has been used for locoregional staging
in patients with proven prostate cancers since the 1980s [8]. The multiparametric
protocol has been introduced to discriminate nonmalignant tissue and potentially
cancerous lesions. Since its introduction, the field of PCa diagnosis has been
revolutionized.
According to the European Society of Urogenital Radiology (ESUR) guidelines,
the multiparametric MRI protocol should include three MRI modalities: triplanar
T2-weighted (T2W) sequences, axial diffusion-weighted imaging (DWI) with
apparent diffusion coefficient (ADC) mapping, and dynamic contrast-enhanced
images (DCE) [8, 9].
To standardize the evaluation and reporting of prostate mp-MRI examinations, a
consensus-based guideline, known as Prostate Imaging Reporting and Data System
(PI-RADS) version 1, was introduced in 2012. Most recently, a revised version of
the document (PI-RADS v2) was published.
One of the main aims of the PI-RADS v2 document was to develop categories
summarizing the levels of suspicion; each detected lesion in the prostate gland
is assigned a score that goes from 1 to 5. The 5-point scoring, based on the like-
lihood that MRI findings correlate with the presence of Cs PCa, is defined as
follows:
1. very low risk (clinically significant PCa is highly unlikely to be present)
2. low risk (clinically significant PCa is unlikely to be present)
3. intermediate risk (the presence of clinically significant PCa is equivocal)
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4.high risk (clinically significant PCa is likely to be present)
5. very high risk (clinically significant PCa is highly likely to be present)
According to PI-RADS v2, a cancer is considered to be clinically significant when
Gleason score (GS) >7, and/or tumor volume >0.5 ml, and/or an extraprostatic
extension is diagnosed [8, 9].
A meta-analysis related to the diagnostic accuracy of PI-RADS v2 shows that the
PCa detection sensitivity is 0.85 and the specificity is 0.71 [10].
The most significant difference between PI-RADS v1 and PI-RADS v2 is that
DWI and T2W are used as the primary determining sequences, respectively, for
peripheral zone (PZ) and transitional zone (PZ) (refer to Tables 1 and 2), while
DCE plays a limited role in the detection of PZ lesions classified as PI-RADS 3.
Likewise, when a TZ lesion has a T2W score 3, DWI may increase the likelihood
that the finding corresponds to a score 4.
Another significant difference is that a size criterion (smaller or larger than
1.5 cm) is taken into account by PI-RADS v2 to differentiate score 4 from 5 in
both the peripheral and transitional zones. Moreover, a 39-sector map has been
introduced to locate the suspicious findings [8, 9]. This has led to an improvement
of the interdisciplinary communications between radiologists and urologists.
Following the PI-RADS score assignment to the suspicious lesion, the region of
interest (ROI) detected through mp-MRI can be biopsied to confirm the diagnosis.
DWI
score
Peripheral zone lesion PI-RADS category
1 No abnormality on ADC and high b-value DWI 1
2 Indistinct hypointense on ADC 2
3 Focal mildly/moderately hypointense on ADC and isointense/mildly
hyperintense on high b-value DWI
3 if DCE is negative
4 if DCE is positive
4 Focal markedly hypointense on ADC and markedly hyperintense on
high b-value DWI; <1.5 cm in greatest dimension
4




PI-RADS v2 categories assignment to peripheral zone lesions based on the scoring of DWI sequence.
T2W
score
Transition zone lesion PI-RADS category
1 Homogeneous intermediate signal intensity (normal) 1
2 Circumscribed hypointense or heterogeneous encapsulated nodules 2
3 Heterogeneous signal intensity with obscured margins
Includes others that do not qualify as 2, 4, or 5
3 if DWI score is <4
4 if DWI score is 5
4 Lenticular or noncircumscribed, homogeneous, moderately
hypointense, and <1.5 cm in greatest dimension
4




PI-RADS v2 categories assignment to transitional zone lesions based on the scoring of T2W sequence.
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hyperplasia) can appear hypoechoic, and some carcinoma can appear isoechoic [4].
A cancer detection rate (DR) of 33–57% can be achieved with the standard biopsy,
and following the first negative biopsy, the detection rate decreases further [5].
Furthermore, the standard biopsy may lead to an underdiagnosis of clinically sig-
nificant prostate cancers, missing 50–80% of cases [6]. The multiparametric mag-
netic resonance imaging plays nowadays an increasingly important role in the
diagnostic approach to prostate cancer. It provides anatomic and functional images
allowing detection and localization of the suspicious lesions that could harbor
prostate cancer.
Several studies indicate that the MRI-targeted biopsy approach improves the
overall and clinically significant PCa detection rate. It also strongly reduces the
number of clinically insignificant prostate cancers diagnosed, therefore preventing
overtreatment.
According to the European Association of Urology (EAU) guidelines, an mp-
MRI evaluation and a subsequent MRI-targeted biopsy should be recommended for
patients with persistent clinical suspicion of prostate cancers even if a previous
standard biopsy has provided negative results. Based on the guideline recommen-
dations, if the targeted and standard biopsies are used in conjunction, significantly
better results can be achieved [7].
The role of mp-MRI in the diagnostic pathway of biopsy-naïve patients is instead
still a matter of debate.
2. Technology and techniques
2.1 Interpretation and reporting of multiparametric MRI
The magnetic resonance imaging (MRI) has been used for locoregional staging
in patients with proven prostate cancers since the 1980s [8]. The multiparametric
protocol has been introduced to discriminate nonmalignant tissue and potentially
cancerous lesions. Since its introduction, the field of PCa diagnosis has been
revolutionized.
According to the European Society of Urogenital Radiology (ESUR) guidelines,
the multiparametric MRI protocol should include three MRI modalities: triplanar
T2-weighted (T2W) sequences, axial diffusion-weighted imaging (DWI) with
apparent diffusion coefficient (ADC) mapping, and dynamic contrast-enhanced
images (DCE) [8, 9].
To standardize the evaluation and reporting of prostate mp-MRI examinations, a
consensus-based guideline, known as Prostate Imaging Reporting and Data System
(PI-RADS) version 1, was introduced in 2012. Most recently, a revised version of
the document (PI-RADS v2) was published.
One of the main aims of the PI-RADS v2 document was to develop categories
summarizing the levels of suspicion; each detected lesion in the prostate gland
is assigned a score that goes from 1 to 5. The 5-point scoring, based on the like-
lihood that MRI findings correlate with the presence of Cs PCa, is defined as
follows:
1. very low risk (clinically significant PCa is highly unlikely to be present)
2. low risk (clinically significant PCa is unlikely to be present)
3. intermediate risk (the presence of clinically significant PCa is equivocal)
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4.high risk (clinically significant PCa is likely to be present)
5. very high risk (clinically significant PCa is highly likely to be present)
According to PI-RADS v2, a cancer is considered to be clinically significant when
Gleason score (GS) >7, and/or tumor volume >0.5 ml, and/or an extraprostatic
extension is diagnosed [8, 9].
A meta-analysis related to the diagnostic accuracy of PI-RADS v2 shows that the
PCa detection sensitivity is 0.85 and the specificity is 0.71 [10].
The most significant difference between PI-RADS v1 and PI-RADS v2 is that
DWI and T2W are used as the primary determining sequences, respectively, for
peripheral zone (PZ) and transitional zone (PZ) (refer to Tables 1 and 2), while
DCE plays a limited role in the detection of PZ lesions classified as PI-RADS 3.
Likewise, when a TZ lesion has a T2W score 3, DWI may increase the likelihood
that the finding corresponds to a score 4.
Another significant difference is that a size criterion (smaller or larger than
1.5 cm) is taken into account by PI-RADS v2 to differentiate score 4 from 5 in
both the peripheral and transitional zones. Moreover, a 39-sector map has been
introduced to locate the suspicious findings [8, 9]. This has led to an improvement
of the interdisciplinary communications between radiologists and urologists.
Following the PI-RADS score assignment to the suspicious lesion, the region of
interest (ROI) detected through mp-MRI can be biopsied to confirm the diagnosis.
DWI
score
Peripheral zone lesion PI-RADS category
1 No abnormality on ADC and high b-value DWI 1
2 Indistinct hypointense on ADC 2
3 Focal mildly/moderately hypointense on ADC and isointense/mildly
hyperintense on high b-value DWI
3 if DCE is negative
4 if DCE is positive
4 Focal markedly hypointense on ADC and markedly hyperintense on
high b-value DWI; <1.5 cm in greatest dimension
4




PI-RADS v2 categories assignment to peripheral zone lesions based on the scoring of DWI sequence.
T2W
score
Transition zone lesion PI-RADS category
1 Homogeneous intermediate signal intensity (normal) 1
2 Circumscribed hypointense or heterogeneous encapsulated nodules 2
3 Heterogeneous signal intensity with obscured margins
Includes others that do not qualify as 2, 4, or 5
3 if DWI score is <4
4 if DWI score is 5
4 Lenticular or noncircumscribed, homogeneous, moderately
hypointense, and <1.5 cm in greatest dimension
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PI-RADS v2 categories assignment to transitional zone lesions based on the scoring of T2W sequence.
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Several studies recommend that the MRI-targeted biopsy be performed for
findings classified as PI-RADS 4 and 5 [11–13]. According to the ESUR guidelines,
biopsy for PI-RADS 3 lesions may or may not be appropriate. Clinical factors should
be considered for lesions pertaining to this category. For findings with PI-RADS
1 or 2, biopsy is not recommended [8, 9].
2.2 Methods of MRI-targeted biopsy
There are currently three techniques for the MRI-targeted biopsy: the
cognitive registration, the software-assisted fusion registration and the in-bore
biopsy [14–17]. This paragraph provides an overview of the pro and cons of these
techniques (Table 3).
In the cognitive registration, also known as visual registration, a prebiopsy
mp-MRI is performed to localize the suspicious lesions. The targeted biopsy is then
performed using TRUS guidance with the objective of estimating the area where
the lesion is [14, 15].
Despite its low cost, the cognitive registration technique is strictly operator-
dependent and is more prone to errors when compared to the other techniques.
In addition, with this technique it is not possible to track the location of each
biopsy core [15, 18].
In the software-assisted fusion registration, known as MRI/TRUS fusion-guided
biopsy, the region of interest is identified in the mp-MRI images. Through a specific
software platform, the MRI images are fused with the real-time ultrasound
images [14, 17, 19].
The targeted prostate biopsy based on mp-MRI and TRUS imaging combine the
advantages of both techniques, i.e., the superior sensitivity of MRI for targeting
suspicious lesions and the practicality of TRUS [5, 18]. The greater reproducibility,
high precision, and lower operator dependence represent some of the main
advantages of the MRI/TRUS fusion-guided biopsy [17].
Various fusion platforms are currently registered by the Food and Drug Admin-
istration (FDA), which differ with respect to image registration (rigid or elastic),
tracking (electromagnetic tracking, mechanical position encoders, and image-based
software tracking) and biopsy approaches (transrectal or transperineal) [19].
In our institution the MRI/TRUS fusion-guided biopsy is performed in an
outpatient setting; we use the BioJet system (DK Technologies GmbH) which is
one of the most approved systems by the FDA [19] (Figure 1).
Techniques Advantages Disadvantages
Cognitive registration • Low cost








• Additional software platform required
• Specialized operators required
In-bore biopsy • High precision • Few sampled cores can be taken
• Specialized MRI equipment and
operators required
• High cost
• Long time required
Table 3.
Comparison between the three techniques for the MRI-targeted biopsy.
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T2 traversal MRI images are used to contour the prostate and the lesions; then,
the system fuses the marked MRI images with live transrectal ultrasound on both
the axial and sagittal image planes to guarantee the best needle placement.
During the biopsy procedure, the TRUS probe is fixed to a stepper provided with
position sensors that transmit the exact position of the probe to the software.
The location of biopsy cores can be tracked and recorded on a 3D map of the
prostate, and a report of the cores collected is provided at the end of the procedure;
it guarantees reproducible re-biopsies which is a very important advantage
particularly for patients in active surveillance (Figures 2–5).
The system supports both transrectal and transperineal biopsies depending on
the surgeon preference; the transperineal route with patients placed in lithotomy
position is our preferred approach. All biopsy samples are obtained after a local
anesthesia with 2% lidocaine and ropivacaine. At least three biopsy cores from each
lesion are taken. Standard 12-core biopsies from the lateral and medial aspects of the
base, mid, and apical prostate are taken during the same procedure.
With the in-bore biopsy technique the target lesion is biopsied with the patient
placed in a fixed position inside the mp-MRI scanner.
Unlike the MRI/TRUS fusion-guided biopsy, the in-bore biopsy procedure is
performed and tracked under MRI fluoroscopy guidance; real-time ultrasound
images are not used. A transrectal, transperineal or transgluteal approach can be
used during the in-bore biopsy [14, 15].
One of the main advantages of this technique is the high precision of the
targeted cores as the high-quality MRI images provide a visual feedback of the
biopsy needle localization [12, 15, 16]. However, the significant time required in the
MRI scanner and the availability of specialized MRI equipment make the costs
associated with this technique higher than the others [14–16].
Even if the determination of the most effective MRI-targeted biopsy technique is
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Several studies recommend that the MRI-targeted biopsy be performed for
findings classified as PI-RADS 4 and 5 [11–13]. According to the ESUR guidelines,
biopsy for PI-RADS 3 lesions may or may not be appropriate. Clinical factors should
be considered for lesions pertaining to this category. For findings with PI-RADS
1 or 2, biopsy is not recommended [8, 9].
2.2 Methods of MRI-targeted biopsy
There are currently three techniques for the MRI-targeted biopsy: the
cognitive registration, the software-assisted fusion registration and the in-bore
biopsy [14–17]. This paragraph provides an overview of the pro and cons of these
techniques (Table 3).
In the cognitive registration, also known as visual registration, a prebiopsy
mp-MRI is performed to localize the suspicious lesions. The targeted biopsy is then
performed using TRUS guidance with the objective of estimating the area where
the lesion is [14, 15].
Despite its low cost, the cognitive registration technique is strictly operator-
dependent and is more prone to errors when compared to the other techniques.
In addition, with this technique it is not possible to track the location of each
biopsy core [15, 18].
In the software-assisted fusion registration, known as MRI/TRUS fusion-guided
biopsy, the region of interest is identified in the mp-MRI images. Through a specific
software platform, the MRI images are fused with the real-time ultrasound
images [14, 17, 19].
The targeted prostate biopsy based on mp-MRI and TRUS imaging combine the
advantages of both techniques, i.e., the superior sensitivity of MRI for targeting
suspicious lesions and the practicality of TRUS [5, 18]. The greater reproducibility,
high precision, and lower operator dependence represent some of the main
advantages of the MRI/TRUS fusion-guided biopsy [17].
Various fusion platforms are currently registered by the Food and Drug Admin-
istration (FDA), which differ with respect to image registration (rigid or elastic),
tracking (electromagnetic tracking, mechanical position encoders, and image-based
software tracking) and biopsy approaches (transrectal or transperineal) [19].
In our institution the MRI/TRUS fusion-guided biopsy is performed in an
outpatient setting; we use the BioJet system (DK Technologies GmbH) which is
one of the most approved systems by the FDA [19] (Figure 1).
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the surgeon preference; the transperineal route with patients placed in lithotomy
position is our preferred approach. All biopsy samples are obtained after a local
anesthesia with 2% lidocaine and ropivacaine. At least three biopsy cores from each
lesion are taken. Standard 12-core biopsies from the lateral and medial aspects of the
base, mid, and apical prostate are taken during the same procedure.
With the in-bore biopsy technique the target lesion is biopsied with the patient
placed in a fixed position inside the mp-MRI scanner.
Unlike the MRI/TRUS fusion-guided biopsy, the in-bore biopsy procedure is
performed and tracked under MRI fluoroscopy guidance; real-time ultrasound
images are not used. A transrectal, transperineal or transgluteal approach can be
used during the in-bore biopsy [14, 15].
One of the main advantages of this technique is the high precision of the
targeted cores as the high-quality MRI images provide a visual feedback of the
biopsy needle localization [12, 15, 16]. However, the significant time required in the
MRI scanner and the availability of specialized MRI equipment make the costs
associated with this technique higher than the others [14–16].
Even if the determination of the most effective MRI-targeted biopsy technique is
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TRUS fusion-guided biopsy is much more accurate and cost-effective than the other
techniques [3, 14, 20–22].
Oberlin et al. have recently compared the MRI/TRUS fusion biopsy with the
cognitive approach. About 231 patients have been enrolled in the study. The study
shows that the targeted biopsy has a greater overall detection rate for prostate
cancer (48.1 vs. 34.6%) and clinically significant PCa when compared with cogni-
tive registration [20]. Similar results were obtained by Cool that performed a study
on 100 patients with the objective of comparing targeted biopsy accuracies of
cognitive registration using 2D or 3D TRUS guidance with MRI/TRUS fusion
biopsy. The detection rate of cognitive registration, with both 2D and 3D TRUS
probe, appears to be lower than that achieved through the MRI/TRUS fusion
biopsy, with less than 50% of the clinically significant PCa successfully sampled (48







sampled by cognitive registration, the percentage of cancerous tissue detected by
the MRI/TRUS fusion biopsy in each biopsy core was significantly higher [21].
A randomized trial was carried out on 210 patients to compare the MRI/TRUS
fusion biopsy and the in-bore technique [23]. No significant difference in the
overall and Cs PCa detection rates was observed between the two groups; the first
constituted of 104 patients that were subjected to fusion biopsy (39 and 32%,
respectively, for the PCa and Cs PCa detection rate), while an in-bore biopsy was
performed on the other 106 patients (37 and 29%, respectively, for the PCa and Cs
PCa detection rate). This is in agreement with the study performed by Vanderink
et al. according to which there is no significant difference in the detection rate
between the two biopsy techniques [24].
It should be noted however that, due to its significant costs, the in-bore
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2.3 Route of biopsy
The route of prostate biopsy (transrectal, transperineal, or transgluteal) may
differ between the various operators, but the transrectal (TR) and transperineal
(TP) are the two primary approaches through which the prostate tissue can be
taken [15, 16].
The TP biopsy is performed with the patient in the lithotomy position with the
needle passing through the perineum skin; the TR biopsy is instead performed in
the left lateral decubitus with the knees and hips flexed 90° and the needle passing
through the anterior rectal wall [25].
Both the TP and TR biopsies are very effective in diagnosing PCa and provide a
superimposable detection rate. However, the TP approach allows a better sampling
of the lesions located in the anterior part of the gland, therefore resulting in a
greater percentage of PCa of the anterior zone compared with the TR approach
(86.7 vs. 46.7%) [26, 27].
Even if there is no significant difference between the TP and TR biopsies in
terms of the overall complication rate, rectal bleeding and infection-related com-
plications are more frequently observed when adopting the TR approach [25, 26,
28, 29]. As the access to the prostate is via the rectal mucosa, the TR biopsy
increases the likelihood of introducing rectal flora into the urinary tract and the
blood circulation. Most of the reported infections result from Escherichia coli [29].
The overall risk of infectious complications, including bacteriuria, bacteremia,
fever, urinary tract infections and sepsis may be up to 6.3% [15, 28].
The likelihood of infections may be reduced by adopting the TP biopsy approach
[15, 28]. To further minimize infectious complications, patients are required to have
antibiotic prophylaxis [28].
According to the EAU guidelines, quinolones are recommended as the first-line
option: ciprofloxacin is prescribed in more than 90% of cases. Although no different
outcomes were observed between oral and systemic administration, a single oral
dose is usually preferred. In the event of antimicrobial resistance to quinolones,
alternative antibiotics of choice are cephalosporins and aminoglycosides [28].
On the other hand, pain management is more challenging with the TP approach
[26]. The average VAS score, used to measure the symptom severity and pain
control, is higher than that related to the TR biopsy. To ensure pain control, the TP
biopsy is usually performed under local anesthesia of both the perineum skin and
the periprostatic region [25, 26, 29].
Another issue to consider is that the TP-targeted biopsy is a relatively complex
procedure requiring a longer learning curve.
In conclusion, the choice of the biopsy method depends on several factors, such




Urologists frequently face the dilemma of patients with a negative prostate
biopsy and an elevated PSA value or a suspicious digital rectal examination
(DRE) [2].
Prior to the introduction of the MRI/TRUS fusion biopsy, patients with negative
TRUS-guided biopsies were regularly subjected to multiple biopsy procedures. This
approach resulted in a higher detection rate of insignificant low-grade tumors,
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therefore increasing overtreatment. The MRI/TRUS fusion biopsy is considered to
be a significant enhancement through which the weaknesses of the systematic
random biopsy can be overcome. Through the use of the mp-MRI for the identifi-
cation of suspicious lesions and the execution of the subsequent targeted biopsy, a
greater number of prostate cancers can be detected [3, 6, 30–34].
The most significant strength of the targeted biopsy, when compared to the
standard technique, is related to its improved detection capability of Cs PCas
needing a definitive treatment. Another advantage relates to the possibility of
avoiding biopsy for patients with a normal mp-MRI therefore reducing the detec-
tion of clinically insignificant cancers and preventing overtreatment of indolent
tumors.
A summary of the results in terms of the overall and Cs PCa detection rates in
the available literature is provided in Table 4. The systematic review performed by
Valerio et al. is aimed to compare the standard and MRI/TRUS fusion biopsy in
terms of detection rate and efficiency [3]. The overall detection rate reported is 43.4
and 50.5%, respectively, whereas the detection rate for clinically significant PCa is
23.6 and 33.3%, respectively. The above study also shows that a considerable num-
ber of Cs PCas can be detected only if a targeted biopsy is performed, particularly if
the anatomical locations of cancer are the transition zone and the anterior
fibromuscular stroma [35].
Moreover, according to Valerio et al., fewer core samples (9.2 vs. 37.2%) are
required to detect the same number of clinically significant cancers making the
targeted approach less uncomfortable for patients [3].
In another study involving more than 1000 patients, Siddiqui et al. show that the
standard and targeted biopsies have diagnosed a similar number of prostate cancers
(469 vs. 461). The significant difference highlighted is that the MRI/TRUS fusion
biopsy has diagnosed a greater percentage (+30%) of high-risk cancers and a lower
percentage (17%) of low-risk cancers than the standard biopsy [30]. Similar
results were obtained by other recent studies [12, 13, 35–37].
However, the diagnostic accuracy of the MRI/TRUS fusion-guided biopsy does
not allow the prostate standard biopsy to be avoided: the combined execution of the
standard and targeted biopsy will result in the detection of a greater number of PCa
cases [30, 36, 38].
The most significant predictive factor for the detection of prostate cancers
through the targeted biopsy is the ROI grade. As several studies have demonstrated,
the likelihood of diagnosing clinically significant PCas increases with the PI-RADS
score, i.e., the greater is the PI-RADS score, the higher is the probability of detecting
PCas [12, 13, 36, 37, 39, 40].
The study performed by Borkowetz et al., including 625 patients subjected to
standard and MRI/TRUS fusion-guided biopsies, shows that PCa was detected in
20, 33 and 70% of patients with PI-RADS 3, 4 and 5 lesions, respectively [37].
These results are consistent with the data recently published by Kasivisvanathan
and Cash [13, 39]. In particular, the Cs PCa detection rates resulting from the latter
study were 16.8, 46.1 and 84.7%, respectively, for PI-RADS categories 3, 4 and 5
[39]. Based on the above, the ESUR guidelines recommend that an MRI-targeted
biopsy be performed in patients with PI-RADS 4 and 5 lesions [8, 9]. The manage-
ment of PI-RADS 3 lesions still remains a challenge. An mp-MRI presenting PI-
RADS 3 lesions should be assessed considering clinical parameters such as PSA
density (PSAD) and total PSA value [36, 33]. An increased PSA density, i.e., the
PSA level related to the total prostate volume, is considered to be the most signifi-
cant clinical predictive factor for prostate cancers. Some studies recommend that
the patient should be subjected to targeted biopsy if the PSA density
>0.10 ng/ml/cc [33].
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plications are more frequently observed when adopting the TR approach [25, 26,
28, 29]. As the access to the prostate is via the rectal mucosa, the TR biopsy
increases the likelihood of introducing rectal flora into the urinary tract and the
blood circulation. Most of the reported infections result from Escherichia coli [29].
The overall risk of infectious complications, including bacteriuria, bacteremia,
fever, urinary tract infections and sepsis may be up to 6.3% [15, 28].
The likelihood of infections may be reduced by adopting the TP biopsy approach
[15, 28]. To further minimize infectious complications, patients are required to have
antibiotic prophylaxis [28].
According to the EAU guidelines, quinolones are recommended as the first-line
option: ciprofloxacin is prescribed in more than 90% of cases. Although no different
outcomes were observed between oral and systemic administration, a single oral
dose is usually preferred. In the event of antimicrobial resistance to quinolones,
alternative antibiotics of choice are cephalosporins and aminoglycosides [28].
On the other hand, pain management is more challenging with the TP approach
[26]. The average VAS score, used to measure the symptom severity and pain
control, is higher than that related to the TR biopsy. To ensure pain control, the TP
biopsy is usually performed under local anesthesia of both the perineum skin and
the periprostatic region [25, 26, 29].
Another issue to consider is that the TP-targeted biopsy is a relatively complex
procedure requiring a longer learning curve.
In conclusion, the choice of the biopsy method depends on several factors, such
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136
Male Reproductive Health
therefore increasing overtreatment. The MRI/TRUS fusion biopsy is considered to
be a significant enhancement through which the weaknesses of the systematic
random biopsy can be overcome. Through the use of the mp-MRI for the identifi-
cation of suspicious lesions and the execution of the subsequent targeted biopsy, a
greater number of prostate cancers can be detected [3, 6, 30–34].
The most significant strength of the targeted biopsy, when compared to the
standard technique, is related to its improved detection capability of Cs PCas
needing a definitive treatment. Another advantage relates to the possibility of
avoiding biopsy for patients with a normal mp-MRI therefore reducing the detec-
tion of clinically insignificant cancers and preventing overtreatment of indolent
tumors.
A summary of the results in terms of the overall and Cs PCa detection rates in
the available literature is provided in Table 4. The systematic review performed by
Valerio et al. is aimed to compare the standard and MRI/TRUS fusion biopsy in
terms of detection rate and efficiency [3]. The overall detection rate reported is 43.4
and 50.5%, respectively, whereas the detection rate for clinically significant PCa is
23.6 and 33.3%, respectively. The above study also shows that a considerable num-
ber of Cs PCas can be detected only if a targeted biopsy is performed, particularly if
the anatomical locations of cancer are the transition zone and the anterior
fibromuscular stroma [35].
Moreover, according to Valerio et al., fewer core samples (9.2 vs. 37.2%) are
required to detect the same number of clinically significant cancers making the
targeted approach less uncomfortable for patients [3].
In another study involving more than 1000 patients, Siddiqui et al. show that the
standard and targeted biopsies have diagnosed a similar number of prostate cancers
(469 vs. 461). The significant difference highlighted is that the MRI/TRUS fusion
biopsy has diagnosed a greater percentage (+30%) of high-risk cancers and a lower
percentage (17%) of low-risk cancers than the standard biopsy [30]. Similar
results were obtained by other recent studies [12, 13, 35–37].
However, the diagnostic accuracy of the MRI/TRUS fusion-guided biopsy does
not allow the prostate standard biopsy to be avoided: the combined execution of the
standard and targeted biopsy will result in the detection of a greater number of PCa
cases [30, 36, 38].
The most significant predictive factor for the detection of prostate cancers
through the targeted biopsy is the ROI grade. As several studies have demonstrated,
the likelihood of diagnosing clinically significant PCas increases with the PI-RADS
score, i.e., the greater is the PI-RADS score, the higher is the probability of detecting
PCas [12, 13, 36, 37, 39, 40].
The study performed by Borkowetz et al., including 625 patients subjected to
standard and MRI/TRUS fusion-guided biopsies, shows that PCa was detected in
20, 33 and 70% of patients with PI-RADS 3, 4 and 5 lesions, respectively [37].
These results are consistent with the data recently published by Kasivisvanathan
and Cash [13, 39]. In particular, the Cs PCa detection rates resulting from the latter
study were 16.8, 46.1 and 84.7%, respectively, for PI-RADS categories 3, 4 and 5
[39]. Based on the above, the ESUR guidelines recommend that an MRI-targeted
biopsy be performed in patients with PI-RADS 4 and 5 lesions [8, 9]. The manage-
ment of PI-RADS 3 lesions still remains a challenge. An mp-MRI presenting PI-
RADS 3 lesions should be assessed considering clinical parameters such as PSA
density (PSAD) and total PSA value [36, 33]. An increased PSA density, i.e., the
PSA level related to the total prostate volume, is considered to be the most signifi-
cant clinical predictive factor for prostate cancers. Some studies recommend that
the patient should be subjected to targeted biopsy if the PSA density
>0.10 ng/ml/cc [33].
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Another issue to consider is that, prior to the introduction of the MRI/TRUS
fusion biopsy, literature did not describe a strong concordance between biopsy and
radical prostatectomy Gleason score (GS). A significant pathological GS (pGS)
upgrading, when compared with that of standard biopsy specimens (bGS), was
observed in 50% of patients, while up to 80% of patients were downgraded [41, 42].
As the GS is a significant decision-making tool for patient treatment, its correct
attribution is absolutely essential [2, 41].
With the introduction of the MRI/TRUS fusion biopsy, a high consistency
between bGS and pGS has been achieved. Its accuracy in predicting the
pathological GS allows minimizing the risk of possible cancer upgradings or
downgradings [37, 42].
The MRI/TRUS fusion biopsy superior performance has been demonstrated by
Porpiglia. About 246 patients subjected to robot-assisted RP were enrolled. For
91.5% of patients the anatomopathological results of surgical specimens were con-
sistent with those achieved through biopsy cores. Also, with the targeted biopsy,
the GS upgrading and downgrading was 7.8 and 0.8%, respectively, significantly
lower than the rates achieved with the standard biopsy (39.3 and 6.8%,
respectively) [42].
3.2 Naïve-biopsy patients
The current guidelines of the European Association of Urology and National
Institute for Health and Care Excellence (NICE) recommend that an mp-MRI
evaluation and a subsequent targeted biopsy be performed in patients with a per-
sistent clinical suspicion of PCa (elevated PSA level and/or abnormal DRE) after a
previous negative biopsy [7, 43].
The use of mp-MRI as the primary diagnostic tool for biopsy-naïve patients is
controversial. However, recent studies support the excellent performance of mp-
MRI in the detection of PCa in biopsy-naïve patients [30, 38, 44–46].
A clinical trial was recently performed with 212 biopsy-naïve patients randomly
assigned to either the targeted or the standard biopsy group. Results shows that
targeted biopsy provides a greater detection rate for both PCa (50.5 vs. 29.5%) and
clinically significant PCa (43.9 vs. 18.1%) [44]. These results agree with those
achieved by a multicentric trial involving 214 biopsy-naïve patients with at least one
suspicious lesion detected through mp-MRI [38].
Although further confirmation is required, men who have never been biopsied
before may benefit from the use of mp-MRI as a preliminary test. In case of a
positive MRI, the combined execution of MRI/TRUS fusion and standard biopsies
would then be recommended and improve the detection of CsPca [38, 45].
A critical issue to consider are the economic resources required if the MRI were
used as the primary diagnostic tool in all patients with clinical suspicious of PCa.
Nevertheless, recent analyses have shown that mp-MRI for the initial detection
of PCa appears to be cost-effective when compared with repeated standard
biopsies [38, 45].
3.3 Patients on active surveillance
Active surveillance (AS) is the strategy of choice in men with localized and very
low/low-risk prostate cancer to avoid or delay treatment that might not be imme-
diately necessary [47–49].
Even if there is still no definitive agreement with regard to the selection criteria
for AS candidates, a widely accepted criteria is based on the following: clinical T1c
or T2a, PSA <10 ng/ml, fewer than two to three positive cores with <50% cancer
141
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between bGS and pGS has been achieved. Its accuracy in predicting the
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sistent with those achieved through biopsy cores. Also, with the targeted biopsy,
the GS upgrading and downgrading was 7.8 and 0.8%, respectively, significantly
lower than the rates achieved with the standard biopsy (39.3 and 6.8%,
respectively) [42].
3.2 Naïve-biopsy patients
The current guidelines of the European Association of Urology and National
Institute for Health and Care Excellence (NICE) recommend that an mp-MRI
evaluation and a subsequent targeted biopsy be performed in patients with a per-
sistent clinical suspicion of PCa (elevated PSA level and/or abnormal DRE) after a
previous negative biopsy [7, 43].
The use of mp-MRI as the primary diagnostic tool for biopsy-naïve patients is
controversial. However, recent studies support the excellent performance of mp-
MRI in the detection of PCa in biopsy-naïve patients [30, 38, 44–46].
A clinical trial was recently performed with 212 biopsy-naïve patients randomly
assigned to either the targeted or the standard biopsy group. Results shows that
targeted biopsy provides a greater detection rate for both PCa (50.5 vs. 29.5%) and
clinically significant PCa (43.9 vs. 18.1%) [44]. These results agree with those
achieved by a multicentric trial involving 214 biopsy-naïve patients with at least one
suspicious lesion detected through mp-MRI [38].
Although further confirmation is required, men who have never been biopsied
before may benefit from the use of mp-MRI as a preliminary test. In case of a
positive MRI, the combined execution of MRI/TRUS fusion and standard biopsies
would then be recommended and improve the detection of CsPca [38, 45].
A critical issue to consider are the economic resources required if the MRI were
used as the primary diagnostic tool in all patients with clinical suspicious of PCa.
Nevertheless, recent analyses have shown that mp-MRI for the initial detection
of PCa appears to be cost-effective when compared with repeated standard
biopsies [38, 45].
3.3 Patients on active surveillance
Active surveillance (AS) is the strategy of choice in men with localized and very
low/low-risk prostate cancer to avoid or delay treatment that might not be imme-
diately necessary [47–49].
Even if there is still no definitive agreement with regard to the selection criteria
for AS candidates, a widely accepted criteria is based on the following: clinical T1c
or T2a, PSA <10 ng/ml, fewer than two to three positive cores with <50% cancer
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involvement of every positive core, and GS 3 + 3 [7]. Patients fulfilling this criteria
may benefit from AS, reducing treatment-related complications without
compromising their survival.
AS consists of a close disease monitoring through clinical and histological
parameters: commonly used tools are serial PSA measurements, DRE, and repeat
biopsies [2, 7]. If biochemical or histological evidence of cancer progression is
observed, a radical treatment will then be proposed [2, 47, 48].
The main limitation associated with the AS protocol is the risk of
underestimating the extent and aggressiveness of prostate cancer. Some authors
have reported that TRUS-guided biopsies may lead to an underestimation in one
third of cases [47, 48, 50].
mp-MRI is currently emerging as a significant diagnostic tool through which the
above risk can be minimized. It can be used in one of the three following stages: at
the time of initial diagnosis of men with low-risk cancer, before confirmatory
biopsy and during follow-up [49].
At the time of initial diagnosis, the mp-MRI is much more accurate in the
identification and characterization of prostate cancers, resulting in a more accurate
patients enrollment for the AS protocol. Its use is recommended to rule out signif-
icant PCas that were missed by the initial biopsy.
Before the confirmatory biopsy, usually performed within the first year from the
initial diagnosis, the mp-MRI can reveal the need to perform a targeted biopsy in
addition to the commonly adopted standard biopsy. The combined use of these two
techniques may lead to a more accurate evidence of disease progression [47–49].
This is in line with the review performed by Schoots et al. [48] according to which
the combined execution of targeted and standard biopsies resulted in 27% cancer
upgrading. It is therefore recommended that both biopsy techniques be adopted at
the stage of the confirmatory biopsy [48, 49].
During the follow-up period, a yearly mp-MRI might allow the annual biopsy to
be avoided for those patients with stable MRI findings. The repeat biopsy should be
performed only in the event that a disease progression is detected by the mp-MRI
[47]. It should be noted however that there is still no definitive agreement on the
use of the mp-MRI as a replacement for the repeat biopsy during the follow-up
period [49].
Key points
• For many years the TRUS-guided biopsy has been considered as the gold
standard in the diagnosis of PCa. Even if the ultrasound-based imaging is a
great tool for guiding a biopsy needle, it cannot identify regions of interest that
could harbor PCa in all cases. This is the reason why in the last decade, the
research activities have focused on the development of imaging methods that
can differentiate between noncancerous tissue and malignant lesions with
greater accuracy.
• The introduction of mp-MRI as an imaging modality for the detection and
localization of regions of interest has nowadays revolutionized the way through
which PCa is managed and treated. According to the ESUR guidelines, the mp-
MRI protocol should include T2W, DWI, and DCE sequences.
• PI-RADS v2 was introduced by the ESUR to standardize the evaluation and
reporting of mp-MRI examinations. This 5-point scoring system is based on the
likelihood that MRI findings correlate with the presence of Cs PCa.
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• According to the EAU guidelines, an mp-MRI followed by an MRI-targeted
biopsy should be recommended for patients with persistent clinical suspicion
of prostate cancer (elevated PSA level and/or abnormal DRE) after a previous
negative standard biopsy.
• mp-MRI is currently emerging as a significant diagnostic tool in patients on
active surveillance protocol both for the enrollment of patients with low-risk
indolent disease and before the confirmatory biopsy.
• The role of mp-MRI in the management of biopsy-naïve patients is still a
matter of debate. However, its diagnostic accuracy is such that recent studies
support the use of mp-MRI as a preliminary test in patients with no prior
biopsies.
• The cognitive registration, software-assisted fusion registration, and in-bore
biopsy are the techniques currently available for the MRI-targeted biopsy. The
MRI/TRUS fusion-guided biopsy appears to be the most accurate and cost-
effective approach when compared with other biopsy procedures.
• A greater number of prostate cancers can be diagnosed through the MRI-
targeted biopsy, resulting in an increased overall detection rate. The great
advantage of this technique is that it increases the detection rate of Cs PCas,
reducing the detection of clinically insignificant cancers.
• The MRI-targeted biopsy has been shown to be more accurate in predicting the
pathological GS, providing a strong consistency between bGS and pGS. The
rate of a possible cancer underestimation or overestimation is therefore
minimized.
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• According to the EAU guidelines, an mp-MRI followed by an MRI-targeted
biopsy should be recommended for patients with persistent clinical suspicion
of prostate cancer (elevated PSA level and/or abnormal DRE) after a previous
negative standard biopsy.
• mp-MRI is currently emerging as a significant diagnostic tool in patients on
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Abstract
Considering prostate adenocarcinoma, the cancer of higher incidence in men, 
having as treatment of choice the prostatectomy, and the high prevalence of urinary 
incontinence (UI) and erectile dysfunction (ED) after the surgery, the physiother-
apy becomes an eligible treatment for such alterations. The rehabilitation of post-
prostatectomy effort urinary incontinence is considered a recommendation grade 
B. Erectile dysfunction has as its first line of treatment penile vacuum therapy. 
Pelvic health physical therapy has as its main tool the rehabilitation of the pelvic 
floor muscles (PFM), which can be assisted by biofeedback and electrotherapy. The 
training of these muscles accelerates the recovery process of post-prostatectomy 
stress urinary incontinence and has greater therapeutic relevance when the phys-
iotherapeutic treatment is initiated in the pre-surgical period. Post-micturition 
dribble is also treated by training the pelvic floor muscles. Urinary urgency, associ-
ated or not with incontinence, can be treated with electrotherapy, which is con-
sidered second or third line of treatment. Erectile rehabilitation has two physical 
resources of treatment, physical therapy, one through the vacuum and the other of 
the shock wave. Both penile vacuum therapy and shock wave therapy are considered 
the first line of treatment in the approach to erectile dysfunction.
Keywords: physical therapy, erectile dysfunction, urinary incontinence,  
prostate cancer, prostatectomy
1. Pelvic health physiotherapy
Pelvic health physiotherapy has as its main therapeutic pillar the rehabilita-
tion of the pelvic floor muscles (PFM). Since the work done by the gynecologist 
Arnold Kegel in the 1940s, the treatment of the pelvic floor has been evolving and 
being recognized by the scientific community. Kegel began his work in this area by 
creating exercises for PFM for the treatment of female urinary incontinence. When 
assumed by physical therapy, the exercises became perineal kinesiotherapy, cur-
rently having a gold standard of recommendation grade A, in the rehabilitation of 
female urinary stress incontinence (SUI).
With evolution, the “Kegel exercises” also reached male pelvic health. However, 
because the anatomy and pathophysiology of urinary incontinence (UI) in men 
are distinct from women, which also influences the lower prevalence of SUI in the 
male population, around 10%, the effectiveness of the treatment may be vari-
able, when compared to the woman’s. The detrusor hyperactivity associated with 
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urinary urgency with or without loss of urine is commonly associated with prostatic 
disease, needing to be investigated, with the pelvic floor having little influence on 
male urinary incontinence.
2. Rehabilitation of urinary continence after prostatectomy
The prostatectomized patient has transient SUI, and maintenance of this condi-
tion may still prevail in 8% of patients, 2 years after surgery. The prevalence that 
precedes this period is variable, since it depends on the definition of incontinence, 
severity, degree of discomfort, and methodology for evaluating the magnitude. The 
evolution of surgical techniques, with regard to the greater or less prevalence of 
post-prostatectomy UI, has still been the subject of debate [1].
When talking about robot-assisted laparoscopic prostatectomy, the prevalence 
of incontinence can be influenced by the patient’s preoperative characteristics, 
surgeon’s experience, surgical technique, and methods used to collect and present 
data. The characteristics of patients that may influence postsurgical continence are 
age, body mass index, comorbidity, presence of lower urinary tract symptoms, and 
prostate volume [2].
The damage generated during the surgical procedure can occur in the urethral 
sphincter complex, in the supporting structures, or in its innervations, leading to 
the high prevalence of UI, being the anatomical support and pelvic innervation, 
important etiological factors of the loss of the continence post-prostatectomy. 
Excessive dissection during surgery, neurovascular bundle injury, and postoperative 
fibrosis also contribute negatively to the maintenance of continence. On the other 
hand, the maintenance of the bladder neck and fixation of the bladder-urethral 
anastomosis, before and after, are favorable for continence [3].
Prostate removal surgery favors stress urinary incontinence and urgency. The 
urgency, associated or not with incontinence, is also present in the detrusor overac-
tivity not infrequently found in patients, making it more prevalent, since they add 
to the age factors, which reduces bladder complacence and prostatic enlargement, 
which leads to emptying dysfunction, obstructive [4].
Post-micturition dribble may also be present post-prostatectomy. There is 
usually no bladder alteration, but rather the inability of PFM, the bulbospongiosus 
muscle in particular, to eject the urinary volume contained in the ureter after the 
end of urination [5].
2.1 Physiotherapeutic treatment of urinary incontinence after prostatectomy
The prostatectomized patient has a great impact on their quality of social life 
and often with important limitations in their physical activities and daily life due to 
loss of urine. Considering the social and pathophysiological aspects of post-prosta-
tectomy urinary incontinence (PPUI), physical therapy for male pelvic health has 
been offering therapeutic strategies through perineal kinesiotherapy, biofeedback, 
electrostimulation, behavioral therapies, and lifestyle changes [6].
2.2 Functional assessment of the pelvic floor
Perineal kinesiotherapy, also known as pelvic floor muscle training (PFMT), is 
performed after a careful functional assessment of the PFM where the muscular 
capacity of resistance and strength, symmetry, tone, and presence of pain are 
observed. This evaluation is not yet standardized for the male pelvic floor, and most 
of the protocols used to evaluate the female PFM are used, such as the modified 
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Oxford scale, for example, which has a bidigital touch reference in the vagina and 
with the patient evaluated in supine. The Ortiz scale (Table 1) does not assume 
patient positioning and does not mention the female anatomy, being quite reason-
able for the evaluation of the pelvic floor of the man.
In the inspection of the male pelvic floor, we observe the retraction of the 
anus and elevation of the penis, which is presented subtly. Dynamic palpation is 
one of the few methods, if not the only one at present, for the assessment of the 
pelvic floor of both sexes. The anorectal touch is necessary for the evaluation of 
the pubococcygeus muscle, assessing its contractile capacity bilaterally, strength, 
and endurance. Palpation of the perineal body can also assess muscle activity and 
tone [8].
The pad test can be a useful tool to quantify urinary loss. It can be 24 or 1 hour. 
However, there is evidence that the 24 hour pad test is statistically more relevant for 
PPUI assessment. The accomplishment of this one becomes important, since some 
authors have it like a criterion of discharge of the treatment or cure of the inconti-
nence. It can enter such criteria from the use of a pad by day to none [9].
The voiding diary is a semi-objective method to quantify symptoms such as 
urinary frequency and incontinence and degree of urgency, use of absorbents, and 
fluid intake. Urinary volume may contribute to the diagnosis of overactive bladder 
(OAB) and polyuria. The diary can be carried out for 3–7 days. Although it is a level 
of evidence 3 and recommendation grade D, it is recommended for the evaluation 
and measurement of the symptoms and discomforts of urinary incontinence, both 
at the beginning of treatment and to assess the impact of therapy [10].
The questionnaires, as well as the scales and index, also serve to measure some 
factors related to urinary incontinence, such as the severity of symptoms and 
quality of life. Some are more generic like Medical Outcomes Study SF-36 Health 
Status Profile, and others bring more specific conditions like the King’s Health 
Questionnaire [3].
Although physical therapy is part of the pull first-line treatment offers, the 
urodynamic examination, requested in the failure of these primary resources, offers 
a functional evaluation of the lower urinary tract. There is limited evidence that the 
preliminary urodynamic examination influences the results of the treatment for 
male urinary incontinence, although it is able to distinguish the different causes of 
incontinence [11].
After the evaluation and a kinetic-functional diagnosis of the pelvic floor, as 
well as a functional diagnosis of the lower urinary tract, a therapeutic program can 
be developed. For pelvic health physiotherapy, the rehabilitation of urinary incon-
tinence consists of behavioral and physical therapies, such as bladder training (BT) 
and the therapeutic exercises of the pelvic floor muscles, respectively.
Functional assessment of pelvic floor
0 No objective perineal function, even to palpation
1 Objective perineal function absent, detectable only by palpation
2 Weak objective perineal function, detectable by palpation
3 Objective perineal function, without resistance to palpation
4 Objective perineal function and resistance not maintained by 
palpation
5 Objective perineal function and resistance by palpation maintained 
for more than 5 seconds
Table 1. 
Functional assessment of pelvic floor by [7].
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muscle in particular, to eject the urinary volume contained in the ureter after the 
end of urination [5].
2.1 Physiotherapeutic treatment of urinary incontinence after prostatectomy
The prostatectomized patient has a great impact on their quality of social life 
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preliminary urodynamic examination influences the results of the treatment for 
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4 Objective perineal function and resistance not maintained by 
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In bladder training, the patient is instructed on bladder function and fluid 
intake, including bowel habits and restriction of caffeine use, for example. Patients 
with independent urination may be advised of micturition habit and time. In the 
case of urgency and nocturnal incontinence, BT is as effective as oxybutynin, 
tolterodine, and solifenacin. It may also promote some improvement in frequency 
and nocturia when associated with other pharmacological therapies [6].
The PFMT increases urethral closure pressure and stabilizes the urethra. It can 
be performed with the aid of biofeedback which can be pressure, electromyography, 
and manual. Visual, auditory, or tactile resources are used to guide the patient 
in performing the contraction and relaxation of the pelvic floor musculature. 
Electrotherapy may be another alternative associated with PFMT. Both resources 
are not superior to PFMT, but when used as a combination therapy, it can favor the 
evolution of the condition, improving the performance and coordination of the 
PFM [12].
The PFMT should be offered as first-line therapy [10]. The therapeutic exercises 
are proposed after a thorough evaluation of the PFM, where the effective time and 
the repetition of the contraction, without reaching the fatigue, are determined. 
From there an exercise program is developed, aiming at endurance, strength, 
coordination, and pre-contraction of muscles.
It should be noted that during PFMT, the patient does not use accessory muscles, 
such as the abdominals, buttocks, and thigh adductors. The inadequate use of these 
muscles leads to poor perception of the effective performance of the PFM. The 
physiotherapist needs to guide the patient on how to perform the most effective 
contraction without using the accessory muscles. Although the abdominal muscles 
are considered accessory, the transverse abdominis muscle in particular has a 
synergistic function to the pelvic floor [13].
The transverse abdomen muscle and the PFM are considered postural muscles, 
with the support function, that is, they have predominance of tonic muscle fibers 
and are responsible for the maintenance of orthostatism. Performing a therapeutic 
exercise program for these synergistic muscles is critical to the functionality and 
daily life activities of the patient. These muscles activated together favor the dissi-
pation of abdominal load, which would lead to increased intra-abdominal pressure 
and consequently loss of urine to the effort [14].
Biofeedback for pelvic floor rehabilitation is used to gain a greater awareness of 
the functions of the PFM, mainly using instruments that provide information about 
the activity of these muscles. Intracavitary (anal) pressure probes can be used, mea-
suring the contraction in millimeters of mercury or electromyographic that detects 
the potential of muscular action in microvolt, the latter being also possible through 
a perineal surface electrode. Its purpose is to better muscle functionality, providing 
greater proprioception, consequently greater effectiveness in the coordination, 
strength, and endurance of the PFM [15].
Functional electral stimulation (FES) is a biphasic current transmitted from 
transcutaneous (Figure 1) or intracavitary (Figure 2) electrodes. The intensity of 
the current is given according to the patient’s sensitivity, without generating any 
discomfort or pain [16].
Usually the contractions generated by the electric current assist the voluntary 
activation of the PFM. Because it is a muscle with a predominance of tonic fibers, 
the frequency (in hertz) used is low and the pulse width (in microseconds) higher, 
for example, 20 Hz and 700 μs. The contraction time is variable, on average over 
4 seconds, but given individually according to the PFM functional evaluation. The 
resting time may be one to two times the contraction time.
155
The Pelvic Health Physical Therapy and the Prostatectomy
DOI: http://dx.doi.org/10.5772/intechopen.86979
It is not uncommon for patients who have undergone prostatectomy to also 
have urinary urgency, associated or not with incontinence. Sometimes the urgency 
is related to a detrusor overactivity, and complaints of nocturia and polaciuria 
are present. OAB may already manifest even before prostate withdrawal surgery. 
Changes in the bladder wall, as well as the increase in prostatic volume related to age 
(elderly), may be related to OAB [17].
In the cases of post-prostatectomy patients who present OAB, the electral 
therapy with (neuro) modulation objective should be used. A different action 
in PFM, the electral therapy used in this case is transcutaneous electrical nerve 
stimulation (TENS). Surface electrodes may be used in the parasacral (Figure 3) or 
tibial (Figure 4) regions. The frequency usually used varies between 5 and 10 Hz 
and the pulse width between 300 and 700 μs; the intensity is given before reaching 
the motor point, remaining at sensitive levels. The treatment should be performed 
under physiotherapeutic assistance, with prescription of the home and/or outpa-
tient electrotherapy device. The treatment time is around 12 weeks [15].
In addition to electrotherapy, BT is also indicated. In the case of urinary urgency, 
it may also be performed through contraction of PFM and inhibition of voiding 
reflex, allowing the patient to lose the urge to urinate and being able to reach the 
bathroom more comfortably or delaying urination, in the case of polaciuria.
Post-micturition dribbling may also be another complaint in prostatectomized 
patients. This situation does not influence the function, or dysfunction, of the 
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Changes in the bladder wall, as well as the increase in prostatic volume related to age 
(elderly), may be related to OAB [17].
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tibial (Figure 4) regions. The frequency usually used varies between 5 and 10 Hz 
and the pulse width between 300 and 700 μs; the intensity is given before reaching 
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under physiotherapeutic assistance, with prescription of the home and/or outpa-
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bathroom more comfortably or delaying urination, in the case of polaciuria.
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the voiding residue present in the bulbar urethra. The treatment consists of the 
therapeutic exercises of this musculature, aiming to acquire greater muscular force 
for the expulsion of the urine of the urethra, after the urination. The urethral milk-
ing maneuver and bulbar massage may also be associated, but the effectiveness of 
bulbospongiosus muscle contraction is greater [5].
The loss of urine during orgasm, climacturia, is not uncommon in these patients. 
The inevitable surgical damages generated in the bladder neck, as well as the event 
in the sympathetic fibers, responsible for contraction of the bladder neck and 
relaxation of the external sphincter during the ejaculation expulsion phase, are one 
of the suggested mechanisms for climacturia [18]. And the proposed physiothera-
peutic treatment is PFMT.
3. Rehabilitation of erectile function after prostatectomy
Climacturia, an orgasmic dysfunction, is one of the affected aspects of the 
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dysfunction (ED), highly prevalent in the second postoperative month, reaching 
around 90%. Complaints about the quality of erection remain frequent even after 
12 months postoperatively in around 75% of patients. At the same time, the preva-
lence of orgasm difficulty was 45% (Table 2) [19].
When talking about the post-prostatectomy sexual quality of life, before the 
complaint of climacturia, which may be presumed that there is penetration, the 
patient usually presents with a severe erectile dysfunction. The impact on sexual life 
may be even greater when ED is associated with urinary loss, requiring a much more 
integral approach to the case, since the patient begins to have an affective distanc-
ing from the partner and consequently sexual avoidance. The sexual behavioral 
approach (Figure 5) is necessary in order to keep the patient stimulated sexually, 
within its limitations. This is the beginning of sexual rehab [20].
Once the behavioral framework is handled, the erectile rehabilitation comes 
to the scene. Because it is a multifactor ED, which begins with neuropraxia of the 
cavernous nerve, which promotes pro-apoptotic and pro-fibrotic factors in the 
penile tissue, thus evolving into a veno-occlusive dysfunction, resources that act in 
these frames are taken into account for the treatment [21].
Penile vacuum therapy (Figure 6) is a physical rehabilitation resource, there-
fore a physiotherapy, which aims to promote, through a negative pressure, daily 
erections with the protective function of the erectile tissue, in the same way that 
nocturnal erections did that no longer occur [22].
By getting into the place of nocturnal erections, which were daily, penile 
vacuotherapy also needs to be performed daily. In the Engel [22] and Raina and 
collaborators [23] studies, the mean time of application of the therapeutic vacuum 
is 10 minutes. However it is known that in 5 minutes of use, the arterial blood is 
equivalent to the venous one, becoming poor in oxygen. It is also known that a rest 
of 30–60 seconds in the vacuum normalizes penile oxygenation, suggesting that 
the application should be done intermittently, with rest between one application 
and another. The therapeutic pressure is between −150 and −200 mmHg [24]. The 
treatment time is over 6 months.
Due to the safety of the patient, the prescription and orientation of use should 
be made by a professional qualified to do so, thus avoiding possible intercurrences 
during the application, such as penile pain, edema, and hematoma. The patient is 
taught to perform the penile vacuotherapy, recognizing the perceptions and sensa-
tions, regarding the sensitivity, size, and color of the penis, being performed by the 
physiotherapist in the office, in order to make home treatment safe.
Sound therapy has been used in the treatment of ED. The main treatment cur-
rently offered is extracorporeal shock wave therapy. But it is common to the treat-
ment by sound waves; this includes the therapeutic ultrasound, to cause mechanical 
stress and microtrauma in the place of its application. This vascular stress and 
microtrauma, which generates a shear stress, induce a cascade of biological 
Sexual function 2 Mo 6 Mo 12 Mo
Poor erections 88% 80% 67%
Difficulty with orgasm 62% 51% 45%
Erections not firm 90% 84% 75%
Erections not reliable 83% 75% 60%
Poor sexual function 83% 74% 61%
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dysfunction (ED), highly prevalent in the second postoperative month, reaching 
around 90%. Complaints about the quality of erection remain frequent even after 
12 months postoperatively in around 75% of patients. At the same time, the preva-
lence of orgasm difficulty was 45% (Table 2) [19].
When talking about the post-prostatectomy sexual quality of life, before the 
complaint of climacturia, which may be presumed that there is penetration, the 
patient usually presents with a severe erectile dysfunction. The impact on sexual life 
may be even greater when ED is associated with urinary loss, requiring a much more 
integral approach to the case, since the patient begins to have an affective distanc-
ing from the partner and consequently sexual avoidance. The sexual behavioral 
approach (Figure 5) is necessary in order to keep the patient stimulated sexually, 
within its limitations. This is the beginning of sexual rehab [20].
Once the behavioral framework is handled, the erectile rehabilitation comes 
to the scene. Because it is a multifactor ED, which begins with neuropraxia of the 
cavernous nerve, which promotes pro-apoptotic and pro-fibrotic factors in the 
penile tissue, thus evolving into a veno-occlusive dysfunction, resources that act in 
these frames are taken into account for the treatment [21].
Penile vacuum therapy (Figure 6) is a physical rehabilitation resource, there-
fore a physiotherapy, which aims to promote, through a negative pressure, daily 
erections with the protective function of the erectile tissue, in the same way that 
nocturnal erections did that no longer occur [22].
By getting into the place of nocturnal erections, which were daily, penile 
vacuotherapy also needs to be performed daily. In the Engel [22] and Raina and 
collaborators [23] studies, the mean time of application of the therapeutic vacuum 
is 10 minutes. However it is known that in 5 minutes of use, the arterial blood is 
equivalent to the venous one, becoming poor in oxygen. It is also known that a rest 
of 30–60 seconds in the vacuum normalizes penile oxygenation, suggesting that 
the application should be done intermittently, with rest between one application 
and another. The therapeutic pressure is between −150 and −200 mmHg [24]. The 
treatment time is over 6 months.
Due to the safety of the patient, the prescription and orientation of use should 
be made by a professional qualified to do so, thus avoiding possible intercurrences 
during the application, such as penile pain, edema, and hematoma. The patient is 
taught to perform the penile vacuotherapy, recognizing the perceptions and sensa-
tions, regarding the sensitivity, size, and color of the penis, being performed by the 
physiotherapist in the office, in order to make home treatment safe.
Sound therapy has been used in the treatment of ED. The main treatment cur-
rently offered is extracorporeal shock wave therapy. But it is common to the treat-
ment by sound waves; this includes the therapeutic ultrasound, to cause mechanical 
stress and microtrauma in the place of its application. This vascular stress and 
microtrauma, which generates a shear stress, induce a cascade of biological 
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reactions that result in the release of angiogenic factors which in turn triggers tissue 
neovascularization with subsequent improvement of blood supply [25].
Penile electrical stimulation (Figure 7) has also been studied for penile rehabili-
tation. Its action consists in the endothelial action. The current generates release 
of endothelium-dependent nitric oxide, leading to increased blood supply and 
vasodilation. Favoring the action of endothelial progenitor cells, which secrete pro-
angiogenic factors, induces neovascularization, repair, and endothelial function. 
Endothelial progenitor cells release vascular endothelial growth factor, acting as a 
mediator of angiogenesis [26].
The erectile latency of the post-prostatectomy patient is variable in duration, 
and we already know the possible damage to penile erectile tissue. But from the 
perspective of the striated muscles, it is known that the penis muscles who have 
a veno-occlusive function, the ischiocavernosus and bulbospongiosus muscles 
(Figure 8), which, besides being in the process of sarcopenia inherent to the senility 
of the patient, may also pass through atrophy due to disuse.
Figure 5. 
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PFMT, focusing on the penile muscles, acts on the veno-occlusion favoring 
penile stiffness. However, the ischiocavernosus muscle in particular does not have 
great relevance in the penile intumescence phase. This suggests that to activate them 
in a functional PFMT, the penis would need to be at least in its maximum turgid-
ity, considering that this patient has great impairment of the postsurgical erectile 
function [27].
4. Conclusion
Several studies show the predictive factors for the evolution of both urinary 
incontinence and erectile dysfunction and that to date no conservative treatment 
has curative action in both situations. However, it is consensual in the rehabilitation 
process of the post-prostatectomy patient, offering treatments, based on the levels 
of evidence and recommendation grade, with the objective of improving the quality 
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1. Introduction
Statistical reports revealed that prostate cancer is the third leading cause of 
cancer deaths in men [1] causing the life of one in every 39 men in United States. 
Related to prostate cancer rates in India, the rates are more than 20 times higher in 
US whites, more than 10 times higher in US Asian Indians/Pakistanis, seven times 
higher among UK South Asians and twice as high among Singapore Indians [2]. 
Factors escalating the risk of prostate cancer include age above 50 years, cancer inci-
dence in family, ethnicity, modern diet, environmental factor, pollutants, etc. The 
role of inflammation in prostate diseases is suggested by the presence of inflam-
matory cells within the prostate of cancer patients [3]. The molecular mechanism 
responsible for inflammation mediated prostate cancer is not yet clear.
However, prostate cancer needs a long period for development from small lesion 
to become a clinical manifestation [4]. Tumor progression is revealed with compli-
cations in erectile dysfunction, skeletal bone pain, obstruction of lymph vessels, 
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and veins causing lower body edema. The development of high-grade prostatic 
intraepithelial neoplasia (HGPIN) is identified as an intermediate stage between 
benign epithelium and the invasive malignant carcinoma at the outset of prostate 
cancer. Four main patterns of high-grade PIN (HGPIN) have been described as 
tufting, micropapillary, cribriform, and flat [5].
Prostate specific antigen (PSA), major constituent in prostatic secretion and is 
used for screening prostatism. PSA testing is primarily associated with benign pros-
tatic hyperplasia (BPH), however there is only rare connectivity of patients having 
BPH to develop prostate cancer. With conditions like BPH, inflammation, and 
disruption of prostate basal membrane increases the permeability and releases PSA 
into the circulation. Prostate cancer antigen 3 (PCA3) is more specific than PSA 
which is an important biomarker in personalized medicine. Also analysis of urinary 
protein markers, such as TMPRSS2-ERG and PCA3 are helpful in early diagnosis 
of the disease. The other tumors markers reported as prostatic acid phosphatase 
(PAP), cytoskeletal proteins, and annexin I are downregulated in PIN whereas 
C-erbB-2 (HER-2/neu) and C-erbB-3 oncoproteins, c-met protooncogene, Bcl-2 
oncoprotein, several growth factors, nitric oxide synthase, alpha-methylacyl-CoA 
racemase, glycoprotein A-80, and apolipoprotein D, are upregulated in PIN. The 
histological grading system of prostate cancer is obtained from the Gleason score 
[6] which provides information that score 1–5 indicates low-grade prostate cancer 
and score 8–10 indicates high-grade prostate cancer. Digital rectal examination 
(DRE), examination of PSA levels, prostate ultrasound, and prostate biopsy are 
the current diagnostic methods in examining the primary and metastatic stages 
for prostate cancer [7, 8]. Prostate cancer stages are generally classified into three 
categories—T category, N category, and M category. T represents the primary 
tumor, N represents the cancer that has spread to regional (nearby) lymph nodes 
and M represents the distant metastasis cancer. The treatment strategies are admin-
istered based on the stage of cancer progression.
2. Androgen-dependent and androgen-independent prostate cancer
Human prostate is a walnut shaped, fibromuscular organ located beneath the 
urinary bladder and is made-up of several glandular and non-glandular components 
that are tightly fused together within a common capsule [9]. It is an exocrine gland 
functioning in secretion of complex proteolytic solution into the urethra during 
ejaculation which is important for sperm motility and nourishment. The growth 
and function of the prostate are regulated by androgens. The growth and develop-
ment of normal prostate requires functioning androgen signaling pathway, which 
is regulated by hypothalamic-pituitary gonadal axis. Androgens (includes testos-
terone and DHT) are responsible for the male secondary sexual characteristics. 
Testosterone is synthesized in the testes and released into the circulation in response 
to specific hormonal signals regulated by GnRH, FSH, and LH. Testosterone is 
transported by steroid hormone binding globulin (SHBG) to the prostate, where it 
is converted by 5α-reductase to its active metabolite 5α-dihydrotestosterone (DHT).
In the prostate, androgens mediate their effects via high affinity to the androgen 
receptor (AR), a nuclear transcription factor that controls expression of genes 
involved in growth, differentiation, homeostatsis, and apoptosis. Receptor for steroid 
and thyroid hormones are mostly cytoplasmic/nuclear receptors and hormone-
receptor complex binding to the promoter regions of responsive genes and stimulate 
or inhibit transcription from those genes. Nuclear receptors are ligand-inducible 
transcription factors that mediate the signals of a broad variety of fat-soluble hor-
mones, including the steroid and vitamin D3 hormones, thyroid hormones retinoids. 
165
Combinatorial Drug Therapy with Phytochemicals as Adjuvants in Prostate Cancer Management
DOI: http://dx.doi.org/10.5772/intechopen.86157
Upon ligand binding, AR translocates to the nucleus, binds to DNA recognition 
sequences, and activates transcription of genes involved in cell proliferation, 
apoptosis, and differentiation [10]. Androgens are involved in the development and 
progression of prostate cancer [11] regulating the AR. During this phase the tumors 
are referred to as androgen sensitive or dependent. The most common therapies done 
with prostate cancer patients are androgen deprivation therapy removing testicles 
partially or completely in addition to administration of drugs inhibiting LHRH secre-
tion and anti-androgen therapy blocking the androgen receptor interaction.
Prostate cancer can evolve into castration resistant cancers which is independent 
of androgen levels [12]. The AR signaling pathway continues to be active in hor-
mone resistant prostate cancer (HRPC) and can inappropriately activate tran-
scription [13]. Recent studies show that cancer progression and metastasis lead to 
alteration in the androgen receptor pathway genes with transition of prostate cancer 
from the androgen dependent to independent stage [14]. Mutations in the ligand-
binding domain alter the specificity of the AR enhancing the binding of estrogens, 
progesterone, and anti-androgens; and thereby decreasing its dependency on 
androgens while stimulating cell growth. In addition to AR mutations, a variety 
of growth factors, including insulin-like growth factor I, epidermal growth factor, 
and keratinocyte growth factor, can activate androgen-responsive genes via the AR, 
suggesting that androgen independence which occurs due to the over expression of 
growth factors in the local environment [15]. There are multiple evidences suggest-
ing that estrogens are involved in prostate carcinogenesis. In worldwide the African-
Americans have the higher risk of prostate cancer with elevated levels of serum 
estrone and estradiol levels even in healthy young men [16]. CCDC62/ERAP75 is a 
new co-activator of ER and this protein is mainly present in the nucleus and widely 
expressed in many prostate cancer cell lines (PC-3, DU145, LNCaP, 22Rv1) than in 
the normal prostate epithelial cells (BPH-1) [17].
3. Molecular regulations in prostate cancer
The inappropriate expression of the growth inhibitory factors appears to con-
tribute to prostate cancer progression. Epidermal growth factor (EGF) promotes 
chemo-migration of metastatic prostate cancer cells to lymph node and medullary 
bone sites [18]. In insulin signaling pathway, the ligand insulin binds to its recep-
tor followed by tyrosine phosphorylation of insulin receptor substrates (IRS) by 
the insulin receptor tyrosine kinase. Several studies suggested that alteration in 
the IGF signaling axis is associated with an increased risk of prostate cancer [19]. 
Signal transduction proteins interact with IRS including GRB2. GRB2 is a part of the 
cascade including SOS, RAS, RAF, and MEK that leads to activation of MAPK and 
mitogenic response in the form of gene transcription.
In AKT signaling pathway, PTEN is a regulator which is down regulated to pro-
tect the cell from tumor growth. The phosphatase activity on phosphatidylinositol 
3,4,5-triphosphate allows dephosphorylation of PIP3 to PIP2. The PIP2 inhibits the 
P13K which is the membrane bound domain. When the phosphatase activity is lost, 
P13K transfers its phosphate group to PDK1 and PDK2 which in turn causes phos-
phorylation of AKT protein and regulatory amino acids Ser473 and Thr308. This 
leads to activation of MDM2, P21, CASP9, mTOR genes leading to apoptosis inhibi-
tion, tumor growth, etc. Smad3 gene plays a key role in prostate cancer serving as an 
essential mediator of most Smad-dependent TGF-beta responses, including control 
of gene expression, cell growth, apoptosis, and tumor suppression. Deregulated/
enhanced expression and activation of AR in prostate carcinomas may intercept the 
tumor suppressor function of TGF-β through transcriptional suppression of Smad3.
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TNFRs are activated by TNF in order to exhibit cellular response. TNF triggers the 
transcription of apoptotic proteins through NF-κB thereby achieving cell survival. 
Activation of TRAFs, such as TRAF2, TRAF5, and TRAF6 results in transduction of 
cellular response by TNFRs. In TNFRs pathway, TRAF3 acts as a repressor. APRL, 
BAFF, BAFF-R, BCMA, and TACI belong to the TNF superfamilies and play vital 
roles in immunity through B cells and T cells. BAFF binds to BAFF-R, BCMA, and 
TACI, while APRIL bands to two of them—BCMA and TACI only. In this pathway 
nuclear factors (NF-κB) are activated in signaling cascades. This activation process 
can be triggered by canonical and non-canonical pathways. The latter is activated by 
activation of BCMA, TCAI, and BAFF-R by BAFF. This counter activates TRAF2 and 
TRAF5 that signals NIK, a mitogen activated protein kinase. Once NIK is activated, 
phosphorylation of IKK-alpha that restrain processing NK-κB2 into NF-κB2 onsets. 
Along with RelB, NF-κB2 activates Bcl2 or Bcl-XL or both. Upon this activation cell 
survival is promoted. BAFF transcription is activated by NF-κB2 resulting in a posi-
tive feedback. I-kB is phosphorylated by IKK alpha, beta, and gamma which is acti-
vated by TRAF2 by canonical pathway. I-kB is disintegrated and ubiquitylated inside 
proteosome 26S. This process discharges NF-κB2 and RelA which are swiftly reposi-
tioned from cytoplasm to nucleus. Following which anti-apoptotic components, such 
as Bcl-2, Bcl-XL, and BFL1 are activated by transcription by NF-κB transfactors.
In non-canonical pathway, IKK alpha is activated by its phosphorylation once 
NIK kinase is promoted by TRAF. NF-κB2 is processed from p100 to p52 by IKK 
alpha which is adhered to RelB. The dimer (RelB-p52-NF-κB) engages in affecting 
gene transcription once it shifts to the nucleus. This pathway does not involve IKK 
beta and gamma. IKK, RelB, and NIK are mediated by TNF-R1 signal or TNF-R2 
signal as well. NF-κB promoted cell growth and proliferation in prostate cancer cells 
by regulating expression of genes, such as c-myc, cyclin D1, and IL-6. Furthermore, 
NF-κB-mediated expression of genes involved in angiogenesis (IL-8, VEGF), and 
invasion and metastasis (MMP 9, uPA, and uPA receptor) may further contribute to 
the progression of androgen depleted prostate cancer [20].
Apoptosis is programmed cell death involving sequential events of elimina-
tion of cells without releasing harmful substances into the surrounding area. 
Apoptosis plays a crucial role in developing and maintaining the health of the body 
by eliminating old cells, unnecessary cells, and unhealthy cells. The two classes of 
regulatory molecules play vital role in the cell cycle progression and apoptosis pro-
cesses are protein kinases, such as cyclin dependent kinases (CDKs), and cyclins. 
Disturbances in the cell cycle regulation due to uncontrolled cell growth and 
divisions through and escaping of the cell cycle checkpoints occur in the mutated 
cells. The cell cycle events are facilitated through the activated cyclin D-CDK4/6 
complexes phosphorylating the retinoblastoma protein (pRb) bound with E2F 
transcriptional factors. This in turn inactivates pRb and weakening its affinity for 
E2F which then becomes free to enter the nucleus and transcription of cell cycle 
progression genes. The hypophosphorylated pRb impounds the transcription factor 
E2F in the cytosol, thus blocking the cell cycle at G1 phase.
Similarly B-cell lymphoma (Bcl-2) family genes are involved in the apoptosis 
pathway, including prostate, breast, and ovarian cancers. The Bcl-2 family proteins 
had the anti-apoptotic subgroup, such as, Bcl-extra-large (Bcl-xL), Bcl2-like 2 
(Bcl-W), myeloid cell leukemia (Mcl-1) that interacted with another subgroup of 
proteins called the pro-apoptotic proteins (Bcl2-associated X protein (Bax) and 
Bcl2 antagonist/killer (Bak)). In the signal transduction cascade of apoptosis the 
pro-apoptotic proteins began induction of apoptosis via mitochondrial outer- 
membrane permeabilization, followed by the release of cytochrome c, and finally 
the activation of cysteine aspartyl proteases (caspases). Second is the intrinsic path-
way, with the release of cyt-c into the cytosol from mitochondria, a multiprotein 
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caspase-activating complex, called “apoptosome” binds procaspase-9 and cyt-c 
with its central component Apaf1, and activates apoptosis. Thus there should be 
a balance in the levels of anti-apoptotic and pro-apoptotic proteins for the proper 
progression of apoptosis (Figure 1).
4.  Phytomedicine: promoting synergistic actions in prostate cancer 
management
The history of ayurvedic and traditional systems of medicine showed that the 
medicinal plants have global importance in treating human diseases and disor-
ders [21]. The references of ancient literature, a Sumerian clay slab from Nagpur, 
approximately 5000 years old suggested that people were depended on drugs from 
the nature [22]. Theophrast (371-287 BC) in his scientific book titled “De Causis 
Plantarium” has referred and classified nearly 500 medicinal plants. About 700 plant 
species including pomegranate, castor oil plant, aloe, senna, garlic, onion, fig, wil-
low, coriander, juniper, common centaury, etc. [23] were reported having medicinal 
properties. The World Health Organization (WHO) estimated that trades of plant-
derived pharmaceutical drugs would account for five trillion US dollars by 2050.
The survey reports on these medicinally valued plants and their preparations 
as tinctures, teas, poultices, powders, and other herbal formulations [24] served as 
the basis for novel drug discovery wherein a large number of synthetic drugs are 
developed on the small-molecule natural chemical entities and has been introduced 
as potential drugs worldwide [25]. Even our natural food intake relays on the 
medicinal aspects followed in our tradition thus have a strong impact on determin-
ing health at different stages/phases of life. In addition many food-based nutrients 
contribute to the prevention and management of deadly diseases like cancer. 
Wholesome diet including vegetables, fruit, and vitamins lowers the risk up to 80% 
of cancers of the large bowel, breast, and prostate.
Figure 1. 
Molecular pathways involved in prostate cancer progression (developed by pathway construction tool—PathVisio).
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by eliminating old cells, unnecessary cells, and unhealthy cells. The two classes of 
regulatory molecules play vital role in the cell cycle progression and apoptosis pro-
cesses are protein kinases, such as cyclin dependent kinases (CDKs), and cyclins. 
Disturbances in the cell cycle regulation due to uncontrolled cell growth and 
divisions through and escaping of the cell cycle checkpoints occur in the mutated 
cells. The cell cycle events are facilitated through the activated cyclin D-CDK4/6 
complexes phosphorylating the retinoblastoma protein (pRb) bound with E2F 
transcriptional factors. This in turn inactivates pRb and weakening its affinity for 
E2F which then becomes free to enter the nucleus and transcription of cell cycle 
progression genes. The hypophosphorylated pRb impounds the transcription factor 
E2F in the cytosol, thus blocking the cell cycle at G1 phase.
Similarly B-cell lymphoma (Bcl-2) family genes are involved in the apoptosis 
pathway, including prostate, breast, and ovarian cancers. The Bcl-2 family proteins 
had the anti-apoptotic subgroup, such as, Bcl-extra-large (Bcl-xL), Bcl2-like 2 
(Bcl-W), myeloid cell leukemia (Mcl-1) that interacted with another subgroup of 
proteins called the pro-apoptotic proteins (Bcl2-associated X protein (Bax) and 
Bcl2 antagonist/killer (Bak)). In the signal transduction cascade of apoptosis the 
pro-apoptotic proteins began induction of apoptosis via mitochondrial outer- 
membrane permeabilization, followed by the release of cytochrome c, and finally 
the activation of cysteine aspartyl proteases (caspases). Second is the intrinsic path-
way, with the release of cyt-c into the cytosol from mitochondria, a multiprotein 
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caspase-activating complex, called “apoptosome” binds procaspase-9 and cyt-c 
with its central component Apaf1, and activates apoptosis. Thus there should be 
a balance in the levels of anti-apoptotic and pro-apoptotic proteins for the proper 
progression of apoptosis (Figure 1).
4.  Phytomedicine: promoting synergistic actions in prostate cancer 
management
The history of ayurvedic and traditional systems of medicine showed that the 
medicinal plants have global importance in treating human diseases and disor-
ders [21]. The references of ancient literature, a Sumerian clay slab from Nagpur, 
approximately 5000 years old suggested that people were depended on drugs from 
the nature [22]. Theophrast (371-287 BC) in his scientific book titled “De Causis 
Plantarium” has referred and classified nearly 500 medicinal plants. About 700 plant 
species including pomegranate, castor oil plant, aloe, senna, garlic, onion, fig, wil-
low, coriander, juniper, common centaury, etc. [23] were reported having medicinal 
properties. The World Health Organization (WHO) estimated that trades of plant-
derived pharmaceutical drugs would account for five trillion US dollars by 2050.
The survey reports on these medicinally valued plants and their preparations 
as tinctures, teas, poultices, powders, and other herbal formulations [24] served as 
the basis for novel drug discovery wherein a large number of synthetic drugs are 
developed on the small-molecule natural chemical entities and has been introduced 
as potential drugs worldwide [25]. Even our natural food intake relays on the 
medicinal aspects followed in our tradition thus have a strong impact on determin-
ing health at different stages/phases of life. In addition many food-based nutrients 
contribute to the prevention and management of deadly diseases like cancer. 
Wholesome diet including vegetables, fruit, and vitamins lowers the risk up to 80% 
of cancers of the large bowel, breast, and prostate.
Figure 1. 
Molecular pathways involved in prostate cancer progression (developed by pathway construction tool—PathVisio).
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Based on the studies done at the US National Cancer Institute, selenium, vitamin 
E, and Omega-3 fatty acid have preventive roles in prostate carcinoma [26]. Plants 
produce a wide range of chemical compounds as by-products of their metabolic 
pathways known as secondary metabolites. These compounds have no direct role 
in growth yet they have significant role in defense mechanisms. The secondary 
metabolites generally flavonoids, tannins, curcumin, resveratrol, and gallocatechin 
are reported as effective anti-cancer drugs [27]. Molecular studies have proved that 
luteolin, quercetin, and kaempferol rich in onions, olives, grapes, tea, pomegranate, 
broccoli, and cauliflower [28] are effective in suppressing tumor development with 
low dose-limiting toxicities and negligible side effects [29].
Plants in nature contain many active compounds which elicit the synergistic 
effects in combination with chemical drugs through its own molecular mechanisms 
of targeting signaling pathways in cancer cells in order to overcome drug resistant 
cancers, also strengthens the therapeutic activity of chemical drugs and subsides 
drug-induced toxicity. The pharmacological efficacies of chemotherapeutic drugs 
are improvised by alteration in the pharmacokinetics of drug compounds regulating 
the receptor targets and downstream effector molecules in the cancer cells.
Sporadically, anti-androgens (anti-hormones) are administered for initial stages 
of prostate cancer which is prone to frequent failures in patients diagnosed with 
recurrent androgen-independent prostate cancer and metastasis. Radiotherapy 
and/or androgen deprivation therapy can be considered as an adjunct to surgery, in 
either the adjuvant or salvage setting, to further control the disease course. These 
combinatorial therapies are highly recommended in combating primary tumors, 
but metastatic tumors are more challenging due to loss of remedial activity and 
disease remission. Also these therapies are reported in exerting complications of 
damaging the normal cells in vicinity of tumor growth, disturbing the functioning 
of immune system, triggering autoimmunity [30], damage to adjacent gastro-
intestinal tract, and bladder incontinence. Hence, multifaceted therapies producing 
synergistic effects and long-term outcomes by lowering the local tumor burden and 
eradicating metastatic disease compared to each individual change are required for 
cancer management.
Prostate cancer is characterized by slow growth and long latency period and 
thus integration of phytochemicals/compounds in combination with other exist-
ing therapies have promising future to manage cancer, controlling the disease 
progression and mortality rate. The WHO has estimated that approximately 80% 
of the world’s population depends on traditional plant-based medicines for meet-
ing their primary health care needs [31]. In prostate cancer, there is an imbalance 
between prostate cell growth and apoptosis. In prostate cancer these proteins are 
over expressed which lead to progression of metastatic prostate cancer through 
inhibition of apoptotic cell death. This over expression also causes resistance to 
heat-shock stress, several chemotherapies, and radiotherapy. Phytochemicals are 
routinely used as an adjuvant to conventional chemo and radio therapies of cancer 
in order to manage the drug-resistance mechanisms and resensitize tumor cells.
Many medicinal plants are reported to possess chemopreventive activities on 
prostate cancer exhibiting significant oestrogenic and anti-androgen effects, such 
as Agathosma betulina [32], Bidens pilosa [33], Prunus Africana, Cucurbita pepo L. 
[34], Andrographis paniculata [35], Vaccinium macrocarpon [36], Linum persicum 
and Euphorbia cheradania [37], Panax ginseng [38], Scutellaria baicalensis [39], 
Wedelia chinensis [40], Urtica membranaceae, Artemisia monosperma and Origanum 
dayi [41], Vitis vinifera [42], an eight-herb Chinese formulation, that consists of 
Isatis indigotica, Glycyrrhiza glabra, Glycyrrhiza uralensis, Scutellaria baicalensis, 
Ganoderma lucidum, Panax ginseng, Dendranthema morifolium, Rabdosia rubescens 
[43]. Combined drugs made of vinca alkaloids, Taxus diterpenes, Podophyllum 
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lignans, and Camptotheca alkaloids were proved with anticancer effects [44]. 
Pentacyclic triterpenoids reported in Hypoxis hemerocallidea reduced the inflam-
mation and swelling in the prostate. Garlic and green tea catechins act as potential 
chemopreventive agents against cancer by inhibiting PIN [45]. Phytochemicals like 
geneistin and quercitin [46], lycopene [47], curcumin, epigallocatechin-gallate, 
resveratrol [48], brassinosteroid [49], derived from medicinal plants have been 
reported through in-vitro studies with potentials of anti-proliferative effects on 
prostate cancer cell lines, such as PC-3, DU-145, and LNCaP. Their protective action 
against cancer may be due to their high concentration of antioxidants that react 
with free radicals thereby neutralizing them [50].
Quercetin and curcumin, plant-derived flavanoids are well established drugs in 
cancer treatment exhibiting antioxidant, anti-inflammatory, and anti-proliferative 
activities [51]. Quercetin has anti-inflammatory role through regulation of NF-κB 
pathway genes [52] inhibiting the expression of pro-inflammatory cytokines, 
TNF-α, IL-6, and IL-1β and inflammatory mediators, nitric oxide, and catalase. 
Combination of quercetin with doxorubicin increases the sensitivity of PC3-
resistant cells by inducing apoptosis via reduction of mitochondrial membrane 
potential, activation of the PI3K/AKT pathway, and acceleration of chemo resis-
tance [53]. The chemopreventive and anti-neoplastic activity of the phytochemicals 
could be achieved through multiple effects including reduction of PSA and AR 
expression, induction of apoptotic pathways, inhibition of angiogenesis, induction 
of PKC-α, suppression of TrkE, induction of p53, inhibition of proteasome activity, 
induction of S-phase and G0/G1 phase and G2/M cell-cycle arrest, suppression of 
DNA synthesis, up-regulation of protein expression WAF1/p21, KIP1/p27, INK4a/
p16, INK4c/p18, down-regulation of protein expression cyclin D1 and D3, cyclin E, 
cdk2, cdk4, cdk6, inhibition of PI3K/PKB phosphorylation of AKT, Inhibition of 
COX-2 expression [54]. Wedelia chinensis extract possesses the ability in reducing 
the gene expressions of proinflammatory cytokines and STAT3 activity in tumor-
elicited myeloid cells [40]. Altogether, the combination of herbal compounds 
includes pharmacokinetic and pharmacodynamic synergisms to provide significant 
therapeutic effects. Baicalein form Scutellaria baicalensis [39] reduces the synthesis 
of eicosanoid that function as important mediators in inflammatory responses 
through inhibiting enzymatic oxidation of essential fatty acids.
One of our studies reported that, a potential medicinal herb Gymnema sylvestre has 
been proved for its potency to control prostate cancer progression [55]. It is (family: 
Asclepiadaceae) described as miracle fruit, is native to central and western India that 
has been used in the traditional health care system, for several centuries [56]. The 
leaves are rich in triterpene classes of oleanane saponins (gymnemic acids and gymne-
masaponins) and dammarene saponins (gymnemasides). The phytocompound dihy-
droxy gymnemic triacetate (DGT) isolated from acetone extract of G. sylvestre leaves 
were effective in inhibiting prostate cancer cell growth, inducing apoptosis, modula-
tion of cell cycle, and downregulation of the protein expressions. Also the depletion 
of PSA observed in the PC-3 cell line caused by DGT was observed. Since PSA gene 
is positively regulated via binding of AR to the androgen responsive elements in the 
promoter of PSA, decline of PSA levels proves down-regulation of AR [57].
5. Conclusion
Thus multimodal approach of treating prostate cancer with the integration of 
phytochemicals as chemopreventive agents in down-regulation of cell proliferation 
and induction of apoptosis has taken forefront in development of potential thera-
peutic drugs in cancer management.
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Based on the studies done at the US National Cancer Institute, selenium, vitamin 
E, and Omega-3 fatty acid have preventive roles in prostate carcinoma [26]. Plants 
produce a wide range of chemical compounds as by-products of their metabolic 
pathways known as secondary metabolites. These compounds have no direct role 
in growth yet they have significant role in defense mechanisms. The secondary 
metabolites generally flavonoids, tannins, curcumin, resveratrol, and gallocatechin 
are reported as effective anti-cancer drugs [27]. Molecular studies have proved that 
luteolin, quercetin, and kaempferol rich in onions, olives, grapes, tea, pomegranate, 
broccoli, and cauliflower [28] are effective in suppressing tumor development with 
low dose-limiting toxicities and negligible side effects [29].
Plants in nature contain many active compounds which elicit the synergistic 
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and/or androgen deprivation therapy can be considered as an adjunct to surgery, in 
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damaging the normal cells in vicinity of tumor growth, disturbing the functioning 
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synergistic effects and long-term outcomes by lowering the local tumor burden and 
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progression and mortality rate. The WHO has estimated that approximately 80% 
of the world’s population depends on traditional plant-based medicines for meet-
ing their primary health care needs [31]. In prostate cancer, there is an imbalance 
between prostate cell growth and apoptosis. In prostate cancer these proteins are 
over expressed which lead to progression of metastatic prostate cancer through 
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in order to manage the drug-resistance mechanisms and resensitize tumor cells.
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as Agathosma betulina [32], Bidens pilosa [33], Prunus Africana, Cucurbita pepo L. 
[34], Andrographis paniculata [35], Vaccinium macrocarpon [36], Linum persicum 
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Wedelia chinensis [40], Urtica membranaceae, Artemisia monosperma and Origanum 
dayi [41], Vitis vinifera [42], an eight-herb Chinese formulation, that consists of 
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lignans, and Camptotheca alkaloids were proved with anticancer effects [44]. 
Pentacyclic triterpenoids reported in Hypoxis hemerocallidea reduced the inflam-
mation and swelling in the prostate. Garlic and green tea catechins act as potential 
chemopreventive agents against cancer by inhibiting PIN [45]. Phytochemicals like 
geneistin and quercitin [46], lycopene [47], curcumin, epigallocatechin-gallate, 
resveratrol [48], brassinosteroid [49], derived from medicinal plants have been 
reported through in-vitro studies with potentials of anti-proliferative effects on 
prostate cancer cell lines, such as PC-3, DU-145, and LNCaP. Their protective action 
against cancer may be due to their high concentration of antioxidants that react 
with free radicals thereby neutralizing them [50].
Quercetin and curcumin, plant-derived flavanoids are well established drugs in 
cancer treatment exhibiting antioxidant, anti-inflammatory, and anti-proliferative 
activities [51]. Quercetin has anti-inflammatory role through regulation of NF-κB 
pathway genes [52] inhibiting the expression of pro-inflammatory cytokines, 
TNF-α, IL-6, and IL-1β and inflammatory mediators, nitric oxide, and catalase. 
Combination of quercetin with doxorubicin increases the sensitivity of PC3-
resistant cells by inducing apoptosis via reduction of mitochondrial membrane 
potential, activation of the PI3K/AKT pathway, and acceleration of chemo resis-
tance [53]. The chemopreventive and anti-neoplastic activity of the phytochemicals 
could be achieved through multiple effects including reduction of PSA and AR 
expression, induction of apoptotic pathways, inhibition of angiogenesis, induction 
of PKC-α, suppression of TrkE, induction of p53, inhibition of proteasome activity, 
induction of S-phase and G0/G1 phase and G2/M cell-cycle arrest, suppression of 
DNA synthesis, up-regulation of protein expression WAF1/p21, KIP1/p27, INK4a/
p16, INK4c/p18, down-regulation of protein expression cyclin D1 and D3, cyclin E, 
cdk2, cdk4, cdk6, inhibition of PI3K/PKB phosphorylation of AKT, Inhibition of 
COX-2 expression [54]. Wedelia chinensis extract possesses the ability in reducing 
the gene expressions of proinflammatory cytokines and STAT3 activity in tumor-
elicited myeloid cells [40]. Altogether, the combination of herbal compounds 
includes pharmacokinetic and pharmacodynamic synergisms to provide significant 
therapeutic effects. Baicalein form Scutellaria baicalensis [39] reduces the synthesis 
of eicosanoid that function as important mediators in inflammatory responses 
through inhibiting enzymatic oxidation of essential fatty acids.
One of our studies reported that, a potential medicinal herb Gymnema sylvestre has 
been proved for its potency to control prostate cancer progression [55]. It is (family: 
Asclepiadaceae) described as miracle fruit, is native to central and western India that 
has been used in the traditional health care system, for several centuries [56]. The 
leaves are rich in triterpene classes of oleanane saponins (gymnemic acids and gymne-
masaponins) and dammarene saponins (gymnemasides). The phytocompound dihy-
droxy gymnemic triacetate (DGT) isolated from acetone extract of G. sylvestre leaves 
were effective in inhibiting prostate cancer cell growth, inducing apoptosis, modula-
tion of cell cycle, and downregulation of the protein expressions. Also the depletion 
of PSA observed in the PC-3 cell line caused by DGT was observed. Since PSA gene 
is positively regulated via binding of AR to the androgen responsive elements in the 
promoter of PSA, decline of PSA levels proves down-regulation of AR [57].
5. Conclusion
Thus multimodal approach of treating prostate cancer with the integration of 
phytochemicals as chemopreventive agents in down-regulation of cell proliferation 
and induction of apoptosis has taken forefront in development of potential thera-
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Sexual and Psychoemotional 
Disorders in Male Patients Treated 
for Prostate Carcinoma
Marta Dąbrowska-Bender, Robert Słoniewski, 




The prostate carcinoma affect the quality of life of most male patients, includ-
ing in particular their sexual and emotional life. The aim of study was to assess 
sexual and psychoemotional disorders in male patients diagnosed with prostate 
carcinoma and receiving cancer treatment. The study’s patients were recruited at the 
Oncological Hospital in Wieliszew, Poland, between September 2016 and December 
2017. The study was performed in 166 male patients diagnosed with prostate cancer. 
Two standardized questionnaires were used in the study, EORTC QLQ-C30 and 
QLQ-PR25, for patients with prostate cancer, developed by the European Quality of 
Life Group. The type and stage of cancer treatments were a significant contributor to 
feeling tense, worried, depressed, and irritable among the study patients. The stage 
of treatment, however, caused a negative effect on these parameters. Pretreatment 
patients declared high or very high satisfaction with their sexual life, while post-
treatment patients and those on cancer treatment indicated low sexual satisfaction. 
However, a feeling of embarrassment during intimate contact as well as erectile 
disorders correlated both with the type and stage of cancer treatment. Our results 
show that affected male patients should be offered continuous psychological care, 
especially those waiting for treatment and those on treatment.
Keywords: prostate carcinoma, quality of life, sexual disorders, psychoemotional 
disorders, oncological treatment
1. Background
Prostate carcinoma (PCa) is one of the most frequent malignant cancers in the 
male population. In terms of incidence, it is second only to lung cancer. Treatment 
of prostate carcinoma includes surgical procedures, radiotherapy, chemotherapy, 
and hormone therapy, and all these procedures have an adverse impact on the sexual 
functioning of men. Erectile disorders, loss of sex drive, and difficulty achieving 
orgasm are the most frequent problems in the course of disease and its treatment 
[1, 2]. The existing studies show that few men with sexual dysfunctions and on 
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The prostate carcinoma affect the quality of life of most male patients, includ-
ing in particular their sexual and emotional life. The aim of study was to assess 
sexual and psychoemotional disorders in male patients diagnosed with prostate 
carcinoma and receiving cancer treatment. The study’s patients were recruited at the 
Oncological Hospital in Wieliszew, Poland, between September 2016 and December 
2017. The study was performed in 166 male patients diagnosed with prostate cancer. 
Two standardized questionnaires were used in the study, EORTC QLQ-C30 and 
QLQ-PR25, for patients with prostate cancer, developed by the European Quality of 
Life Group. The type and stage of cancer treatments were a significant contributor to 
feeling tense, worried, depressed, and irritable among the study patients. The stage 
of treatment, however, caused a negative effect on these parameters. Pretreatment 
patients declared high or very high satisfaction with their sexual life, while post-
treatment patients and those on cancer treatment indicated low sexual satisfaction. 
However, a feeling of embarrassment during intimate contact as well as erectile 
disorders correlated both with the type and stage of cancer treatment. Our results 
show that affected male patients should be offered continuous psychological care, 
especially those waiting for treatment and those on treatment.
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1. Background
Prostate carcinoma (PCa) is one of the most frequent malignant cancers in the 
male population. In terms of incidence, it is second only to lung cancer. Treatment 
of prostate carcinoma includes surgical procedures, radiotherapy, chemotherapy, 
and hormone therapy, and all these procedures have an adverse impact on the sexual 
functioning of men. Erectile disorders, loss of sex drive, and difficulty achieving 
orgasm are the most frequent problems in the course of disease and its treatment 
[1, 2]. The existing studies show that few men with sexual dysfunctions and on 
cancer treatment seek the help of a specialist to effectively eliminate such problems 
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[3]. Other studies show that this population of patients frequently experiences, as a 
result of changes in the sexual functioning, fear, anxiety, and depression as well as 
loss of male identity [4]. Therefore, psychological care and social support (includ-
ing their closest family and friends) are increasingly considered an important 
component of many chronic diseases. At the same time, studies suggest that men 
who find no emotional support in their social environment are more exposed to 
depression and more seldom achieve positive mental well-being [5]. Additionally, it 
was demonstrated that specialist (psychological) and social support are associated 
with significantly reduced mental stress and general improvement of the quality of 
life in the population of men with prostate carcinoma.
2. Material and methods
The study’s patients were recruited at the Oncological Hospital in Wieliszew, 
Poland,between September 2016 to December 2017. The study was performed 166 
male patients diagnosed with prostate cancer. The study included men who gave 
informed, written consent to participate. In the study was used two standard-
ized questionnaire: EORTC QLQ-C30 (version 3.0) and QLQ-PR25 for patients 
with prostate cancer, developed by the European Quality of Life Group. These 
questionnaires are used to research the summary sense of health and evaluation of 
performance in various dimensions (physical, emotional and social) and typical 
symptoms of prostate cancer.
2.1 Ethics
The Ethical Committee consent for the presented research is not required. 
According to the statement of the Ethical Committee of the Medical University 
of Warsaw: “The Committee does not provide opinions on surveys, retrospec-
tive studies, or other non-invasive research” (Detailed information and tem-




The study included 166 men. The mean age of participants was 67.66 ± 7.25 (range: 
51–84 years). The main part of population taking part in the study comprised people 
aged 65–69 years (37.35%). The majority (68.7%) of patients, during the study, were 
undergoing the treatment. The treatment analysis revealed that 66% of the par-
ticipants subjected to radiotherapy. Smaller numbers were found for the remaining 
therapy: 16.9% hormonal therapy, 2.38% surgery (4.8%), and 3.6% chemotherapy. 
The proportion of patients was treated with combined therapies: radiotherapy + sur-
gery (8.33%), radiation + hormonal therapy (6.03%), and surgery + hormonal + che-
motherapy (2.41%). The characteristics of the patients are shown in Table 1.
3.1 Emotional problems
No correlation was found between the study variable and the health status or 
quality of life score or the age of patients. However, feeling tense may be affected 
by the type of treatment administered to the patients (Chi2 = 94.15, p = 0.0000; 
R = 0.21, p > 0.05). The results of statistical analysis show that the greatest number 
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of men who declared that they did not feel tense during the last week underwent 
radiotherapy (58.82%) or radiotherapy and surgical treatment (57.14%). On the 
other hand, all the patients who received surgical treatment, chemotherapy, and 
hormone therapy indicated that they felt very tense. A similar correlation was 
shown in relation to the stage of cancer treatment (Chi2 = 19.73, p = 0.00310; 
R = −0.00, p > 0.05).
Feeling worried also depends on the stage of cancer treatment (Chi2 = 21.67, 
p = 0.00139; R = 0.20, p > 0.05). Posttreatment patients significantly more often 
indicated that they did not worry during the last week (56.25% of the group), while 
patients waiting for treatment more often declared to feel worried or very worried  
(40% of the group in total). Similarly to the question about feeling tense, the results 
show that feeling worried affected all the patients undergoing surgical treatment, 
chemotherapy, and hormone therapy. Patients receiving radiotherapy (27.45% of the 
group) or both radiotherapy and surgical treatment (28.57%) (Chi2 = 69.06, p = 0.0000; 
R = 0.13, p > 0.05) most often indicated that they did not feel worried. However, no 
correlation was found between feeling worried and the patients’ age (p > 0.05).
The impact of health status on patients feeling worried was also insignificant 
(Chi2 = 44.87, p = 0.00043; R = −0.04, p > 0.05), although it could be observed 
that patients with a greater health status score more rarely indicated that they felt 
worried. A similar correlation was observed with regard to the quality of life score 
(Chi2 = 43.38, p = 0.00071; R = −0.11, p > 0.05).
None of the patients who received cancer treatment declared to be very or 
significantly irritable. However, these responses were indicated by 40% of the 
patients waiting for treatment (Chi2 = 16.24, p = 0.01251; R = −0.03, p > 0.05). The 
Characteristics of the patients in the survey Number of patients (N = 166 (100%))
Age
 <54 2 (1.2)
 55–59 16 (9.6)
 60–64 26 (15.7)
 65–69 62 (37.3)
 70–74 24 (14.5)
 75–79 24 (14.5)
 >80 12 (7.2)
Stage of oncology treatment
 Before treatment 20 (12)
 During the course of treatment 114 (68.7)
 After treatment 32 (19.3)
Type of oncology treatmenta
 Surgery 8 (4.8)
 Radiotherapy 110 (66)
 Hormonal therapy 28 (16.9)
 Chemotherapy 6 (3.6)
 I do not know 20 (12)
aThe question with multiple answers.
Table 1. 
Characteristics of the group of patients participating in the survey.
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[3]. Other studies show that this population of patients frequently experiences, as a 
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radiotherapy (58.82%) or radiotherapy and surgical treatment (57.14%). On the 
other hand, all the patients who received surgical treatment, chemotherapy, and 
hormone therapy indicated that they felt very tense. A similar correlation was 
shown in relation to the stage of cancer treatment (Chi2 = 19.73, p = 0.00310; 
R = −0.00, p > 0.05).
Feeling worried also depends on the stage of cancer treatment (Chi2 = 21.67, 
p = 0.00139; R = 0.20, p > 0.05). Posttreatment patients significantly more often 
indicated that they did not worry during the last week (56.25% of the group), while 
patients waiting for treatment more often declared to feel worried or very worried  
(40% of the group in total). Similarly to the question about feeling tense, the results 
show that feeling worried affected all the patients undergoing surgical treatment, 
chemotherapy, and hormone therapy. Patients receiving radiotherapy (27.45% of the 
group) or both radiotherapy and surgical treatment (28.57%) (Chi2 = 69.06, p = 0.0000; 
R = 0.13, p > 0.05) most often indicated that they did not feel worried. However, no 
correlation was found between feeling worried and the patients’ age (p > 0.05).
The impact of health status on patients feeling worried was also insignificant 
(Chi2 = 44.87, p = 0.00043; R = −0.04, p > 0.05), although it could be observed 
that patients with a greater health status score more rarely indicated that they felt 
worried. A similar correlation was observed with regard to the quality of life score 
(Chi2 = 43.38, p = 0.00071; R = −0.11, p > 0.05).
None of the patients who received cancer treatment declared to be very or 
significantly irritable. However, these responses were indicated by 40% of the 
patients waiting for treatment (Chi2 = 16.24, p = 0.01251; R = −0.03, p > 0.05). The 
Characteristics of the patients in the survey Number of patients (N = 166 (100%))
Age
 <54 2 (1.2)
 55–59 16 (9.6)
 60–64 26 (15.7)
 65–69 62 (37.3)
 70–74 24 (14.5)
 75–79 24 (14.5)
 >80 12 (7.2)
Stage of oncology treatment
 Before treatment 20 (12)
 During the course of treatment 114 (68.7)
 After treatment 32 (19.3)
Type of oncology treatmenta
 Surgery 8 (4.8)
 Radiotherapy 110 (66)
 Hormonal therapy 28 (16.9)
 Chemotherapy 6 (3.6)
 I do not know 20 (12)
aThe question with multiple answers.
Table 1. 
Characteristics of the group of patients participating in the survey.
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least irritability were experienced by patients undergoing radiotherapy or surgi-
cal treatment, the greatest irritability—by patients receiving surgical treatment, 
chemotherapy, and hormone therapy (Chi2 = 69.05, p = 0.0000; R = 0.06, p > 0.05). 
On the other hand, no correlation was found between feeling irritable and the 
patients’ age, health status, or quality of life score (p > 0.05 for all the cases).
Even though no correlation was found between the age or the quality of life score 
and feeling depressed (p > 0.05), a statistical analysis of the study results showed 
that feeling depressed may depend on the patient’s health status (Chi2 = 33.34, 
p = 0.01517; R = −0.36, p = 0.00681). Patients with a lower health status score much 
more often declared that they felt depressed during the last week.
As with the above-described correlations, feeling depressed is also corre-
lated (although weakly) with the stage of the patient’s treatment (Chi2 = 13.11, 
p = 0.04122; R = 0.06, p > 0.05) and the type of treatment (Chi2 = 67.37, 
p = 0.0000; R = 0.11, p > 0.05). No depression was most often indicated by patients 
who underwent cancer treatment (56.25% of this group), radiotherapy (45.10%), or 
both radiotherapy and surgery (42.86%).
The greatest difficulties in remembering were indicated by pretreatment 
patients (30% of responses “to a significant degree” and “very much” in this 
group of patients compared to 7% of the patients on treatment and 0% of the 
posttreatment patients) (Chi2 = 19.25, p = 0.00376; R = −0.07, p > 0.05) and those 
receiving surgical treatment, hormone therapy, and chemotherapy (100% of 
the group) (Chi2 = 97.20, p = 0.0000; R = 0.08, p > 0.05). Additionally, a strong 
correlation was found between difficulties in remembering and health status score 
(Chi2 = 34.89, p = 0.00976; R = −0.45, p = 0.0000). The higher health status score is 
correlated with an absence of difficulties in remembering or only slight difficulties 
in remembering. Serious and very serious difficulties in remembering were indi-
cated only by the patients with a health status score less than 5. A similar correlation 
exists with regard to the quality of life score. Patients with the lowest quality of life 
score did not indicate any considerable or significant problems in remembering. 
Patients who declared frequent problems in remembering had a lower quality of life 
score (Chi2 = 32.30, p = 0.02024; R = −0.26, p = 0.00071). However, no correlation 
was found between difficulties in remembering and the patients’ age (p > 0.05) 
(Tables 2 and 3).
3.2 Urination problems
Among the study patients, 12% of them frequently passed urine during the 
day. This problem has a significant impact on the quality of life of the patients 
Emotional problems Question 
no.a
Number of patients (N = 166) N (%)
Not at 
all




Feeling circuit 21 86 (51.8) 72 (43.4) 4 (2.4) 4 (2.4)
Feeling worried 22 40 (24.1) 98 (59) 22 (13.3) 6 (3.6)
The feeling of annoyance 23 68 (40.9) 70 (42.2) 22 (13.3) 6 (3.6)
Feeling depressed 24 70 (42.2) 72 (43.4) 18 (10.8) 6 (3.6)
Difficulty in remembering 25 84 (50.6) 68 (41.0) 10 (6) 4 (2.4)
aNumber of issues in accordance with the questionnaire QLQ-C30.
Table 2. 
Emotional problems of the patients.
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(Chi2 = 30.86, p = 0.02988; R = −0.24, p = 0.02967). Patients with no problems with 
frequent urination during the day had a higher quality of life score compared to 
patients who had to urinate very frequently during the day. Similar but significantly 
weaker correlation was identified between the quality of life score and frequent 
nighttime urination (Chi2 = 33.42, p = 0.01484; R = −0.11, p > 0.05) or the quality 
of life score and the need to hurry into the toilet before passing urine (Chi2 = 33.83, 
p = 0.01321; R = 0.05, p > 0.05).
Over 60% of the patients indicated that having to get up at night to urinate 
affected their night’s rest. This problem had a strong impact on how the patients 
assessed their quality of life (Chi2 = 54.09, p = 0.0000; R = −0.52, p = 0.0000). The 
quality of life score was also affected by problems related to going out of the house 
due to the fact that the patients had to be close to a toilet. Problems with involun-
tary release of urine were indicated by nearly half of the patients, and 17% of the 
patients considered this problem to be considerable or significant. This group of 
patients usually has a lower quality of life score, even though this correlation is not 
strong (Chi2 = 43.87, p = 0.00060; R = −0.21, p > 0.05). Nearly 50% of the patients 
declared to have painful urination; however, no correlation was found between 
pain and the quality of life score (p > 0.05). Among the study patients, 32.53% 
of them use protection products against urinary incontinence. Using this type of 
protection was considered a nuisance only by 40% of the patients and affected 
how they perceived their quality of life (Chi2 = 55.22, p = 0.00001; R = −0.23, 
p = 0.03563). Generally, limitations related to everyday functioning due to urina-
tion problems were indicated by nearly 40% of men. This effect was considered 
significant or highly significant by 12% of the patients. However, the correlation 
between the limitation of everyday activities and the quality of life score is insig-
nificant (Chi2 = 38.50, p = 0.00332; R = 0.17, p > 0.05). Detailed results are given in 
Tables 4 and 5.
3.3 Sexual activity of the study patients
Nearly 60% of the patients indicated that they experienced a sense of loss of 
manhood due to the disease or its treatment. Younger patients more often declared 
a strong or very strong sense of loss of manhood (100% of patients under the age 
of 54 years, 62.5% of patients aged 55 to 59 compared to 50% of patients aged 
75–79 or 16.67% of patients over the age of 80 years) (Chi2 = 40.61, p = 0.00172; 
R = 0.09, p > 0.05). A sense of loss of manhood was mostly declared by the post-
treatment patients or the patients on cancer treatment (the responses “very strong” 
and “strong” were given by 57.89 and 75% compared to 30% of patients waiting 
Emotional problems Question no.a Quality of life
p-value R-Spearmanb
Feeling circuit 21 0.727 —
Feeling worried 22 0.000 —
The feeling of annoyance 23 0.353 —
Feeling depressed 24 0.174 —
Difficulty in remembering 25 0.020 −0.364
aNumber of issues in accordance with the questionnaire QLQ-C30.
bSignificant correlation p < 0.05.
Table 3. 
Emotional problems of the patients and felt the quality of life.
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least irritability were experienced by patients undergoing radiotherapy or surgi-
cal treatment, the greatest irritability—by patients receiving surgical treatment, 
chemotherapy, and hormone therapy (Chi2 = 69.05, p = 0.0000; R = 0.06, p > 0.05). 
On the other hand, no correlation was found between feeling irritable and the 
patients’ age, health status, or quality of life score (p > 0.05 for all the cases).
Even though no correlation was found between the age or the quality of life score 
and feeling depressed (p > 0.05), a statistical analysis of the study results showed 
that feeling depressed may depend on the patient’s health status (Chi2 = 33.34, 
p = 0.01517; R = −0.36, p = 0.00681). Patients with a lower health status score much 
more often declared that they felt depressed during the last week.
As with the above-described correlations, feeling depressed is also corre-
lated (although weakly) with the stage of the patient’s treatment (Chi2 = 13.11, 
p = 0.04122; R = 0.06, p > 0.05) and the type of treatment (Chi2 = 67.37, 
p = 0.0000; R = 0.11, p > 0.05). No depression was most often indicated by patients 
who underwent cancer treatment (56.25% of this group), radiotherapy (45.10%), or 
both radiotherapy and surgery (42.86%).
The greatest difficulties in remembering were indicated by pretreatment 
patients (30% of responses “to a significant degree” and “very much” in this 
group of patients compared to 7% of the patients on treatment and 0% of the 
posttreatment patients) (Chi2 = 19.25, p = 0.00376; R = −0.07, p > 0.05) and those 
receiving surgical treatment, hormone therapy, and chemotherapy (100% of 
the group) (Chi2 = 97.20, p = 0.0000; R = 0.08, p > 0.05). Additionally, a strong 
correlation was found between difficulties in remembering and health status score 
(Chi2 = 34.89, p = 0.00976; R = −0.45, p = 0.0000). The higher health status score is 
correlated with an absence of difficulties in remembering or only slight difficulties 
in remembering. Serious and very serious difficulties in remembering were indi-
cated only by the patients with a health status score less than 5. A similar correlation 
exists with regard to the quality of life score. Patients with the lowest quality of life 
score did not indicate any considerable or significant problems in remembering. 
Patients who declared frequent problems in remembering had a lower quality of life 
score (Chi2 = 32.30, p = 0.02024; R = −0.26, p = 0.00071). However, no correlation 
was found between difficulties in remembering and the patients’ age (p > 0.05) 
(Tables 2 and 3).
3.2 Urination problems
Among the study patients, 12% of them frequently passed urine during the 
day. This problem has a significant impact on the quality of life of the patients 
Emotional problems Question 
no.a
Number of patients (N = 166) N (%)
Not at 
all




Feeling circuit 21 86 (51.8) 72 (43.4) 4 (2.4) 4 (2.4)
Feeling worried 22 40 (24.1) 98 (59) 22 (13.3) 6 (3.6)
The feeling of annoyance 23 68 (40.9) 70 (42.2) 22 (13.3) 6 (3.6)
Feeling depressed 24 70 (42.2) 72 (43.4) 18 (10.8) 6 (3.6)
Difficulty in remembering 25 84 (50.6) 68 (41.0) 10 (6) 4 (2.4)
aNumber of issues in accordance with the questionnaire QLQ-C30.
Table 2. 
Emotional problems of the patients.
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(Chi2 = 30.86, p = 0.02988; R = −0.24, p = 0.02967). Patients with no problems with 
frequent urination during the day had a higher quality of life score compared to 
patients who had to urinate very frequently during the day. Similar but significantly 
weaker correlation was identified between the quality of life score and frequent 
nighttime urination (Chi2 = 33.42, p = 0.01484; R = −0.11, p > 0.05) or the quality 
of life score and the need to hurry into the toilet before passing urine (Chi2 = 33.83, 
p = 0.01321; R = 0.05, p > 0.05).
Over 60% of the patients indicated that having to get up at night to urinate 
affected their night’s rest. This problem had a strong impact on how the patients 
assessed their quality of life (Chi2 = 54.09, p = 0.0000; R = −0.52, p = 0.0000). The 
quality of life score was also affected by problems related to going out of the house 
due to the fact that the patients had to be close to a toilet. Problems with involun-
tary release of urine were indicated by nearly half of the patients, and 17% of the 
patients considered this problem to be considerable or significant. This group of 
patients usually has a lower quality of life score, even though this correlation is not 
strong (Chi2 = 43.87, p = 0.00060; R = −0.21, p > 0.05). Nearly 50% of the patients 
declared to have painful urination; however, no correlation was found between 
pain and the quality of life score (p > 0.05). Among the study patients, 32.53% 
of them use protection products against urinary incontinence. Using this type of 
protection was considered a nuisance only by 40% of the patients and affected 
how they perceived their quality of life (Chi2 = 55.22, p = 0.00001; R = −0.23, 
p = 0.03563). Generally, limitations related to everyday functioning due to urina-
tion problems were indicated by nearly 40% of men. This effect was considered 
significant or highly significant by 12% of the patients. However, the correlation 
between the limitation of everyday activities and the quality of life score is insig-
nificant (Chi2 = 38.50, p = 0.00332; R = 0.17, p > 0.05). Detailed results are given in 
Tables 4 and 5.
3.3 Sexual activity of the study patients
Nearly 60% of the patients indicated that they experienced a sense of loss of 
manhood due to the disease or its treatment. Younger patients more often declared 
a strong or very strong sense of loss of manhood (100% of patients under the age 
of 54 years, 62.5% of patients aged 55 to 59 compared to 50% of patients aged 
75–79 or 16.67% of patients over the age of 80 years) (Chi2 = 40.61, p = 0.00172; 
R = 0.09, p > 0.05). A sense of loss of manhood was mostly declared by the post-
treatment patients or the patients on cancer treatment (the responses “very strong” 
and “strong” were given by 57.89 and 75% compared to 30% of patients waiting 
Emotional problems Question no.a Quality of life
p-value R-Spearmanb
Feeling circuit 21 0.727 —
Feeling worried 22 0.000 —
The feeling of annoyance 23 0.353 —
Feeling depressed 24 0.174 —
Difficulty in remembering 25 0.020 −0.364
aNumber of issues in accordance with the questionnaire QLQ-C30.
bSignificant correlation p < 0.05.
Table 3. 
Emotional problems of the patients and felt the quality of life.
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for treatment) (Chi2 = 14.74, p = 0.02230; R = 0.15, p > 0.05). The type of treat-
ment had no impact on a sense of loss of manhood (p > 0.05). Nearly half of the 
patients had no interest in sexual life during the last 4 weeks (45.8%). No interest 
in having sex was mostly indicated by elderly patients over 70 years of age. None 
of the patients under 60 years of age selected the response “none” (Chi2 = 41.22, 
Problems with urination Question 
no.a
Number of patients (N = 166) N (%)




Frequent urination during the day 31 14 (8.4) 76 (45.8) 56 (33.7) 20 (12.1)
Frequent urination during the night 32 22 (13.3) 82 (49.4) 44 (26.5) 18 (10.8)
The need to accelerate the toilet before 
urinating
33 48 (28.9) 64 (38.6) 28 (16.9) 26 (15.7)
The impact of waking up at night to night 
stay
34 56 (33.7) 64 (38.6) 36 (21.7) 10 (6)
Problems with leaving home because of the 
frequent need to use the toilet
35 80 (48.2) 60 (36.1) 14 (8.43) 12 (7.2)
Involuntary leakage of urine 36 86 (51.81) 52 (31.33) 18 (10.8) 10 (6)
Pain when urinating 37 84 (50.6) 70 (42.2) 6 (3.6) 6 (3.6)
Problems with wearing protection against 
incontinence
38b 32 (59.3) 16 (29.6) 6 (3.6) 0 (0)
Limitation of daily activities by problems 
with urination
39 102 (61.5) 44 (26.5) 14 (8.4) 6 (3.6)
aNumber of issues in accordance with the questionnaire QLQ-C30.
bQuestion applies only to patients wearing protection against urinary incontinence (N = 54).
Table 4. 
Problems with urinating in the group of patients studied.
Problems with urination Question no.a Quality of life
p-value R-Spearmanb
Frequent urination during the day 31 0.029 0.239
Frequent urination during the night 32 0.014 —
The need to accelerate the toilet before urinating 33 0.013 —
The impact of waking up at night to night stay 34 0.000 −0.518
Problems with leaving home because of the frequent need to 
use the toilet
35 0.002 −0.314
Involuntary leakage of urine 36 0.000 —
Pain when urinating 37 0.060 —
Problems with wearing protection against incontinence 38c 0.000 −0.231
Limitation of daily activities by problems with urination 39 0.003 —
aNumber of issues in accordance with the questionnaire QLQ-C30.
bDemonstrated statistically significant correlations only; p < 0.05.
cQuestion applies only to patients wearing protection against urinary incontinence (N = 54).
Table 5. 
Problems with urination and the evaluation of the quality of life for patients.
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p = 0.00142; R = 0.08, p > 0.05). As regards the stage of oncological treatment, 
43.75% of the posttreatment patients and 52.63% of the patients on treatment 
had no interest in sex. Among the patients waiting for treatment, it was 10% 
(Chi2 = 26.89, p = 0.00015; R = 0.18, p > 0.05). Patients undergoing radiotherapy 
or radiotherapy and hormone therapy showed least interest in sexual life, while 
patients undergoing surgical treatment or surgical treatment, chemotherapy, 
and hormone therapy—greatest interest in sexual life (Chi2 = 55.75, p = 0.00001; 
R = 0.09, p > 0.05). Nearly 60% of the patients were not sexually active during the 
last 4 months, and there is no correlation between the level of sexual activity and 
the patient’s age (p > 0.05). The posttreatment patients and those on treatment were 
least sexually active (the response “none” was indicated by 64.91% and 50% of the 
patients in these groups, respectively). Among the patients waiting for treatment, 
30% of the patients declared lack of sexual activities (Chi2 = 20.32, p = 0.00234; 
R = 0.12, p > 0.05). Based on an analysis of the type of treatment, it can be shown 
that patients who underwent surgical treatment or chemotherapy and hormone 
therapy were characterized by greatest sexual activity (100% in both cases). In the 
other treatment categories, the percentage of sexually active men was about 40% 
(Chi2 = 46.43, p = 0.00026; R = 0.04, p > 0.05).
Among the patients who were sexually active during the last 4 months, 37% 
of them were satisfied or very satisfied with their sexual life. High or very high 
satisfaction with sexual life was indicated by 50% of the patients prior to cancer 
treatment, 12.5% of the posttreatment patients, and 7% of the patients on treat-
ment (Chi2 = 23.89, p = 0.00239; R = 0.33, p = 0.00228). The type of treatment also 
affected satisfaction with sexual life (Chi2 = 76.52, p = 0.0000; R = 0.05, p > 0.05). 
Patients undergoing surgical procedures, hormone therapy, and chemotherapy 
were very satisfied with their sexual life, while patients undergoing only surgical 
procedures or surgical procedures combined with radiotherapy declared low or no 
satisfaction with their sexual life. The patient’s age has no effect on his satisfaction 
with sexual life (p > 0.05).
Difficulties with achieving or maintaining erection were declared by 73.3% of 
the sexually active patients, regardless of their age (p > 0.05). Significant or consid-
erable difficulties were most often indicated by patients on cancer treatment (30% 
of the patients) (Chi2 = 16.71, p = 0.03328; R = 0.29, p = 0.00839) or patients under-
going radiotherapy (43.33%) (Chi2 = 61.98, p = 0.00003; R = −0.01, p > 0.05).
Difficulties with ejaculation were declared by 66.7% of the sexually active 
patients, even though these problems are not related to the patients’ age (p > 0.05). 
Problems with ejaculation were least frequent among patients prior to cancer treat-
ment (50%), while all the posttreatment patients reported having such difficulties 
(Chi2 = 34.44, p = 0.00003 R = 0.27, p = 0.01530). Patients who received surgical 
treatment, hormone therapy, or both radiotherapy and hormone therapy had no 
difficulties with ejaculation (Chi2 = 45.58, p = 0.00496; R = 0.04, p > 0.05).
A feeling of embarrassment during intimate contact was indicated only by 
56.7% of the sexually active patients. The above variable was not age-dependent 
(p > 0.05). However, a feeling of embarrassment was correlated with the stage of 
cancer treatment (Chi2 = 16.85, p = 0.03164; R = 0.30, p = 0.00526) and the type of 
treatment (Chi2 = 40.05, p = 0.02111; R = 0.00, p > 0.05). Embarrassment during 
sexual contact was not experienced by pretreatment patients, patients receiving 
surgical treatment, hormone therapy or radiotherapy in combination with hormone 
therapy.
It should be pointed out that none of the discussed aspects of sexual activity, in 
relation to all the patients or only those sexually active during the last 4 months, 
had no impact on the quality of life score (p > 0.05 for all cases). The above results 
are shown in Tables 6 and 7.
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for treatment) (Chi2 = 14.74, p = 0.02230; R = 0.15, p > 0.05). The type of treat-
ment had no impact on a sense of loss of manhood (p > 0.05). Nearly half of the 
patients had no interest in sexual life during the last 4 weeks (45.8%). No interest 
in having sex was mostly indicated by elderly patients over 70 years of age. None 
of the patients under 60 years of age selected the response “none” (Chi2 = 41.22, 
Problems with urination Question 
no.a
Number of patients (N = 166) N (%)




Frequent urination during the day 31 14 (8.4) 76 (45.8) 56 (33.7) 20 (12.1)
Frequent urination during the night 32 22 (13.3) 82 (49.4) 44 (26.5) 18 (10.8)
The need to accelerate the toilet before 
urinating
33 48 (28.9) 64 (38.6) 28 (16.9) 26 (15.7)
The impact of waking up at night to night 
stay
34 56 (33.7) 64 (38.6) 36 (21.7) 10 (6)
Problems with leaving home because of the 
frequent need to use the toilet
35 80 (48.2) 60 (36.1) 14 (8.43) 12 (7.2)
Involuntary leakage of urine 36 86 (51.81) 52 (31.33) 18 (10.8) 10 (6)
Pain when urinating 37 84 (50.6) 70 (42.2) 6 (3.6) 6 (3.6)
Problems with wearing protection against 
incontinence
38b 32 (59.3) 16 (29.6) 6 (3.6) 0 (0)
Limitation of daily activities by problems 
with urination
39 102 (61.5) 44 (26.5) 14 (8.4) 6 (3.6)
aNumber of issues in accordance with the questionnaire QLQ-C30.
bQuestion applies only to patients wearing protection against urinary incontinence (N = 54).
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Problems with urinating in the group of patients studied.
Problems with urination Question no.a Quality of life
p-value R-Spearmanb
Frequent urination during the day 31 0.029 0.239
Frequent urination during the night 32 0.014 —
The need to accelerate the toilet before urinating 33 0.013 —
The impact of waking up at night to night stay 34 0.000 −0.518
Problems with leaving home because of the frequent need to 
use the toilet
35 0.002 −0.314
Involuntary leakage of urine 36 0.000 —
Pain when urinating 37 0.060 —
Problems with wearing protection against incontinence 38c 0.000 −0.231
Limitation of daily activities by problems with urination 39 0.003 —
aNumber of issues in accordance with the questionnaire QLQ-C30.
bDemonstrated statistically significant correlations only; p < 0.05.
cQuestion applies only to patients wearing protection against urinary incontinence (N = 54).
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p = 0.00142; R = 0.08, p > 0.05). As regards the stage of oncological treatment, 
43.75% of the posttreatment patients and 52.63% of the patients on treatment 
had no interest in sex. Among the patients waiting for treatment, it was 10% 
(Chi2 = 26.89, p = 0.00015; R = 0.18, p > 0.05). Patients undergoing radiotherapy 
or radiotherapy and hormone therapy showed least interest in sexual life, while 
patients undergoing surgical treatment or surgical treatment, chemotherapy, 
and hormone therapy—greatest interest in sexual life (Chi2 = 55.75, p = 0.00001; 
R = 0.09, p > 0.05). Nearly 60% of the patients were not sexually active during the 
last 4 months, and there is no correlation between the level of sexual activity and 
the patient’s age (p > 0.05). The posttreatment patients and those on treatment were 
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Sexuality is an important aspect of human life, and emotions related to sexual 
activity influence mental well-being, relationship, or how we see ourselves. Sexual 
function disorders (e.g., erectile dysfunction) caused by prostate carcinoma 
significantly reduces the quality of life of men [6–8]. Cancer treatment is also 
related to reduced sex drive and penile dysfunction manifesting itself through, for 
example, reduced ability to have an orgasm, erectile disorders, or urinary inconti-
nence [9, 10]. The above changes in sexual functions are also related to anxiety and 
depression, challenges in everyday life, and disrupted intimate relations with the 
patient’s partner [11–14]. However, other studies indicated that many patients with 
Sexual activity Question 
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Not at 
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aNumber of issues in accordance with the questionnaire QLQ-C30.
bQuestion applies only to patients who are sexually active within the last 4 weeks (N = 60).
Table 6. 
Sexual activity patients.




Feeling perdition masculinity 49 0.134 —
The interest in sexual intercourse 50 0.420 —
The degree of sexual activity 51 0.384 —
Satisfaction with sexual intercourse 52c 0.509 —
Difficulty getting or maintaining an erection 53c 0.142 —
Difficulties with ejaculation 54c 0.361 —
The feeling of embarrassment during intimacy 55c 0.585 —
aNumber of issues in accordance with the questionnaire QLQ-C30.
bDemonstrated statistically significant correlations only; p < 0.05.
cQuestion applies only to patients who are sexually active within the last 4 weeks (N = 60).
Table 7. 
Sexual activity and quality of life of the patients.
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prostate carcinoma suffer at a later stage from complications in the course of disease 
and its treatment [15, 16].
On the other hand, feeling worried also depends on the stage of cancer treat-
ment. Patients waiting for treatment more often declared to be worried (to a 
considerable or significant extent) than posttreatment patients. At the same time, 
all the patients who received surgical treatment, chemotherapy, and hormone 
therapy indicated that they felt worried. No fatigue was most often indicated 
by patients receiving radiotherapy or both radiotherapy and surgical treatment. 
However, health status also had an insignificant impact on patients feeling worried, 
even though patients with a greater quality of life score more rarely declared that 
they felt worried. Other studies suggest that hot flushes were strongly associated 
with insomnia and they caused depression particularly in the group of elderly men 
receiving hormone therapy [17–19]. However, Yang et al. [20] determined that 
physical condition of cancer patients was closely related to the fatigue index and 
it was also the major factor affecting the quality of life of patients. Other studies 
showed that regular monitoring of fatigue and its elimination could improve physi-
cal condition of patients and therefore improve their quality of life [21, 22]. It is 
well documented in the literature that all types of cancer treatment, and especially 
chemotherapy, are associated with side effects such as fatigue, depression, pain, and 
many other problems [23–25]. Urination problems during the day had a significant 
negative impact on the quality of life of patients. A similar but significantly weaker 
correlation was identified between the quality of life score and frequent nighttime 
urination or the quality of life score and the need to hurry into the toilet before 
passing urine. At the same time, having to get up frequently at night to urinate 
affects the night’s rest and has a strong impact on how patients perceive their quality 
of life. However, pain during urination was declared by half of the patients, and 
no correlation was found between pain and the quality of life score. Vogl et al. [26] 
showed that an insignificant number of men undergoing cancer treatment had 
certain difficulties passing urine which were reversible over time. However, Arscott 
et al. [27] demonstrated that urinary tract symptoms are frequently associated with 
sexual disorders after surgical treatment and radiotherapy.
An analysis of the sexual activity of the study patients showed that younger men 
more often indicated a strong or very strong sense of loss of manhood due to the 
disease or its treatment. A sense of loss of manhood was mostly declared by posttreat-
ment patients or patients on cancer treatment. The type of treatment had no impact on 
a sense of loss of manhood (p > 0.05). In one of their studies, Zaider et al. [1] 
found that 1/3 of the male patients lost an important aspect of their manhood as a 
side effect of disease treatment, which proved to be a significant obstacle to their 
sexuality. O′ Shaughnessy et al. [2] determined that the affected patients may not be 
fully aware of their sexual losses. In another study, an inability to perform sexually 
by men diagnosed with a chronic disease was described as a source of suffering  
[28, 29]. Harrington et al. [30] argued that a body image is an important aspect of 
human quality of life, especially in patients diagnosed with cancer. On the other 
hand, the loss of sexual functions in posttreatment patients may undermine their 
concept of manhood [31, 32].
Patients undergoing surgical treatment or chemotherapy and hormone therapy 
showed the least interest in sexual life. On the other hand, there is no correlation 
between the level of sexual activity and the patients’ age (p > 0.05). Posttreatment 
patients and patients on treatment were least sexually active. Additionally, tak-
ing into account the type of treatment, patients receiving surgical treatment or 
chemotherapy and hormone therapy were characterized by greatest sexual activ-
ity. Another study demonstrated that unwillingness to meet people or have sex is 
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prostate carcinoma suffer at a later stage from complications in the course of disease 
and its treatment [15, 16].
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considerable or significant extent) than posttreatment patients. At the same time, 
all the patients who received surgical treatment, chemotherapy, and hormone 
therapy indicated that they felt worried. No fatigue was most often indicated 
by patients receiving radiotherapy or both radiotherapy and surgical treatment. 
However, health status also had an insignificant impact on patients feeling worried, 
even though patients with a greater quality of life score more rarely declared that 
they felt worried. Other studies suggest that hot flushes were strongly associated 
with insomnia and they caused depression particularly in the group of elderly men 
receiving hormone therapy [17–19]. However, Yang et al. [20] determined that 
physical condition of cancer patients was closely related to the fatigue index and 
it was also the major factor affecting the quality of life of patients. Other studies 
showed that regular monitoring of fatigue and its elimination could improve physi-
cal condition of patients and therefore improve their quality of life [21, 22]. It is 
well documented in the literature that all types of cancer treatment, and especially 
chemotherapy, are associated with side effects such as fatigue, depression, pain, and 
many other problems [23–25]. Urination problems during the day had a significant 
negative impact on the quality of life of patients. A similar but significantly weaker 
correlation was identified between the quality of life score and frequent nighttime 
urination or the quality of life score and the need to hurry into the toilet before 
passing urine. At the same time, having to get up frequently at night to urinate 
affects the night’s rest and has a strong impact on how patients perceive their quality 
of life. However, pain during urination was declared by half of the patients, and 
no correlation was found between pain and the quality of life score. Vogl et al. [26] 
showed that an insignificant number of men undergoing cancer treatment had 
certain difficulties passing urine which were reversible over time. However, Arscott 
et al. [27] demonstrated that urinary tract symptoms are frequently associated with 
sexual disorders after surgical treatment and radiotherapy.
An analysis of the sexual activity of the study patients showed that younger men 
more often indicated a strong or very strong sense of loss of manhood due to the 
disease or its treatment. A sense of loss of manhood was mostly declared by posttreat-
ment patients or patients on cancer treatment. The type of treatment had no impact on 
a sense of loss of manhood (p > 0.05). In one of their studies, Zaider et al. [1] 
found that 1/3 of the male patients lost an important aspect of their manhood as a 
side effect of disease treatment, which proved to be a significant obstacle to their 
sexuality. O′ Shaughnessy et al. [2] determined that the affected patients may not be 
fully aware of their sexual losses. In another study, an inability to perform sexually 
by men diagnosed with a chronic disease was described as a source of suffering  
[28, 29]. Harrington et al. [30] argued that a body image is an important aspect of 
human quality of life, especially in patients diagnosed with cancer. On the other 
hand, the loss of sexual functions in posttreatment patients may undermine their 
concept of manhood [31, 32].
Patients undergoing surgical treatment or chemotherapy and hormone therapy 
showed the least interest in sexual life. On the other hand, there is no correlation 
between the level of sexual activity and the patients’ age (p > 0.05). Posttreatment 
patients and patients on treatment were least sexually active. Additionally, tak-
ing into account the type of treatment, patients receiving surgical treatment or 
chemotherapy and hormone therapy were characterized by greatest sexual activ-
ity. Another study demonstrated that unwillingness to meet people or have sex is 
more common among men treated for cancer and it is most likely best observable 
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in men with prostate carcinoma who receive hormone therapy. The study at hand 
showed that more than 95% of men treated with this method reported subjective 
sex drive disorders [6]. However, DiBlasio et al. [13] demonstrated that more than 
95% of men receiving hormone therapy reported libido and sex drive disorders. The 
loss of libido is frequently observable in patients with Hodgkin disease (Hodgkin 
lymphoma), where more than 40% of men reported this side effect [14]. The loss of 
libido was also observable in patients with hematologic cancers [15, 16]. Different 
results were obtained by Olsson et al. [33] who argued that low libido may originate 
from fatigue and/or feeling unwell. Furthermore, this condition may be associated 
with the stage of disease and intensive cancer therapy.
Our study showed that among sexually active men, pretreatment and posttreat-
ment patients as well as patients on cancer treatment were satisfied or very satisfied 
with their sexual life. The level of satisfaction with sexual life was also affected by 
the type of treatment, while the patients’ age had no effect on their satisfaction with 
sexual life (p > 0.05). Given that good mental well-being depends on many factors, 
it cannot be stated without ambiguity that men can achieve sexual satisfaction only 
through a successful sexual intercourse. However, for men with chronic erectile 
disorders, inability to achieve penetration may be a source of considerable difficul-
ties and frustration. For example, couples open to changes and willing to cooperate 
were able to adapt to the needs of the affected partner and to accept the side effects 
of cancer treatment [34–36].
However, our studies showed that men receiving treatment or radiotherapy 
have considerable or major difficulties in achieving or maintaining erection. Other 
study [3] shown that erectile disorders were observed in 77% of men treated for 
prostate carcinoma who underwent radical prostatectomy and in 60% of patients 
receiving radiotherapy. It was also observed that post-radiotherapy erectile 
disorders were usually delayed (1 or 2 years after therapy) in contrast to a quick 
response achieved in a group of patients immediately after surgical treatment [28]. 
Erectile disorders were also observed in other populations, for example, in patients 
treated for anal diseases or rectal and testicular cancer [9, 11]. Difficulties with 
ejaculation were not correlated with the age of patients (p > 0.05). Problems with 
ejaculation were least frequent among patients prior to cancer treatment, while 
all the posttreatment patients reported having such difficulties. Patients who 
received surgical treatment, hormone therapy or both radiotherapy and hormone 
therapy had no problems with ejaculation. Sullivan et al. [37] determined that 
radiotherapy, especially if it is focused on the prostate gland, may be associated 
with anejaculation (inability to ejaculate). A study in 364 men diagnosed with 
prostate carcinoma and undergoing radiotherapy showed that as many as 72% of 
the patients experienced anejaculation. However, elderly men and patients receiv-
ing lower doses of radiation were less exposed to this side effect. This situation may 
lead to an intentional avoidance of orgasm by men suffering from prostate carci-
noma. On the other hand, Wassersug et al. [12] noticed that the lack of ejaculation 
in men having homosexual relations caused particular discomfort. However, in our 
study, a feeling of embarrassment during intimate contact (in sexually active men) 
was not correlated with age but with the stage of cancer treatment and the type 
of therapy.
Embarrassment during sexual contact was not experienced by pretreatment 
patients, patients receiving surgical treatment, hormone therapy, or radiotherapy 
combined with hormone therapy. Additionally, none of the discussed aspects of 
sexual activity, in relation to all the patients or only those sexually active during 
the last 4 months, had no impact on the quality of life score (p > 0.05 for all cases). 
Harrington et al. [38] showed that men who underwent hormone therapy are 
exposed to verbal abuse due to changes in their appearance as a side effect of the 
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therapy (weight gain, loss of muscle mass, reduced hair, gynecomastia). Reduced 
embarrassment and dissatisfaction with one’s own body was reported by men 
with the same diagnosis but undergoing treatment other than hormone therapy. 
A feeling of embarrassment is also caused by changes in body weight (weight gain 
or weight loss) which in turn affects the image of one’s own manhood [39, 40]. 
However, problems related to the body image are not necessarily focused only 
on the penis. In male patients treated for colorectal cancer, intestinal stoma was 
associated not only with erectile disorders but also with a feeling of shame before 
themselves and their partner.
5. Conclusions
1. Despite the existing psychoemotional disorders, no correlation was 
found between the age of patients and feeling tense, worried, irritable, or 
depressed. Additionally, complaints reported by sexually active patients 
showed no correlation between age and a sense of loss of manhood, erectile 
disorders, satisfaction with sexual life, or embarrassment during intimate 
contact.
2. The type and stage of cancer treatment (mostly prior to therapy) had a 
significant impact on feeling tense, worried, depressed, and irritable. It 
was also shown that feeling depressed affects the patient’s health status to a 
considerable extent. Our results show the urgent need to provide the patients 
with continuous psychological care, especially those waiting for treatment and 
those on treatment.
3. The method of treatment had no major impact on a sense of loss of manhood 
and the degree of sexual activity, while the stage of treatment (posttreat-
ment patients and patients on treatment) had a negative effect on these 
parameters. Pretreatment patients declared high or very high satisfaction 
with their sexual life, while posttreatment patients and those on cancer 
treatment indicated low sexual satisfaction. However, feeling embarrassed 
during intimate contact as well as erectile disorders correlated both with the 
type and stage of cancer treatment. An analysis of the sexual functioning of 
prostate carcinoma men suggests that the patients should be under the care 
of a clinical sex therapist.
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